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In 2016, 58 cases of invasive Haemophilus influenzae disease 
were notified in Ireland (1.22 cases per 100,000 total 
population). This is a 15.4% increase on the number reported 
in 2015, which was a decrease of 14.8% in 2014. In 2004 the 
incidence rate was 0.89 cases/100,000. No imported cases 
or outbreaks were reported in 2016.
The main change in 2016, when compared to 2015, is the 
increase in the number of non-typeable/non-capsular strains 
from 24 to 34 and the decrease in untyped cases from 21 to 
13 (Figure 1). 
Non-typeable/non-capsular cases accounted for the majority 
of the invasive H. influenzae cases notified in 2016 (58.6%, 
n=34/58). The remaining cases were due to H. influenzae 
type f (10.3%; n=6), type b (5.2%; n=3), types e and ‘not b’ 
(1.7%, n=1 each) and isolates that were not typed (22.4%; 
n=13), of which 6 (10.3%) were diagnosed by PCR testing 
only. The median age of cases was 47 years (range 11 days 
to 91 years). The incidence rates were highest in infants <1 
year (11.2/100,000) and those aged 65+ years (3.3/100,000) 
(Table 1).
Cases occurring in children <10 years of age (n=12) and in 
elderly adults (65 years of age and older (n=21)) accounted 
for 56.9% of all invasive H. influenzae notifications in 2016 
(Table 1). One notable trend since 2004 is the increase in the 
overall proportion of cases 65+ years of age from 26.3% to 
36.2% in 2016. 
In 2016, the highest frequency of cases occurs in the 0-4 year 
age group (19.0%; n=11), after which it falls sharply before 
increasing again among those aged 65+ years (34.6%; n=21) 
(Table 1), a pattern consistent with what has been observed 
since 2004 (Figure 2).
In 2016 the number of male cases (n=18) was less than half 
that of females (n=39) giving a male to female ratio of 0.46:1.
1.1 Haemophilus influenzae (invasive) 
Number of cases, 2016:  58
Number of cases, 2015:  52
Number of cases, 2014:  61
Crude incidence rate, 2016: 1.2/100,000
Summary
Figure 1. Number of invasive H. influenzae cases and proportion of cases attributable to type b and non-typeable strains with 95% confidence 
intervals, Ireland, 2004-2015
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The M:F ratio has been observed to vary considerably in recent 
years with a 1:1 ratio recorded in 2015 and 1.8:1 in 2014 (Figure 
3).
Between 2004 and 2016, a period of 13 years, the fewest 
quarterly number of cases has been in the third quarter on 
eight occasions (Figure 3). 
Incidence of disease in 2016 was highest in the HSE M 
area (2.1/100,000) with the lowest in the HSE SE area 
(0.98/100,000) (Table 2). No HSE area had an incidence rate 
that was significantly different from the national rate (Figure 
4).
A breakdown by clinical diagnosis for all cases by age group 
between 2004 and 2016 is presented in Table 3. In 2016, 17.2% 
(n=10/58) of cases did not have a clinical diagnosis recorded. 
Two deaths were reported among the 58 cases in 2016; both 
aged 80-84 years. The cause of death in one was not caused 
by the H. influenzae infection itself and in the other, it was not 
known. Both had a confirmed non-typeable infection with 
pneumonia.
 
In 2016, there were three cases of H. influenzae type b (Hib) 
reported compared to none in 2015. In 2014, only one case of 
Hib occurred, with two cases in 2013 and 18 cases notified in 
both 2004 and 2005. Between Q3-2007 and Q4-2016, a nine 
and a half year period, only one true Hib vaccine failure was 
reported, highlighting the continuing positive impact that the 
Hib booster catch up campaign has had in Ireland. 
Since September 2008, the Hib booster dose has been 
administered at 13 months of age as part of the routine 
childhood immunisation schedule in addition to the three 
doses given during infancy (at 2, 4 and 6 months of age). 
Furthermore, vaccination is routinely recommended for those 
at increased risk of Hib disease due to underlying medical 
conditions or treatments.
HPSC Annual Epidemiological Report 2015
Figure 2. Number of H. influenzae cases by agegroup and type*, Ireland, 2004-2016
* Typed includes b, e, f, not-b
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Table 1. Number and incidence rates of invasive H. influenzae cases by serotype and age group, Ireland, 2016
Age 
Group type b type e type f not type b
non-typeable/
non-capsular
not 
typed 
(all)
not typed, 
PCR only 
diagnosis
not 
typed Total ASIR 
<1 1 0 0 1 2 3 3 0 7 11.24
1-4 0 0 0 0 3 1 1 0 4 1.49
5-9 0 0 0 0 0 1 1 0 1 0.28
10-14 0 0 1 0 0 0 0 0 1 0.31
15-19 0 0 0 0 1 0 0 0 1 0.33
20-24 0 0 0 0 3 0 0 0 3 1.10
25-34 0 0 0 0 5 1 0 1 6 0.91
35-44 0 1 0 0 5 0 0 0 6 0.80
45-54 0 0 2 0 2 0 0 0 4 0.64
55-64 2 0 1 0 1 0 0 0 4 0.79
65+ 0 0 2 0 12 7 1 6 21 3.29
Total 3 1 6 1 34 13 6 7 58 1.22
CIR 0.06 0.02 0.13 0.02 0.71 0.27 0.13 0.15 1.22 -
CIR, crude incidence rate per 100,000 total population; ASIR, age specific incidence rate per 100,000 population; ASIR values calculated using Census 2016 data
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Figure 3. Number of H. influenzae cases by year/quarter and gender, Ireland, 2004-2016
Table 2. Incidence rates per 100,000 population of invasive H. influenzae by HSE area, Ireland, 2004-2016
HSE 
Area 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016
E 1.07 1.00 0.87 0.80 0.53 0.74 0.56 1.11 1.11 0.62 0.93 1.52 1.11
M 1.19 1.19 0.40 1.19 0.79 1.06 0.35 1.06 0.35 1.42 1.71 0.34 2.05
MW 0.83 0.28 0.83 0.55 0.83 2.11 0.53 0.53 1.05 0.79 2.08 1.04 1.30
NE 0.25 1.27 0.25 0.00 0.00 0.23 0.45 1.59 0.91 1.36 1.52 0.87 1.08
NW 0.42 0.00 2.11 0.42 0.00 0.39 0.39 0.77 0.77 1.16 0.39 0.78 1.95
SE 1.08 0.43 0.87 1.08 0.65 1.00 1.00 0.80 1.21 1.00 2.35 1.18 0.98
S 1.13 0.32 1.29 0.32 0.64 1.20 1.05 0.30 0.60 0.90 1.16 0.72 1.01
W 0.48 1.45 0.72 1.45 0.48 1.12 0.22 1.35 0.45 0.90 0.88 0.88 1.32
Ireland 0.90 0.80 0.90 0.73 0.52 0.94 0.61 0.96 0.89 0.89 1.28 1.09 1.22
Table 3. Number of invasive H. influenzae cases by clinical diagnosis, Ireland, 2004-2016
Clinical diagnosis
20
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20
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20
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07
20
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20
0
9
20
10
20
11
20
12
20
13
20
14
20
15
20
16
Septicaemia 8 14 13 6 3 9 9 11 11 14 15 14 18
Pneumonia 5 0 3 6 3 8 5 12 12 4 12 8 12
Other 1 2 1 0 0 0 0 3 4 7 7 3 9
Bacteraemia 
(without focus) 1 0 1 1 2 0 0 3 5 6 9 8 6
Meningitis 3 9 3 2 2 2 1 3 2 2 7 3 1
Epiglottitis 1 3 3 1 1 0 2 0 0 3 1 1 1
Cellulitis 1 1 2 1 1 0 0 1 0 0 0 1 1
Meningitis & 
septicaemia 1 0 1 0 1 1 1 1 1 0 0 2 0
Septic arthritis 0 1 0 0 1 0 0 0 0 0 0 0 0
Osteomyelitis 1 0 0 0 0 0 0 0 0 0 0 0 0
Not specified 16 4 11 14 8 23 10 10 6 5 10 12 10
Total 38 34 38 31 22 43 28 44 41 41 61 52 58
% Not specified 42.1% 11.8% 28.9% 45.2% 36.4% 53.5% 35.7% 22.7% 14.6% 12.2% 16.4% 23.1% 17.2%
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Figure 4. Crude incidence rates per 100,000 population with 95% confidence intervals for H. 
influenzae notifications by HSE area, Ireland, 2016 (Incidence rates based on Census 2016 data)
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The figures presented in this summary are based on data 
extracted from the Computerised Infectious Disease 
Reporting (CIDR) system on 9th November, 2017. These 
figures may differ from those published previously due to on-
going updating of notification data on CIDR.
There were 43 measles cases (0.9/100,000) in 2016 
compared to two cases in 2015 (figure 1). All cases in 2016 
were classified as confirmed. 
Forty (93%) of the cases in 2016 were part of a national 
measles outbreak which occurred following importation of 
measles virus from Romania. One further case in a resident 
of Slovenia, exposed on a flight, was linked to the outbreak. 
This confirmed case is not included in the Irish data but was 
reported by Slovenian national public health authorities. Of 
the 40 cases, 27 (68%) were in the HSE S, five (13%) were 
in the HSE SE, four (10%) were in the HSE MW, three (8%) 
were in the HSE E and one (3%) was in the HSE NE. The 
cases ranged in age from three months to 40 years with a 
median age of eight years and a mean age of 12 years. Thirty 
(75%, n=30/40) of the cases were unvaccinated; eight of 
these were less than one year of age. One case (3%, n=1/40) 
had received one dose of MMR, three cases (8%, n=3/40) 
were reported to have received two doses while vaccination 
status was unknown for the remainder (15%, n=6/40). Of the 
cases reported to have received MMR vaccine only one had 
vaccination dates reported. Nineteen cases (48%, n=19/40) 
were hospitalised. Length of hospitalisation was reported for 
18 cases with a median duration of stay of four days (range 
two to eight days). Reported complications of measles 
included pneumonia (3%, n=1/33) and shortness of breath 
(n=1). Measles virus from 33 of the cases were genotyped 
by the NVRL and all were genotype B3. Information on the 
outbreak investigation was published in Eurosurveillance.1
Two of the 43 cases were part of a separate localised 
outbreak. Genotype D8 was identified in this outbreak. 
The index case had arrived from the United Kingdom but 
reported exposure to a hospitalised measles in Germany 8-17 
days before rash onset. The secondary case in Ireland was a 
health care student and had contact with the index case in 
an Emergency Department in Ireland. The index case was in 
the age group 20-24 years and the secondary case was in 
the age group 25-34 years. The index case was unvaccinated 
and the secondary case had one dose of MMR, however, the 
date of vaccination was not available. 
One of the 43 cases was reported as exposed to measles 
cases in Pakistan. No secondary cases were identified. The 
case was genotyped by the NVRL and was genotype B3. The 
case was less than one year of age and was unvaccinated.
The total 43 cases by age group and the age specific 
incidence rates are shown in figures 2 and 3. Nineteen of 
the 43 cases (44%) were hospitalised. The country of birth 
was recorded as Ireland for 27 cases; country of birth was 
1.2 Measles 
Summary
Number of cases, 2016: 43
Number of confirmed cases, 2016: 43
Crude incidence rate, 2016: 0.9/100,000
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Figure 1. Number of measles cases by year and case classification, 2004-2016
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outside of Ireland for twelve cases and was unknown for 
four cases. Of the 43 cases, the setting where the case most 
likely acquired measles was reported as home (42%, n=18), 
hospital in-patient (12%, n=5), overseas (7%, n=3), hospital 
out-patient (5%, n=2), work (5%, n=2), other healthcare 
facility (2%, n=1) and was unreported for the remainder 
(28%, n=12). Twenty four (56%) of the cases were male and 
19 (44%) were female. A breakdown of the total cases and 
the crude incidence rate per 100,000 population by HSE 
Area is given in table 1.
The figures presented above are based on data extracted 
from the Computerised Infectious Disease Reporting (CIDR) 
system on 25th July 2017. These figures may differ slightly 
from those published previously due to ongoing updating of 
notification data on CIDR. The 2016 census data was used 
here to calculate rates.
WHO require information on discarded measles cases ie 
measles cases investigated and who were found not to meet 
the case definition. The HSE Areas reported the number of 
discarded CIDR cases to HPSC. For 2016, 154 cases were 
discarded from CIDR as following investigation as they were 
not considered to be measles cases. Discarded cases are not 
available in CIDR for reporting and are not included in the 
analysis above.
The Regional Verification Commission for Measles and 
Rubella Elimination (RVC) was established in the WHO 
European Region in 2011 to evaluate the documentation 
submitted by Member States with a view to verifying the 
elimination of measles and rubella at the regional level. The 
RVC has recommended establishment of national verification 
committees (NVC) in all Member States and suggested a 
standard format for annual status reports from countries. 
These reports include information on measles and rubella 
epidemiology, virologic surveillance supported by molecular 
epidemiology, the analysis of vaccinated population cohorts 
and the quality of surveillance, and the sustainability of the 
country’s National Immunisation Programme. The review 
and evaluation of annual national reports will continue for 
at least three years after the RVC confirms that, according 
to established criteria, endemic measles and rubella 
transmission have been interrupted in all Member States of 
the Region. Only then can Regional elimination be declared.2 
The WHO European RVC concluded at the sixth meeting 
of the European RVC for measles and rubella elimination 
in June 2017 that Ireland provided evidence for interrupted 
transmission of measles virus for 24 months.3
The NVRL is the WHO accredited National Measles Rubella 
laboratory for Ireland. Laboratories that perform measles/
rubella investigations in their own laboratories are requested 
to send all positive samples for measles or rubella to the 
NVRL for confirmatory testing. In addition, a selection of 
negative specimens should also be referred. Genotyping is 
undertaken in the NVRL on a selection of specimens. 
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Figure 2. Number of measles cases in 2016 by age group and 
outbreak identifier
HPSC-1-6-2016 is the outbreak identifier for the 2016 national measles 
outbreak
5320 is the outbreak identifier for a 2016 localised measles outbreak 
with two cases
One case in 2016 was not related to an outbreak in Ireland
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Figure 3. The age specific incidence rate (per 100,000) of measles cases 
in 2016 by age group and outbreak identifier
HPSC-1-6-2016 is the outbreak identifier for the 2016 national measles 
outbreak
5320 is the outbreak identifier for a 2016 localised measles outbreak 
with two cases
One case in 2016 was not related to an outbreak in Ireland
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Table 1. Number of measles cases and the crude incidence rate per 
100,000 population (CIR) by HSE Area in 2016
HSE Area Number CIR
HSE E 4 0.2
HSE M 0 0.0
HSE MW 4 1.0
HSE NE 1 0.2
HSE NW 0 0.0
HSE SE 5 1.0
HSE S 27 3.9
HSE W 2 0.4
Total 43 0.9
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Between 1999 and 2012, a marked downward trend in 
invasive meningococcal disease (IMD) incidence was 
observed: in 1999 there were 536 cases (14.8/100,000) 
and in 2012 there were 66 cases (1.4/100,000), a decline of 
almost 88%. In 2016, however, 87 cases (1.8/100,000) of 
IMD were notified, 13 more reported than in the previous year 
(n=74). 
Typically, most cases in 2016 were diagnosed by blood/CSF 
culture testing, blood/CSF PCR testing or by detection of 
Gram negative diplococci in skin lesions/culture or in CSF 
specimens. Isolation of the organism from non-sterile sites 
(such as the eye, nose or throat) in clinically compatible 
cases is considered a possible case. 
Of the 87 cases notified in 2016, 85 (97.7%) were case 
classified as confirmed and two (2.3%) as possible. Of the 
85 confirmed cases, 37 (43.5%) were confirmed by PCR 
testing alone and another 17 confirmed cases (20.0%) were 
diagnosed by culture of sterile specimens alone. Of the 
remaining 31 (36.4%) confirmed cases, all were diagnosed 
by both culture and PCR testing of sterile specimens. 
Additional laboratory testing was done on the 85 confirmed 
cases: six had positive CSF microscopy test results and one 
had a positive skin lesion culture. Of the two possible cases 
reported in 2016, one had a positive a bronchial lavage test 
result.
In 2015, male cases (n=49) exceeded female cases (n=38), 
resulting in a male to female ratio of 1.28:1, following a 
consistent pattern observed since 2001. IMD cases in 2016 
ranged in age from one week to 93 years (median age of 14.2 
years). 
Overall incidence in Ireland was 1.8/100,000 population in 
2016. Age specific incidence rate (ASIR) was highest among 
infants <1 year of age (28.9/100,000; n=18), followed by 
children in the 1 to 4 years (5.9/100,000; n=16), and 15 to 19 
year age groups (4.6/100,000; n=14) (Table 1, Figure 1). 
Figure 2 presents the number of IMD cases by gender and 
age group between 1999 and 2016 and shows the decline 
in numbers across all of the age groups, with the steepest 
declines observed in the <1, 5-9 and 10-24 year age groups 
following the introduction of the meningococcal C conjugate 
(MCC) vaccine in late 2000.
At regional level, incidence was highest in the HSE NW 
area (4.7/100,000) and lowest in the HSE MW area 
(1.3/100,000) (Table 2). No area had an incidence rate that 
was significantly different from the national rate (Figure 3). 
There was one imported case identified in 2016, (from the 
United Kingdom with a menB infection (aged 20-24 years)). 
In December 2016, a cluster of two cases was reported in 
HSE NW in Donegal, both aged 10-14 with a serogroup B 
infection; both cases recovered.
1.3  Meningococcal Disease      
(Neisseria meningitidis) (invasive) 
Summary
Number of cases, 2016: 87
Number of cases, 2015: 74
Number of cases, 2014: 82
Crude incidence rate, 2016: 1.8/100,0000
Table 1. Number of cases, deaths, age-group specific incidence rates per 100,000 population and case fatality ratios of IMD, Ireland, 2016
Age Group No. Cases ASIR No. Deaths %CFR
<1 18 28.9 0 0.0%
1-4 16 5.9 0 0.0%
5-9 4 1.1 0 0.0%
10-14 8 2.5 0 0.0%
15-19 14 4.6 1 7.1%
20-24 6 2.2 0 0.0%
25+ 21 0.7 4 19.0%
All ages 87 1.8 5 5.7%
ASIR, age specific incidence rate per 100,000 population calculated using Census 2016 data; %CFR, case fatality ratio, 
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Apart from the years 2003, 2013, 2014 and 2016, IMD cases 
have tended to occur most frequently in the first quarter of 
each calendar year (Figure 4). 
Most cases of IMD occurred in cases whose ethnic 
background was described as ‘White’ (51.7%; n=45/87) 
followed by ‘Irish Traveller’ (12.6%; n=11), ’Indian 
Subcontinent’ (3.4%; n=3) ‘Other’ (2.3%; n=2) and ‘not 
known’/not specified (29.9%; n=26).
Neisseria meningitidis serogroup B was the pathogen most 
commonly associated with IMD in 2016 and accounted for 
48 of the 87 (55.2%) notifications. However, this is a marked 
decline on what was previously reported between 2002 
and 2015 when serogroup B accounted for more than 80% 
(n=1746/2105) of all IMD notifications (Figure 5). 
There were five IMD related notified deaths in 2016 (case 
fatality ratio of 5.8%) (age range 17 months to 81 years) 
Figure 1. Age-specific rates per 100,000 population for invasive meningococcal disease (IMD), 
Ireland, 1999-2016
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Table 2. Age specific incidence rates per 100,000 population of IMD by HSE area and age group, Ireland, 2016
HSE Area <1 1-4 5-9 10-14 15-19 20-24 25+ Total
HSE E 26.4 4.2 0.8 0.0 3.9 1.8 0.6 1.4
HSE M 0.0 5.6 0.0 0.0 15.5 0.0 1.1 2.1
HSE MW 20.3 0.0 0.0 3.8 3.9 4.6 0.4 1.3
HSE NE 15.4 0.0 2.5 0.0 9.7 4.4 0.7 1.7
HSE NW 94.6 14.2 5.1 21.7 5.8 0.0 0.6 4.7
HSE SE 15.4 17.5 2.6 0.0 3.0 0.0 0.0 1.6
HSE S 34.0 7.9 0.0 4.4 2.3 5.1 1.5 2.6
HSE W 52.3 4.0 0.0 3.3 0.0 0.0 0.3 1.3
Ireland 28.9 5.9 1.1 2.5 4.6 2.2 0.7 1.8
ASIR, age specific incidence rate per 100,000 population calculated using Census 2016 data
Table 3. Number of cases, deaths and case fatality ratios (%CFR) by year for meningococcal B and C disease, Ireland, 1999-2016
Meningococcal B Meningococcal C
Year No. Cases No. Deaths %CFR No. Cases No. Deaths %CFR
1999 292 12 4.1 135 5 3.7
2000 258 13 5.0 139 11 7.9
2001 245 8 3.3 35 3 8.6
2002 199 8 4.0 14 0 0.0
2003 206 11 5.3 5 1 20.0
2004 163 7 4.3 5 1 20.0
2005 169 5 3.0 5 0 0.0
2006 168 5 3.0 4 0 0.0
2007 158 6 3.8 2 0 0.0
2008 149 6 4.0 4 1 25.0
2009 119 6 5.0 5 0 0.0
2010 93 4 4.3 4 0 0.0
2011 84 2 2.4 2 0 0.0
2012 58 1 1.7 0 0 0.0
2013 68 4 5.9 1 0 0.0
2014 69 3 4.3 6 1 16.7
2015 43 2 4.7 11 0 0.0
2016 48 2 4.2 22 1 4.5
%CFR, case fatality ratio
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(Table 1). Two of the deaths were attributable to a serogroup 
B infection, one to a serogroup W135 infection, one case had 
a serogroup C infection at the time of death, but the cause 
of death was not known and another, with no serogroup 
reported, is awaiting a coroner’s report at the time of writing.
IMD due to serogroup C (MenC) had remained at low levels 
between 2003 and 2014 with an average of 3.4 cases 
occurring annually. However, since then, numbers have risen 
with 11 cases in 2015 and 22 in 2016 (Table 3). Of the cases 
in 2016, 11 were unvaccinated (aged between 1 month and 
69 years), six were complete vaccine failure failures (aged 8 
to 17 years), two were incomplete vaccine failures (aged 12-
14 years) and the vaccination status of the remaining three 
cases were either unknown or not specified (aged 30-81 
years) (Table 4).
The recent increase in MenC cases, which began in 2014, 
may be attributable to waning population herd immunity. 
Recent studies undertaken in the United Kingdom have 
reported waning immunity to serogroup C disease following 
infant vaccination in early childhood. Furthermore, 
protection given by vaccination at 12 months also wanes 
by the teenage years, but vaccination later in childhood 
provides higher levels of antibody that persist for longer.1-4 
Evidence shows that MCC vaccination significantly reduces 
nasopharyngeal carriage of the serogroup C meningococcus, 
providing indirect protection through herd immunity.5-6 The 
Figure 2. Number of IMD cases by gender and age group in Ireland, 1999-2016 (excludes one case 
with unknown gender details in 2009)
N
um
be
r o
f I
M
D
 c
as
es
 
Year 
0 
40 
80 
120 
160 
200 
19
99
 
20
02
 
20
05
 
20
08
 
20
11
 
20
14
 
19
99
 
20
02
 
20
05
 
20
08
 
20
11
 
20
14
 
19
99
 
20
02
 
20
05
 
20
08
 
20
11
 
20
14
 
19
99
 
20
02
 
20
05
 
20
08
 
20
11
 
20
14
 
19
99
 
20
02
 
20
05
 
20
08
 
20
11
 
20
14
 
<1 1-4 5-9 10-24 25+ 
Table 4. Details of the MenC cases notified in 2016 including age group, outcome and age at vaccination
Case No. Age Grp Outcome Vaccination Status No. MenC doses given Age at (Last) Vaccination
1 <1 Not known Unvaccinated 0 .
2 <1 Not known Unvaccinated 0 .
3 <1 Recovering Unvaccinated 0 .
4 <1 Recovering Unvaccinated 0 .
5 5-9 Recovering Complete 3 6 months
6 10-14 Recovering Complete 3 6 months
7 10-14 Recovered Incomplete 1 6 months
8 10-14 Recovering Incomplete 3 5 months
9 15-19 Recovering Complete 1 3.5 years
10 15-19 Recovered Complete 1 3.3 years
11 15-19 Recovered Complete 1 3.3 years
12 15-19 Recovering Complete 1 2.5 years
13 15-19 Recovered Unvaccinated 0 .
14 20-24 Recovering Unvaccinated 0 .
15 30-34 Recovering Unknown . .
16 45-49 Recovering Unknown . .
17 50-54 Recovering Unvaccinated 0 .
18 55-59 Recovering Unvaccinated 0 .
19 60-64 Not known Unvaccinated 0 .
20 65-69 Recovered Unvaccinated 0 .
21 65-69 Recovering Unvaccinated 0 .
22 80-84 Died Not specified . .
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Figure 4. Number of IMD cases by quarter and serogroup, Ireland, 1999-2016
continuing increase in MenC cases in Ireland in 2016 may 
reflect a decline in this herd immunity. 
The routine meningococcal C conjugate (MCC) vaccination 
programme in Ireland has recently changed in response 
to the recent increase in MenC cases and the emerging 
evidence of waning immunity. Instead of three doses of the 
MCC vaccine being administered to children at 4, 6 and 
13 months of age, from July 2015 a single dose is given at 
4 months, 13 months and at 12-13 years (if not previously 
vaccinated at >10 years of age) (http://www.hse.ie/eng/
health/immunisation/hcpinfo/guidelines/chapter13.pdf). 
The National Immunisation Advisory Committee (NIAC) 
also recommended a booster dose of the MCC vaccine for 
those considered at increased risk of MenC disease, and 
since 2011, the MCC vaccine booster has been recommended 
for close contacts of cases if their last dose was more than 
one year before. In August 2014, NIAC recommended an 
adolescent booster at 12-13 years to be offered in the first 
year of secondary level school. The adolescent booster MenC 
programme commenced in January 2015. 
Despite the marked reduction in the overall incidence in 
the past decade, IMD is still an important public health 
concern due to its associated severity, high mortality rate 
and serious adverse sequelae. Complete IMD prevention 
and control requires effective vaccination. Effective vaccines 
are now available against serogroups A, B, C, W135 and 
Y forms of the disease. In 2012, Bexsero®, a recombinant 
multicomponent vaccine (4CMenB) against serogroup B 
disease was approved by the European Medicines Agency. 
In March 2014, the United Kingdom’s Joint Committee on 
Vaccination and Immunisation (JCVI) recommended the 
vaccination of infants against serogroup B7. In Ireland, 
the primary childhood immunisation (PCI) schedule were 
updated in July 2016 so that all babies born on or after 1st 
October 2016 are now offered the MenB vaccine at 2, 4 
and 12 months of age (https://www.hse.ie/eng/health/
immunisation/infomaterials/newsletter/newsletter23.pdf). 
The MenB vaccine cannot be given at same time as MenC 
vaccine, which is given at 6 and 13 months of age.
The figures presented in this summary are based on data 
extracted from the Computerised Infectious Disease 
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Figure 3. Crude incidence rates per 100,000 population with 95% confidence intervals for IMD 
notifications by HSE area, Ireland, 2016
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Reporting (CIDR) system on 9th November, 2017. These 
figures may differ from those published previously due to 
on-going updating of notification data on CIDR.
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There was a decrease in mumps in 2016 with 488 
(10.2/100,000) mumps cases notified compared to 2015 
when 2,014 cases were notified (figure 1). Sixty three percent 
(n=305) of the cases in 2016 were notified between January 
and May (figure 2). 
In 2016, the largest number of cases was notified in the HSE 
E while the highest crude incidence rate was in the HSE S 
(table 1).
Of the 488 mumps cases notified 52% (n=252) were 
classified as confirmed, eight percent (n=41) as probable and 
40% (n=195) were classified as possible.
The median age of cases was 22 years (mean age was 
27 years) with cases ranging in age from one to 87 years 
(age was unknown for one case). The highest age specific 
incidence rates were in those aged 15-19 years and 20-24 
years (figure 3). Fifty one per cent (n=247) of cases were 
female and 48% (n=235) were male while gender was not 
reported for one percent (n=6).
Mumps vaccine in Ireland is available as part of the 
combined measles mumps rubella (MMR) vaccine. In 
Ireland, vaccination with the first dose of MMR is routinely 
recommended at twelve months of age and the second dose 
at four to five years of age. A MMR vaccination campaign 
started in April 2009 for students in fourth, fifth and sixth 
year of second level schools. A MMR catch up campaign 
started during the academic year 2012/2013 and continued 
during the academic year 2013/2014 for children/students 
attending primary schools, second level schools and 
special schools and home-schooled students who had not 
completed (or were not sure they had) their two dose MMR 
1.4 Mumps 
Summary
Number of cases, 2016: 488
Number of cases, 2015: 2,014
Crude incidence rate, 2016: 10.2/100,000
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A MMR catch-up campaign was conducted during the 2012/2013 and 2013/2014 academic years for children/students attending primary schools, second level 
schools and special schools and home-schooled students who had not completed (or were not sure they had) their two dose MMR vaccination schedule
MMR1- first dose of MMR
MMR2- second dose of MMR
1988-June 2000 data collated by DoHC
July 2000-2016 data collated by HPSC
vaccination schedule. Additionally, MMR vaccine continued 
to be recommended for students in college or universities if 
not previously vaccinated. 
Of the 488 mumps cases, 11% (n=53) were unvaccinated, 
11% (n=54) had one dose of MMR, 23% (n=111) were reported 
to have received two doses of MMR while for 55% (n=270) 
of cases the number of doses of MMR were not reported. 
The vaccination date was reported for 74% (n=40/54) of 
cases reported to have received one dose of MMR. Both 
vaccination dates were reported for 55% (n=61/111) of cases 
vaccinated with two doses of MMR. Forty per cent (n=44/111) 
of the cases reported to have received two doses of MMR 
were classified as confirmed; 45% (n=20/44) of these cases 
had both MMR vaccination dates reported. 
The country of birth was recorded as Ireland for 15% (n=71) of 
cases, was recorded as being a country other than Ireland for 
7% (n=32) of cases and was unknown or not specified for the 
remainder.
Twenty three cases were hospitalised, representing five per 
cent (n=23/488) of all cases and nine per cent (n=23/266) 
of cases where hospitalisation data was known. The number 
of days hospitalised was reported for five of the hospitalised 
cases; the median number of days hospitalised was two days 
(range two to five days). 
The most commonly reported complications of mumps 
included orchitis (8%, n=8/99), pancreatitis (0.5%, n=1/185) 
and deafness (0.5%, n=1/185).
The setting where the case most likely acquired mumps was 
reported for 23% (n=111/488) of cases. The identified settings 
were: university/college (7%, n=36), social setting (6%, 
n=28), secondary school (5%, n=24), family/household (3%, 
n=14), work (1%, n=5), international travel (0.4%, n=2), day-
care/pre-school (0.2%, n=1) and primary school (0.2%, n=1).
The probable countries of infection were recorded as Ireland 
(n=142), Spain (n=1), United Kingdom (n=1), Vietnam (n=1) 
and was unknown or not specified for the remainder.
Ten localised outbreaks of mumps were notified during 2016 
with a total of 58 associated cases of illness. The outbreak 
locations included one university/college outbreak (with 31 
ill), seven private houses (with 18 ill), one school outbreak 
(with 7 ill), and one outbreak reported as an outbreak among 
close social contacts (with two ill). 
The figures presented in this summary are based on data 
extracted from the Computerised Infectious Disease 
Reporting (CIDR) system on 4th September 2017. These 
figures may differ slightly from those published previously 
due to ongoing updating of notification data on CIDR. The 
2016 census data was used here to calculate rates.
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Figure 3. The age specific incidence rates (per 100,000 population) 
of mumps cases in 2016 by case classification
Figure 2. Number of mumps cases in 2016 by month 
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Table 1. Number of mumps cases and the crude incidence rate per 
100,000 population (CIR) by HSE Area in 2016
HSE Area Number CIR
HSE E 140 8.2
HSE M 42 14.4
HSE MW 31 8.1
HSE NE 21 4.6
HSE NW 19 7.4
HSE SE 66 12.9
HSE S 111 16.1
HSE W 58 12.8
Total 488 10.2
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Other Forms of Bacterial Meningitis* 
Apart from Neisseria meningitidis, which is the most common 
cause of bacterial meningitis in Ireland, other pathogens 
cause this disease, including those caused by non-notifiable 
organisms. For information on invasive meningococcal 
disease (Neisseria meningitidis), see that chapter within 
this report. Information on bacterial meningitis caused 
by specified notifiable diseases is summarised below and 
further pathogen-specific data are available in the relevant 
chapter. The figures presented in this chapter are based on 
data extracted from the Computerised Infectious Disease 
Reporting (CIDR) system on 9th November, 2017. Census data 
from 2016 were used to calculate 2016 incidence rates. These 
figures may differ from those published previously due to on-
going updating of notification data on CIDR. 
Bacterial meningitis caused by diseases not otherwise specified 
(NOS):
In total, 15 cases of meningitis under this disease category 
were notified in 2016, none of whom died. Five each (33.3%) 
of the 15 cases were case classified as confirmed, probable 
and possible (Table 1). The causative pathogens were 
identified in five (33.3%) of cases (Table 2).
Prior to 1st January 2012, all cases of Group B streptococcus, 
also known as S. agalactiae, were notifiable under the 
‘Bacterial Meningitis (NOS)’ disease category. In 2012, this 
changed when Streptococcus agalactiae in children < 90 days 
of age was notifiable in its own right, including those which 
were meningitis-related. This has meant that the overall 
number of bacterial meningitis (NOS) cases has, as a result, 
declined between 2012 and 2016 compared to previous 
years. In other words, without this change there would have 
been 27 extra cases reported under the bacterial meningitis 
(NOS) category between 2012 and 2016. Furthermore, there 
is evidence of an additional 54 possible meningitis-related 
cases of this disease in this same age group during this 
same five year period where S. agalactiae was either isolated 
from or detected in CSF specimens from patients that were 
not clinically categorised as having ‘meningitis’. These 54 
cases have been excluded from Table 3, which is a summary 
breakdown of all bacterial meningitis cases by their causative 
pathogen (both specified and not specified types except for 
meningococcal disease) between 2011 and 2016.
Among the bacterial meningitis (NOS) cases notified in 2016 
were five caused by Escherichia coli (age range two weeks 
to 87 years; three were confirmed and none of which had 
serotype details reported). There were 10 other cases whose 
causative organism was not identified. 
Bacterial meningitis caused by specified notifiable diseases:
Haemophilus influenzae
One case of meningitis related H. influenzae was notified 
in 2016, aged 6-11 months old with a non-typeable/non-
capsular strain. See Table 3 and the chapter on invasive H. 
influenzae disease for further details.
Listeria species
Four cases of listeriosis meningitis were notified in 2016 (age 
range 1 week to 74 years), none of whom died from their 
infections. All serotypes were identified, two were type 4b 
and one each of type 1/2a and 1/2b. Of the four cases, three 
had an underlying medical condition reported. See Table 3 
and the chapter on listeriosis disease for further details.
Streptococcus pneumoniae
In 2016, 37 cases of pneumococcal meningitis were notified, 
compared to 32 in the previous year (Table 3). The median 
age was 56 years (range two months to 83 years). Five 
pneumococcal meningitis-related deaths were reported 
during 2016. Of the 37 cases, nine were vaccinated with 
either the PCV13 (three cases aged <10 years) or PPV23 
vaccine (seven cases aged between 34-83 years), 19 were not 
vaccinated with either vaccine and nine had a vaccination 
status that was either unknown or not specified. Table 4 
1.5  Other forms of Bacterial Meningitis*    
(*excluding meningococcal disease)
Summary
Number of cases, 2016: 15 
Number of cases, 2015: 32 
Number of cases, 2014: 23 
Crude incidence rate, 2016: 0.31/100,000
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Table 1. Number and percentage of bacterial meningitis (NOS) cases reported by case classification, Ireland, 2011-2016
Case Classification 2011 2012 2013 2014 2015 2016 2011-2016
Confirmed 18 12 6 13 16 5 70
Probable 4 5 5 8 9 5 36
Possible 13 12 10 2 7 5 49
Total 35 29 21 23 32 15 155
% Confirmed 51.4% 41.4% 28.6% 56.5% 50.0% 33.3% 45.2%
Note: Meningitis related-Streptococcus agalactiae < 90 days of age excluded from 2012, 2013, 2014, 2015 and 2016 figures
Table 2. Number and percentage of bacterial meningitis (NOS) cases reported with and without an identified causative organism, Ireland, 2011-
2016
Causative Organism 2011 2012 2013 2014 2015 2016 2011-2016
Known 20 11 6 13 17 5 72
Unknown/Not specified 15 18 15 10 15 10 83
Total 35 29 21 23 32 15 155
% Known 57.1% 37.9% 28.6% 56.5% 53.1% 33.3% 46.5%
Note: Meningitis related-Streptococcus agalactiae < 90 days of age excluded from 2012, 2013, 2014, 2015 and 2016 figures
Table 3. Annual notifications of bacterial meningitis (specified and NOS) except invasive meningococcal disease, Ireland, 2011-2016
Notified under Causative organism 2011 2012 2013 2014 2015 2016
2011-
2016
Haemophilus influenzae disease (invasive) Haemophilus influenzae 4 3 2 7 5 1 22
Leptospirosis Leptospira spp. 1 1 0 0 0 0 2
Listerosis Listeria spp. 2 2 2 1 6 4 17
Streptococcus pneumoniae infection 
(invasive) Streptococcus pneumoniae 23 37 33 39 32 37 201
Streptococcus Group A infection 
(invasive) (iGAS) Streptococcus pyogenes 0 1 3 0 4 0 8
Streptococcus Group B infection 
(invasive) (Group B Strep) < 90 days of 
age
Streptococcus agalactiae† NA 11 5 5 4 2 27
Tuberculosis* Mycobacterium spp.* 2 3 3 1 2 0 11
Total Bacterial Meningitis, specified 32 58 48 53 53 44 288
Bacterial Meningitis, not otherwise 
specified
Enterococcus faecium 0 1 0 0 0 0 1
Enterococcus spp 0 0 0 1 0 0 1
Escherichia coli 1 7 4 8 15 5 40
Group C Streptococcus 0 1 0 0 0 0 1
Klebsiella oxytoca 1 0 0 0 0 0 1
Klebsiella pneumoniae 0 0 0 1 0 0 1
Micrococcus luteus 0 0 0 1 0 0 1
Pasteurella multocida 0 0 0 0 1 0 1
Staphylococcus aureus 2 1 0 0 1 0 4
Staphylococcus aureus & 
Staphylococcus capitis
0 1 0 0 0 0 1
Streptococcus agalactiae** 16 0 1 1 0 0 18
Streptococcus salivarius 0 0 1 0 0 0 1
Streptococcus suis 0 0 0 1 0 0 1
Unknown 1 2 2 1 4 3 13
Not specified 14 16 13 9 11 7 70
Total Bacterial Meningitis, not 
otherwise specified   35 29 21 23 32 15 155
Total Bacterial Meningitis, specified 
and not otherwise specified   67 87 69 76 85 59 443
*Tuberculosis meningitis figure for 2016 is provisional        
†Streptococcus agalactiae < 90 days of age in 2012 to 2016-these figures do not include 54 meningitis-related cases where the causative organism was 
isolated from or detected in CSF specimens from patients that were not clinically categorised as having ‘meningitis’     
**Streptococcus agalactiae for all ages only in 2011 and for cases > 90 days of age only in 2012 to 2016     
NA not applicable
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presents the vaccination status, serotype and additional risk 
factor, if any, for each case. See chapter on pneumococcal 
disease for further details.
Streptococcus Group B infection (invasive) (Group B Strep) < 
90 days of age
Two cases of Streptococcus agalactiae under 90 days of age 
were notified to CIDR during 2016, compared to four in 2015 
(Table 3). Both cases in 2016 were male and one week old. 
  
Table 4. Details of the 37 pneumococcal meningitis cases reported, Ireland, 2016
Age Group 
(years) Died
Vaccination 
Status
No. of PCV13 
/ Prevenar 
13 Doses
No. of PPV23 / 
Pneumovax 23 
Doses
Serotype of 
Infection
Serotype Covered by 
Vaccine Type
Additional Risk Factors 
(excluding age 65+ 
years)
<1
  N 0 0 38 Not covered NA
  NA NA NA NA . NA
1-4
  Y 3 0 10A PPV23 N
  Y 3 0 NA . N
5-9   Y 3 NA NA . N
30-34
  N 0 0 19A PCV13, PPV23 Y
  Y 0 1 NA . Y
  Y 0 1 NA . Y
  N 0 0 6C Not covered Y
40-44
  N 0 0 NA . N
  N 0 0 15C Not covered N
  NA 0 NA 19F PCV13, PPV23 Y
45-49
  N 0 0 3 PCV13, PPV23 N
  N 0 0 10A PPV23 Y
55-59
  NA 0 NA 12F PPV23 N
  N 0 0 NA . Y
  N 0 0 15B/C Undetermined Y
  N 0 0 15B/C Undetermined Y
  N 0 0 9N PPV23 Y
  NA 0 NA 11A PPV23 Y
  N 0 0 20 PPV23 Y
  N 0 0 NA . N
  NA 0 NA NA . Y
60-64
  N 0 0 NA . N
  NA NA NA 15A Not covered N
Died N 0 0 NA . N
Died U U U 19A PCV13, PPV23 N
Died NA NA NA 3 PCV13, PPV23 NA
  N 0 0 35B Not covered N
Died U U 0 NA . Y
65+
  N 0 0 NA . NA
  N 0 0 7F PCV13, PPV23 Y
  Y 0 1 23B Not covered Y
  N 0 0 15B/C Undetermined Y
Died Y 0 1 12F PPV23 Y
  Y 0 1 22F PPV23 Y
  Y 0 1 11A PPV23 Y
Vaccinated: Y=Yes, N=No; U=Unknown; NA=not applicable or not available
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Pertussis increased 1.8 fold in 2016 compared to 2015 with 
213 cases notified in 2016 (4.5/100,000) and 117 cases 
(2.5/100,000) notified in 2015 (figures 1 and 2).
Of the 213 cases in 2016, 79% (n=169) were classified as 
confirmed, seven percent (n=14) were classified as probable 
and 14% (n=30) were classified as possible.
The largest number of cases notified and the highest crude 
incidence rate was in the HSE E (table 1).
Fifty-four per cent of cases (n=114) were female and 46% 
(n=99) were male.
The largest number of cases and the highest age-specific 
incidence rate were in children aged less than one year 
followed by those in the age group 1-4 years (figures 3 and 
4). Thirty five percent (n=74/213) of all cases were aged less 
than six months of age. Fourteen percent (n=30/213) of all 
cases were aged less than two months of age.
Maternal antibodies from women immunised before 
pregnancy wane quickly and the concentration of pertussis 
1.6 Pertussis
Summary
Number of cases, 2016: 213
Number of cases, 2015: 117
Crude incidence rate, 2016: 4.5/100,000
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Figure 1. Number of notified pertussis cases in Ireland by year, 1948-2016
1948-June 2000 data collated by DoHC
July 2000-2016 data collated by HPSC
Figure 2. Number of notified pertussis cases in Ireland by year, 2000-2016
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antibodies is unlikely to be high enough to provide passive 
protection to their infants prior to primary vaccination. The 
National Immunisation Advisory Committee (NIAC) has 
recommended that pregnant women should be offered 
tetanus and low dose diphtheria and acellular pertussis 
(Tdap) vaccine as early as possible after 16 weeks and up to 
36 weeks gestation in each pregnancy, to protect themselves 
and their infant. Tdap can be given at any time in pregnancy 
after 36 weeks gestation although it may be less effective in 
providing passive protection to the infant. Tdap should be 
offered in the week after delivery to those women who were 
not vaccinated during their pregnancy.
In 2016, data on maternal antenatal vaccination status 
was provided for 74 children aged less than one year (88%, 
n=74/84). The mothers of 70 of these infant pertussis cases 
(83%, n=70/84) were unvaccinated during the antenatal 
period. Four of the mothers of the infant pertussis cases (5%, 
n=4/84) reported vaccination during the antenatal period; 
one was vaccinated at 27 weeks gestation, one at 34 weeks 
gestation, one at 38 weeks gestation while the number of 
weeks gestation at vaccination was unreported for the fourth 
case.
In Ireland, it is recommended that children be vaccinated 
with an acellular pertussis containing vaccine at two, four 
and six months of age and a booster dose at four to five
years of age. In 2008, NIAC recommended a booster with 
low dose acellular pertussis vaccine for children aged 11-14 
years. The adolescent pertussis booster was introduced into 
the school programme, in 19 LHOs, in 2011 and to all schools 
in 2012. In August 2012, an additional pertussis booster was 
recommended for health care workers and pregnant women; 
please see the HSE National Immunisation Office website at 
http://www.immunisation.ie for additional information on 
pertussis vaccination recommendations.
In 2016, the number of doses of pertussis vaccine the cases 
received was reported for 67% (n=142/213) of cases. Thirty 
seven per cent of cases (n=78/213) were unvaccinated; these 
cases ranged in age from one month to 81 years, with 73% 
(n=57/78) of these cases aged less than six months. Thirty 
six per cent of the unvaccinated cases (n=28/78) were less 
than two months of age and were therefore not eligible for 
pertussis vaccine in the Irish schedule.
Eight per cent (n=17/213) of cases were reported to have 
one dose of pertussis vaccine, these cases ranged in age 
from two months to five years. One per cent (n=3/213) had 
two doses of pertussis vaccine, these cases were six to 10 
months of age. Fifteen per cent (n=31/213) had three doses 
of pertussis vaccine, these cases ranged in age from eight 
months to 15 years. Six per cent (n=12/213) had four doses 
of pertussis vaccine, these cases ranged in age from six to 
16 years. One of the 213 cases had five doses of pertussis 
vaccine, this case was 16 years. Of the cases reported to 
have four or five doses of pertussis vaccine forty percent 
were classified as confirmed (n=5/13) and forty six percent 
(n=6/13) had four vaccine dates recorded. 
Country of birth was reported as Ireland for 69 cases, a 
country other than Ireland for three cases, and was unknown 
or not specified for the remainder (n=141).
Where data were provided, reported symptoms included 
cough (98%, n=146/149), paroxysmal cough (92%, 
n=136/148), any inspiratory whoop (64%, n=86/134), 
post-tussive vomiting (54%, n=75/140), choking episodes 
in infant (44%, n=23/52), apnoea (30%, n=40/134) and 
cyanosis (27%, n=35/130). Where data were provided, 
reported complications included conjunctival haemorrhages, 
(7%, n=9/124), pneumonia (2%, n=3/133), acute 
encephalopathy (1%, n=1/134) and seizures (0.7%, n=1/135).  
One death was reported in a seven week old child; the child’s 
mother was not vaccinated during pregnancy.
Table 1. Number of pertussis cases notified and the crude incidence 
rate per 100,000 population (CIR) by HSE Area in 2016
HSE Area Number CIR
HSE E 110 6.4
HSE M 6 2.1
HSE MW 3 0.8
HSE NE 12 2.6
HSE NW 5 1.9
HSE SE 29 5.7
HSE S 35 5.1
HSE W 13 2.9
Total 213 4.5
Figure 3. Number of notified pertussis cases in 2016 by age group and 
case classification.
‘Mo’ in graph indicates months ie 0-5 months and 6-11 months, the remaining 
age groups are in years
Figure 4. The age specific incidence rate (per 100,000 population) of 
notified pertussis cases in 2016 by case classification
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Sixty four cases were hospitalised, representing 30% 
(n=64/213) of all cases and 41% (n=64/155) of cases where 
hospitalisation data was known. Eighty three per cent 
(n=53/64) of those hospitalised were aged less than one 
year and 33% (n=21/64) were less than two months of age.
Of the 213 cases, the likely setting of exposure to pertussis 
included home (21%, n=44), other family setting (2%, n=5), 
work (1%, n=2), school (0.5%, n=1), social setting (0.5%, 
n=1), and was unreported or not specified for the remainder 
(75%, n=160).
The likely source of exposure included sibling (8%, n=16), 
other relative (5%, n=10), mother (2%, n=5), father (1%, 
n=3), and was unknown or not specified for the remainder 
(84%, n=179).
Antibiotic usage was reported for 95% (n=145/153) of cases 
where this data was provided and for 68% of all cases 
(n=145/213). A second antibiotic was known to be given 
for 28% (n=40/145) of cases and known not to be given 
for 26% (n=37/145) of cases given a first antibiotic while 
this information was not provided for the remainder (47%, 
n=68/145).
Eleven localised pertussis outbreaks were notified during 
2016, with 29 associated cases of illness. Nine outbreaks 
were associated with private houses, with 24 associated 
cases of illness, one was in a residential institution with 
three ill and one was at a scout event with two ill.
The figures presented in this summary are based on data 
extracted from the CIDR system on 24th August 2017. These 
figures may differ slightly from those published previously 
due to ongoing updating of notification data on CIDR. The 
2016 census data was used here to calculate rates.
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In 2016, one case (0.02/100,000) of rubella was notified in 
Ireland compared to two cases notified in 2015. The case 
in 2016 was in the age group <1 year and was classified 
as possible; unfortunately no samples for testing were 
obtained. These figures are based on data extracted from the 
Computerised Infectious Disease Reporting (CIDR) system 
on 25th July 2017. These figures may differ slightly from those 
published previously due to ongoing updating of data on 
CIDR.
WHO require information on discarded rubella cases ie 
rubella cases investigated and who were found not to meet 
the case definition. The HSE Areas reported the number 
of discarded CIDR cases to HPSC. For 2016, 14 cases were 
discarded from CIDR as following investigation they were 
not considered to be rubella cases. Discarded cases are not 
available in CIDR for reporting and are not included in the 
analysis above.
The Regional Verification Commission for Measles and 
Rubella Elimination (RVC) was established in the WHO 
European Region in 2011 to evaluate the documentation 
submitted by Member States with a view to verifying the 
elimination of measles and rubella at the regional level. 
The RVC has recommended establishment of national 
verification committees (NVC) in all Member States and 
suggested a standard format for annual status reports from 
countries. These reports include information on measles 
and rubella epidemiology, virologic surveillance supported 
by molecular epidemiology, the analysis of vaccinated 
population cohorts and the quality of surveillance, and 
the sustainability of the country’s National Immunisation 
Programme. The review and evaluation of annual national 
reports will continue for at least three years after the RVC 
confirms that, according to established criteria, endemic 
measles and rubella transmission have been interrupted in 
all Member States of the Region. Only then can Regional 
elimination be declared.1 
At the meetings of the European RVC for measles and 
rubella elimination, in October 2015, October 2016 and 
June 2017, the WHO European RVC concluded, that Ireland 
provided evidence for the elimination of rubella.2,3,4
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1.7 Rubella
Summary
Number of cases, 2016: 1
Number of confirmed cases, 2016: 0
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Background
Invasive Streptococcus pneumoniae infection is a notifiable 
disease in Ireland; clinicians and laboratories are legally 
obliged to notify this infection. For the purposes of this 
report the term invasive pneumococcal disease (IPD) will be 
used to describe these infections. IPD includes meningitis, 
bloodstream infection (BSI) with and without pneumonia, 
and invasive disease from other sterile sites.
Surveillance
A number of different initiatives are in place in Ireland 
for the surveillance of IPD. Data on IPD notifications are 
collated in the Computerised Infectious Disease Reporting 
(CIDR) system. Enhanced surveillance of IPD notifications 
is undertaken by Departments of Public Health. A separate 
surveillance strand (EARS-Net project) involving the 
microbiology laboratories and HPSC is used to monitor 
in detail the antimicrobial resistance profiles of invasive 
S. pneumoniae isolates from blood and/or CSF. EARS-
Net laboratories can also collect additional information, 
including risk factors, admission and outcome for each 
patient notified with S. pneumoniae isolate. These data are 
collated by HPSC through the Enhanced Surveillance of 
Bloodstream Infection (ESBSI) system. In order to improve 
data quality, regular processes for cross-checking CIDR data 
with other data sources were established in 2012. To identify 
missing IPD notifications and/or missing information CIDR 
data were linked to both the typing and ESBI databases and 
additional information on either of these systems which is 
missing or incomplete in CIDR was collated.
Since April 2007, the Irish Pneumococcal Reference 
Laboratory (IPRL) has provided a typing service to Irish 
laboratories for all invasive S. pneumoniae isolates. This is a 
collaborative project involving the Royal College of Surgeons 
in Ireland/Beaumont Hospital, the Children’s University 
Hospital, Temple Street and HPSC. In addition, since August 
2012 HPSC has participated in a European Centre for Disease 
Prevention and Control (ECDC) project called SpIDnet and 
since 2015 HPSC has joined the ECDC project I-MOVE+. 
Both projects aim to strengthen or set up long term active 
population-based IPD surveillance in order to estimate the 
direct and indirect impact of the pneumococcal conjugate 
vaccines (PCV) in all age groups: children less than five 
years of age, in those aged 5-64 years of age and in adults 
aged 65 and over in Europe. The I-Move+ study is now also 
studying the effectiveness of pneumococcal polysaccharide 
vaccine which offers protection against 23 serotypes (PPV23) 
and is recommended for those at risk of IPD and those older 
than 65 years. For more information please see following 
links to I-Move+: http://www.i-moveplus.eu/wp3 and 
SpIDnet (Epiconcept): http://www.epiconcept.fr/
Pneumococcal conjugated vaccine – use in national 
immunisation programme
In September 2008, the 7-valent pneumococcal conjugate 
vaccine (PCV7) was introduced into the Irish infant 
immunisation schedule at 2, 6 and 12 months of age. A 
catch-up campaign was also implemented at that time, 
targeting children <2 years of age. In December 2010, the 
13-valent PCV vaccine (PCV13) replaced PCV7 in the infant 
schedule. Due to the introduction of Men B vaccine in to 
routine immunisation the third dose of PCV 13 was shifted 
to 13 months of age in December 2016 for children born on 
or after 1st October 2016. Uptake of three doses of PCV by 24 
months of age for 2016 was 91%.
1.8 Streptococcus pneumoniae (invasive)
Summary
Number of confirmed cases in 2016: 381
Number of confirmed cases in 2015: 368
Number of deaths in 2016: 48
Number of deaths in 2015: 37
Crude incidence rate of confirmed cases in 2016: 
8.3/100,000
Figure 1. Number of confirmed invasive pneumococcal disease 
(IPD) notifications by typing status and the incidence rate (IR) of 
confirmed IPD with 95% confidence intervals, 2008-2016
Data source: CIDR
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Definitions
In brief, isolation or detection of S. pneumoniae from a 
normally sterile site was classified as confirmed; detection 
of S. pneumoniae antigen from urine was classified as 
possible case. Since 2012, the previously used probable case 
definition is no longer applicable and any case in which 
S. pneumoniae antigen was detected from urine (previously 
defined as a probable case) was classified as possible, 
and antigen detection from a sterile site was categorised 
as confirmed. Since July 2015, the case definition of S. 
pneumoniae was amended and only those cases of IPD 
meeting the laboratory criteria for laboratory confirmed are 
now notifiable and urinary antigen detection (possible cases) 
are no longer notifiable.
PCV vaccine failure was defined as confirmed IPD case in a 
child caused by a PCV-serotype who has completed a PCV 
immunisation course appropriate for his age and disease 
onset is ≥ 14 days after last dose of PCV.
For this report notification data for IPD was extracted from 
CIDR on 3rd May 2017. These figures may differ slightly from 
those previously published due to ongoing updating of 
notification data on CIDR. For the 2012 - 2014 notifications, 
the 2012 HPSC case definition for IPD was used. For 
calculation of incidences 2011 CSO data were used.
Results
All ipd notifications
In 2016, 381 cases of IPD (8.3/100,000) were notified 
in Ireland, a decrease compared with 2015 (549 cases; 
12.0/100,000). This decrease is related to an absence of 
possible cases notified in 2016 in comparison to 2015 due 
to case definition changes. Since July 2015 only confirmed 
cases have been notifiable. Consequently, in 2016 all 
notifications were classified as confirmed. 
confirmed ipd notifications
Focusing specifically on the confirmed IPD notifications 
only, 381 cases were notified in 2016 (8.3/100,000; 95% CI 
7.5 - 9.1/100,000), a slight increase (not significant) in the 
number of cases compared with 2015 (8.0/100,000; 95% 
CI 7.2 - 8.8/100,000; 368 cases) (Figure 1). In 2016, the 
incidence of confirmed IPD decreased by 10% compared with 
2008 (9.5/100,000; 95% CI 8.6 – 10.5/100,000; 404 cases; 
p<0.05) (Figure 1).
In 2016, 84% of the confirmed IPD notifications had an 
isolate submitted for serotyping, more than the proportion of 
cases in 2015 (77%), 2014 (81%), and 2008 and 2009 when 
79% of notifications had an isolate typed. In 2012, 86% of all 
isolates were typed (Figure 1). In 2016, 40% of notifications 
(17/42) relating to children <5 years of age did not have an 
isolate submitted for serotyping. For six of the 17 cases IPD 
was confirmed by PCR only and no isolate was available. For 
the remaining eleven isolates (26%; 11/42) from a sterile site, 
no sample was available for typing.
During 2016, incidence rates by HSE area ranged from 6.1 per 
100,000 (HSE W) to 10.2 per 100,000 (HSE SE,) (Figure 2). 
However, the incidence rates in each of the eight HSE areas 
were not statistically different from the national one.
In 2016, a clinical diagnosis was reported for 313 of the 381 
confirmed cases (82%), which included BSI with pneumonia 
(n=222), meningitis (n=37), and other BSI for the remainder 
(n=54). This reflects an improvement in completeness of 
data provided in comparison to 2015 and 2014, when the 
clinical diagnosis was reported for 229 of the 368 (62%) and 
168 of the 350 (48%) confirmed cases respectively, 20% 
more than in 2015 and 34% than in 2014. 
More cases occurred in males (n=207, 54%) than in females. 
The median age of cases was 64 years (range 1 month to 94 
years). Those aged 65 years and older accounted for half of 
the cases (49%, n=188). Within this age category the age 
specific incidence rate (ASIR) was highest in the oldest age 
groups; >85 years of age (75.3/100,000; n=44); 75-84 year 
age group (43.6/100,000; n=75); 65-74 year age group 
(22.3/100,000; n=68) (Figure 3). In children <2 years of age 
the ASIR was 17.2 cases per 100,000 population (n=26). 
A statistically significant decline (60%) in IPD incidence 
was seen in this age group when compared with 2008 
(42/100,000; n=52; p<0.0001), highlighting the positive 
impact of the introduction of PCV7 and PCV13 in 2008 and 
2010 respectively (Figure 3). 
Medical risk factor for IPD was reported for 256 (67%) 
confirmed cases; 65 cases (17%) did not have an identified 
risk factor; for the remaining 60 cases this information was 
either unknown or not specified. The main medical risk 
factors reported included immunosuppressive condition or 
therapies (n=54; 21%), chronic lung disease (n=59; 41%), 
chronic heart disease (n=101; 39%), chronic liver disease 
Figure 2. Crude incidence rate of confirmed invasive pneumococcal 
disease notifications by HSE area, 2016
Data source: CIDR
Figure 3. Age specific incidence rate of confirmed invasive 
pneumococcal disease notifications by age group, 2008-2016
Data source: CIDR
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(n=21; 8%) and renal diseases (n=19; 7%). It should also 
be noted that being aged 65 years and older is also a 
recognised IPD risk factor; 188 (49%) cases in 2016 were in 
this age group, of whom 153 (81%) also reported a medical 
risk factor.
ipd death notifications
Outcome was reported in 85% (n=323) of the IPD 
notifications in 2016 versus 56% in 2015 and 39% in 2014. 
Among those whose outcome was reported, case fatality 
among IPD notifications was overall 18.8% (61/323); for 
27 (8.3%) case-patients the cause of death was reported 
as directly due to IPD, in 13 case-patients it was not due 
to IPD and for the remaining 21, the cause of death was 
not specified or was unknown. Most of these deaths (60) 
occurred in adults (age range 36-94 years) and one in a child 
(<3 years of age). All deaths were in confirmed cases. 
The increased completion in the reported outcome field 
since 2014 reflects improve enhanced data collection 
undertaken by the public health staff in the HSE areas 
as well as the input of a HPSC based research nurse who 
is funded by the EU projects (SpIDnet and IMOVE+). 
Additionally by linking CIDR data to the ESBI database it has 
been possible to identify missing outcome information in 
CIDR which can then be updated by HSE areas.
Impact of pneumococcal conjugate vaccines (PCV)
Serotyping data from the IPRL were used to assess the 
impact of the PCV programme on the distribution and 
burden of S. pneumoniae serotypes associated with IPD. 
In 2016, of the 381 confirmed IPD notifications reported in 
CIDR, 318 (84%) had isolates sent for serotyping; 4% of IPD 
infections were due to PCV7 serotypes (4, 6B, 9V, 14, 18C, 
19F and 23F); 20% were associated with the six additional 
serotypes included in PCV13 (1, 3, 5, 6A, 7F and 19A); the 
remaining 76% of infections were due to non-vaccine types 
(NVTs). 
Since introducing PCV7 to the Irish childhood immunisation 
schedule towards the end of 2008, there has been a 
substantial reduction in the overall burden of IPD disease. 
Reductions in the incidence of IPD due to PCV7 serotypes 
have been seen in all age groups (Figure 4a). Overall, the 
incidence of IPD due to PCV7 serotypes has significantly 
declined in 2016 compared with 2008 (90% decline, p<0. 
001). The greatest impact has been seen in children <5 
years of age where the incidence due to PCV7 serotypes 
has declined by 100% (p<0. 001) (Figure 4a). In 2016 the 
incidence of disease due to the additional six serotypes 
covered by the PCV13 declined by 90% in children <2 years 
of age compared with 2008 (Figure 4b). The decline was 
also observed in the other age groups with these additional 
six serotypes compared with 2008; however, this decline 
was not significant (Figure 4b). An increase in incidence 
due to NVTs was also seen in 2016 compared with 2008. In 
those aged <2 years and 65 years and older, an increase in 
incidence was observed in 2016 compared with 2015. There 
has been little change in the incidence of NVTs among other 
age groups (Figure 4c). 
The predominant serotypes in circulation in 2016, were 8 
and 12F (NVT), 19A and 3 (both included in PCV13), followed 
by serotypes 33F and 22F (both NVT). In children <5 years 
of age, the predominant serotypes were 19A and 3 (included 
in PCV13); 24F, 38, 33F, 35F and 23B (all NVTs). All these 
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Figure 4. Age specific incidence rate by age group of confirmed 
invasive pneumococcal disease cases due to (a) PCV7 serotypes, (b) 
the additional six serotypes covered by PCV13 and (c) non-vaccine 
types , 2008-2016. 
Data source: Irish Pneumococcal Reference Laboratory
Figure 4a Figure 4b
Figure 4c
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serotypes accounted for 69% of the isolates serotyped in this 
age group (Figure 5).
For ongoing updates, see “Slides – Impact of PCV in 
Ireland” at http://www.hpsc.ie/A-Z/VaccinePreventable/
PneumococcalDisease/PostersPresentations/
PCV vaccine failures
Based on data obtained through the IPD enhanced 
surveillance system, two PCV vaccine failures were reported 
in 2016, one due to serotype 19A and one due to serotype 7F 
(both included in PCV 13). Since 2008, a total of 13 vaccine 
failures have been reported in addition to the two reported 
in 2016, two in 2015 (19A) two in 2014 (19A), three in 2013 
(19A), two in 2012 (19F and 19A) and two in 2010 (19F and 
14). 
Penicillin non-susceptible S. pneumoniae (PNSP)
In 2016, the proportion of penicillin non-susceptible invasive 
S. pneumoniae (PNSP) was 16.5%, (0% and 16.5% with high 
and intermediate level resistance, respectively) while 13.2% 
of isolates were resistant to erythromycin (Data source: 
HPSC/EARS-Net Ireland). This compares to 17.5% and 
15.2% in 2015, respectively. In 2016, the proportion of PNSP 
decreased slightly compared to 2015, and the overall trend 
for the past four years has been downward. In 2016, the 
proportion of S. pneumoniae with resistance to erythromycin 
decreased compared to 2015, and the overall trend for the 
past four years has been downward.
The predominant PNSP serotypes in 2016 were 8, 
12F, 3 and 19A, whereas in 2008 serotypes 9V and 
14 were the predominant serotypes associated with 
PNSP. For details on the antimicrobial resistance 
patterns of S. pneumoniae, please see the link on 
EARS-Net Report, Quarters 1-4 2016 https://www.
hpsc.ie/a-z/microbiologyantimicrobialresistance/
europeanantimicrobialresistancesurveillancesystemearss/ea
rsssurveillancereports/2016reports/EARS-Net%20annual-
quarterly%20data%20summary%20sheet_website_2016Q4.
pdf
Laboratory survey
During 2016, in collaboration with the IPRL we undertook 
a survey of Irish clinical laboratories in relation to testing, 
diagnosis and notification of IPD in order to assess the 
quality and completeness of the national IPD surveillance 
programme. 
Thirty-five of the 39 clinical microbiology laboratories 
participated (response rate 89.7%). Most laboratories (94%) 
had notification systems and processes in place to ensure 
that all IPD cases were notified. Most (91.4%) sent isolates to 
the IPRL for serotyping, with most (71.4%) sending isolates 
as soon as culture was positive. Based on the results of 
this survey it is evident that national IPD surveillance is 
comprehensive, however some potential gaps in notification 
and referral for serotyping were identified which will be 
addressed in 2017, with all laboratories encouraged to send 
isolates on a timely and regular basis to the IPRL. 
Discussion
There was a slight increase (not significant) in the incidence 
of confirmed cases of IPD in Ireland in 2016 compared 
with 2015. Since its introduction in 2008, PCV7 has had 
a significant impact in reducing the overall burden of the 
disease in the total population. There has been a decline 
in IPD in all age groups due to serotypes covered by PCV7, 
indicating the indirect/herd immunity effect the vaccine 
confers on the population. The greatest impact has been 
in children <5 years of age where disease incidence due 
to PCV7 serotypes has fallen by 100%. The impact due 
to additional six serotypes covered by PCV13 vaccine was 
observed in children <2 years of age, amongst whom the 
reduction in the incidence of disease was 60%.
However, despite reductions in the IPD burden during 
childhood, the incidence of disease due to non-PCV7 
serotypes has increased in other age groups. There has been 
a shift in the prevalent serotypes associated with invasive 
disease. Serotypes 8, 19A and 12F were the predominant 
serotypes identified in 2016. 
Ireland’s (HPSC’s) participation in the EU funded projects, 
SpIDnet (since 2012) and I-Move+ (since 2015) is supporting 
efforts to strengthen IPD surveillance in Ireland. Through 
this project additional support for the collection of enhanced 
surveillance data that has been possible in a number of HSE 
regions. This has resulted in improved data collection for all 
cases (paediatric and adults). As a result, at national level it 
Figure 5. Serotype distribution of invasive Streptococcus pneumoniae isolates by age 
group (years) in Ireland, 2016
* Denotes serotypes included in PCV7
*^ Denotes additional six serotypes included in PCV13 (PCV13-7)
Data source: Irish Pneumococcal Reference Laboratory
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is evident that a greater proportion of IPD notifications now 
have data on clinical presentation, risk factors, outcome and 
vaccination history. 
To accurately assess the impact of PCV on immunisation 
programmes and to monitor for vaccine failures in Ireland, 
it is crucial that samples from sterile sites are obtained 
for culture and susceptibility. Isolates obtained by culture 
are required for serotyping and antibiotic susceptibility. 
Furthermore it is crucial that laboratories continue to 
send all invasive S. pneumoniae isolates for typing to the 
IPRL. Although 84% of confirmed notifications had an 
isolate submitted for serotyping in 2016, 16% (n=64) did 
not, including 17 cases in children <5 years of age. In six 
of these 17 cases, an isolate was not available for typing 
and confirmation was by PCR only. Serotype information is 
unavailable for 26% of confirmed notifications in this age 
group and the absence of this data is of concern.
Continued good quality IPD surveillance including the 
monitoring of invasive S. pneumoniae serotypes is crucial in 
identifying any epidemiological changes in the disease, in 
assessing the impact of PCV13 and PPV23 on public health 
and in guiding further vaccination strategies, including 
expanded valency vaccines.
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Diphtheria is an acute infectious disease affecting the upper 
respiratory tract and occasionally the skin. It is caused 
by toxigenic strains of Corynebacterium diphtheriae, an 
aerobic, pleomorphic, Gram-positive bacillus. Occasionally 
the disease may also be caused by C.ulcerans or 
C.pseudotuberculosis. Before introduction of immunisation, 
epidemics occurred every 10 years, with mortality rates of up 
to 50%. Effective protection against the disease is provided 
by active immunisation.
One case of non-fatal diphtheria was notified in 2016. The 
case, an unvaccinated male, aged 45-55 years was classified 
as confirmed. The case reported travel to an Asian country 
where there is a high incidence of diphtheria. C. diphtheriae 
(toxin producing) was isolated from a skin ulcer. The case did not 
develop any systemic complications associated with the disease 
but was hospitalised and treated for the illness.
The case that was reported in 2015 was female, aged 
45-54 years, with no history of travel outside Ireland. 
This case presented with a skin wound that was culture 
positive for C.ulcerans (toxin producing). This latter case 
had an uncertain history of diphtheria vaccination. No 
epidemiological links to persons or animals with the 
organism could be identified for this case. 
Summary of diphtheria epidemiology since 1948:
Since the 1940s the number of diphtheria cases has declined 
markedly, no cases were notified between 1968-2014 (Figure 
1). In 2015 one case was notified, with another case notified 
in 2016 (Figure 2 shows data from 1963 to 2016). 
Vaccination with five doses of diphtheria is recommended for 
all children and adolescents. The primary series (consisting 
of three doses of a diphtheria containing vaccine) is normally 
given in the first year of life. A booster is recommended at 
4-5 years of age and another at 11-14 years of age. Almost 
100% of vaccinated persons achieve protective antibody 
levels. However, immunity decreases with age and, with time 
since vaccination; over 50% may have insufficient protection 
10 years after a booster diphtheria vaccine. Additional 
booster doses (as ‘Tdap’) may be given every 10 years for life.
For further information on diphtheria vaccination please see 
the HSE National Immunisation Office website at   
www.immunisation.ie.
The figures presented in this report are based on data 
extracted from the Computerised Infectious Disease 
Reporting (CIDR) system on 8th December, 2017.
1.9 Diphtheria
Summary
Number of cases, 2016: 1
Number of cases, 2015: 1
Figure 1. Diphtheria cases notified from 1948 to 2016 Figure 2. Diphtheria cases notified from 1963 to 2016
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2.1  Influenza and other Seasonal Respiratory 
Viruses
2016/2017 influenza season summary: 
-38-HPSC Annual Epidemiological Report 2016 2. Respiratory and Direct Contact Diseases
Peak influenza-like illness rate: 90.4/100,000 population
Influenza predominant type/subtype: Influenza A(H3N2)
Confirmed influenza cases hospitalised: 1425
Confirmed influenza cases admitted to ICU: 51
Total notified influenza cases that died: 95
Excess mortality in those aged 65 years and older: Weeks 49 
2016 - 4 2017 
Number of acute respiratory infection/influenza outbreaks: 111
 
HPSC has worked in collaboration with the National 
Virus Reference Laboratory (NVRL), the Irish College of 
General Practitioners (ICGP) and the Departments of Public 
Health on the influenza sentinel surveillance project since 
2000. During the 2016/2017 influenza season, 61 general 
practices (located in all HSE-Areas) were recruited to report 
electronically, on a weekly basis, the number of patients 
who consulted with influenza-like illness (ILI). Sentinel GPs 
send combined nose and throat swabs to the NVRL from ILI 
patients each week. The NVRL routinely test sentinel GP and 
non-sentinel respiratory specimens for influenza and a panel 
of other respiratory viruses.  
Other surveillance systems set up to monitor ILI/influenza 
activity include: 
•   Surveillance of all calls to GP out-of-hours (OOHs) centres, 
monitored for self-reported influenza. These data were 
provided by HSE-NE.  
•   Surveillance of all confirmed influenza notifications, 
including hospitalisation status reported to the 
Computerised Infectious Disease Reporting System (CIDR) 
in Ireland 
•   Enhanced surveillance of hospitalised influenza cases 
aged 0-14 years   
•   Intensive Care Society of Ireland (ICSI) and the Critical 
Care Programme (CCP) enhanced surveillance of all 
critical care patients with confirmed influenza 
•   Surveillance of all reported influenza deaths
•   All-cause excess mortality monitoring associated with the 
European mortality monitoring group (EuroMOMO)
•   A network of sentinel hospitals reporting admissions data
•   Acute respiratory infection and influenza outbreak 
surveillance 
•   Monitoring influenza vaccine effectiveness (I-MOVE study)
This report summarises influenza and other seasonal 
respiratory virus activity in Ireland during the 2016/2017 
influenza season. The 2016/2017 season commenced on 3rd 
October 2016 (week 40 2016) and ended on 21st May 2017 
(week 20 2017). The data presented in this summary were 
based on all data reported to HPSC by the 18th December 
2017. 
Sentinel GP Clinical Data
Influenza activity reported from the sentinel GP network in 
Ireland was at moderate intensity levels for all ages, and very 
high intensity levels for those aged 65 years and older during 
the 2016/2017 influenza season. Sentinel GP ILI consultation 
rates peaked at 90.4 per 100,000 population during week 1 
2017 (the first week in January), the highest peak rate since 
the 2010/2011 season (figure 1). ILI rates first increased 
above baseline levels (18.3 per 100,000) during week 49 
2016 and remained there for nine consecutive weeks, which 
is the average length of time above baseline in Ireland. ILI 
rates for all ages were above the medium intensity levels 
during weeks 1 and 2 2017 (figure 1). The highest age specific 
ILI rates were reported in those aged 65 years and older 
(peaking at 115.0/100,000), followed by the 15-64 year age 
group (peaking at 105.4/100,000). It is notable that the 
age specific rates in those aged 65 years and older were the 
highest ever reported and the peak rate during week 1 2017 
exceeded the very high intensity threshold level for this age 
group. 
Virological Data from National Virus Reference Laboratory 
(NVRL) – Influenza 
Sentinel GP data: The NVRL tested 943 sentinel GP 
specimens for influenza virus during the 2016/2017 season. 
Four hundred and twenty (44.5%) sentinel specimens were 
positive for influenza: 407 influenza A (403 A(H3N2) and 4 
A not subtyped) and 13 influenza B. There were no influenza 
A(H1N1)pdm09 influenza positive specimens detected by 
the sentinel GP network during the 2016/2017 season. 
Ninety seven percent of all confirmed influenza sentinel 
cases were positive for influenza A and 3% for influenza B. 
Of subtyped influenza A specimens, 100% were positive for 
influenza A(H3N2). Overall, 83% of ILI patients (with known 
vaccination status) were not vaccinated with the  2016/2017 
influenza vaccine. Only three ILI patients were reported as 
having commenced antiviral treatment. 
Non-sentinel data: The NVRL tested 11,245 non-sentinel 
respiratory specimens during the 2016/2017 season, 1429 
(12.7%) of which were positive for influenza: 1361 influenza A 
(1304 A(H3N2), 5 A(H1N1)pdm09  and 52 A (not subtyped)) 
and 68 influenza B. Ninety-five percent of all confirmed 
influenza non-sentinel cases were positive for influenza A 
and 5% were positive for influenza B. Of subtyped influenza 
A specimens, 99.6% were positive for influenza A(H3N2). 
Influenza A(H3N2) was the predominant influenza virus 
circulating during the 2016/2017 season. Influenza A 
accounted for 96% of all influenza positive specimens and 
influenza B for 4%. Of the 1712 influenza A sentinel and non-
sentinel specimens that were subtyped, influenza A(H3N2) 
accounted for 99.7% and influenza A(H1N1)pdm09 for 0.3%. 
In total 1707 positive influenza A(H3N2) specimens were 
detected by the NVRL during the 2016/2017 season, this 
is the highest number of A(H3N2) viruses detected since 
this surveillance system began in 2000. Influenza positive 
specimens peaked during week 1 2017, with a total of 353 
influenza positive specimens taken from patients during this 
week.
Influenza Virus Characterisation: 
For the 2016/2017 influenza season, genetic characterisation 
of influenza viruses circulating in Ireland was carried out 
by the NVRL, on 117 influenza A(H3N2), one influenza 
A(H1N1)pdm09 and eight influenza B positive specimens. 
The majority of A(H3N2) viruses (72%, n=84/117) clustered 
in the genetic subclade 3C.2a1, a group represented by A/
Bolzano/7/2016 and characterised by the hemagglutinin 
amino acid mutation N171K, often with N121K. Group 3C.2a1 
was the dominant strain in Europe during the 2016/2017 
season. Antigenic characterisation confirmed that these 
viruses were antigenically similar to the 2016/2017 
vaccine strain, 3C.2a. Of particular interest in Ireland, 
14.5% (17/117) of characterised A(H3N2) viruses clustered 
within the genetic subgroup 3C.3a, represented by A/
Switzerland/9715293/2013 (the strain included in the 
2015/2016 Northern Hemisphere vaccine), and had amino 
acid substitutions Q197K, S198P and S312N in HA1 antigenic 
sites B and C. 3C.3a viruses were rarely idenitfied elsewhere 
in Europe during the 2016/2017 season, representing less 
than 1% of circulating A(H3N2) viruses characterised. A 
further 16 A(H3N2) viruses (16/117; 14%) fell in the 2016/2017 
vaccine component clade 3C.2a, represented by A/Hong 
Kong/4801/2014, the strain also recommended for the 
2017/2018 vaccine. The 3C.2a viruses detected in Ireland 
fell into two clusters – one associated with N144K and one 
with R261Q. Influenza A(H1N1)pdm09 was infrequently 
detected in Ireland during the 2016/2017 season. One 
A(H1N1)pdm09 virus was characterised  and belonged to the 
6B.1 genetic clade, represented by A/Michigan/45/2015. 
Antigenic characterisation data has found this group to be 
antigenically indistinguishable from the 2016/2017 vaccine 
strain. The A/Michigan/45/2015 virus was selected for 
inclusion in the 2017/2018 Northern Hemisphere vaccine. 
Eight influenza B viruses were genetically characterised, 
Figure 1: ILI sentinel GP consultation rates per 100,000 population, baseline ILI threshold, medium and high intensity ILI thresholds1 and 
number of positive influenza A and B specimens tested by the NVRL, by influenza week and season. Source: Clinical ILI data from ICGP and 
virological data from the NVRL. 
1  For further information on the Moving Epidemic Method (MEM) to calculate ILI thresholds: http://www.ncbi.nlm.nih.gov/pubmed/22897919
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seven of which were B/Yamagata lineage viruses and one 
belonged to the B/Victoria lineage. All B/Yamagata viruses 
clustered in clade 3 represented by B/Phuket/3073/2013. 
The influenza B/Victoria lineage virus fell into the 1A 
group represented by B/Brisbane/60/2008, the virus 
recommended for the 2017/2018 vaccine. 
http://www.who.int/influenza/vaccines/virus/
recommendations/en/
Virological Data from NVRL - Other seasonal respiratory 
viruses 
During the 2016/2017 season respiratory syncytial virus 
(RSV) was at very high levels, with 1228 (10.9%) positive 
detections reported from non-sentinel sources, peaking 
during mid-December 2016. High levels of adenovirus 
(n=336; 3.0%), human metapneumovirus (hMPV) (n=345; 
3.1%) and parainfluenza virus (PIV) type 3 (n=273; 2.4%) 
were also reported during the 2016/2017 season. In addition, 
64 PIV-4, 24 PIV-2 and seven PIV-1 positive detections were 
reported during the season. RSV, adenovirus, hMPV and 
PIV-3 positive detections reached the highest numbers ever 
reported by the NVRL for any season. 
Of the 943 sentinel GP specimens tested during the 
2016/2017 season, 45 (4.8%) were positive for RSV, 32 
(3.4%) hMPV, 15 (1.6%) adenovirus, 10 (1.1%) PIV-3, four 
(0.4%) PIV-2 and four (0.4%) PIV-4. There were no positive 
detections of PIV-1 from sentinel GP sources during the 
2016/2017 season. 
The total number of sentinel GP and non-sentinel specimens 
positive for seasonal respiratory viruses (including influenza, 
RSV, adenovirus, hMPV and parainfluenza virus types 1-4) 
peaked during week 1 2017 at 457. It should be noted that 
these data reported from the NVRL are analysed by the date 
the specimens were taken from patients.   
Outbreaks
For the 2016/2017 season, 111 acute respiratory infection 
(ARI) and influenza outbreaks were notified to HPSC, 66 of 
which were associated with influenza A, four associated with 
influenza B, 21 with influenza (type/subtype not reported), 
four associated with RSV, two with human metapneumovirus 
(hMPV), one with parainfluenza virus and 13 ARI outbreaks 
with no pathogens identified. Of the 91 influenza outbreaks 
reported during the 2016/2017 season, the majority were 
in residential care facilities/community hospitals, mainly 
associated with influenza A and affecting those aged 65 
years and older. All influenza A subtyped outbreaks were 
associated with influenza A(H3N2). The majority of outbreaks 
were notified from HSE-east and –south, table 1. Seventy-
nine influenza outbreaks were reported from residential 
care facilities/community hospitals, 11 from acute hospital 
settings and one outbreak occurred on a coach tour. In total 
35 deaths were recorded associated with these 91 influenza 
outbreaks. For all ARI and influenza outbreaks, vaccination 
status was reported for patients from nine residential care/
healthcare facilities, with over 79% (296/374) of patients 
vaccinated prior to these outbreaks. Vaccination status was 
reported for staff from only six residential care/healthcare 
facilities, with only 17% (53/309) of staff reported as 
vaccinated prior to these outbreaks.Further information on 
influenza vaccine uptake is detailed in the Immunisation 
uptake chapter of the HPSC Annual Epidemiological Report, 
2016. 
GP Out-Of-Hours (OOHs)
The percentage of influenza-related calls to GP out-of-
hours services in Ireland, peaked during week 1 2017 at 7.7%, 
coinciding with the peak in sentinel GP ILI consultation rates. 
The peak in influenza-related calls was the highest peak 
since the 2010/11 season. During the peak of activity, each 
service received on average 2.3 calls per hour relating to 
influenza.
 
Sentinel hospital admissions 
Hospital respiratory admissions reported from a network 
of sentinel hospitals during the 2016/2017 season, peaked 
at 599 during week 52 2016. This is the highest peak level 
in recent years. The peak coincided with high levels of 
influenza activity. Total emergency admissions reported from 
sentinel hospitals peaked during weeks 47 (n=3056) and 
48 (n=3050) 2016, coinciding with peak RSV activity and 
elevated influenza activity. 
Influenza and RSV notifications
A total of 3336 influenza notifications were reported on 
Ireland’s Computerised Infectious Disease Reporting System 
(CIDR) during the 2016/2017 influenza season; less than the 
2015/2016 season (n=4252). Of the 3336 notifications, 3299 
were reported as confirmed cases, 16 probable cases and 
21 possible cases. Of the 3299 confirmed influenza cases, 
1632 (49.5%) were positive for influenza A(H3N2), 7 (0.2%) 
influenza A(H1N1)pdm09, 1514 (45.9%) influenza A (not 
subtyped), 138 (4.2%) influenza B and 8 (0.2%) were notified 
with influenza type/subtype not recorded. Of the 1639 
confirmed influenza A cases subtyped, 99.6% were influenza 
A(H3N2). A total of 2583 RSV notifications were reported to 
HPSC during the 2016/2017 season; the highest number of 
RSV notifications reported since RSV was made notifiable in 
2012. 
Table 1: Number of influenza outbreaks by HSE-Area for the 2016/2017 influenza season (n=91). 
HSE-Area No. of outbreaks Total number ill Total number lab confirmed
Total number 
hospitalised Total number dead
HSE-E 26 241 69 28 4
HSE-M 5 63 22 3 4
HSE-MW 10 134 32 18 3
HSE-NE 8 98 31 7 1
HSE-NW 8 107 29 8 3
HSE-SE 7 121 33 17 6
HSE-S 22 354 42 14 10
HSE-W 5 39 22 25 4
Total 91 1157 280 120 35
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Confirmed influenza cases hospitalised 
During the 2016/2017 season, 1425 confirmed influenza 
cases (30/100,000 population) were reported as 
hospitalised; 43% of all confirmed influenza notified 
cases. The highest age specific rates in hospitalised cases 
for the 2016/2017 season were in those aged less than 
one year of age (n=74; 118.9 per 100,000 population) and 
those aged 65 years and older (n=699; 109.6 per 100,000 
population) (table 2). The age specific rates in those aged 
65 years and older were at the highest rate ever recorded 
in this age group, with 46% (319/699) of cases in this age 
group notified in the first two weeks of January. Of the 1425 
hospitalised cases, 1361 (95.5%) were confirmed influenza 
A cases, 59 (4.1%) were influenza B cases and five (0.4%) 
influenza cases were notified with no influenza type/subtype 
recorded. Of the 567 subtyped influenza A cases, 99.5% 
were influenza A(H3N2) and only 0.5% were influenza 
A(H1N1)pdm09.  Further data on confirmed influenza 
hospitalised cases for are detailed in tables 1-4. 
Enhanced surveillance hospital data on 0-14 year age group 
A total of 470 confirmed influenza cases aged between 
0 and 14 years were notified on CIDR for the 2016/2017 
influenza season, 268 (57%) of these cases were 
hospitalised. Over 95% (n=255) of hospitalised cases 
were positive for influenza A [118 A(H3N2) and 137 A (not 
subtyped)] and 5% (n=13) were positive for influenza B. The 
median age of cases was 2 years. Over 69% of cases were 
aged between 0 and 4 years, with 27% of cases aged less 
than one year. The most frequently reported symptoms 
included: fever (92.7%), cough (87.3%) and fatigue (70%). 
The most frequently reported complications included 
primary influenza viral pneumonia, secondary bacterial 
pneumonia, and other respiratory complications. The 
median length of stay in hospital was 2 days (ranging from 
1 - 28 days). Approximately, 49% of hospitalised cases in 
this age group were reported as belonging to a risk group 
for influenza, with chronic respiratory disease (including 
asthma) being the most frequently reported risk group. Of 
the 84 cases with reported underlying medical conditions 
and known vaccination status, 88% were not vaccinated. 
Approximately, 45% of cases (81/182) commenced antiviral 
treatment. Additional surveillance data on paediatric cases 
admitted to critical care units are detailed below.
Confirmed influenza cases admitted to ICU  
Of the 1425 hospitalised confirmed influenza cases reported 
during the 2016/2017 influenza season, 51 (4%) were 
admitted to critical care units (37 adults and 14 paediatric 
cases). Of the 51 critical care cases, 23 (45.1%) were infected 
with influenza A(H3N2), 22 (43.1%) with influenza A (not 
subtyped) and 6 (11.8%) with influenza B. No influenza 
A(H1N1)pdm09 critical care cases were notified during the 
2016/17 season. Age specific rates for patients admitted 
to critical care units were highest in those aged 65 years 
and over (4.5 per 100,000 population) (table 2). The 
overall median age of all cases was 67 years. Underlying 
medical conditions were reported for 33 adults. The most 
frequently reported underlying medical conditions for 
adults were chronic heart disease (23/33, 69.7%) and 
chronic respiratory disease (18/33, 54.5%). No adult cases 
were reported as pregnant. Nineteen (51%) adult cases 
were reported as current/former smokers and two (5%) 
adult cases were reported to have alcohol related disease. 
Six paediatric cases were reported to have the following 
underlying medical conditions: neurological/neuromuscular, 
respiratory, cardiovascular and metabolic conditions. Thirty-
three adult and six paediatric cases were ventilated during 
their stay in critical care units. The median length of stay in 
critical care for adult cases was 5 days and for paediatric 
cases 3 days. Of the 24 adult cases with known vaccination 
status, 58% were not vaccinated. Of the 12 paediatric cases 
with known vaccination status, 92% were not vaccinated. 
Eighty-four percent of all cases were reported to have 
received antiviral therapy. Seventeen adult (17/37; 46%) 
and three paediatric (3/14; 21%) cases admitted to critical 
care units during the 2016/2017 season died, giving a case 
fatality rate of 39%. 
Mortality data 
During the 2016/2017 influenza season, of the 3336 
influenza cases notified, 95 (2.9%) cases were reported 
as having died. The case classification was confirmed for 
87 of these cases, probable for one case and possible for 
seven cases. Of the 87 cases with known virology, 46 were 
associated with influenza A(H3N2), 36 with influenza A (not 
subtyped), one with influenza B and four with influenza 
type/subtype not recorded. No influenza A(H1N1)pdm09 
associated deaths were reported. Influenza was reported 
as a cause of death (either on the death certificate or by 
the physician) for 68 cases. The median age of cases who 
died during the 2016/2017 influenza season was 80 years 
(interquartile range: 73-87). Cumulative excess all-cause 
mortality was reported in those aged 65 years and older for 
Table 2: Age specific rate for confirmed influenza cases hospitalised and admitted to critical care during the 2016/2017 influenza season. Age 
specific rates are based on the 2016 CSO census.
Hospitalised Admitted to ICU
Age (years) Number Age specific rate per 100,000 pop. Number Age specific rate per 100,000 pop.
<1 74 118.9 2 3.2
1-4 111 41.2 6 2.2
5-14 83 12.3 5 0.7
15-24 54 9.4 1 0.2
25-34 106 16.1 1 0.2
35-44 82 12.4 1 0.1
45-54 88 14.1 1 0.2
55-64 126 24.8 5 1.0
≥65 699 109.6 29 4.5
Unknown 2 − 0 −
Total 1425 29.9 51 1.1
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eight consecutive weeks between weeks 49 2016 and 4 2017, 
reaching higher levels than previously recorded. 
Summary tables of confirmed influenza hospitalised and 
critical care cases and notified influenza-associated deaths 
for all ages are detailed in 2-5.
Overview of the 2016/2017 season 
In Ireland, the 2016/2017 influenza season commenced and 
peaked earlier than usual, with a peak in the first week in 
January. The season was characterised by almost complete
predominance of influenza A(H3N2), which resulted in 
higher incidence of severe disease for those aged 65 years 
and older. The impact of influenza during the 2016/2017 
season resulted in high hospitalisation rates in older 
age groups, an older median age of hospitalisation and 
admission to critical care units, a large number of outbreaks 
in residential care facilities and excess mortality in older 
age groups. This is in contrast to the 2015/2016 influenza 
season, when influenza A(H1N1)pdm09 predominated and 
mainly affected younger age groups.  
Sentinel GP ILI consultation rates were above baseline 
levels for nine consecutive weeks during the 2016/2017 
season, which is the average length of time ILI rates remain 
above baseline in Ireland. ILI rates were at the highest 
levels reported since the 2010/2011 season, with rates in 
those aged 65 years and older exceeding the very high 
intensity level threshold for this age group for the first time 
since surveillance began in 2000. The NVRL reported the 
highest number of influenza A(H3N2) viruses detected since 
surveillance began in 2000. Very high levels of RSV and 
high levels of adenovirus, human metapneumovirus and 
parainfluenza virus type 3 were also observed during the 
2016/2017 season, compared to recent seasons.
The vast majority of influenza A(H3N2) viruses circulating in 
Ireland and Europe during the 2016/2017 season, belonged 
to the genetic subclade, 3C.2a1, a subclade that remained 
antigenically similar to the 2016/2017 vaccine strain, 3C.2a. 
Both the vaccine clade (3C.2a) and subclade (3C.2a1) are 
rapidly evolving and require close monitoring. For the 
2017/2018 influenza season in the northern hemisphere, 
WHO recommended trivalent influenza vaccines contain the 
following strains: an A/Michigan/45/2015 (H1N1)pdm09-
like virus; an A/Hong Kong/4801/2014 (H3N2)-like virus; 
and a B/Brisbane/60/2008-like virus (B/Victoria lineage).2 
The number of influenza outbreaks reported during the 
2016/2017 season was at the highest level recorded since 
Table 3: Summary table of confirmed influenza cases hospitalised for all ages by influenza season: 2009/10-2016/17. Rates for 2009/10-
2013/14 are based on the 2011 CSO census; rates for 2014/15-2016/17 are based on the 2016 CSO census.
Hospitalised
Season 2009 pdm 
period 2010/11 2011/12 2012/13 2013/14 2014/15 2015/16 2016/17
Predominant flu type AH1pdm09 AH1pdm09; B AH3 B; AH3 & 
AH1pdm09
AH3; 
AH1pdm09 AH3; B AH1pdm09; B AH3
Total cases 1059 968 147 469 693 1009 1856 1425
Crude rate /100,000 23.1 21.1 3.2 10.2 15.1 21.2 39.0 29.9
Median age (years) 17 29 27 32 51 59 30 67
Females 50% 55% 56% 57% 57% 53% 53% 52%
Total deaths - all causes 25 42 6 22 34 47 75 67
Case fatality rate 2% 4% 4% 5% 5% 5% 4% 5%
Table 4: Summary table of confirmed influenza cases admitted to critical care units for all ages by influenza season: 2009/10-2016/17. Rates 
for 2009/10-2013/14 are based on the 2011 CSO census; rates for 2014/15-2016/17 are based on the 2016 CSO census.
Admitted to ICU
Season
2009 pdm 
period 2010/11 2011/12 2012/13 2013/14 2014/15 2015/16 2016/17
Predominant flu type AH1pdm09 AH1pdm09; B AH3
B; AH3 & 
AH1pdm09
AH3; 
AH1pdm09 AH3; B
AH1pdm09; 
B AH3
Total cases 100 121 15 39 83 69 161 51
Crude rate /100,000  2.2 2.6 0.3 0.8 1.8 1.4 3.4 1.1
Median age (years) 34 49 60 39 50 63 51 67
Females 50% 53% 80% 49% 41% 41% 42% 33%
Pregnant/postpartum (No.) 8 8 0 4 4 1 5 0
Cases with co-morbidities 82% 74% 93% 90% 85% 86% 83% 93%
% Vaccinated NA 17% - - 32% 47% 18% 31%
Antiviral treatment NA NA 86% 88% 90% 83% 94% 84%
ICU: Hospital ratio 9% 13% 10% 8% 12% 7% 9% 4%
ICU Median LOS - Adult 12 14 5 9 9 9 9 5
ICU Median LOS - Paediatric 8 7 3 5 8 3 5 3
Mechanical ventilation (%) 86% 90% 77% 91% 94% 93% 92% 98%
ECMO (No.) 5 10 0 0 2 1 11 0
Total deaths - all causes 18 35 5 11 27 23 47 20
Case fatality rate 18% 29% 33% 28% 33% 33% 29% 39%
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the 2009 pandemic. The majority of these outbreaks were 
caused by influenza A and mainly affected the elderly in 
residential care facilities. Reported influenza vaccination 
status of patients/clients in these outbreaks was high, whilst 
vaccination status of staff was low, highlighting the need 
to improve influenza vaccine uptake amongst health-care 
workers in order to reduce influenza-related morbidity and 
mortality. Further information on seasonal influenza vaccine 
uptake in hospitals and long term care facilities is available 
in the Immunisation uptake chapter of the HPSC Annual 
Epidemiological Report, 2016. 
Excess all-cause mortality was reported in Ireland during 
the 2016/2017 season, with higher excess deaths than 
previously recorded among those aged 65 years and older, 
over 8 consecutive weeks, from early December 2016 to late-
January 2017. Excess all-cause mortality in older age groups 
was also reported throughout Europe during the 2016/2017 
season.1
The Irish overall adjusted influenza vaccine effectiveness 
(VE) estimates in preventing influenza confirmed infection in 
primary care during the 2016/2017 season for all influenza, 
influenza A(H3N2) and for all influenza in at risk groups 
were at moderate levels. 
For the 2017/2018 season, existing surveillance systems in 
Ireland are being further strengthened. HPSC are currently 
reviewing severe influenza surveillance systems, with a 
view to improving their efficiency and reporting. A severe 
influenza surveillance working group has been established 
to review and implement the required changes to improve 
severe influenza surveillance in Ireland. 
HPSC are focusing on improving influenza vaccine uptake 
and antiviral data on severe influenza cases, outbreaks, 
health care workers and those in risk groups for influenza. 
HPSC, ICGP and the NVRL are continuing to work on the 
European influenza vaccine effectiveness study (I-MOVE 
project), working together to increase GP and patient 
participation during the 2017/2018 season, in order to 
improve the precision of Irish influenza VE estimates. 
HPSC are also collaborating with the NVRL to increase 
influenza genetic testing, which will result in additional 
epidemiological information on evolving influenza genetic 
clades and subclades circulating each season in Ireland. 
Data from all of these surveillance projects will assist in 
guiding the management and control of influenza and of any 
future epidemics or pandemics. www.hpsc.ie
References 
1.  Vestergaard Lasse S, et al.  Excess all-cause and influenza-attributable 
mortality in Europe, December 2016 to February 2017. Euro 
Surveill. 2017;22(14):pii=30506.     
https://doi.org/10.2807/1560-7917.ES.2017.22.14.30506   
2.  WHO recommendations on the composition of influenza virus vaccines 
http://www.who.int/influenza/vaccines/virus/recommendations/en/
Acknowledgements
HPSC would like to thank the sentinel GPs, ICGP, NVRL, Departments 
of Public Health, sentinel hospitals, ICSI, CCP and HSE-NE for their 
contributions towards influenza surveillance throughout the influenza 
season. 
Table 5: Summary table of notified influenza cases that died from all causes and were reported on Ireland’s Computerised Infectious Disease 
Reporting System (CIDR) by influenza season: 2009/10-2016/17. Rates for 2009/10-2013/14 are based on the 2011 CSO census; rates for 
2014/15-2016/17 are based on the 2016 CSO census.
  Influenza notifications - Deaths from all causes
 
Pandemic 
period 2010/11 2011/12 2012/13 2013/14 2014/15 2015/16 2016/17
Total deaths 32 43 12 38 58 66 84 95
Crude rate /100,000 0.7 0.9 0.3 0.8 1.3 1.4 1.8 2.0
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In 2016, there were 10 cases of Legionnaires’ disease notified 
in Ireland, a rate of 2.1 per million population, which is a slight 
decrease from the rate of 2.5 per million observed in 2015. 
One death due to Legionnaires’ disease was reported among 
the 10 cases, giving a case fatality rate of 10%.
The HSE areas who reported the cases in 2016 are shown in 
Table 1.
The majority of cases were male (60%). The median age for 
all cases was 62 years with a range from 28 to 82 years.
All ten cases were classified as confirmed. The organism 
involved in all confirmed cases, which was detected by urinary 
antigen test, was Legionella pneumophila serogroup 1. One 
case also had a confirmatory sputum sample culture of 
Legionella pneumophila serogroup 1. Monoclonal subtyping 
was not performed on the cultured isolate and was not 
available for any of the remaining cases because cultures 
were not available. 
Seven cases were travel-associated. Countries of travel 
included Estonia (1), Hungary (1), Lithuania (2), Singapore 
(1) and Spain (2). Two of these travel-associated cases were 
linked to international travel related clusters. The remaining 
three cases were assumed to be community acquired.
No seasonality was evident in the cases in 2016, as described 
in Figure 1. The number of cases of Legionnaires’ disease 
2.2 Legionellosis
Summary
Number of cases in 2016: 10
Crude incidence rate: 2.1 per million
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Table 2. Number of Legionnaires’ disease cases per million population in Ireland, 2009-2016
Legionnaires’ events excluding Pontiac Fever cases
Age Group (years) 2009 2010 2011 2012 2013 2014 2015 2016
<30 0 1 0 0 0 0 0 1
30-39 0 0 0 1 1 1 1 1
40-49 0 2 0 1 3 1 1 1
50-59 2 1 1 1 4 2 3 1
60-69 3 3 4 6 1 3 1 2
70+ 2 4 2 6 5 1 6 4
Total 7 11 7 15 14 8 12 10
Total CIR per million 1.5 2.4 1.5 3.3 3.1 1.7 2.5 2.1
To calculate the crude incidence rate (CIR), Census of the Population data was used as the denominator with Census 2016 for the analysis of 2014-2016 data and 
Census 2011 for the analysis of 2009-2013 data.
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Figure 1. Number of Legionnaires’ disease cases by month of 
notification in Ireland, 2016
Table 1. Number of Legionnaires’ disease cases by HSE area of 
reporting in Ireland, 2016
Area of Reporting No. of Cases
HSE-East 3
HSE-North East 3
HSE-Midlands 2
HSE-North West 1
HSE-West 1
Ireland 10
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Figure 2. Number of Legionnaires’ disease cases by month of 
notification and annually, 2013-2016
Figure 3. Number of Legionnaires’ disease cases by month of 
notification in 2016 compared to the mean and range for the years 
2011-2015
Figures for the year 2016 presented in this report were extracted from the computerised infectious disease reporting (CIDR) 
system on the 22nd August, 2017.
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by month of notification between 2013 and 2016 is given in 
Figure 2. The annual trend over the past four years indicates 
that the number of notifications has been decreasing over 
time.
When the numbers of cases in 2016 were compared with the 
mean for the previous five years (see Figure 3), numbers were 
within historical limits. 
Notifications
In 2016, both the number and rate per 100,000 population 
of invasive group A streptococcal (iGAS) infection increased 
in comparison with 2015. n=148; rate = 3.11 [95% confidence 
interval (CI): 2.63-3.65] versus n=107; rate = 2.25 [95% CI: 
1.84 – 2.72].
Case classification
The vast majority of cases were confirmed iGAS (n=147; 
99%), with one probable case (n=1; 1%). A confirmed case 
has GAS or Streptococcus pyogenes isolated from a sterile 
site. A probable case has a diagnosis of streptococcal toxic 
shock syndrome (STSS) or necrotising fasciitis and GAS 
isolated from a non-sterile site.
 
Patient demographics
Of the 148 cases, 77 (52%) were male. The mean age was 
44 years (range = 9 months – 92 years) and iGAS was more 
common in young children and older adults (Figure 1). 
Geographic location and seasonal variation
Table 1 displays annual numbers and crude incidence rates 
(CIRs) of iGAS by HSE region (2012 – 2016). The highest 
number of cases and CIR in 2016 were from HSE East (n=68; 
CIR = 3.97 per 100,000 population). In six other HSE regions, 
increased iGAS notifications were observed. In HSE Midwest 
and HSE West, both cases and CIRs decreased in 2016. The 
peak month in 2016 was March (25 cases), followed by June 
(16 cases), January and December (14 cases each) (Figure 2). 
Figure 3 displays cumulative monthly iGAS cases from 2012 
to 2016 inclusive. Following a dip in iGAS notifications in 
early 2015, the numbers subsequently increased in late 2015 
and this increase was sustained in 2016. Data presented are 
based on the date the case was notified to public health, not 
on the date the case was first detected. 
Isolate details
Of 147 confirmed cases, GAS was isolated from a sterile 
site in 110, with source site not reported for 37. Of reported 
sterile sites, GAS was isolated primarily from blood cultures 
2.3  Invasive Group A Streptococcal 
 Disease
Summary
Number of cases = 148
Crude incidence rate (CIR) = 3.11 per 100,000 population
The figures presented in this summary are based on data 
extracted from the Computerised Infectious Disease 
Reporting (CIDR) System on 10th August 2017. 
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Figure 1.  Age and sex specific rates of iGAS infection (2016)
(n=85; 77%), abscesses (n=9; 8%), deep tissue (n=8; 7%), 
joints (n=6; 5%), pleural fluid (n=1; 1%). For two cases, GAS 
was isolated from a second sterile site in addition to blood: 
pleural and pericardial aspirates (n=1) and joint (n=1). 
There was one probable case in 2016 where GAS was 
isolated from a non-sterile site (eye swab). The case 
presented with orbital cellulitis, which represents a severe 
GAS infection but is not an iGAS case according to the case 
definition.
Typing data, based on sequencing of the emm genes that 
encode the M protein (the major virulence factor), were 
available on 127 isolates submitted from 26 laboratories: 
emm-types 1 (n=51; 40%), 12 (n=14; 11%), 28 (n=10; 8%), 3, 
4 and 89 (n=6; 5% each) comprised 73% of all the isolates 
typed. Fifteen other emm-types (each represented by five 
isolates or less) were also detected. Of the 23 patients with 
STSS for whom emm-typing was undertaken, nine GAS 
isolates belonged to emm1 (39%) and four each to emm3 and 
emm28 (17%). 
Enhanced surveillance data
Enhanced data were provided for 120 iGAS cases (81%), 
with variation in completeness of data supplied. Table 2 
summarises characteristics of iGAS cases in Ireland from 
2012 to 2016.
Clinical details
Clinical details were provided for 111 cases (75%). An iGAS 
case could have more than one clinical manifestation 
of infection. As in previous years, bloodstream infection 
(BSI) (n=90) and cellulitis (n=50) were the commonest 
presentations, followed by STSS (n=25), pneumonia (n=9), 
necrotising fasciitis (n=8), septic arthritis (n=7), peritonitis 
(n=5), erysipelas (n=2), myositis (n=2) and puerperal sepsis 
(n=2).
Risk factors
Risk factors were described for 93 iGAS cases (62%). An 
iGAS case could have more than one risk factor. No risk 
factors were identified for 27 cases. 
Reported risk factors included; presence of skin or wound 
lesions (n=38), diabetes mellitus (n=10), malignancy (n=16), 
steroid use (n=8), varicella infection (n=8), injecting drug use 
(IDU) (n=4), alcoholism (n=2), recent childbirth (n=3) and 
non-steroidal anti-inflammatory drug (NSAID) use (n=2).
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Figure 2. Monthly distribution of iGAS cases, 2014-2016
Table 1. Annual iGAS cases and crude incidence rates (CIRs) per 100,000 population by HSE area (2012-2016).
CIRs for 2012-2013 were calculated using the 2011 census and for 2014-2016 using the 2016 census
HSE Area 2012 2013 2014 2015 2016
 n   CIR    n   CIR    n   CIR    n   CIR    n CIR
HSE E 51 3.15 67 4.14 65 3.80 40 2.34 68 3.97
HSE M 7 2.48 7 2.48 4 1.37 7 2.39 10 3.42
HSE MW 8 2.11 16 4.22 13 3.39 6 1.56 12 3.13
HSE NE 11 2.50 14 3.18 12 2.60 10 2.17 15 3.25
HSE NW 5 1.94 6 2.32 3 1.17 7 2.73 3 1.17
HSE SE 16 3.22 21 4.22 18 2.61 9 1.30 15 2.17
HSE S 14 2.11 18 2.71 27 5.28 11 2.15 12 2.35
HSE W 10 2.25 19 4.27 22 4.86 17 3.75 13 2.87
IRELAND 122 2.66 168 3.66 164 3.44 107 2.25 148 3.11
Clinical management/severity
Surgical intervention was required for 28 patients (19%), 
with an age range = 11 months – 81 years. Of those, four 
were notified as STSS, five as necrotising fasciitis and two as 
having both STSS and necrotising fasciitis. Risk factor data 
on 23 of the surgical cases (82%) was described, with skin 
and wound lesions (n=10), age ≥65 years (n=6), diabetes 
(n=2), NSAID use (n=2), varicella (n=2), childbirth (n=1), IDU 
(n=1) and malignancy (n=1). An iGAS case requiring surgery 
could have more than one risk factor. No risk factors were 
identified for seven patients.
Intensive care unit (ICU) admission was required for 36 
patients (24%), with an age range = 11 months – 88 years. Of 
those, 15 were notified as STSS, four as necrotising fasciitis 
and three as having both STSS and necrotising fasciitis. 
Risk factor data on 31 of the ICU cases (86%) was described, 
with age ≥65 years (n=16), skin and wound lesions (n=12), 
malignancy (n=5), steroid use (n=4), varicella infection 
(n=4), diabetes mellitus (n=3), alcoholism (n=2) and IDU 
(n=2). An iGAS case requiring ICU admission could have 
more than one risk factor. No risk factors were identified for 
six patients. Length of ICU stay was provided for 22 cases 
(61%); median = 3 days (range = 1 – 15). 
Outcome
Outcome at seven days following GAS detection was 
reported for 74 cases (50%): 
• Still alive = 70
•  Died = 4, where GAS was listed as the main or contributory 
cause of death. The seven-day case fatality rate (CFR) for 
iGAS overall was 5%. Of 25 STSS cases, outcome at seven 
days was reported for 15 cases, with two deaths due to 
GAS (CFR = 13%)
Antimicrobial susceptibility testing
Twenty-eight microbiology laboratories reported 
antimicrobial susceptibility test (AST) data on 119 GAS 
isolates (blood; 110 and other specimens; 9) via the 
European Antimicrobial Resistance Surveillance Network 
(EARS-Net), with variation in AST panels. All isolates tested 
were susceptible to penicillin (n=119) and vancomycin (n=91). 
Resistance to erythromycin was reported in eight (7%) of 116 
isolates, to clindamycin in seven (8%) of 89 isolates and to 
tetracycline in eight (13%) of 61 isolates tested.
Other epidemiological information
Seven cases of iGAS were reported as hospital-acquired 
(5%). There were no iGAS outbreaks reported in 2016 versus 
one outbreak in 2015. 
Conclusion
Antimicrobial susceptibility data confirm that GAS remains 
susceptible to penicillin and that penicillin should continue 
to be the treatment of choice for iGAS.  
Invasive GAS is a potentially life-threatening disease. In 
2016, the CFR for iGAS infection was 5%. 
A national service typing GAS emm genes has been 
provided since 2012 by the Irish Meningitis and Sepsis 
Reference Laboratory (IMSRL), based at Temple Street 
Children’s University Hospital. In both 2016 and 2015 emm1 
predominated, comprising 40% and 29% of all isolates 
typed, respectively. However, in 2014, emm3 predominated 
(36% of all isolates typed). Certain emm types, including 
emm1 and emm3, are associated with STSS, and STSS 
in turn is strongly associated with increased mortality. 
The changes observed in the predominant emm types in 
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Figure 3. Cumulative monthly numbers of iGAS cases, 2012-2016
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Table 2. Characteristics of iGAS cases (2012–2016) Data as of 16/08/2017
** Degree of completion of enhanced surveillance forms varies from case to case: information may not be available on all variables/categories, 
thus calculations of percentages take into account only those cases for which data are provided
†Note: A patient may have more than one clinical presentation or risk factor
2012 2013 2014 2015 2016
Notifications
Total iGAS cases notified 122 168 164 107 148
iGAS incidence rate per 100,000 population 2.66 3.66 3.44 2.25 3.11
Cases for which enhanced data provided** (%) 106 (87%) 156 (93%) 150 (91%) 95 (89%) 120 (81%)
Patient Demographics
Male (%) 59 (48%) 95 (57%) 94 (57%) 60 (56%) 77 (52%)
M:F ratio 0.94:1 1.30:1 1.34:1 1.28:1 1.08:1
Mean age 44 41 43 42 44
Median age 42 40 44 42 43
Age range 0-92 0-93 0-99 0-99 0-92
Paediatric cases (aged <18 years) (%) 28 (23%) 45 (27%) 47 (29%) 26 (24%) 40 (27%)
Older cases (aged 65+ years) (%) 42 (34%) 50 (30%) 56 (34%) 34 (31%) 52 (35%)
Clinical Presentation†
Data on Clinical Presentation (%) 102 (84%) 141 (84%) 133 (81%) 88 (82%) 111 (75%)
Streptococcal Toxic Shock-like Syndrome 
(STSS) without NF (%) 22 (22%) 28 (20%) 18 (14%) 11 (13%) 22 (20%)
Necrotising fasciitis (NF) without STSS (%) 2 (2%) 6 (4%) 4 (3%) 5 (6%) 2 (2%)
STSS and NF (%) 4 (4%) 4 (3%) 3 (2%) 0 (0%) 3 (3%)
Bacteraemia with focal presentations (%) 37 (36%) 43 (30%) 43 (32%) 33 (38%) 43 (39%)
Bacteraemia with no focal presentations (%) 26 (25%) 37 (26%) 37 (28%) 21 (24%) 25 (23%)
Other focal presentations with no bacteraemia 
(%) 11 (11%) 23 (16%) 28 (21%) 18 (20%) 13 (12%)
Bacteraemia (%) 78 (76%) 106 (75%) 100 (75%) 64 (73%) 90 (81%)
Other focal presentations:
Cellulitis (%) 40 (39%) 43 (30%) 57 (43%) 34 (39%) 50 (45%)
STSS (%) 26 (25%) 32 (23%) 21 (16%) 11 (13%) 25 (23%)
Pneumonia (%) 16 (16%) 24 (17%) 14 (11%) 12 (14%) 9 (8%)
Necrotising fasciitis (%) 6 (6%) 9 (6%) 7 (5%) 5 (6%) 8 (7%)
Septic arthritis (%) 7 (7%) 10 (7%) 10 (8%) 13 (15%) 7 (6%)
Peritonitis (%) 1 (1%) 4 (3%) 1 (1%) 3 (3%) 5 (5%)
Erysipelas (%) 3 (3%) 3 (2%) 2 (2%) 1 (1%) 2 (2%)
Myositis (%) 4 (4%) 3 (2%) 5 (4%) 2 (2%) 2 (2%)
Puerperal sepsis (%) 3 (3%) 4 (3%) 3 (2%) 6 (7%) 2 (2%)
Meningitis (%) 1 (1%) 3 (2%) 0 (0%) 4 (5%) 0 (0%)
Risk Factors†
Data on risk factors (%) 95 (78%) 138 (82%) 126 (77%) 77 (72%) 93 (62%)
Skin lesions/wounds (%) 34 (36%) 56 (41%) 50 (40%) 32 (42%) 38 (41%)
Malignancy (%) 10 (11%) 23 (17%) 10 (8%) 6 (8%) 16 (17%)
Diabetes (%) 5 (5%) 16 (12%) 11 (9%) 7 (9%) 10 (11%)
Varicella (%) 8 (8%) 5 (4%) 6 (5%) 3 (4%) 8 (9%)
Steroid use (%) 8 (8%) 11 (8%) 6 (5%) 6 (8%) 8 (9%)
Injecting drug user (%) 6 (6%) 5 (4%) 5 (4%) 3 (4%) 4 (4%)
Childbirth (%) 6 (6%) 6 (4%) 4 (3%) 5 (6%) 3 (3%)
Alcoholism (%) 5 (5%) 6 (4%) 5 (4%) 3 (4%) 2 (2%)
Non-steroid anti-inflammatory drug use (%) 2 (2%) 4 (3%) 2 (2%) 1 (1%) 2 (2%)
No identified risk factor (%) 25 (26%) 47 (34%) 48 (38%) 24 (31%) 27 (29%)
Outcome at 7 days
Data on outcome at 7 days (%) 65 (53%) 108 (64%) 102 (62%) 73 (68%) 74 (50%)
RIP/GAS main cause or contributory (%) 8 (12%) 16 (15%) 10 (10%) 6 (8%) 4 (5%)
STSS cases: Data on outcome at 7 days (%) 17 (65%) 26 (81%) 17 (81%) 7 (64%) 7 (64%)
STSS cases: RIP/GAS main cause or 
contributory (%) 6 (35%) 10 (38%) 6 (35%) 1 (14%) 1 (14%)
Severity
Data on admission to ITU (%) 99 (81%) 153 (91%) 144 (88%) 92 (86%) 112 (76%)
Admitted to ITU (%) 40 (40%) 44 (29%) 36 (25%) 25 (27%) 36 (32%)
Data on surgical intervention (%) 85 (70%) 136 (81%) 127 (77%) 86 (80%) 99 (67%)
Surgical intervention required (%) 25 (29%) 39 (29%) 41 (32%) 26 (30%) 28 (28%)
Typing
iGAS isolates that were typed (%) 109 (89%) 140 (83%) 130 (79%) 92 (86%) 127 (86%)
Emm-1 (%) 53 (49%) 41 (29%) 21 (16%) 27 (29%) 51 (40%)
Emm-3 (%) 4 (4%) 33 (24%) 47 (36%) 4 (4%) 6 (5%)
Emm-12 (%) 11 (10%) 4 (3%) 6 (5%) 14 (15%) 14 (11%)
Emm-28 (%) 8 (7%) 8 (6%) 12 (9%) 12 (13%) 10 (8%)
Emm-89 (%) 4 (4%) 13 (9%) 8 (6%) 8 (9%) 6 (5%)
Other emm-types (%) 29 (27%) 41 (29%) 36 (28%) 27 (29%) 40 (31%)
circulation highlight the dynamic nature of iGAS infection. 
Ongoing surveillance is essential, specifically completion 
of the enhanced data questionnaire to gain a greater 
understanding of iGAS. There has been a reduction in the 
proportion of iGAS cases with accompanying enhanced 
surveillance data from 93% (2013) to 81% (2016). Referral 
of GAS isolates to IMSRL for epidemiological typing is also 
important, as certain emm types are associated with greater 
morbidity and mortality.
Acknowledgement
HPSC would like to thank colleagues in microbiology 
laboratories and Departments of Public Health for 
submitting data on iGAS and colleagues in IMSRL for 
sharing emm typing information.
Notes to colleagues in microbiology laboratories
1.  Please forward any GAS isolates from normally sterile sites to IMSRL 
for typing, along with a completed IMSRL request form available from: 
https://www.cuh.ie/wp-content/uploads/2014/03/IMSRL-Request-
Form-29-11-16.pdf
2.  Please submit AST data on all iGAS cases along with EARS-Net quarterly 
returns
3.  Please return a completed enhanced iGAS surveillance form on every 
patient with iGAS. The form can be downloaded from the HPSC website 
at: http://www.hpsc.ie/a-z/other/groupastreptococcaldiseasegas/
surveillanceforms/ 
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Background
Invasive group B streptococcal (iGBS; Streptococcus 
agalactiae) infection in infants <90 days old or stillborn 
infants has been notifiable in Ireland since January 2012. In 
neonates, two syndromes exist:
1.  Early-onset disease (EOD) where age at onset/diagnosis <7 
days
2.  Late-onset disease (LOD) where age at onset/diagnosis 
7 – 89 days
Both include sepsis, pneumonia and meningitis. Stillbirth 
associated with isolation/detection of Streptococcus 
agalactiae from the placenta or amniotic fluid is also 
notifiable. The rate is expressed per 1,000 live births. In 
2016, there were 63,897 live births according to the Central 
Statistics Office (CSO). 
http://www.cso.ie/en/releasesandpublications/ep/p-vsys/
vitalstatisticsyearlysummary2016/ 
Notifications
In 2016, 65 iGBS cases were notified. The majority were EOD 
(n=42; 65%); rate = 0.66. LOD accounted for 23 cases (35%); 
2.4  Invasive Group B Streptococcal 
Infections
Summary
Number of cases = 65 
• Early-onset disease (EOD) = 42
• Late-onset disease (LOD) = 23
EOD rate per 1,000 live births = 0.66
LOD rate per 1,000 live births = 0.36
The figures presented in this summary are based on data 
extracted from Computerised Infectious Disease Reporting 
(CIDR) System on 11th August 2017.
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Figure 1. iGBS by age (in days) at diagnosis (2016) (EOD <7 days; LOD 7 – 89 days)
 
Table 1. Annual iGBS cases and rates, stratified by EOD & LOD (2012 – 2016)
EOD LOD TOTAL
Year n (%) Rate* n (%) Rate* n (%) Rate*
2012 57 (75%) 0.80 19 (25%) 0.27 76 1.06
2013 42 (64%) 0.61 24 (36%) 0.35 66 0.96
2014 46 (68%) 0.68 22 (32%) 0.33 68 1.01
2015 43 (62%) 0.65 26 (38%) 0.39 69 1.05
2016 42 (65%) 0.66 23 (35%) 0.36 65 1.02
EOD, early-onset disease; LOD, late-onset disease
* Incidence rate per 1,000 live births
Live births in the Republic of Ireland (source: www.cso.ie): 2012, 71,674; 2013, 68,954; 2014, 
67,295; 2015, 65,909; and 2016, 63,897
rate = 0.36 (Figure 1 and Table 1). Two cases presented with 
meningitis and two were associated with stillbirth.
The Irish Meningitis and Sepsis Reference Laboratory 
(IMSRL), based at Temple Street Children’s University 
Hospital, provides a national typing service for Group B 
Streptococcus. IMSRL performs serotyping and multi-locus 
sequence typing (MLST) on iGBS isolates. Between 2012 and 
2016, 167 iGBS isolates were received by IMSRL. Figure 2 
displays the annual breakdown (2012 – 2016) of isolates by 
serotype. Serotype III has predominated as a cause of both 
EOD and LOD since typing began.
There are ten capsular serotypes of GBS (serotypes 1a, 1b 
and II – IX). Based on MLST data, GBS may be categorised 
into five main clonal complexes (1, 12, 17, 19 & 23). Figure 3 
displays the annual breakdown (2012 – 2016) of isolates by 
MLST clonal complex. Clonal complex 17 includes serotype 
III and has predominated as a cause of both EOD and LOD 
since typing began.
Notes to colleagues in microbiology laboratories
Please forward any GBS isolates from normally sterile sites 
to IMSRL for typing, along with a completed IMSRL request 
form available from: 
http://www.cuh.ie/healthcare-professionals/departments/
irish-meningitis-sepsis-reference-laboratory-imsrl/
Acknowledgement
HPSC would like to thank colleagues in microbiology laboratories and 
Departments of Public Health for submitting data on iGBS since 2012 and 
colleagues in IMSRL for sharing typing information.
Figure 3. MLST clonal complex distribution of iGBS isolates 2012 - 2016. 
Source: IMSRL
Figure 2. Serotype distribution of iGBS isolates 2012 - 2016.
Source: IMSRL
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In 2016, 318 cases of tuberculosis (TB) were notified in 
Ireland, corresponding to a crude incidence rate (CIR) of 6.9 
per 100,000 population*, remaining stable in comparison to 
the CIR of 6.4 reported for 2015 (n=294). A summary of the 
epidemiology of TB in Ireland during 2016 is shown in table 
1 while the number of cases and crude incidence rates from 
2007-2016 with three-year moving averages are shown in 
figure 1. 
The highest crude incidence rate was reported by HSE-E 
(8.4/100,000) while the lowest rate was reported by HSE-
NW (1.9/100,000). 
Cases ranged in age from two months to 89 years, with a 
median age of 41 years. The highest age-specific rate (ASIR) 
in 2016 occurred among those aged 25-34 years (10.6) 
followed by those aged 65 years and older (10.5). The rate 
among males (8.5) was higher than that among females 
(5.4). Rates among males were higher than females for all 
age groups except the 0-14 and 55-64 year age groups. The 
highest ASIR among males (13.2) was observed in those 
aged 65 years and older while the highest ASIR among 
females was observed in those aged 55-64 years. The male 
to female ratio (1.6:1) reported in 2016 was consistent with 
that reported in previous years. 
Geographic origin
The proportion of TB cases born outside Ireland increased 
to 50.3% during 2016, compared to 43.2% reported in 
2015. Correspondingly the crude rate in the foreign-born 
population increased from 16.6 per 100,000 population in 
2015 to 20.9 per 100,000 population in 2016. The crude 
rate in the indigenous population remained stable at 3.9 per 
100,000, the same as reported in 2015. There was a notable 
difference in age between cases born in Ireland and foreign 
born cases, with a median age of 54 years and 33 years 
respectively. 
Site of infection 
Pulmonary TB was reported in 211 (66.4%) cases and 97 
(30.5%) had exclusively extrapulmonary disease. Site of 
infection was not reported for the remaining 10 cases. There 
were no cases of TB meningitis reported during 2016.
Microbiology
Culture results were available for 246 (77.4%) cases. Of the 
246, 237 (96.3%) cases were culture confirmed and nine 
(3.7%) were culture negative. Species identification showed 
M. tuberculosis in 97.9% (232 cases), M. bovis in 1.3% (3 
2.5  Tuberculosis 
Summary
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Table 1: Summary of the epidemiology of TB in Ireland, 2016
Parameter
2016
Number of cases CIR % of total cases
Total number of cases 318 6.9 n/a
Cases in indigenous population 145 3.9 45.6
Cases in foreign-born persons 160 20.9 50.3
Culture positive cases 237 5.2 74.5
Pulmonary cases 211 4.6 66.4
Smear positive pulmonary cases 85 1.9 26.7
TB meningitis cases 0 0.00 0.0
Multi-drug resistant cases 5 0.11 1.6
Extensively drug resistant cases 1 0.02 0.3
Mono-resistant to isoniazid 10 0.2 3.1
Deaths attributable to TB 7 0.2 2.2
Number of cases in 2016:  318
Number of cases in 2015: 294
 *All rates reported are calculated per 100,000 population using the 2011 Census
cases) and M. africanum in 0.8% (2 cases). Of the 211 cases 
with a pulmonary component, 170 (80.6%) were reported as 
culture confirmed, and 85 (40.3%) were reported as smear 
positive. 
Drug sensitivity 
Information on antibiotic sensitivity testing was available for 
230 (97.0%) of the 237 culture confirmed cases. Resistance 
was documented in 32 (13.5% and 10% of total cases) cases 
that reported antibiotic sensitivity, five of which were MDR-
TB (1.6% of total cases) and one additional case was XDR-
TB. Mono-resistance to isoniazid was recorded in 10 cases, 
to streptomycin in six, to pyrazinamide in four cases and 
rifampicin in one case. Five further cases reported non-MDR 
polyresistance (to isoniazid and an additional drug other 
than rifampicin). 
HIV status
Information on HIV status was reported for 131 (41.2%) cases 
in 2016, an increase compared to 40.8% with HIV status 
reported in 2015. Of the cases with HIV status reported, four 
(3.1%) were HIV positive and 127 (96.9%) were HIV negative.
Outbreaks
During 2016, five outbreaks of TB were reported to HPSC, 
with 19 reported cases of active TB and 15 hospitalisations. 
No LTBI cases were reported for any of the 2016 outbreaks. 
Two outbreaks were reported by HSE-W and one outbreak 
each was reported by HSE-E, -NW and -S. There were three 
general outbreaks, two of which occurred in a community 
setting with six and three cases of active TB respectively. 
The remaining general outbreak occurred in a multi-
occupancy private residence with three associated cases of 
active TB. There were also two family outbreaks, comprising 
three and four cases each. One family outbreak occurred 
in a private house and one occurred across an extended 
family. 
The number of outbreaks reported during 2016 remained 
stable compared to 2015. Figure 2 shows a summary 
of reported TB outbreaks from 2007 to 2016 by year of 
outbreak, number of active TB cases and number of persons 
with LTBI. Please note that numbers of LTBI for outbreaks 
reported during 2016 are provisional and may increase as 
outbreak investigations continue.
Further details on the epidemiology of TB cases reported 
in 2016 will be available in the HPSC Report on the 
Epidemiology of TB in Ireland, 2016   
(www.hpsc.ie/a-z/vaccinepreventable/tuberculosistb/
epidemiology/annualreports). 
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Figure 1: Notified cases of TB in Ireland with crude rates per 100,000 population, 2007 to 2016 and 3-year moving 
averages, 2007-2015
Year 
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Figure 2: TB outbreak summary by year, 2007-2016
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Chickenpox-hospitalised cases
The Health Act, 1947 entitles the Minister for Health to 
declare by regulation diseases that are infectious, covered 
by legislation and that require notification to a Medical 
Officer of Health. The infectious diseases notifiable in Ireland 
are regulated in the 1981 Infectious Diseases Regulations. 
The amendment S.I. No. 452 of 2011 to these regulations 
specified for the first time the disease chickenpox, 
hospitalised cases only, as notifiable. Chickenpox is caused 
by varicella-zoster virus. The case definition is available at 
www.hpsc.ie.
In 2016, 106 (2.2/100,000) hospitalised chickenpox cases 
were notified in Ireland compared to 69 (1.4/100,000) in 
2015. In 2016, the largest number of cases was in the HSE 
E (table 1). Of the 106 cases, 72 (68%) were classified as 
confirmed, five (5%) as probable and 29 (27%) as possible. 
The highest age specific incidence rates were in those aged 
less than five years (figure 1). Of the 106 cases, 54 (51%) were 
female and 51 (48%) were male while sex was unreported for 
one case (1%).
Chickenpox/varicella outbreaks
The amendment S.I. No. 707 of 2003 to the infectious 
disease regulations specified that unusual clusters or 
changing patterns of illness that may be of public health 
concern must be reported. Therefore, outbreaks of 
chickenpox must be notified regardless of hospitalisation 
status. Two outbreaks of chickenpox were notified in 2016. 
Both outbreaks occurred in a childcare facility with a total of 
12 ill.
The figures presented in this summary are based on data 
extracted from the Computerised Infectious Disease 
Reporting (CIDR) system on 6th September 2017. These 
figures may differ slightly from those published previously 
due to ongoing updating of notification data on CIDR. The 
2016 census data was used here to calculate rates.
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2.6 Chickenpox-hospitalised cases
Summary
Number of cases, 2016: 106
Crude incidence rate, 2016: 2.2/100,000
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Figure 1. The age specific incidence rate (per 100,000 population) of 
notified hospitalised chickenpox cases in 2016 by case classification
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Table 1. Number of notified hospitalised chickenpox cases and the 
crude incidence rate per 100,000 population (CIR) by HSE Area in 
2016
HSE Area Number CIR
HSE E 54 3.2
HSE M 7 2.4
HSE MW 2 0.5
HSE NE 14 3.0
HSE NW 3 1.2
HSE SE 8 1.6
HSE S 13 1.9
HSE W 5 1.1
Total 106 2.2
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Campylobacteriosis is an acute zoonotic bacterial disease 
characterised by diarrhoea, abdominal pain, malaise, fever, 
nausea and vomiting. Symptoms generally last for only a few 
days. It is the commonest bacterial cause of gastroenteritis in 
Ireland and Europe.1  Campylobacteriosis became a notifiable 
disease in Ireland in 2004 under the Infectious Diseases 
(Amendment) Regulations.
During 2016, 2513 cases were notified, an increase of 
2.6% observed, compared with 2015. Among the 95% of 
notifications for which patient type was available, 27% of 
cases were hospital in-patients.
This corresponds to a crude incidence rate of 52.8/100,000 
population, which is lower than the European crude 
incidence rate of 65.5 per 100,000 population.1 This is 
sixth consecutive year for which campylobacteriosis levels 
were elevated compared with rates reported between 
2004 and 2010 (Figure 1). Increasing use of PCR since 2013 
as a primary diagnostic method may have impacted on 
ascertainment rates, however, this would seem not to explain 
the increase from 2011. During the period 2008-2015, 12 
other EU MS (Austria, Estonia, France, Hungary, Italy, Latvia, 
Lithuania, Malta, Poland, Slovakia, Slovenia and Spain) also 
reported significantly increasing trends.1
During 2016, the highest CIRs occurred in HSE-M 
(70/100,000), HSE-SE (67/100,000) and HSE-W 
(66/100,000); similar to last year, the lowest CIRs were 
reported by HSE-NW (36/100,000) and -NE (37/100,000) 
(Figure 2). 
There was variation in the size of the increase in reported 
incidence in the last six years between HSE-areas, with the 
largest increase reported by HSE-SE (74% increase in annual 
mean number of cases between 2011-2016 compared with 
the period 2004-2010) compared with a more modest 12% 
increase in annual mean number of cases in the HSE-NW 
between 2011-2016 compared with the period 2004-2010. 
Campylobacteriosis occurs in all age groups with the highest 
rate of notification reported in the 0-4 year age group. 
This elevated rate in younger children is a well described 
characteristic of the disease and is also observed at 
European level. A comparison of the age-specific rate in 2016 
and the mean age-specific incidence rate between 2004-
3.1 Campylobacteriosis
Summary
Number of cases, 2016: 2513
Crude incidence rate: 52.8/100,000
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Figure 1. CIR per 100,000 population, Ireland 2004-2016
1 Rates are calculated per 100,000 population
1. Rates are calculated per 100,000 population
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2010 (before the commencement of elevated rates in 2011) 
shows a marked increase in the CIRs among older people 
since 2010 (Figure 3); most notably, there has been a 2.5-
fold increase in CIR in those aged 65 years and older in 2016 
compared to the period 2004-2010.
Campylobacteriosis has a well-documented seasonal 
distribution with a peak in early summer. In Ireland, 
notifications typically peak during May to July. During 
2016, notifications peaked between May and July (although 
more modest than observed in 2014 and 2015); there were 
elevated case numbers also in January 2016 (small January 
peaks have been observed since 2011 in the EU). A sharp 
peak in September 2016 coincided with a general outbreak in 
a CCF described below (Figure 4). 
All Campylobacter cases notified in Ireland during 2016 were 
reported as laboratory confirmed. Formally, only culture 
confirmed Campylobacter cases are notifiable, however, 
there has been increasing implementation of culture 
independent methods for Campylobacter diagnosis since 
2013 (i.e. PCR), and, although not all PCR-diagnosed cases 
have subsequently been culture confirmed, informally all 
laboratory diagnosed cases of Campylobacter have been 
accepted as notifications. Moreover, as there is currently no 
national reference facility for routine typing of Campylobacter 
isolates and only a small number of laboratories speciating 
isolates, information on Campylobacter species in the 
notification dataset is limited. In 2016, 17.9% (n=451) of 
isolates were speciated. Of the 451 speciated isolates, 93.1% 
(n=420) were C. jejuni and 6.0% (n=27) were C. coli. 
Public health investigation of Campylobacter cases is 
not routine which limits data on the role of travel to the 
information which accompanied the specimen upon 
submission to the diagnosis laboratory. Travel is believed 
to be a relatively minor risk factor for campylobacteriosis in 
Ireland; in a case control study across the island of Ireland, 
20% of cases reported travel outside of the island of Ireland 
during their potential incubation period.2 Moreover, travel 
was not found to be significantly associated with infection 
after adjustment for other risk factors in the study. In the 
2016 dataset, country of infection was completed for only 
88 cases, of which eight were foreign-travel related (9%). 
Unascertainment of travel as a risk factor was reported 
previously in the United Kingdom for campylobacter 
laboratory surveillance data.3
During 2016, there were five notified outbreaks which 
included cases of campylobacteriosis (Table 1). Four were 
family outbreaks in private houses with a total of 9 persons 
ill (eight laboratory confirmed). There was one VTEC/
Campylobacter outbreak which included 32 confirmed 
campylobacter cases; the reported mode of transmission was 
foodborne and person-to-person spread. No food vehicles 
were implicated in any of three foodborne outbreaks, 
although chicken cooked at home was suspected for one 
family outbreak. Notification of outbreaks of Campylobacter 
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Figure 2. CIR by HSE-area, campylobacteriosis 
2016
Table 1. Campylobacteriosis outbreaks summary, 2016 (CIDR)
Outbreak location Mode of transmission Number outbreaks
Number of 
confirmed 
campylobacter 
cases
Private house
P-P - Person-to-person 1 2
Foodborne+-P-P 2 5
Unknown 1 1
Childcare facility* Foodborne and P-P 1 32
Total 5 40
*VTEC and Campylobacter outbreak
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Figure 3. Age-specific incidence rate campylobacter 2016, mean age-specific incidence rate campylobacter 2004-
2010, Ireland
Figure 4. Weekly number of campylobacteriosis notifications in Ireland 2013-2016
are less common than for other bacterial gastrointestinal 
pathogens; increasingly this is being regarded as a reflection 
of our present ability to detect them as traditionally typing 
of Campylobacter strains has been of limited value. A recent 
Danish study using whole genome sequencing suggests that 
Campylobacter case clustering and even outbreaks appear to 
occur more often than previously assumed.4
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Cryptosporidium is a protozoal parasite that causes a 
diarrhoeal illness in humans known as cryptosporidiosis. 
It is transmitted by the faeco-oral route, with both animals 
and humans serving as potential reservoirs. Human 
cryptosporidiosis became a notifiable disease in Ireland in 
2004, and the case definition in current use is published on 
the HPSC website. 
In 2016, 561 cases of cryptosporidiosis were notified in 
Ireland, a crude incidence rate (CIR) of 11.8 per 100,000 
population (Figure 1). This is a 23% increase in the CIR from 
2015. There is no definitive trend for cryptosporidiosis in 
Ireland since the disease became notifiable. The most recent 
data available from ECDC shows a CIR across the EU of 3.1 
per 100,000 in 2015, however, many countries do not have 
reporting systems for cryptosporidiosis. Ireland has reported 
the highest CIR of any MS since 2012, with the United 
Kingdom typically reporting the second highest incidence 
rate.1 Of the notified cases in Ireland in 2016, 36.9% (n=202) 
were hospitalised. There were no reported deaths. 
Consistent with previous years, the highest age-specific 
incidence rate was in children under five years of age, with 75 
cases per 100,000 population in this age group (Figure 2). 
While there is likely to be a bias towards testing of diarrhoeal 
stool specimens from children (as opposed to adults) for 
Cryptosporidium, it is also likely that this distribution reflects 
to some extent a true difference in risk between adults and 
children. 
Compared with 2015, the incidence rate in 2016 increased 
in all of the eight HSE areas (Figure 3). As in previous years, 
there was a strong urban-rural divide, with HSE-E having the 
lowest incidence rate (4.0 per 100,000). Although incidence 
remains low in HSE-E in 2016, the incidence rate has been 
increasing over the last three years (Figure 3). HSE-W, HSE-
SE and HSE-M reported the highest incidence rates (19.0, 
22.9 and 19.8 per 100,000, respectively).
As in previous years, the highest number of cases was 
notified in spring and peaked in April, followed by a second 
less intense peak in September (Figure 4). In 2016, 5.9% of 
the cryptosporidiosis cases (n=30) were reported as being 
acquired abroad (Table 1). This is lower than the percentage 
of travel-related cases in 2015 (12.7%) but higher than was 
reported in 2014 (3.7%). The highest proportion of travel-
related cases in 2015 occurred in late summer/early autumn, 
with France and Spain being the most commonly reported 
travel-destinations (Figure 4).
3.2 Cryptosporidiosis
Summary
Number of cases, 2016: 561
Number of cases, 2015: 439
Crude incidence rate, 2016: 11.8/100,000
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Figure 1.  Annual number and crude incidence rate cryptosporidiosis, 
Ireland, 2004-2016
Figure 2.  Age-specific incidence rate cryptosporidiosis, Ireland, 2016
Year 
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Risk factors
Reviewing case-based enhanced surveillance data, 
exposure to farm animals or their faeces either by virtue of 
residence on a farm or by visiting a farm during the potential 
incubation period was common among cases; 63.5% of 
cases reported one or both of these exposures (Table 1). 
This is consistent with the low incidence of cryptosporidiosis 
among residents in the largely urban HSE-E population 
and the higher incidence reported in more rural parts of the 
country. The proportion of cases reporting exposure to pets 
and swimming pools was similar to last year (Table 1). 
Table 2 shows the distribution of notified cases by home 
water supply type. Persons who are not served by public 
water supplies have an increased risk of cryptosporidiosis; 
they are over-represented among cases relative to the 
distribution of households by water supply type nationally. 
This was particularly noticeable for private well users (25.1% 
and 10.6%, respectively). However, it should be borne in 
mind that persons whose household drinking water is not 
from a public supply are more likely to be rural dwellers and 
therefore may also have a higher likelihood of exposure to 
farm animals and rural environments which are also likely to 
increase their risk. 
Outbreaks
In total 20 cryptosporidiosis outbreaks were reported in 
2016 (1 general and 19 family outbreaks), similar to the total 
number reported in 2014 and 2015. Overall since 2011 there 
has been an increase in the number of outbreaks notified. 
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Figure 3.  Regional crude incidence rates (CIR) cryptosporidiosis, 
Ireland, 2013-2016 
Figure 4.  Seasonal distribution of cryptosporidiosis cases based on 
country of infection, Ireland, 2016
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Table 2.  Number of cases (and percentage of cases where information is available) by home water supply type compared to the number and 
percentage of households by water supply type, Ireland 2016
Home water supply of notified cases
Number of 
cases
% of known 
cases
No. households served by these water 
supply types in the general population 
2016 (Census 2016)
% of known 
households P value*
Group water scheme (private) 30 5.8% 40952 2.5%
<0.001
Group water scheme (public) 32 6.2% 106278 6.5%
Other 1 0.2% 2281 0.1%
Private well 130 25.1% 171926 10.6%
Public water supply 325 62.7% 1306678 80.3%
Unknown/not specified 43 69550
Total 561 1697665 100%
*Comparing the proportion of cases and households served by public water supplies versus all other supply types: X2=100.25, P<0.001  
Table 1. Number of cases (and percentage of cases where information available) where selected risk factors were reported for cryptosporidiosis 
cases (n=561), Ireland, 2016
Risk factor Yes No Unknown / 
Not specified % of known
Travel outside of Irelanda 30 477 54 5.9%
Lives/cared for on farm 163 345 53 32.1%
Visited farm 183 279 99 39.6%
Lives/works on or visited farmb 303 174 84 63.5%
Swimming pool visit 121 375 65 24.4%
Other water based activities 31 353 177 8.1%
Contact with domestic pets 329 162 70 67.0%
aBased on country of infection variable
bComposite of the two previous variables
This is most likely due to the increased recognition of small 
family outbreaks following the introduction of enhanced 
surveillance for cryptosporidiosis cases late in 2010.
The one general outbreak notified was associated with 
a childcare facility (Table 3 and Figure 5). This is fewest 
number of general cryptosporidiosis outbreaks reported in a 
single year since 2010.
The 19 family outbreaks notified in 2016 occurred in private 
homes; 43 cases were ill and seven were hospitalised. 
The most common transmission route reported in these 
outbreaks was by animal contact (seven outbreaks, 17 
persons ill, five hospitalised), followed by person-to-person 
spread (three outbreaks, seven persons ill and no-one 
hospitalised), and waterborne (two outbreaks, six persons ill, 
no-one hospitalised). The transmission route was unknown 
for the remaining seven family outbreaks; 13 persons ill 
including two hospitalised cases (Table 3).
Summary
In 2016, the incidence of cryptosporidiosis in Ireland 
increased compared with 2015, being the highest reported 
incidence since 2012. It also remains high relative to most 
other EU countries with surveillance for cryptosporidiosis. 
The seasonal, age and regional distribution in incidence 
reported in 2016 was also typical of previous years; 
consistently there has been a higher incidence in springtime, 
in young children and in non HSE-E areas. 
Outbreak and case-based surveillance data are consistent 
with animal contact being an important risk factor for 
cryptosporidiosis in Ireland; over half of notified cases 
reported contact with a farm. Person-to-person spread also 
appears to be an important mode of transmission. From 
the enhanced information on CIDR, exposure to water 
from non public supplies appears to present a higher risk 
of cryptosporidiosis; persons who are not served by public 
water supplies were over-represented among the sporadic 
cases relative to the distribution of households by water 
supply type nationally. 
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Figure 5. Number of general cryptosporidiosis outbreaks by 
transmission route and year, Ireland 2004-2016
Note: In this figure, reported transmission routes were grouped for 
simplicity. Any outbreak where food contributed was reported as foodborne, 
any outbreak where water contributed was reported as waterborne, any 
outbreak where animal contact contributed was reported as animal contact. 
Person-to-person outbreaks include only those outbreaks reported as being 
due only to person-to-person transmission. 
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Table 3: Number of outbreaks and number ill by transmission route and location, Ireland 2016
Outbreak 
location
Person-to-person Waterborne Animal/ Environmental 
contact UNK/Not specified Total
No. out-
breaks No. ill No. outbreaks No. ill No. outbreaks No. ill No. outbreaks No. ill No. outbreaks No. ill
Childcare facility 1 4 0 0 0 0 0 0 1 4
Extended family 0 0 0 0 1 5 0 0 1 5
Private house 3 7 2 6 6 12 6 10 17 35
Travel related 0 0 0 0 0 0 1 3 1 3
Total 4 11 2 6 7 17 7 13 20 47
Introduction
For many years, Ireland has the highest verotoxigenic 
Escherichia coli (VTEC) notification rate in Europe, with the 
exception of 2011 when Germany reported the highest rate 
due to a large VTEC O104 outbreak linked with fenugreek 
seeds.1-2  In 2015 (the most recent data available), the 
notification rate for confirmed VTEC cases in the European 
Union/European Economic Area was 1.33 per 100,000 
(similar to 2014; 1.56/100,000) and the highest country-
specific rates were in Ireland, the Netherlands and Norway 
(12.9, 5.1 and 4.3 per 100,000 population, respectively).3
The dominant transmission routes reported for VTEC 
infection in Ireland have been person-to-person spread, 
especially in childcare facilities and among families with 
young children, and waterborne transmission associated 
with exposure to water from untreated or poorly treated 
private water sources. 4-8 Other important transmission 
routes identified internationally include food (often minced 
beef products or fresh produce such as lettuce and spinach), 
and contact with infected animals or contaminated 
environments.2, 9-10
Materials and Methods
Infection with verotoxigenic E. coli became a notifiable 
disease in 2012; prior to that, VTEC had been notifiable 
under the category Enterohaemorrhagic E. coli (EHEC) 
since 2004. Enhanced epidemiological information was 
supplied as in previous years by HSE personnel, and the 
VTEC National Reference Laboratory at the Public Health 
Laboratory, Cherry Orchard Hospital Dublin (VTEC-NRL at 
PHL) provided VTEC confirmation and typing data. Data from 
all sources are maintained in the Computerised Infectious 
Disease Reporting (CIDR) system. Outbreaks of VTEC are 
notifiable since 2004 and these data are reported to CIDR by 
the eight regional Departments of Public Health. 
Data from the Central Statistics Office (CSO) 2016 census 
were used to provide denominators for the calculation of 
national, regional and age-specific incidence rates in 2016.  
Results
Incidence
In 2016, 839 cases of VTEC were notified in Ireland, equating 
to a crude incidence rate (CIR) of 17.6 per 100,000 (95% CI 
16.4-18.8). Compared with 2015 (15.9 per 100,000) there was 
a 15% increase in the incidence of VTEC. Of the 839 VTEC 
notifications in 2016, 740 (88%) were classified as confirmed 
cases, 96 (11%) as probable cases and three as possible 
cases. The criteria under which notified cases were reported 
in 2016 are outlined in Table 1.  As the classification of VTEC 
cases changed significantly upon the amendment of the 
Irish VTEC case definition in 2012, it is not valid to directly 
compare the number of notifications by case classification 
before 2012. 
Of the 832 cases with laboratory evidence of infection, 
697 were culture confirmed (268 with VTEC O26 and 174 
with VTEC O157, with the remaining 255 caused by other 
serogroups), 135 were confirmed by PCR but were culture 
negative (includes 7 in which genes for serogroup O26 
3.3 Verotoxigenic E. coli 
Summary
Number of VTEC cases, 2016: 839
Crude incidence rate, 2016: 17.6/100,000
Number of VTEC-associated HUS, 2016: 32
Number of VTEC cases, 2015: 730
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Table 1. Number of VTEC notifications by criteria for notification and case classification, Ireland, 2016
Notification criteria Confirmed Probable Possible Total
Laboratory confirmation by culturea 623 74 697
Laboratory confirmation by PCR onlyb 117 18 135
Reported solely on the basis of epidemiological link 4 4
Clinical HUS not meeting lab or epi criteria 3 3
Total 740 96 3 839
a Symptomatic culture confirmed cases are classified as confirmed cases, while asymptomatic culture confirmed cases are classified as probable cases
b Symptomatic PCR-confirmed cases are classified as confirmed cases, while asymptomatic PCR-confirmed cases are classified as probable cases
detected and 10 in which genes for serogroup O157 detected) 
(Tables 1 and 2). Until 2012, VTEC O157 were more commonly 
reported in Ireland than other serogroups; this trends was 
reversed since then with VTEC O157 accounting for just a 
quarter of notified cases in 2016 (Figure 1). VTEC O26 is now 
the most common serogroup reported accounting for almost 
40% of cases in 2016. The crude incidence rate for VTEC O26 
infections stands at 5.78/100,000 and for O157 stands at 
3.86 per 100,000. 
Severity of illness
Of the 839 notified cases in 2015, 713 (85%) were 
symptomatic. Among symptomatic cases (and where 
information available), 675/700 (91%) reported diarrhoea, 
246/641 (38%) reported vomiting, 200/597 (34%) reported 
fever, 247/533 (46%) reported nausea, 425/600 (71%) 
reported abdominal pain and 261/666 (39%) developed 
bloody diarrhoea. Thirty two individuals developed HUS 
(3.8% of all notifications; 4.5% of symptomatic cases). This is 
the highest number of HUS cases since 2012 (n=33).  
In 2016, 313 VTEC cases were hospitalised (38% of all 
notified cases; 42% of symptomatic). Six deaths occurred 
among VTEC cases, however none of these deaths was 
attributed to VTEC infection.
Of the 32 HUS cases, 12 were culture confirmed with E. coli 
O26, seven with E. coli O157, two with E. coli O145, one each 
Figure 1. Annual number of confirmed and probable VTEC cases by 
serogroup, Ireland 1999-2016
Note: For simplicity in this figure, cases with mixed VTEC O157/other serogroup 
infections are included in the data for O157, as are probable cases linked to 
known E. coli O157 outbreaks. Non-O157 data includes cases with mixed 
non-O157 infections and probable cases linked to known O26 outbreaks
Figure 2. Seasonal distribution of the number of VTEC notifications in 
Ireland, 2016 and the mean of 2013-2015
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Table 2. Number of VTEC notifications by serogroup, verotoxin and HUS status, Ireland, 2016
Serogroupa Verotoxin HUS non-HUS Total % with HUS
laboratory confirmation by culture
o26
vt1 0 81 81 0%
vt2 4 8 12 33%
vt1+vt2 8 166 174 4.6%
Not reported 0 1 1 0.0%
o157
vt1 0 0 0 0.0%
vt2 4 95 99 4.0%
vt1+vt2 3 69 72 4.2%
Not reported 0 3 3 0.0%
other
vt1 1 99 100 1.0%
vt2 6 88 94 6.4%
vt1+vt2 0 53 53 1.9%
Not reported 0 8 8 0%
laboratory confirmation by pcR only
vt1 0 45 45 0%
vt2 3 54 57 5.3%
vt1+vt2 0 29 29 0.0%
Not reported 0 4 4 0.0%
Reported solely on the basis of epidemiological link - 0 4 4 0.0%
clinical Hus not meeting lab or epi criteria - 3 0 3 100%
total - 32 807 839 3.8%
*For simplicity mixed infections were recorded as O157 if at least one strain was O157, as O26 if at least one strain was O26 but not O157, and as Other if 
only non-O157 or non-O26 strains were detected. 
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with E. coli O182, O2, O113, O103, and O148. Three were 
reported on the basis of a PCR positive result without culture 
confirmation and three were possible cases (i.e. clinical HUS, 
without meeting laboratory or epidemiological criteria). 
HUS cases ranged in age from 1 month to 80 years and 69% 
(n=22) were in children under 15 years of age. Twenty-two of 
the HUS cases were considered sporadic, seven were part of 
family outbreaks and three were part of general outbreaks.
Seasonal distribution
Figure 2 shows the seasonal distribution of notifications 
in 2016 relative to the mean monthly number of cases in 
the years 2013-2015. Two peaks were observed in 2016; a 
smaller peak in April with a larger more protracted peak 
from June to October. As in previous years 19, VTEC O26 cases 
were more prevalent in the April-June period with VTEC O157 
being more prevalent in July to October; infections due to all 
serogroups were uncommon in winter months (Figure 3). 
Regional distribution
In 2016, the highest VTEC incidence rates were reported 
in the HSE-M and the HSE-MW. The rates were also 
significantly higher than the national crude incidence rate 
in the HSE-S, -SE and –W (Table 3). The incidence rates of 
VTEC in HSE-E, HSE-NE and HSE-NW were significantly 
lower than the national crude incidence rate. The highest 
incidence of VTEC-associated HUS was in HSE-MW and 
HSE-W (Table 3).
In the HSE areas except the HSE-E, the incidence of E. coli 
O26 in 2016 exceeded or equaled that of E. coli O157 (Figure 
4). 
Age-sex distribution
As in previous years, the highest reported age-specific 
incidence rate in 2016 was in the 0-4 year age group (94.7 
per 100,000) (Figure 5). 
Laboratory typing
In 2016, serogroup (culture positives only) and the verotoxin 
profiles of VTEC isolates/samples referred to the VTEC-NRL 
at PHL, Cherry Orchard Hospital are presented in Table 
4. The most common serogroup reported among culture 
positive notifications was E. coli O26 (n=268), followed by E. 
coli O157 (n=174). Among the other serogroups listed by the 
World Health Organisation as having the highest association 
with HUS internationally, there were 45 E. coli O145, 12 E. 
coli O103 cases and 11 E. coli O111. Other serogroups with 
significant numbers of cases in 2016 included O91, O146 and 
O182. 
As usual among E. coli O157 cases in Ireland, isolates 
containing the genes for vt2 were more common (57%) 
than strains containing genes for both vt1 and vt2, although 
a higher proportion of vt1 and vt2- containing strains of 
VTEC O157 were reported than in 2015. Among the VTEC 
O26 strains, those containing the genes for both vt1 and vt2 
accounted for the majority (65%), followed by vt1 only (30%) 
and those containing vt2 making up the remaining 4% of E. 
coli O26 cases (Table 4).
Risk factors
Under the enhanced surveillance system for VTEC, risk factor 
information is routinely collected on all notifications (Table 
5). Exposure to farm animals or their faeces and exposure to 
private well water were relatively common among cases in 
2016; 38% and 44% reported these exposures, respectively. 
According to CSO data, in the general population, around 
10.6% of households are served by private wells, indicating 
Figure 3: Seasonal distribution of VTEC notifications by serogroup, 
Ireland, 2016
For simplicity mixed infections were recorded as O157 if at least one strain 
was O157, as O26 if at least one strain was O26 but not O157, and as Other if 
only non-O157 or non-O26 strains were detected. 
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Table 3. Number and crude incidence rate VTEC by HSE area, and number and crude incidence rate of VTEC-associated HUS by HSE area, 
Ireland, 2016
HSE-area Number of VTEC cases Crude incidence rate /100,000 
(95% CI)
Number HUS cases Incidence of HUS /100,000 
(95% CI)
E 131 7.7 (6.3-9.0) 4 0.2 (0.0-0.5)
M 92 32 (25-38) 1 0.3 (-0.3-1.0)
MW 124 32 (27-38) 7 1.8 (0.5-3.2)
NE 52 11 (8.2-14) 4 0.9 (0.0-1.7)
NW 31 12 (7.8-16) 1 0.4 (-0.4-1.1)
S 159 23 (19-27) 5 0.7 (0.1-1.4)
SE 131 26 (21-30) 4 0.8 (0.0-1.6)
W 119 26 (22-31) 6 1.3 (0.3-2.4)
IE 839 18 (16-19) 32  0.7 (0.4-0.9)
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that, on a national basis, exposure to private wells appears 
to be more common among VTEC cases than among the 
general population. Unlike salmonellosis, foreign travel 
plays only a minor role in VTEC infection in Ireland, with the 
majority of infections acquired indigenously (96%). Where the 
information was available, just under a fifth of VTEC cases in 
2016 were attending a childcare facility (CCF). When these 
analyses were restricted to notified VTEC under five years of 
age, 45% reported attendance at a childcare facility. This is 
similar to the proportion of children in the general population 
who use non-parental childcare (42%) as reported by the 
Central Statistics Office.11
Outbreak and environmental investigations
The outbreak surveillance system plays a key role in our 
understanding of the transmission of VTEC infection in 
Ireland. Ninety-eight VTEC outbreaks were notified in 2016, 
which included 250 of the 839 VTEC notifications. Forty-six 
outbreaks were due to E. coli O26, 21 to E. coli O157, 14 were 
mixed E. coli strain outbreaks, and 17 were caused by other 
VTEC strains. 
The majority of outbreaks (n=91, 93%) were family outbreaks, 
with seven general outbreaks also notified. The 91 family 
outbreaks resulted in 175 persons becoming ill, with 30 
hospitalised. The seven general outbreaks resulted in 52 
persons becoming ill, with eight hospitalised. Eighty-four 
outbreaks occurred in private homes, six involved extended 
families, five involved childcare facilities, and there was one 
outbreak each in the community, associated with a pet farm 
(family outbreak) and associated with a restaurant.  The 
suspected modes of transmission are listed in Table 6.
Person-to-person spread is consistently the most common 
mode of VTEC transmission reported in Ireland, particularly 
between young children, and was suspected to have played a 
role in 42 (56%) VTEC outbreaks in 2016 in which 107 persons 
were reported ill (Table 6 and Figure 5). Thirty-three of these 
outbreaks were reported as being solely due to person-to-
person transmission, including four outbreaks which occurred 
in CCFs. 
Waterborne transmission was reported to have contributed to 
11 outbreaks (11%) with 29 persons ill. 
This is lower than the number of waterborne VTEC outbreaks 
reported in 2015 (n=19) and 2012 (n=21) but similar to the 
number reported in 2013 (n=8) and 2014 (n=9) (Figure 6). Of 
the 11 outbreaks with links to waterborne transmission, ten 
were family outbreaks and one an extended family outbreak. 
At least nine outbreaks were associated with exposure to 
private wells; in five cases, the water quality was reported to 
be unsatisfactory. 
Animal/environmental contact was reported to have 
contributed to 13 outbreaks (13%) with 22 persons ill (Figure 
6). All were linked with private houses.
Three outbreaks were reported where food was believed to 
have contributed to transmission. Two were family outbreaks, 
while one general outbreak was reported associated with a 
restaurant. During the general outbreak investigation,eleven 
outbreak-related cases were identified, four of whom 
were hospitalised. Epidemiological, environmental 
and microbiological findings pointed to the serving of 
undercooked burgers as the likely cause. 
For 39% (n=38) of VTEC outbreaks in 2015, the transmission 
route was reported as unknown (Table 6 and Figure 6).
Summary
The number of VTEC notifications in Ireland continued to 
rise in 2016. Within the European Union, Ireland continues 
to have the highest incidence rate for VTEC, reporting over 
seven times the European average in 2015.3 
The upward trend observed in Ireland in recent years of 
non-O157 notifications continued in 2016 and reflects the 
more widespread use by the primary hospital laboratories 
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Figure 4: Crude incidence rate VTEC O157, O26 and other serogroups 
by HSE area, Ireland, 2016
For simplicity mixed infections were recorded as O157 if at least one strain 
was O157, as O26 if at least one strain was O26 but not O157, and as Other if 
only non-O157 or non-O26 strains were detected. 
Table 4. Serotype and verotoxin (vt) profiles for strains associated with 
laboratory confirmed VTEC cases, as determined at the VTEC-NRL at 
PHL, Cherry Orchard Hospital, 2016
Serogroup VT1 VT1 + 
VT2
VT2 Not 
reported
Total
Culture 
positive 
notifications
O26 81 174 12 1 268
O157 0 72 99 3 174
O145 2 5 38 0 45
O91 4 11 5 0 20
O146 11 2 2 0 15
O182 12 1 0 0 13
O103 9 0 2 1 12
O113 0 2 9 0 11
O111 3 7 1 0 11
O5 11 0 0 0 11
Other* 48 25 37 7 117
PCR positive culture 
negative notifications 45 29 57 4 135
*Other includes Ungroupable strains
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of diagnostic methods that detect a broader range of E. coli 
serogroups and the use of more sensitive molecular methods 
that detect verotoxin genes directly in stool samples12 
National guidance developed for the laboratory diagnosis of 
human VTEC in Ireland provides a co-ordinated approach to 
VTEC diagnosis in Ireland.13
Foodborne transmission was the first recognised 
transmission route for VTEC infection historically, with 
minced beef, unpasteurised dairy products, and fresh 
produce consumed raw all having been implicated in 
outbreaks across the world. Foodborne outbreaks typically 
comprise a small percentage of the total number of VTEC 
outbreaks in Ireland; this was also true for 2016, however, 
the general outbreak in 2016 associated with undercooked 
burgers underscored the importance of vigilance in relation 
to thorough cooking of burgers. The FSAI updated its 
advice to caterers in its Feb 2017 factsheet ‘Advice for 
Caterers on Serving Burgers that are Safe to Eat’.20 The 
advice emphasised that minced meat burgers should be 
fully cooked to ensure they are safe to eat and that ‘caterers 
should not serve, offer or advertise undercooked or ‘pink’ 
burgers’.
Transmission by person-to-person spread, however, 
remained the most common transmission route reported 
in VTEC outbreaks and was involved in 56% of outbreaks. 
As usual, person-to-person spread was most frequently 
associated with private house and childcare facility 
outbreaks. Hand-washing and exclusion of cases in risk 
groups from high risk settings remains a key prevention 
measures for VTEC.14
In 2016, after person-to person spread, animal/
environmental contact was reported as the second most 
common route of transmission for VTEC outbreaks. This 
has long been recognised as a risk factor for VTEC infection 
9-10 and cases due to this transmission route are not 
unexpected in Ireland given the large cattle population, the 
high proportion of rural dwellers, and the large number of 
farming families.8 Advice is available on the HPSC website 
on how to minimise the risk of gastrointestinal infections 
following exposure to farm animals and environments, and 
for the safe recreational use of farmland.16
Contaminated drinking water was the third most commonly 
suspected mode of transmission. As in previous years, 
the outbreaks reported were linked with private water 
supplies. Exposure to water from contaminated untreated 
or poorly treated private water supplies has historically 
been recognised as a strong risk factor for VTEC infection in 
Ireland.6-8, 15This has been particularly pronounced following 
periods of heavy rainfall. 
The focus for reducing the incidence of VTEC should be on 
reducing person-to-person and waterborne transmission. 
Efforts should focus initially on publicizing materials already 
developed in Ireland, including national guidance for crèche 
owners on the management of infectious-disease spread 
in CCFs 17, guidance for public health professionals on the 
Figure 5. Number of notifications by age group, and age-specific VTEC 
incidence rates, Ireland 2016
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Table 5. Number of cases of VTEC (and percentage where information available) for selected risk factors, Ireland, 2016 (n=839)
Risk factor Yes(% of known) No Unknown or not reported
Food suspected 44 (7.8%) 522 273
Exposure to farm animals or their faeces 289 (38%) 476 74
Exposure to private well watera 229 (44%) 523 87
Travel-associatedb 30 (4.0%) 741 68
Attendance at a CCFc 140 (19%) 616 83
Attendance at a CCFc (among <5 yrs) 130 (45%) 159 22
aComposite variable recoded from two different water supply exposure enhanced variables in CIDR
bInferred from CIDR core variable Country of Infection
c CCF=childcare facility
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management of VTEC cases and outbreaks in CCFs14 and a 
leaflet developed for well owners outlining the infectious 
disease risks associated with drinking water from private 
wells, providing advice on actions that can be taken and 
what to do in the event the well water is contaminated.18
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Figure 6. Number of VTEC outbreaks by suspected transmission route 
and year, Ireland, 2006-2016
Note: In this figure, reported transmission routes were grouped for 
simplicity. Any outbreak where food contributed was reported as foodborne, 
any outbreak where water contributed was reported as waterborne, any 
other outbreak where animal contact contributed was reported as animal 
contact. Person-to-person outbreaks include only those outbreaks reported 
as being due only to person-to-person transmission.
Table 6. VTEC outbreaks by suspected mode of transmission, Ireland, 2016 
Transmission route Number of  outbreaks Number ill Number of associated CIDR 
eventsa
Person-to-person 33 84 80
Foodborne +/- person-to-person 3 16 31
Waterborne +/- person-to-person 11 24 29
Animal contact/Environment  +/- person-to-person 13 22 26
Unknown/Not specified 38 80 84
Total 98 226 250
a These figures may differ from the number ill, as asymptomatic cases identified as a result of screening will also be reported in CIDR
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Hepatitis A is an acute self-limiting disease of the liver caused 
by the hepatitis A virus. The most common symptoms are 
fever, loss of appetite and nausea, followed within a few days 
by jaundice. Disease severity varies, with some people having 
a relatively mild disease course lasting one to two weeks and 
others having more severe and prolonged symptoms lasting 
several months. Many infected children are asymptomatic. 
Chronic infection does not occur. The virus is shed in the 
faeces of infected people and is primarily spread from person 
to person by the faecal-oral route (via hands or other objects 
or through food or water that has been contaminated with 
the faeces of an infected person, or directly through oral-anal 
contact).1
Hepatitis A infection occurs worldwide, but the risk of infection 
varies with levels of sanitation and personal hygiene. Ireland 
is considered a low incidence country. Over the past decade 
the number of cases reported each year has ranged from 19 
to 50. Most cases notified in Ireland have a history of recent 
3.4 Hepatitis A
Summary
Number of cases, 2016: 38
Crude notification rate, 2016: 0.8/100,000 population
Number of cases, 2015: 36
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Figure 1. Number of hepatitis A notifications, by sex, 1997-2016
Figure 2. Notification rate for hepatitis A by HSE area, 2016
travel or are part of small family outbreaks, often including an 
index case who has travelled outside Ireland. There is a safe, 
effective vaccine for hepatitis A.1
The incidence of hepatitis A in Ireland has been low in recent 
years and remained low in 2016, with 38 cases notified 
(0.8/100,000 population) (figure 1). This was very similar 
to 2015 (n=36, 0.8/100,000 population) and the average 
number of cases notified annually over the past ten years 
(mean: 36, median: 37). Case classification was reported for 
all cases and thirty seven (97%) were laboratory confirmed. 
The notification rate in each HSE area is shown in figure 2.
Forty two percent (n=16) of cases in 2016 were male and 58% 
(n=22) were female. The highest notification rates were in 
children and young to middle-aged adults, with 53% (n=20) 
of cases aged between 0 and 14 years and 39% (n=15) aged 
25-44 years (figure 3). 
There were 14 sporadic cases of hepatitis A in 2016 and 24 
cases associated with nine distinct outbreaks. Eight of the 
sporadic cases were likely to have been infected outside 
Ireland and six were infected in Ireland. One of the cases 
infected in Ireland was linked to a household contact visiting 
from an endemic country. The index cases in eight of the nine 
outbreaks were infected outside Ireland. The one outbreak 
not associated with travel involved two children in HSE E and 
no source of infection was identified. Aside from Ireland, the 
most common countries of infection were Sudan (n=6, 4 cases 
associated with two outbreaks and 2 sporadic cases), Egypt 
(n=5, 4 linked cases and one sporadic case), Pakistan (n=4, 
3 linked cases and 1 sporadic case) and Spain (n=3, 2 cases 
associated with an outbreak and 1 index case in an outbreak 
with additional cases infected in Ireland).
The figures presented in this summary are based on data 
extracted from the Computerised Infectious Disease Reporting 
(CIDR) System on 2nd October 2017. These figures may differ 
from those published previously due to ongoing updating of 
notification data on CIDR. Notification rates are expressed 
per 100,000 population and are calculated using the 2016 
census.
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Figure 3. Hepatitis A age and sex-specific notification rates/100,000 population, 2016
Hepatitis E infection is a disease of the liver caused by 
hepatitis E virus (HEV), a virus which can infect both animals 
and humans. Most HEV infections are asymptomatic or 
mildly symptomatic. Therefore, a large proportion of cases 
are not diagnosed. However, hepatitis E infection can 
cause liver failure in those with pre-existing liver disease or 
in pregnant women. Infection is usually self-limiting and 
resolves in one to five weeks without any treatment. Rarely, 
chronic hepatitis E infection may develop in people who have 
a suppressed immune system.1 
In developed countries, HEV is usually spread from animals 
to humans through the consumption of undercooked pig 
and game meat, processed pork or shellfish. It can also be 
spread directly through handling animals, particularly pigs.1 
A study of pigs in the United Kingdom found that 6% were 
infected with HEV at the time of slaughter and that 93% had 
antibodies against HEV (current or past infection).2 Direct 
spread of hepatitis E from person to person is very rare, 
although the virus has passed between people through blood 
transfusions.3
Traditionally, hepatitis E was considered an infection 
associated with travel to areas with poor sanitation. 
However, an increasing number of indigenous cases have 
been identified across Europe in recent years and this led to 
hepatitis E becoming notifiable in Ireland on December 15th 
2015 (Amendment to the Infectious Diseases Regulations, SI 
566). The Irish Blood Transfusion Service (IBTS) introduced 
HEV screening for all blood donations on January 4th 2016. 
In order to collect information on the clinical features and 
risk factors for HEV infection in Ireland, the Departments 
of Public Health and the IBTS agreed to complete 
enhanced surveillance forms (ESF) for hepatitis E cases                     
(www.hpsc.ie/a-z/hepatitis/hepatitise/surveillanceforms/) 
for a one year trial period from the start of July 2016 to the 
end of June 2017. The IBTS completed the ESF developed 
by Public Health England from January to June 2016 and 
3.5 Hepatitis E
Summary
Number of cases notified, 2016: 90
Number of clinical cases: 56
Crude notification rate clinical cases, 2016: 1.2/100,000 
population 
Number of cases detected through blood donor screening: 34
Combined clinical and blood donor screening notification rate: 
1.9/100,000 population 
Percentage of blood donors HEV positive, 2016: 0.044% 
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Table 1. Number and percentage of cases who responded “yes” to each symptom and Fisher’s exact test p-value for a difference between clini-
cal and IBTS blood donor screening cases (p<0.05 indicates a significant difference)*
  Clinical cases
IBTS blood donor screening 
cases All P-value
  Num % Num % Num %  
Any symptoms 15 88.2 10 33.3 25 53.2 0.001
Loss of appetite 11 68.8 3 10.0 14 30.4 <0.001
Joint pain 10 62.5 0 0.0 10 21.7 <0.001
Dark coloured urine 8 50.0 1 3.3 9 19.6 <0.001
Fever 7 46.7 2 6.7 9 20.0 0.003
Jaundice 7 43.8 1 3.3 8 17.4 0.001
Weakness of limbs/tingling 6 37.5 0 0.0 6 13.0 0.001
Nausea 5 33.3 2 6.7 7 15.6 0.032
Abdominal pain 4 26.7 3 10.0 7 15.6 0.199
Headaches 4 26.7 0 0.0 4 8.9 0.009
Vomiting 3 18.8 0 0.0 3 6.7 0.039
Diarrhoea 0 0.0 2 6.7 2 5.3 1
Other neurological symptoms 4 30.8 0 0.0 4 9.3 0.006
Other symptoms 9 64.3 7 23.3 16 36.4 0.017
*Information only available for those for whom enhanced forms were completed (17 clinical and 30 IBTS blood donor screening cases, cases with no 
response for a given question were not included in the denominator for that question)
they provided copies of these forms to HPSC. This form was 
similar to the one adopted in Ireland in July 2016 and the 
data collected were comparable. The IBTS also provided 
data on the total number of blood donors and the number 
who tested positive for current HEV infection, by age and 
sex, in 2016. 
This is the first report on hepatitis E notifications in 
Ireland. The figures presented in this summary are based 
on data extracted from the Computerised Infectious 
Disease Reporting (CIDR) System on 13th September 2017 
and from an in-house database used for enhanced data. 
HEV notification rates for clinical cases are expressed per 
100,000 population and are calculated using the 2016 
census. IBTS blood donor denominator data were  used 
for calculating the percentage of blood donors who tested 
positive for HEV.
Results
There were 90 notifications of hepatitis E in 2016 
(1.9/100,000 population). The most likely country of 
infection was available for 46% (n=41) of cases. Of these, 
90% (n=37) were likely to have been infected in Ireland. 
Country of birth was available for 41% (n=37) and 89% 
(n=33) of these were born in Ireland. There were no cases 
notified in females who were pregnant and only a small 
number of cases reported regular medications or pre-
existing serious diseases that would be likely to impact on 
the severity of their HEV infection. 
Clinical cases (n=56)
Sixty two percent (n=56, 1.2/100,000 population) of 
HEV notifications were clinical cases. These cases were 
detected because they presented with clinical symptoms 
or liver function test results consistent with viral hepatitis. 
Enhanced surveillance forms were available for 71% (n=17) of 
clinical cases notified since July 2016, of whom 88% (n=15) 
were symptomatic. The most common symptoms reported 
were loss of appetite (69%), joint pain (63%), dark urine 
(50%), fever (47%) and jaundice (44%) (table 1). One patient 
with HEV died in 2016. His death was not attributed to HEV.
Notification rates for clinical HEV cases were significantly 
higher in older age groups. Almost two thirds of clinical 
cases (66%, n=37) were aged 50 years or older and the 
median age at notification was 57 years (55 years for males 
and 57 years for females).There were slightly more males 
than females, with males accounting for 55% (n=31) of 
clinical cases of HEV (figure 1). 
Cases were distributed across all regions but notification 
rates were lower in HSE SE, S and W (figure 2). 
Cases diagnosed through IBTS blood donor screening 
(n=34) 
Thirty eight percent (n=34) of HEV cases notified in 2016 
were blood donors detected through routine screening 
of blood donations. Enhanced surveillance forms were 
available for 88% (n=30). Cases diagnosed through 
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Figure 1. Age and sex specific notification rates per 100,000 population for clinical cases of hepatitis E, 2016
Figure 2. Notification rate for clinical cases of hepatitis E by HSE area, 2016
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Figure 3. Percentage of blood donors who tested positive for hepatitis E, by age group and sex, 2016 (IBTS data)
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screening of blood donations were mostly asymptomatic, 
but one third (n=10) disclosed mild symptoms (mostly 
fatigue and gastrointestinal symptoms) when questioned 
post-diagnosis (table 1). 
The age and sex distribution of HEV cases diagnosed 
through blood donor screening is influenced by the 
age and sex profile of blood donors. The IBTS provided 
denominator data on the number of blood donors in 2016 
so that the percentage of donors testing HEV positive could 
be calculated. Although the age and sex profile of blood 
donors is not the same as that of the general population, 
the percentage who test positive for HEV provides a useful 
estimate of the incidence and prevalence of acute HEV 
infection in Ireland. The overall prevalence of HEV in blood 
donors in 2016 was 0.044%.
Over three quarters (76%, n=26) of HEV notifications 
detected through blood donor screening were male. 
The IBTS HEV positivity rate was significantly higher in 
male blood donors (0.059%) compared to female donors 
(0.025%) in 2016 (figure 3). The age profile of the blood 
donors who tested positive for HEV was much younger than 
that of clinical cases. Eighty five percent of cases identified 
through donor screening (n=29) were aged between 18 and 
49 years and the median age at notification was 37.5 years 
(41 years for males and 25 years for females). The prevalence 
of HEV among blood donors aged less than 50 years 
(0.053%) was more than double that of those aged 50 years 
or older (0.024%) (figure 3).
Food preferences and animal exposures
Food histories were completed for 45 cases of HEV (15 
clinical cases and 30 IBTS blood donor screening cases). 
All but one responded that they were likely to have eaten 
one or more pork products in the nine weeks before illness 
or diagnosis (table 2). The most commonly consumed 
pork products were bacon (86%), pork meat (84%), pork 
sausages (84%) and sliced ham (74%). Except for cured 
pork, there were no statistically significant differences in 
food exposures between clinical and blood donor screening 
cases. 
Although physical contact with animals was also very 
common (78% of cases), this was not a likely source of 
infection as contact was mostly with pets such as dogs and 
cats. No cases reported contact with pigs. 
Discussion 
The number of notifications of HEV in Ireland in 2016 was 
higher than was predicted prior to HEV becoming notifiable. 
Older males have previously been reported as being at 
higher risk of HEV infection4 and indeed notification rates 
for clinical cases of HEV in Ireland in 2016 were marginally 
higher in males compared to females, and were significantly 
higher in those aged 50 years and over. Male blood donors 
were also more likely to test positive than female blood 
donors. However, the age profile of cases diagnosed 
through blood donor screening was very different to that of 
symptomatic cases, with younger donors more likely to test 
positive. Overall indications in Ireland are that older age is 
not associated with higher likelihood of HEV infection, just of 
symptomatic infection, and that males are more likely to be 
infected with HEV.
Although pork consumption was almost universal amongst 
cases of HEV in Ireland in 2016, we cannot definitively 
state that infection was due to pork consumption as we 
Table 2. Number and percentage of cases who responded “yes” to 
each exposure in the 9 weeks before illness or HEV diagnosis*
  All
  Num %
One or more pork products 44 97.8
Bacon 38 86.4
Pork meat 37 84.1
Pork sausages 37 84.1
Sliced ham, pre-packed 29 74.4
Black pudding 28 65.1
Cured pork e.g. salami 28 63.6
Ham, off the bone/joint 24 61.5
Pork pate 10 23.3
Pork pie 2 4.7
Pork liver 2 4.6
Other pork offal 0 0.0
Other pork products 7 17.5
Undercooked pork 1 3.1
Game 7 15.6
Shellfish 22 48.9
Worked at/visited farm/stable/petting farm/zoo 8 19.1
Physical contact with animals 35 77.8
*Information only available for those for whom food histories on the 
enhanced forms were completed (15 clinical and 30 IBTS blood donor 
screening cases, cases with no response for a given question were not 
included in the denominator for that question)
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do not have data from a comparable general population 
control group to indicate that pork consumption is higher 
in cases compared to non-cases. Pork consumption is 
likely to be very high in the general population in Ireland, 
particularly over a nine week time period. In a national 
adult nutrition survey carried out between 2008 and 2010, 
1,500 participants were asked to record all food consumed 
over a four day time period. Meat was consumed by 98% 
of respondents. Seventy three percent reported consuming 
bacon or ham and 38% had consumed sausages.5
Similarly high levels of pork consumption have been found 
in other studies. A hepatitis E case control study, carried 
out in England and Wales in 2011, found that 88% of cases 
had consumed sausages compared to 75% of controls and 
that 96% of cases had consumed ham compared to 83% 
of controls. These differences between cases and controls 
were not statistically significant. However, a statistically 
significant association was found between the consumption 
of sausages and ham purchased at a particular supermarket 
chain and hepatitis E infection.6 
Only one HEV case notified in Ireland in 2016 reported 
consumption of undercooked pork. Results from studies 
looking at the different combinations of time and 
temperature required to inactivate HEV in food have varied 
depending on the food or food substitute used (71°C for 
between 5 and 20 minutes).4 The Food Safety Authority of 
Ireland currently recommends cooking pork thoroughly to a 
minimum of 75°C in the thickest part of the meat.7 
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Rotavirus is the commonest global cause of paediatric 
gastrointestinal infection and causes sporadic, seasonal 
and occasionally severe gastroenteritis of infants and 
young children, characterised by vomiting, fever and watery 
diarrhoea. Transmission is usually person-to-person, mainly 
via the faecal-oral route. Children less than two years of 
age are most susceptible to infection, although cases are 
often seen in elderly and immunocompromised adults, 
particularly in institutional settings. By the age of six years, 
virtually all children will have had at least one episode of 
rotavirus infection. Symptoms usually last for only a few days 
but in severe cases hospitalisation may be required due to 
dehydration. 
Prior to 2004, rotavirus cases were notified under the 
“Gastroenteritis in children under two years” disease 
category. From 2004 to 2010, rotavirus was notifiable in 
all age groups under the “Acute Infectious Gastroenteritis” 
(AIG) disease category, until it became notifiable as a 
disease in its own right under the Infectious Diseases 
(Amendment) Regulations 2011 (S.I. No. 452 of 2011). Since 
March 2013, rotavirus notifications from HSE-East are based 
on laboratory testing results rather than patient episodes. 
Notifications from HSE-E may also refer to area of laboratory 
testing rather than area of patient residence.
Rotarix™ vaccine was introduced in Ireland in December 
2016 for all babies born from 1st October 2016 onwards. 
Rotarix™ is a live attenuated monovalent vaccine. Vaccine is 
administered orally in two doses at 2 months and 4 months. 
Both doses must be administered by 8 months old. 
During 2016, there were 2,372 cases of rotavirus notified in 
Ireland, corresponding to a national crude incidence rate 
(CIR) of 51.7 per 100,000 population (figure 1).*  This is a 
marked decrease of 43% compared to 2015 (90.6) and a 
decrease of 6.7% compared to the mean CIR during 2006-
2015 (56.7). 
Significant geographical variation was observed in regional 
3.6 Rotavirus
Summary
Number of cases: 2,372
Crude incidence rate: 51.7/100,000 population
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Figure 1: Number of rotavirus notifications and crude incidence rate per 100,000 population by year (CIDR)
Number of notifications Rate per 100,000 population 
2112 
2328 2318 2354 2501 2451 
2652 2514 
2061 
4158 
2372 
0.0 
10.0 
20.0 
30.0 
40.0 
50.0 
60.0 
70.0 
80.0 
90.0 
100.0 
0 
500 
1000 
1500 
2000 
2500 
3000 
3500 
4000 
4500 
20
06
 
20
07
 
20
08
 
20
09
 
20
10
 
20
11
 
20
12
 
20
13
 
20
14
 
20
15
 
20
16
 
R
at
e 
pe
r 1
00
,0
00
 p
op
ul
at
io
n 
N
um
be
r o
f n
ot
ifi
ca
tio
ns
 
Year of notification 
* All rates are per 100,000 population
rotavirus CIR. The highest regional CIRs were observed in 
HSE-M (73.3), -SE (58.3) and -W (54.8). The lowest regional 
CIR was observed in HSE-NW (38.3) and HSE-NE (44.5). 
Rotavirus infection has a well-documented seasonal pattern 
in Ireland with the number of cases typically peaking during 
March to May. During 2016, rotavirus notifications peaked 
during May (n=594) and June (n=476). Figure 2 illustrates 
the seasonal variation in rotavirus cases by month of 
notification for 2016 compared to the mean monthly number 
of notifications reported during 2006 to 2015. 
During 2016, 1,100 cases (46.4%) were female and 1,269 
(53.5%) were male. Sex was not reported for the remaining 
three cases. 
Seven outbreaks of rotavirus were notified during 2016 
with 55 cases of associated illness, five of whom were 
hospitalised. Five general outbreaks occurred, two in child-
care facilities, two in nursing homes and one in a hospital. 
The remaining two outbreaks were family outbreaks that 
occurred in private homes. Six outbreaks reported mode of 
transmission as person to person or airborne spread while 
mode of transmission was unknown for the remaining 
outbreak.
Figure 2: Number of rotavirus notifications by month, 2016 compared to mean monthly number of notifications 2006-2015 (CIDR)
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Salmonellosis typically presents clinically as an acute 
enterocolitis, with sudden onset of abdominal pain, 
diarrhoea, nausea, headache and occasionally vomiting. 
Fever is almost always present. Dehydration, especially 
amongst vulnerable populations such as infants, the 
immunocompromised and the elderly, may be severe. 
Invasive infection occurs in a proportion of cases. S. Typhi 
and S. Paratyphi can cause enteric fever, a severe systemic 
life threatening condition, but these are not common in 
Ireland and are almost invariably travel-associated.
The common reservoirs for non-typhoidal Salmonella are 
the intestinal tract of domestic and wild animals (including 
birds), which may result in a variety of foodstuffs, of both 
animal and plant origin, becoming contaminated with faecal 
organisms either directly or indirectly. The organism may 
also be transmitted through direct contact with infected 
animals or humans or faecally contaminated environments. 
Infected food handlers may also act as a source of 
contamination for foodstuffs. Of particular concern is the 
number of cases of infection associated with direct contact 
with reptiles kept as companion animals. 
During 2016, 302 cases of salmonellosis were notified, 
corresponding to a crude incidence rate (CIR) of 6.3 per 
100,000 population (Figure 1). The annual CIR has been 
decreasing gradually over the last eight years (from 
10.8/100,000 in 2007 to between 5.7 and 6.3 in the last 
three years). The 302 cases notified in 2016 represent a 
12% increased compared to 2015. The highest CIR in 2016 
occurred in HSE-M (8.9/100,000) and the lowest in HSE-NE 
(4.6/100,000). 
The highest age-specific incidence rate among both sexes 
was in children under 5 years of age (19.9/100,000). 
This is likely to be influenced by clinicians more readily 
seeking clinical samples in that age group. The lowest age 
specific rate was observed in the 35-44 year age group 
(3.4/100,000). The male to female ratio was in general 
higher in children and adults under 25 years (1.4:1), and 
lower in adults 25 years and older (0.6:1).
Disease Severity
Diarrhoea was the most common symptom (94% of 
cases) among notified cases in 2016 (Table 1), followed by 
abdominal pain (80%). Bloody diarrhoea occurred among 
3.7 Salmonella 
Summary
Number of confirmed cases: 302
Crude incidence rate: 6.3/100,000 population
Figure 1: Salmonellosis notifications and CIR by year of notification (CIDR)
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Figure 2: Salmonellosis notifications by month of notification and country of infection, 2016 (CIDR)
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28% of cases. Median duration of illness was seven days 
(range 1-50 days), based on observations for 161 cases. 
Forty-one per cent of cases (121/292) were hospitalised. 
There was one death reported in an elderly woman as being 
due to salmonellosis among the notifications in 2016.
Foreign travel as a risk factor for salmonellosis in Ireland
Country of infection was reported for 91% of notifications in 
2016. Where country of infection was reported, 46% of cases 
were travel-associated (126/275). Overall, case numbers 
peaked between May and November. This was true for both 
indigenous and travel-related cases, although there was less 
pronounced seasonal variation for indigenous cases than for 
travel-related cases (Figure 2).
Among travel associated cases (n=126), the most common 
countries of infection reported were Spain (n=38), Thailand 
(n=13), Poland (n=9) and Turkey (n=8). The popularity of a 
country as a travel destination is likely to be an important 
factor in determining the number of cases associated with 
each country. 
As might be expected, cases who acquired their disease 
in Ireland or other parts of Europe were younger than 
cases who acquired their disease during long-haul travel 
(Table 2). Disease acquired in Ireland was more commonly 
caused by S. Typhimurium and monophasic Typhimurium 
strains (40%) than by S. Enteritis strains (20%), with 
other strains making up the remaining 40% of cases. By 
contrast, disease acquired in Europe was associated most 
commonly associated with S. Enteritidis (56%), followed by 
other strains (28%), with S. Typhimurium and monophasic 
Typhimurium strains accounting for only 16% of cases. For 
cases associated with acquisition in the rest of the world, 
non-Enteritis, non-Typhimurium cases predominated (65%), 
S. Enteritidis accounting for 24% and S. Typhimurium and 
monophasic Typhimurium strains for 11% of cases (Table 2).
Animal contact as a risk factor
Contact with pets (in particular exotics like snakes and 
turtles), contact with pet food (e.g. frozen rodents), contact 
with wildlife (e.g. hedgehogs), and contact with cattle, have 
all been associated with an increased risk of salmonellosis, 
especially in children. In 2016, 36% (86/237) of salmonellosis 
cases reported contact with pets (five of which were reptiles), 
4% (9/231) reported contact with farm animals, 2% (2/127) 
reported contact with wildlife, and 12% (22/189) reported 
contact with pet feed (none with frozen feeder rodents). 
Typhoid/Paratyphoid:
In 2016 ten cases of typhoid were notified. All were 
associated with travel to Asia, principally Pakistan (n=5) and 
India (n=3). Four cases occurred in children aged 5 years or 
less. Seven paratyphoid cases were notified. Six were adult 
Table 1: Disease severity of notified salmonella cases 2016 (CIDR)
Symptom/disease feature Number with 
Symptom
Number without 
Symptom
Number symptom 
Unknown
Percentage of cases with symptom 
(among known)
Diarrhoea 259 18 25 94%
Bloody diarrhoea 73 184 45 28%
Nausea 151 89 62 63%
Abdominal pain 199 50 53 80%
Fever 161 89 52 64%
Headache 58 134 110 30%
Myalgia 32 152 118 17%
Rash 13 183 106 7%
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and one was a child. Six were associated with travel to Asia 
–all were S. Paratyphi A. For one elderly case of S. Paratyhi B, 
acquisition was reported to have been in Ireland.
National Salmonella, Shigella and Listeria Reference 
Laboratory (NSSLRL) data:
The National Salmonella, Shigella and Listeria Reference 
Laboratory (NSSLRL) based in Galway has been providing 
reference services nationally since 2000. In 2016, the 
NSSLRL analysed 310 human Salmonella isolates referred 
for further typing, including eleven S. Typhi and seven S. 
Paratyphi. Figure 3 shows the distribution of serotypes over 
this time period. Cases due to S. Typhimurium decreased by 
10% compared to 2015, while those due to S. Enteritidis and 
other serotypes increased by 20% and 22% respectively. 
More detail on the distribution of human Salmonella isolates 
by phage type and their resistance to antimicrobials is reported 
in the National Salmonella, Shigella & Listeria Reference 
Laboratory of Ireland, Annual Report for 20161. This report 
also details new developments in relation to the use of whole 
genome sequencing during 2017.
Outbreaks
During 2016, nine small outbreaks of salmonellosis 
were reported, comprising 24 cases of illness and four 
hospitalisations.  Seven were in private homes while two 
involved extended family. Three outbreaks were reported as 
due to person to person spread, three were foodborne+/- 
person-to-person spread, two animal contact +/- person-to-
person spread, while mode of transmission for the remaining 
outbreak was reported as unknown. 
References: 
National Salmonella Shigella & Listeria Reference Laboratory of Ireland, 
Annual Report for 2016. Available at: 
http://www.saolta.ie/documents/nsslrl-annual-report-2016 
Table 2: Salmonellosis notifications acquired in Ireland, Europe and Rest of the World by age group and serotype, 2016 (CIDR)
Characteristic Ireland Europe Rest of the world Unknown /Not Specified Total
Age group
<15 yrs 64 28 10 4 106
15-44 yrs 41 15 35 14 105
45-64 yrs 22 18 7 6 53
65+ yrs 22 9 4 3 38
Serotype
Typhimurium 27 5 4 7 43
4,[5],12:i:- 30 6 2 4 42
Enteritidis 28 39 13 4 84
Other 58 19 35 11 123
Not specified 6 1 2 1 10
Total 149 70 56 27 302
Figure 3: Annual number of Salmonella isolates referred to NSSLRL by serotype (NSSLRL)
Year 
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Listeriosis 
In 2016, 13 cases of listeriosis were notified, a decrease 
compared to 2015 when 19 cases were reported. For 2016, 
this equates to a crude incidence rate of 0.27 per 100,000 
population.
In 2016, two neonatal cases and one pregnancy-related 
case were reported (Figure 1). The number of adult/juvenile 
cases reported in 2015 decreased by 29% (n=10) compared 
with 2015 (n=14) (Figure 1). Seven of the ten adult/juvenile 
cases were male, cases ranged in age from 51 to 88 years 
and half (n=5) were 65 years of age and older. Three adult/
juvenile cases had septicaemia, three had meningitis and 
septicaemia, two had other symptoms and symptoms were 
not specified for two. One patient died; the cause of death 
was not reported but the patient had an underlying illness.  
Since 2007, the National Salmonella, Shigella and Listeria 
Reference Laboratory (NSSLRL) in Galway provides a national 
service for the typing of Listeria strains. Isolates from eleven 
of the 13 notified cases in 2016 were referred by the primary 
laboratories for serotyping. Serotype 4b was the most 
common (n=6) followed by serotype 1/2a (n=5) (Table 1).
In Ireland, listeria remains a hazard for the elderly, persons 
with underlying illness, and other vulnerable groups most 
especially pregnant women and neonates. Occasionally, 
neonatal losses are reported in women for whom English 
is not their first language. Safefood has an advice leaflet 
outlining the risks to pregnant women from Listeria in a range 
of languages.    
3.8  Less common gastroenteric    
infections
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Figure 1: Number listeriosis notifications by case type, Ireland, 2004-2016
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Table 1: Listeriosis notifications by case type and serotype, Ireland, 2016*
Type Serotype 1/2a Serotype 1/2b Serotype 4b Not referred for 
serotyping
Total
Adult or juvenile 6 0 3 1 10
Pregnancy-related 0 0 0 1 1
Neonatal 0 0 2 0 2
Total 6 0 5 2 13
* Typing data provided by the National Salmonella, Shigella and Listeria Reference Laboratory (NSSLRL)
Giardiasis
In 2016, there were 202 cases of giardiasis notified, 
corresponding to a crude incidence rate (CIR) of 4.2 per 
100,000 population, an increase of 30% in CIR compared 
to 2015. This increase appears to be largely due to recent 
changes in laboratory practice with respect to selection of 
stools for testing consequent to the introduction of newer, 
more sensitive, molecular detection methods. 
Cases ranged in age from ten months-90 years with a 
median age of 34 years. The male to female ratio was 
1.3:1.0. The majority of cases were diagnosed in GP patients 
(65.0%). 
Country of infection was reported for 70.2% of cases in 2016, 
an increase compared to 2015 (Figure 2). Of the 142 cases 
where country of infection was reported, 58 (41.0%) were 
reported as being associated with foreign travel. Twenty 
eight different countries were reported, the most common 
of which were India (n=12), Spain (n=5), and Pakistan (n=4). 
Eighty-four cases (59.0% of those with country of infection 
information) were reported as being acquired in Ireland, 
a further increase compared to the 51% reported in 2015. 
Country of infection was not reported for the remaining 60 
cases. 
It is likely that there is a degree of under-ascertainment of 
indigenous Irish cases of giardiasis, when the incidence in 
Ireland is compared with that in England & Wales. It would 
be important for practitioners to bear in mind that the 
majority of cases of giardiasis in Ireland are likely not to be 
travel related were the true incidence known with any degree 
of accuracy. 
Nine family outbreaks of giardiasis were notified in 2016, 
with 25 persons ill. One was considered to be due to person 
to person transmission, with transmission route unknown 
for the remaining family outbreaks. In addition, one MSM 
outbreak with two persons ill was reported.  
 Yersiniosis
In 2016, there were three cases of yersiniosis reported. All 
three infections were in adult females and were due to Y. 
enterocolitica. The reported incidence of yersiniosis in Ireland 
is low relative to the EU as a whole, and to Northern Europe 
in particular. 
Foodborne intoxications 
There were no cases or outbreaks of Bacillus cereus, botulism, 
Clostridium perfringens (type A) food-borne intoxication or 
staphylococcal food poisoning notified in 2016.
Figure 2: Number of giardiasis notifications by travel status, 2004-2016
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Summary
Number of notifications: 84
Crude incidence rate: 1.8/100,000
Shigellosis is caused by the bacterium Shigella. There are 
four species of this bacterium S. sonnei, S. boydii, S. flexneri 
and S. dysenteriae. S. dysenteriae produces a very powerful 
toxin that produces severe damage to the lining of the gut. 
The bacteria are only found in humans. Anyone can get 
shigellosis, but those who are at greater risk include children 
in child care centres and their parents, overseas travellers, 
institutionalized people and men who have sex with men 
(MSM). 
Eighty four cases of shigellosis were notified in Ireland in 
2016, corresponding to a crude incidence rate (CIR) of 1.8 
per 100,000. This represents a decrease of 7% compared to 
2015. Of 82 cases where hospitalisation status was recorded, 
24 (29%) were reported as hospital in-patients. All were 
laboratory confirmed. 
The excess of male cases compared to females was slightly 
lower compared to 2014 and 2015 at 1.5: 1.0 (figure 1). 
During 2016, cases ranged in age from 10 months to 89 
years (median age=31 years). The male to female ratio was 
highest in the age range 25-44 years (2.5:1.0). 
3.9 Shigellosis
-82-HPSC Annual Epidemiological Report 2016 3. Infectious Intestinal Diseases
Figure 1: Annual number of notifications shigellosis by sex and year, Ireland 2004-2016 (Data source: CIDR)
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Table 1: Number of Shigella notifications by species and country of infection, Ireland 2016
Organism Ireland Africa Asia Caribbean South America Unknown/Not 
specified
Total
S. boydii 1   1       2
S. dysenteriae   2 2
S. flexneri 16 2 2 0 3 4 27
S. sonnei 19 6 12 1 1 6 45
S. species 1   3 1 3 8
Total 37 8 20 2 4 13 84
Information on travel history is very valuable when reviewing 
surveillance data for possible indigenous clusters. Data on 
country of infection was available for 85% of shigellosis 
notifications this year. Thirty-four cases were reported as 
being associated with foreign travel in at least 22 countries 
during 2016. Thirty-seven cases were reported as being 
acquired in Ireland (52% of known), while no country of 
infection information was available for 13 cases. 
S. sonnei was the most common species reported (n=45), 
followed by S. flexneri (n=27), both of which were commonly 
associated with indigenous acquisition. 
Two general shigellosis outbreaks were notified in 2016, 
resulting in 19 cases of illness and seven associated 
hospitalisations (Table 2). A small outbreak of Shigella 
flexneri 2a comprising 5 cases was reported among MSM. A 
foodborne outbreak comprising 14 cases of S. sonnei across 
the Republic and Northern Ireland was epidemiologically 
linked to consumption of pre-prepared toasted sandwiches 
at a restaurant chain. 
More detailed typing of Shigella isolates can provide useful 
information on the relatedness of strains which is used by 
public health personnel to outrule/provide evidence for 
links between cases during investigations of case clusters. 
The National Salmonella, Shigella and Listeria Reference 
Laboratory (NSSLRL) provide laboratory services for 
speciation, serotyping, antimicrobial resistance profiling, 
and most recently, Whole Genome Sequencing (WGS) of 
Shigella isolates. The species/serotype and antimicrobial 
resistance patterns of these cases are reported in Table 3. 
During 2016, almost 90% of Shigella isolates recovered in 
primary hospital laboratories were referred for typing at the 
NSSLRL in Galway. Speciation and antimicrobial resistance 
(AMR) profiling were key in defining the extent of the two 
general outbreaks reported in 2016, demonstrating the 
importance of referral of all Shigella isolates for typing. 
Table 2: Shigellosis outbreaks 2016 (Data source: CIDR)
HSE-area Outbreak type Location Transmission mode Number ill Serotype
HPSC General Community Foodborne 14 S. sonnei
HSE-E General Community Person-to-person 5 S. flexneri 2a
Table 3: Shilgella isolates referred to NSSLRL in 2016 by species and 
AMR profile
Species
Number 
by 
species
AMR profile Number by 
species and 
AMR
Shigella boydii 2
none 1
SuTTm 1
Shigella dysen-
teriae
3
ASSuTTm 1
SuTTm 1
SuTTmNa 1
Shigella flexneri 1a 1 SSuTTm 1
Shigella flexneri 1c 2
ASSuTTmAzt 1
T 1
Shigella flexneri 2a 19
ACSAzt 1
ACSSuTTm 5
ACSSuTTmNaCp 1
ACST 2
ACSTTm 2
ACTTmNaCp 5
ASSuTmNaCp 2
SSuTm 1
Shigella flexneri 3a 1 ACST 1
Shigella flexneri 3b 1 ACT 1
Shigella flexneri 4c 2
ACSSuTTmNaCp 1
SuTTm 1
Shigella flexneri 6 1 SuTTmNaCp 1
Shigella flexneri X 
variant 1
ACST 1
Shigella sonnei 41
ASSuTm 1
ASSuTTm 1
ASSuTTmCtx 1
ASSuTTmNa 1
ASSuTTmNaAzt 2
ASSuTTmNaCpAzt 1
ASSuTTmNaGm 1
ASuTTmNaCpAzt 1
SSuTm 1
SSuTTm 5
SSuTTmNa 6
SSuTTmNaCp 5
Su 1
SuTm 1
SuTTm 2
SuTTmNa 3
Tm 8
Total 74 Total 74
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In 2016, 88 malaria cases were notified in Ireland, an 
increase of 8.6% in comparison to 81 cases reported in 
2015 (Figure 1). Among European Union (EU) member 
states reporting malaria data to the European Centre for 
Disease Prevention and Control, Ireland had the fifth highest 
incidence rate for imported malaria in 2014 (the latest year 
for which comparative data are available); only Belgium, 
Norway, Sweden and the United Kingdom had higher 
reported incidence rates.
In common with the rest of the EU, males predominated 
with a male:female ratio of 2.2:1.0. The highest numbers of 
cases were aged between 25 and 54 years. The number of 
paediatric cases reported was 14, an increase compared to 
six cases reported during 2015 (Figure 1). Nine paediatric 
cases did not have details on endemic areas visited, reason 
for travel or on malarial prophylaxis taken. For the five 
paediatric cases with such details reported, all reported 
visiting family in their country of origin as their reason 
for travel to countries in sub-Saharan Africa. Of these 
five paediatric cases, only one reported taking malaria 
prophylaxis but no details on compliance were available for 
this case. Three paediatric cases reported not taking any 
prophylaxis for their travel, while the remaining paediatric 
case did not have information on prophylaxis reported. 
Among all age groups, the category of traveller most 
affected in Ireland continued to be African immigrants 
and their families who were exposed while returning to 
visit family in their country of origin. This almost certainly 
reflects the greater frequency with which this group travels 
to malarious areas, but also reflects Ireland’s importance as 
a destination for those emigrating from English speaking 
West Africa. Of the 31 cases (35.2%) in 2016 where reason 
for travel was reported, 61.3% cited visiting family in their 
country of origin, all of whom travelled to Africa. Other 
reasons cited for travel this year were business/professional 
travel (n=6), Irish citizen living abroad (n=2), other reason for 
travel (n=2), foreign visitor ill in Ireland (n=1) and new entrant 
to Ireland (n=1). 
Probable country of infection was reported for 36 cases 
(40.9%). Nigeria remained the country most frequently 
visited, accounting for 52.8% of cases where country of 
infection was reported. The remaining 17 cases were exposed 
in 13 other countries within Africa and one case acquired 
their infection in India. The majority of cases who reported 
travel to Nigeria were visiting family in country of origin 
(16/19) with known reason for travel. One case reported no 
4.1 Malaria 
Summary
Number of cases: 88
Crude incidence rate1: 1.8/100,000
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Figure 1: Annual number of malaria notifications by age, Ireland 2007-2016
Year of notification 
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1  Rates calculated per 100,000 population as per Census 2016
recent history of travel to an endemic area. This case was 
thought to have acquired their malaria in an airport in a non-
endemic country. 
Plasmodium falciparum accounted for 86.9% of infections in 
2016, reflecting the dominance of exposure in Africa as the 
source of the majority of notifications. Five cases of P. ovale, 
five cases of P. vivax and one case of P. malariae were also 
reported. The remaining four cases did not have Plasmodium 
species specified.
HPSC resources for health professional include a poster 
which can be downloaded from the HPSC website for 
display in GP surgeries, maternity/paediatric hospitals and 
emergency departments. The material advises immigrant 
families travelling to Africa to consult their doctor about 
malaria before travelling. A leaflet for intending travellers, 
available in English and French, highlights the value of 
antimalarial prophylaxis and protection against mosquito 
bites. Clinical Guidelines on the Management of Suspected 
Malaria are also available on the HPSC website.
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Figure 2: Annual number of notifications malaria by reason for travel, Ireland 2007-2016
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During 2016, 26 cases of leptospirosis were notified in 
Ireland, corresponding to a crude incidence rate (CIR) of 
0.6 per 100,000 population. This represents an increase 
compared to 16 cases notified in 2015 (Figure 1). The EU 
crude incidence rate was 0.2 per 100,000 in 2015, latest 
year for which data was available. Among the countries that 
reported leptospirosis incidence in 2015, Ireland reported the 
fifth highest incidence rate after Croatia, Slovenia, Portugal 
and the Netherlands. 
The age range of cases was 9-67 years (mean age=39.5 
years, median age=39 years). Cases in the younger age 
groups are more likely to be associated with recreational 
exposure and history of foreign travel while older cases 
are mainly indigenous and associated with occupational 
exposure. Figure 1 illustrates the annual trend by travel 
history. The leptospirosis notification dataset is typically 
dominated by adult males, and this year was no exception 
with male cases accounting for 80.8% of cases (Table 1).
Of the 23 cases who reported details of potential exposures, 
11 cases (47.8%) were believed to have acquired their illness 
occupationally. Of the occupationally exposed cases, 
five were farmers, two had animal contact, two had river 
water contact and two had exposure to contaminated 
environments. Six cases (26.1%) were reported as being 
associated with recreational activities, including river water 
exposure. Five cases (21.7%) reported residential exposure 
and one case reported accidental exposure to potentially 
contaminated environments. Exposure details were not 
reported for the remaining three cases (11.5%). Figure 2 
shows the trend in notifications by exposure group and year. 
Among the 21 cases for which hospital admission status was 
reported, 16 (76%) required hospitalisation. 
Activities that continue to be associated with leptospirosis 
risk in Ireland include farming and recreational activities 
such as water sports. In recent years, travel to Asia and 
other tropical destinations has emerged as a risk factor for 
leptospirosis. 
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4.2 Leptospirosis           
Summary
Number of cases: 26
Crude incidence rate: 0.6/ 100,000 population
Figure 1: Annual number of leptospirosis notifications by year and 
travel history (Data source: CIDR)
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Figure 2: Annual number of leptospirosis notifications by exposure 
group by year (Data source: CIDR)
Year
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Table 1: Leptospirosis notifications by age and sex, 2016 
Age group (years) Female Male Total
5-9 yrs 1 1
15-19 yrs 1 1 2
20-24 yrs 1 1 2
25-34 yrs 1 3 4
35-44 yrs 1 5 6
45-54 yrs 6 6
55-64 yrs 3 3
65+ yrs 2 2
Total 5 21 26
Brucellosis
Two cases of brucellosis were notified. This compares to a 
mean number of 1.8 cases annually between 2011 and 2015. 
Echinococcosis
Two cases were reported during 2016, the first cases 
reported since 2007. Country of infection was not reported 
for either case.
Q Fever
Six cases of Q fever were reported in Ireland in 2016, an 
increase compared to four cases reported during 2015. Five 
cases were male and the median age was 51.5 years. 
Toxoplasmosis
During 2016, 24 cases of toxoplasmosis were notified 
which remains stable compared to 26 cases reported in 
2015. Among cases where patient type was reported, 25% 
were hospitalised. Cases ranged in age from 5 to 47 years 
(median: 32.5 years). No congenital cases were reported in 
2016. 
As in previous years, more cases were reported among 
females then males, (M:F ratio 0.5:1.0). This was particularly 
evident among females in the 25-44 year age group, which 
accounted for half of the total cases. This is most likely a 
reflection of enhanced testing during pregnancy. 
Trichinosis 
No cases of trichinosis were notified in Ireland in 2016. 
4.3  Other Notifiable Non-IID Zoonotic 
Diseases
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Table 1: Non-IID zoonoses notifications by age and sex, 2016
Disease Short 
Name
Age 
Group
Female Male Total
Brucellosis
45-54 yrs 1 1
65+ yrs 1 1
Echinococcosis
5-9 yrs 1 1
15-19 yrs 1 1
Q fever
35-44 yrs 2 2
45-54 yrs 1 1
55-64 yrs 1 2 3
Toxoplasmosis
5-9 yrs 1 1
10-14 yrs 1 1
15-19 yrs 2 2
20-24 yrs 1 2 3
25-34 yrs 4 3 7
35-44 yrs 8 8
45-54 yrs 2 2
Total 19 15 34
Table 2: Non-IID zoonoses notifications by HSE, 2016
HSE area Brucellosis Echinococcosis Q fever Toxoplasmosis Total
HSE-E 8 8
HSE-M 1 1
HSE-MW 1 1 1 3
HSE-NE 1 2 3
HSE-NW 1 1
HSE-SE 1 1 1 3
HSE-S 6 6
HSE-W 1 2 6 9
Total 2 2 6 24 34
Table 3: Non-IID zoonoses notifications by patient type, 2016
Patient Type Brucellosis Echinococcosis Q fever Toxoplasmosis Total
GP Patient 1 2 9 12
Hospital Day Patient 1 1
Hospital Inpatient 1 3 5 9
Hospital Outpatient 1 6 7
Not Specified 1 1
Unknown 4 4
Total 2 2 6 24 34
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In addition to malaria, there are nine further notifiable 
vectorborne diseases in Ireland, chikungunya, dengue, lyme 
neuroborelliosis, tularemia, typhus, tickborne encephalitis 
(TBE), West Nile fever, yellow fever and zika virus infection. 
The case definitions for these diseases are outlined on the 
HPSC website at: 
http://www.hpsc.ie/NotifiableDiseases/CaseDefinitions/.
A summary of vectorborne diseases notified during 2016 
is reported below. Table 1 displays the number of cases of 
vectorborne diseases by HSE area, Table 2 displays cases by 
age group in years while Table 3 displays cases by probable 
country of infection.
Chikungunya fever
Chikungunya is a mosquito-borne viral infection that causes 
fever and severe joint pain. Other symptoms include muscle 
pain, headache, nausea, fatigue and rash. The disease 
mostly occurs in Africa, Asia and the Indian subcontinent. 
However a major outbreak in 2015 affected several countries 
of the Region of the Americas.
One case of chikungunya was reported in Ireland during 
2016, with a recent travel history to Kenya. 
Dengue fever
Dengue is a mosquito-borne viral infection that can cause 
flu-like illness and occasionally develops potentially lethal 
complications. Dengue is found in tropical and sub-tropical 
climates worldwide, mostly in urban and semi-urban areas. 
The global incidence of dengue has grown dramatically in 
recent decades with about half of the world’s population now 
at risk. 2016 was characterized by large dengue outbreaks 
worldwide, with the WHO Region of the Americas region 
reporting more than 2.4 million cases, approximately 3 
times higher than in 2014. During 2016, a dengue vaccine 
Dengvaxia (CYD-TDV)®, was registered in several countries 
for use in individuals 9-45 years of age living in endemic 
areas.
Eighteen confirmed cases of dengue fever were notified 
in Ireland during 2016. Seven cases were reported as GP 
patients, two were admitted to hospital and one case each 
attended Emergency Department and hospital out-patient 
services. The remaining seven cases did not have patient 
type reported. Country of infection was reported for three 
cases (16.7%). One case each reported probable country 
of infection as Brazil, Malaysia and Philippines (table 3). 
The remaining 15 cases (66.7%) did not have a country of 
infection specified. Just over two thirds of cases were female.
4.4 Other Vectorborne Diseases
Table 1: Vectorborne notifications by HSE area, 2016
HSE area Chikungunya disease Dengue fever Lyme disease Zika virus infection Total
HSE-E 11 3 9 23
HSE-M 1 2 3
HSE-MW 1 5 6
HSE-NE 1 2 3
HSE-NW 1 1 2
HSE-SE 1 1
HSE-S 1 2 8 11
HSE-W 1 2 1 4
Total 1 18 21 13 53
Table 2: Vectorborne notifications by age group, 2016
Age group Chikungunya disease Dengue fever Lyme disease Zika virus infection Total
0-4 yrs 1 1
5-9 yrs 4 4
10-14 yrs 1 1
15-19 yrs 2 2
20-24 yrs 2 1 1 4
25-34 yrs 6 2 4 12
35-44 yrs 1 2 5 6 14
45-54 yrs 5 3 1 9
55-64 yrs 3 3
65+ yrs 3 3
Total 1 18 21 13 53
Lyme neuroborreliosis
Lyme neuroborreliosis is an infection caused by a spiral-
shaped bacterium called Borrelia burgdorferi that is 
transmitted to humans by bites from infected ticks, 
generally hard-bodied ticks (Ixodidae). Lyme disease can 
affect anyone but is commonest among people whose 
leisure or work activities takes place in heathland, light 
woodland and other grassy areas or brings them in contact 
with certain animals e.g. deer and sheep. 
During 2016, 21 cases of lyme neuroborreliosis were notified 
in Ireland, eight female (38.1%) and 13 male (61.9%). Cases 
were reported from six of the eight HSE areas (table 1). Nine 
patients were GP patients, six were hospital in-patients, 
four were reported as hospital out-patients and two were 
hospital day patients (table 2). Probable country of infection 
was reported as Ireland for four cases, Ecuador for one case 
and the United States for one case. The remaining 15 (71.4%) 
cases did not report country of infection (table 3). 
West Nile virus 
West Nile virus (WNV) is a mosquito-borne viral infection 
transmitted primarily by Culex mosquitoes. WNV can cause 
a fatal neurological disease in humans but approximately 
80% of people who are infected will not show any 
symptoms. In addition to vector-borne transmission, the 
virus may also be transmitted through contact with other 
infected animals, their blood, or other tissues. WNV is 
maintained in a cycle involving transmission between birds 
and mosquitoes. Humans, horses and other mammals can 
be infected. WNV is commonly found in Africa, Europe, the 
Middle East, North America and West Asia. Vaccines are 
available for use in horses but not yet available for people. 
No cases of West Nile virus were notified in Ireland in 2016. 
Zika virus infection: 
Zika virus infection is a mosquito-borne viral infection 
transmitted primarily by Aedes mosquitoes. People with 
zika virus infection can have symptoms including mild fever, 
skin rash, conjunctivitis, muscle and joint pain, malaise 
or headache, which normally last for two to seven days. 
There is scientific consensus that Zika virus is a cause of 
microcephaly and Guillain-Barré syndrome. 
During 2016, 13 cases of zika virus infection were notified in 
Ireland, seven female (53.8%) and six male (46.2%). Cases 
were reported from four of the eight HSE areas (Table 1). 
Nine patients were GP patients, two were hospital out-
patients, one was a hospital in-patient and one was reported 
as other unspecified patient type (Table 2). 
Three cases reported probable country of infection as Brazil, 
three as Trinidad and Tobago, two as Mexico while one case 
each reported Bahamas, Costa Rica, Guatemala, Jamaica 
and Nicaragua (Table 3). 
Twelve cases were due to mosquito-borne transmission and 
one case of congenital infection was reported. Microcephaly 
was subsequently detected in the infant with congenital zika 
virus infection. 
Tickborne encephalitis
No cases of tickborne encephalitis were notified in Ireland in 
2016.
Tularaemia
No cases of tularaemia were notified in Ireland in 2016.
Typhus
No cases of typhus were notified in Ireland in 2016.
Yellow fever
No cases of yellow fever were notified in Ireland in 2016.
Table 3: Vectorborne notifications by probable country of infection, 2016 
Country of infection Chikungunya disease Dengue fever Lyme disease Zika virus infection Total
Bahamas 1 1
Brazil 1 3 4
Costa Rica 1 1
Ecuador 1 1
Guatemala 1 1
Ireland 4 4
Jamaica 1 1
Kenya 1 1
Malaysia 1 1
Mexico 2 2
Nicaragua 1 1
Philippines 1 1
Trinidad and Tobago 3 3
United states 1 1
Unknown 15 15 30
Total 1 18 21 13 53
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Hepatitis B is a vaccine preventable disease caused by the 
hepatitis B virus. It is transmitted through percutaneous or 
mucocutaneous contact with the blood or body fluids of an 
infected person. Symptoms of acute infection may include 
anorexia, abdominal discomfort, nausea and vomiting, 
often followed by jaundice. Symptoms are frequently milder 
and without jaundice in children. Acute infection is usually 
asymptomatic in infants. After acute HBV infection, the risk of 
developing chronic hepatitis B declines with increasing age.1 
Approximately 90% of infants infected at birth will develop 
chronic infection, compared to 20-50% of children infected 
between the ages of one and five years. Only 1-10% of those 
infected as older children or adults will develop chronic 
hepatitis B. An estimated 15-25% of those who develop 
chronic infection with die prematurely of either cirrhosis of 
the liver or hepatocellular carcinoma.
The prevalence of hepatitis B in the general population 
in Ireland is low (less than 1%). This is similar to other 
northern European countries (0.1-0.7%).2 Most cases fall 
into defined risk groups such as people with multiple sexual 
partners, sexual or household contacts of known cases, 
people who inject drugs (PWID) and people who were born in 
countries with intermediate (2-7%) or high (≥8%) hepatitis B 
endemicity.
The number of hepatitis B cases reported in Ireland 
decreased by 11% in 2016, with 488 cases (10.2/100,000 
population) notified compared to 548 in 2015. Hepatitis 
B notifications had been generally decreasing since their 
highest levels in 2008 (n=898, 21.2/100,000 population), 
but recent trends indicate that notifications are stabilising 
rather than continuing to decline. Annual hepatitis B 
notifications since 1997 are shown in figure 1. 
The highest notification rates were in HSE E (17.2/100,000 
population, n=295) and HSE NE (9.8/100,000 population, 
n=45). Geographic trends for the past four years are shown in 
figure 2.
All cases were laboratory confirmed. Ninety three percent 
(n=454) of the 488 notifications contained information 
on acute/chronic status. Of these, 7% (n=32, 0.7/100,000 
population) of cases were acutely infected and 93% (n=422, 
8.9/100,000 population) were chronically infected. Both 
5.1 Hepatitis B
Summary
Number of cases, 2016: 488
Crude notification rate, 2016: 10.2/100,000 population
Number of cases, 2015: 548
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Figure 1. Number of hepatitis B notifications by acute/chronic status, 1997-2016
acute and chronic cases of hepatitis B are notifiable in 
Ireland.
Acute cases (recent infections)
The number of acute cases of hepatitis B notified in Ireland 
was relatively low, but increased slightly in 2016 (n=32) 
compared to 2015 (n=26) (figure 3). Seventy eight percent 
(n=25) of acute cases notified in 2016 were male. Seventy 
two percent of cases (n=23) were aged between 25 and 44 
years and the median age at notification was 35.5 years 
(figures 3 & 4). 
 
Information on risk factor was available for 81% (n=26) of the 
acute cases notified in 2016. Of these, 65% (n=17) were likely 
to have been sexually acquired (ten heterosexual and seven 
men who have sex with men (MSM)). The most likely risk 
factor for one case was injecting drug use and two additional 
cases reported snorting cocaine but had not injected drugs. 
Other risk factors were reported for two cases and no risk 
factor was identified for four cases despite public health 
follow up. 
Country of birth was specified for 78% (n=25) of acute 
cases, 64% (n=16) of whom were born in Ireland. Country 
of infection was reported for 60% (n=19), 74% (n=14) of 
whom were infected in Ireland. The reason for testing was 
known for 28 cases and most were tested because they 
were experiencing symptoms (n=21, 75%) or because they 
requested STI screening (n=3, 11%). 
Chronic cases (long-term infections)
Notifications of chronic hepatitis B almost halved between 
peak levels in 2008 (n=768) and 2013 (n=387). The number 
of chronic cases reported then increased by 6% in 2014 
and by 22% in 2015, but decreased by 16% in 2016 (n=422) 
(figure 5). Of the 422 chronic cases notified in 2016, 56% 
(n=237) were male, 42% (n=177) were female and sex was 
not reported for 8 cases. Eighty seven percent (n=369) of 
chronic cases were aged between 20 and 54 years when 
notified and the median age at notification was 34 years 
(figures 5 & 6). 
Although primary risk factor was reported for a minority of 
chronic cases in 2016, data on country of birth or asylum 
seeker status was available for 53% (n=223). Of these, 78% 
Figure 3. Number of acute cases of hepatitis B notified, by sex and median age, 2004-2016
Figure 2. Hepatitis B notification rates/100,000 population, by HSE area, 2013-2016
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(n=175) were either born in a hepatitis B endemic country 
(hepatitis B surface antigen prevalence >2%) or were 
asylum seekers. Most of these cases are likely to have been 
infected outside Ireland, but the actual mode of acquisition 
of infection is unknown for the majority. Where country of 
birth was available (48%, n=202), the most common birth 
countries were in Asia (34%, n=69), central or  eastern 
Europe (33%, n=67), sub-Saharan Africa (23%, n=47) and 
western Europe (6%, n=13). Of those born in western Europe, 
eleven were born in Ireland. 
The reason for testing was known for 64% (n=269) of chronic 
cases. The main reasons were: antenatal screening (26%, 
n=69), re-testing of known cases (not previously notified) 
(20%, n=53), asylum seeker screening (11%, n=30) and STI 
screening (8%, n=21).
Immigration and hepatitis B notifications
Hepatitis B notifications are influenced by trends in 
immigration to Ireland. The large increase in the number of 
hepatitis B cases between 1997 and 2008 (figure 1) coincided 
with significant numbers of people migrating to Ireland from 
hepatitis B endemic countries.3 The economic downturn in 
2008 was reflected in a decline in both immigration and 
hepatitis B notifications. The subsequent economic recovery 
has resulted in increased immigration in recent years and 
this is likely to have contributed to the recent increase in 
hepatitis B notifications. Figure 7 shows trends in hepatitis B 
notifications alongside immigration trends.
Co-infections
Co-infection with other bloodborne viruses, such as hepatitis 
C and HIV, can lead to more severe liver disease and an 
increased risk of liver cancer in people with hepatitis B 
infection. Four hepatitis B cases notified in 2016 were co-
infected with hepatitis C and thirteen additional cases were 
co-infected with HIV. Other sexually transmitted infections 
were also reported for some of the cases of hepatitis B 
notified in 2016. Five had recently been diagnosed with 
chlamydia, three with syphilis (two HIV positive), one with 
gonorrhoea and one with genital herpes simplex (HIV 
positive). 
Figure 5. Number of chronic cases of hepatitis B notified, by sex and median age, 2004 to 2016
Figure 4. Age and sex-specific notification rates/100,000 population for acute cases of hepatitis B, 2016
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Discussion
Hepatitis B notifications more than halved between 2008 and 
2013. However, this rapid rate of decline has not continued 
in recent years and the notification rate now appears to be 
stabilising. The vast majority of hepatitis B notifications in 
Ireland are chronic cases and largely reflect people migrating 
to Ireland from hepatitis B endemic countries. The number 
of acute cases of hepatitis B increased in 2016 but remained 
relatively low. Most acute cases notified in Ireland are 
sexually acquired.
The figures presented in this summary are based on data 
extracted from the Computerised Infectious Disease 
Reporting (CIDR) System on 12th October 2017. These figures 
may differ from those published previously due to ongoing 
updating of notification data on CIDR. Notification rates are 
expressed per 100,000 population and are calculated using 
the 2016 census.
Acknowledgements
HPSC would like to thank all those who provided data for this report – 
Departments of Public Health, laboratories and clinicians.
References
1.  American Public Health Association, Heyman DL, Editor. Control of 
Communicable Diseases Manual. 20th Edition. Washington: American 
Public Health Association, 2015.
2.  European Centre for Disease Prevention and Control. Epidemiological 
assessment of hepatitis B  and C among migrants in the EU/EEA. 
Stockholm: ECDC; 2016.
3.  Central Statistics Office (2016) Immigrants (thousand) by country of origin. 
Accessed 12th October 2017. Available from:    
http://www.cso.ie/multiquicktables/quickTables.aspx?id=pea18_
Figure 6. Age and sex-specific notification rates/100,000 population for chronic cases of hepatitis B, 2016
Figure 7. Number of hepatitis B notifications and number of immigrants from EU16-28 & non EU/EEA countries 
(*excluding north America and Australia)
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Hepatitis C is a major cause of liver disease worldwide. The 
hepatitis C virus (HCV) is primarily transmitted through 
sharing contaminated equipment when injecting drugs or 
through receipt of unscreened blood or blood products (this 
is no longer a risk in Ireland).1,2 Sexual, occupational and 
vertical transmission can also occur but are less common. 
The risk of sexual transmission is increased in men who have 
sex with men (MSM), particularly those who are HIV positive 
or have other sexually transmitted infections.3
Infection is initially asymptomatic in most cases, but 
approximately 75% of those infected fail to clear the virus and 
develop chronic infection. Between 5 and 20% of chronically 
infected individuals develop cirrhosis of the liver after 20 
years of infection. Of those with cirrhosis, 1.5 to 2.5% will go 
on to develop hepatocellular carcinoma (liver cancer) each 
year.1 There have been major advances in the treatment of 
hepatitis C in recent years. The latest generation of direct-
acting antivirals (DAAs) can cure more than 90% of patients 
using all-oral drug regimes, which have fewer side effects 
than previous treatments.4 
The overall prevalence of chronic hepatitis C in Ireland is 
estimated to be between 0.4 and 0.8%5 and is comparable 
to other northern European countries (0.1-0.6%).6 Most cases 
fall into defined risk groups such as people who inject drugs 
(PWID) and people who received unscreened blood or blood 
products in the past.7
There were 645 notifications of hepatitis C in 2016 
(13.5/100,000 population). This is a slight decrease 
compared to 2015 (n=674, 14.2/100,000 population) (figure 
1). Notifications have declined by 58% since peak levels in 
2007 (n=1538). However recent trends indicate that the rate 
of decline is slowing and levels are stabilising. Notification 
rates for each HSE area for the past four years are shown in 
figure 2. Seventy percent of notifications in 2016 were from 
HSE E (n=450, 26.3/100,000 population).
More than two thirds of the cases of hepatitis C reported in 
2016 were male (71%, n=460), 28% (n=182) were female and 
sex was not reported for three cases. The highest notification 
rates were in young to middle aged adults, with 80% (n=519) 
of cases aged between 25 and 54 years. The median age at 
notification has gradually increased from 31 years in 2004 to 
a high of 39 years since 2014 (figures 1&3). 
Risk factors
Information on most likely risk factor was reported for 49% 
(n=313) of the cases of hepatitis C notified in 2016 (figure 
4). Almost two thirds (66%, n=206) of cases were PWID. 
The proportion of cases attributed to injecting drug use has 
decreased in recent years (80% in 2014, 72% in 2015), but 
risk factor data completeness varies from year to year so this 
trend must be interpreted with caution (figure 4).
5.2 Hepatitis C
Summary
Number of cases, 2016: 645
Crude notification rate, 2016: 13.5/100,000 population
Number of cases in 2015: 674
  
Figure 1. Number of notifications of hepatitis C and median age at notification, by sex, 2004-2016
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Twelve percent (n=36) of cases were likely to have been 
infected sexually (24 were MSM, 9 were heterosexual and 
sexual orientation was not reported for the remaining 
3 cases). There were five additional cases of hepatitis C 
identified as MSM in 2016, but sexual acquisition was not 
reported as their risk factor for infection. Two of these cases 
also injected drugs and this was reported as their most likely 
source of infection. The remaining three MSM cases currently 
have risk factor entered as unknown on CIDR. There was 
an increase in the number of hepatitis C cases identified as 
MSM in 2016 (n=29 compared to 8 in 2015 and 4 in 2014). A 
significant proportion of these cases were co-infected with 
HIV and had multiple other sexually transmitted infections 
(STIs), indicating that sexual transmission of hepatitis C is 
likely to be occurring in a particularly high risk cohort (figure 
5). Of the 29 MSM cases, 66% (n=19) were HIV positive 
and 58% (n=11) of these cases had at least one diagnosis 
of gonorrhoea, syphilis, chlamydia, lymphogranuloma 
venereum or genital herpes simplex virus in 2015 or 2016. 
Half of the 10 HIV negative MSM cases had also recently 
been diagnosed with one or more sexually transmitted 
infections (figure 5). Nineteen of the MSM cases of hepatitis 
C were acute (new) infections, 2 were chronically infected at 
diagnosis and the acute/chronic status was not known for 
the remaining 8 cases.
Other reported risk factors for hepatitis C cases included 
contaminated blood or blood products (4%, n=13), tattooing 
or body piercing (3%, n=8) and vertical (mother to baby) 
transmission (2%, n=5). No risk factor was identified for 
28 cases despite Public Health follow up. Six of the cases 
infected through blood or blood products were infected in 
Ireland. The exposure had occurred many years in the past, 
but these cases were notified for the first time in 2016. Figure 
4 shows recent risk factor trends for hepatitis C in Ireland.
Country of birth
Data on country of birth were available for just over a third of 
hepatitis C cases (34%, n=219) in 2016. Where information 
was available, 40% (n=87) of cases were born in Ireland, 
35% (n=76) were central or eastern European, 11% (n=23) 
were born in other western European countries, 7% (n=16) 
were Asian, 5% (n=10) were African, 2% (n=4) were from 
Latin American countries and 1% (n=3) were born in North 
America. Just under a third of cases with information on 
country of birth or asylum seeker status were born in a 
hepatitis C endemic country (>2% anti-HCV prevalence) or 
were asylum seekers. However, information on country of 
birth is more likely to be reported for non-Irish nationals and 
the actual proportion of hepatitis C cases born in Ireland is 
likely to be higher than this. Figure 6 shows the most likely 
Figure 3. Age and sex-specific notification rates/100,000 population for hepatitis C, 2016
Figure 2. Notification rates/100,000 population for hepatitis C by HSE area, 2013-2016
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risk factor for infection by region of birth for the 219 cases 
where country of birth was known. 
Genotype
Hepatitis C genotype data were collected retrospectively 
from National Virus Reference Laboratory and were available 
for 23% (n=146) of notifications in 2016. Of these, 62% (n=91) 
were genotype 1, 30% (n=44) were genotype 3, 6% (n=8) 
were genotype 2 and 2% (n=3) were genotype 4.  Subtype 
was available for 95% (n=86) of genotype 1 cases, 79% of 
which were genotype 1a. This may not be representative as 
genotype data were very incomplete in 2016. Genotype was 
available for 52% of hepatitis C cases notified between 2013 
and 2015. Over this period 60% of cases with data were 
genotype 1, 33% were genotype 3, 4% were genotype 2 and 
3% were genotype 4. 
Co-infections
Co-infection with HIV can increase the risk of acquiring 
hepatitis C sexually, and both HIV and hepatitis B co-
infections can lead to more severe liver disease and an 
increased risk of liver cancer in those with hepatitis C 
infection. The number of hepatitis C cases who were HIV 
positive at diagnosis doubled to 38 in 2016 (6% of all cases). 
The increase was particularly evident in MSM. Of those with 
information on risk factor or sexual orientation, 18 were MSM 
(53%), 15 were PWID (44%) and one was an MSM who also 
injected drugs (3%). In contrast, of the 19 HIV co-infected 
cases in 2015 with risk factor information, 9 (64%) were 
PWID, 4 (29%) were MSM and 1 (7%) was an MSM who also 
injected drugs.
Five of the cases of hepatitis C notified in 2016 were co-
infected with hepatitis B. Two were born in countries which 
are endemic for both hepatitis B and C and no enhanced 
data were available for the remaining three.
Discussion
Hepatitis C notifications have decreased in recent years. 
The decline was fairly dramatic in 2012 but this may have 
been partially attributable to the introduction of new case 
definitions specifically excluding cases known to have 
resolved infection. While notifications have continued to 
decline each year since 2012, the rate of decline is slowing. 
Trends in notifications of hepatitis C are difficult to interpret 
as acute and chronic infections are frequently asymptomatic 
and most cases diagnosed and notified are identified as a 
result of screening in risk groups. Therefore, notification 
patterns are heavily influenced by testing practices which 
Figure 5. Number of hepatitis C cases identified as MSM between 2013 and 2016, by HIV status at the time of hepatitis C notification and other recent 
STI* status.
*Gonorrhoea, syphilis, chlamydia, lymphogranuloma venereum or genital herpes simplex in the same year as hepatitis C notification or in the year prior to hepatitis C notification
Figure 4. Number of hepatitis C notifications by most likely risk factor (where risk factor known, 52%, n=5,422) 2007-2016 
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may vary over time and thus may not accurately reflect 
incidence.
Risk factor data were available for almost half of the cases 
of hepatitis C notified in 2016. The distribution of risk 
factors for these cases may differ from cases where data 
were not available. Where information on risk factor was 
available, approximately two thirds of cases were PWID 
who were likely to have been infected through unsafe 
injecting practices. Anecdotally, the proportion of drug 
users who are injecting is decreasing and the incidence of 
hepatitis C appears to be decreasing in this population. This 
is supported by a reduction in the proportion of hepatitis 
C notifications attributed to drug use in recent years. The 
proportion of sexually acquired cases of hepatitis C has 
increased in the last 18 months, particularly amongst MSM. 
Increases in HIV and other sexually transmitted infections 
were also identified in MSM in 2015 and 2016 and a national 
multidisciplinary outbreak response group was established 
in early 2016 to develop an action plan for Public Health 
intervention (www.hpsc.ie/a-z/specificpopulations/
menwhohavesexwithmenmsm/).
The figures presented in this summary are based on data 
extracted from the Computerised Infectious Disease 
Reporting (CIDR) System on 5th October 2017. These figures 
may differ from those published previously due to ongoing 
updating of notification data on CIDR. Notification rates are 
expressed per 100,000 population and are calculated using 
the 2016 census.
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Summary
Number of notifications: 508
Crude notification rate: 10.7 per 100,000 population
In 2016, 508 people were newly diagnosed with HIV in 
Ireland, giving a rate of 10.7 per 100,000 population. 
Between 2010 and 2014, HIV diagnosis rates in Ireland were 
stable but increased by 30% between 2014 and 2015 and by 
5% between 2015 and 2016. However, excluding those with 
a previous HIV diagnosis in another country, the number of 
diagnoses decreased by 6% in 2016. For a summary of new 
HIV diagnoses in 2016, see Table 1.
Age and gender
In 2016, 77% of diagnoses were in men and 23% in women. 
Most people (73%) were aged between 25 and 49 years at 
diagnosis and the median age was 35 years.  
Probable route of transmission (see figure 1)
Information on probable route of transmission was available 
for 84% of diagnoses. Among all notifications, sex between 
men remains the predominant mode of HIV transmission 
reported in Ireland (51%) followed by heterosexual 
transmission (28%). Four percent were among people who 
inject drugs (PWID). There were three cases where the route 
of transmission was reported as mother to child transmission 
(MTCT). Two had previously been diagnosed HIV positive 
abroad and the third was a baby born in Ireland in 2016. 
Geographic origin
Of the diagnoses in 2016, 61% were born abroad, 26% were 
born in Ireland and 13% did not have information on country 
of birth. The geographic origin varied by risk group: the 
majority of heterosexual cases (64%) were born in sub-
Saharan Africa; the majority of cases among men who have 
sex with men (MSM) were either born in Latin America (36%) 
or Ireland (32%) and the majority of cases among PWID 
(71%) were born in Ireland. 
Previous testing abroad
Notifications of HIV include all people who are diagnosed 
HIV positive for the first time in Ireland and include a number 
of people who have been previously diagnosed HIV positive 
abroad. In 2016, 34% of diagnoses were in people known 
to be previously diagnosed HIV positive abroad, and the 
majority of these (86%) had transferred their HIV care to 
Ireland. The proportion of diagnoses who are previously 
positive abroad has increased in recent years (21% in 2012).
Late diagnosis
Information on stage of diagnosis (CD4 count at diagnosis or 
AIDS defining illness at diagnosis) was available for 63% of 
cases in 2016. From the available information, 37% of people 
newly diagnosed in 2016 were late presenters (with CD4 
<350 cells/µl or an AIDS defining illness at diagnosis) and 
19% had advanced HIV infection (with CD4 <200 cells/µl or 
an AIDS defining illness at diagnosis). However, excluding 
those with a previous HIV diagnosis abroad, the proportion 
of people who presented late was 44%. Among the people 
5.3 HIV
-100-HPSC Annual Epidemiological Report 2016 5 Blood-borne and Sexually Transmitted Infections
Figure 1: Trends in HIV diagnoses by route of transmission, 2006 to 2016
being diagnosed with HIV for the first time, the groups with 
the highest proportion presenting late were females (57%), 
heterosexual males (58%), heterosexual females (57%), 
people aged over 50 years (61%) and people born in sub-
Saharan Africa (57%). 
Discussion
While there was a slight increase in the overall number of 
diagnoses of HIV in Ireland in 2016, there was a welcome 
reduction in the number of diagnoses among people who 
had not been previously diagnosed abroad. Given the 
increasing number of cases new to Ireland already known to 
be HIV positive, it is essential to focus on early engagement 
in care and immediate initiation of antiretroviral therapy 
(ART) which will be of direct clinical benefit and will also 
prevent onward transmission. This is in line with advice from 
both the World Health Organization (WHO) and the HSE (1, 
2). 
MSM accounted for just over half of diagnoses in 2016 and 
are the group most affected by HIV in Ireland. However, the 
proportion of MSM diagnosed with HIV prior to arrival in 
Ireland has been increasing and was 42% in 2016 compared 
to 16% in 2012. The number of new diagnoses in MSM 
not previously diagnosed abroad dropped by 14% in 2016 
compared to 2015. 
Diagnoses among heterosexuals remained stable since 
2010 with an average of 130 notifications per year. As in 
previous years, the majority of heterosexual cases were born 
in sub-Saharan Africa and it is of concern that people from 
sub-Saharan Africa presented later in the course of their HIV 
infection compared to other groups. 
Diagnoses among PWID decreased in 2016 compared to 
2015 and accounted for 4% of cases. An outbreak of HIV 
among homeless drug users in Dublin occurred in 2014 
and 2015. Prevention and control efforts were targeted to 
this group and the outbreak was declared over in February 
2016 (3). However, this group remains vulnerable to future 
outbreaks of HIV and other blood borne viruses.  
The detailed 2016 annual report and slide set are available at 
http://www.hpsc.ie/a-z/hivstis/hivandaids/hivdataandreports/ 
The latest report on Antenatal HIV Testing in Ireland is 
available at http://www.hpsc.ie/a-z/hivstis/hivandaids/
antenatalhivtesting/reportsonantenatalhivtestinginireland
Note: Data for this chapter were extracted from CIDR in 
August, 2017 and were correct at the time of publication.
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Table 1: Characteristics of HIV diagnoses, 2016 
Number of HIV diagnoses 508
Rate of diagnoses (per 100,000 population) 10.7
Gender
Males (%) 77.4
Females (%) 22.6
Male to female ratio 3.4
Age
Median age of adult cases (years) 35
Age range of adult cases (years) 18-72
Young people aged 15-24 years (%) 7.9
Aged 50 and older (%) 9.5
Probable Route of Transmission
MSM (%) 51.4
Heterosexual (%) 27.6
Injecting Drug Use (%) 4.1
Mother to Child transmission (%) 0.6
Other (%) 0.4
Unknown (%) 15.2
Region of Birth
Born in Ireland (%) 25.4
Born Abroad (%) 61.2
Unknown (%) 13.4
Previous history of testing
Previously tested positive abroad (%) 34.4
Transfer of care overall (% among those previously positive abroad) 29.1 (86.3%)
Summary
During 2016, a total of 12,984 cases of sexually transmitted 
infections (STIs) were reported. The most frequently reported 
STIs were Chlamydia trachomatis infection (n=6,893), 
gonorrhoea (n=1,957), ano-genital warts (n=1,593) and 
herpes simplex (genital) (n=1,369) (table 1). Compared to 
2015, the largest increase was in cases of gonorrhoea which 
increased by 51% (to 1,957).
The burden of STIs is greatest among those aged 15-24 
years, and among men who have sex with men (MSM). 
Notifications among those aged 15-24 years accounted 
for 48% of chlamydia notifications, 37% of gonorrhoea 
notifications and 43% of herpes simplex (genital) 
notifications.  MSM accounted for 67% of gonorrhoea, 88% 
of syphilis, and 100% of lymphogranuloma venereum (LGV) 
cases where mode of transmission was known. 
Chlamydia trachomatis infection
Chlamydia trachomatis infection was the most frequently 
reported STI with 6,893 notifications in 2016. The notification 
rate (NR) increased to 144.7 per 100,000 population, from 
142.7/100,000 in 2015. The NR among males increased 
by 6% and decreased by 2% in women compared to 2015. 
Chlamydia infections were steady in the years from 2011 to 
2013, with rates between 139.6/100,000 and 136.4/100,000 
population (figure 1). More than three-quarters of chlamydia 
cases were among those under 30 years, with the largest 
proportion aged 20-24 years (40%).  Just over half of cases 
were among women with the highest rate among women 
aged 20-24 years. The rate in females in this age group is 
consistently higher than males. In 2016, the rate in females 
(1,165.7 per 100,000) was almost 1.4 times greater than in 
males in this age group (843.8 per 100,000).
Gonorrhoea
In 2016, 1,957 cases of gonorrhoea were reported in Ireland, 
giving a notification rate of 41.1 per 100,000 population. This 
was a 51% increase on the notification rate in 2015 (27.2 per 
100,000); there has been a more than fourfold increase in 
the rate since 2009. In 2016, the notification rate in males 
increased by 59% from 45.7/100,000 population in 2015 
to 72.6/100,000 population in 2016 and amongst women 
the NR increased by 11% to 10.1/100,000. The vast majority 
of gonorrhoea cases were among men (n=1,709, 87%). 
Almost a third of cases (27%, n=524) were among people 
aged between 20 and 24 years old. Mode of transmission 
was available for 64% of cases (n=1,249) in 2016. Where 
data were known, mode of transmission was reported as 
MSM for 67% of cases (n=839) and heterosexual for 33% 
of cases (n=408; 169 males and 239 females). There were 
two cases of mother to child transmission in 2016. Genital 
and pharyngeal sites were the most frequently first reported 
sites of infection among males (32%, n=547 and 28%, 
n=467 respectively). Pharyngeal infections were the first 
reported site in 26% of all gonorrhoea cases in 2016, which 
has important implications for treatment of gonorrhoea as 
the pharynx may be a reservoir for antimicrobial resistant 
gonorrhoea. In all, 511 (26%) cases diagnosed with 
gonorrhoea were also diagnosed with another STI in 2016, 
including 17% who also had chlamydia and 2% who were 
newly diagnosed with HIV.
5.4  Sexually Transmitted Infections  
 (STIs)
Summary
Total number of STIs in 2016: 12,984
Most frequently reported STI in 2016: Chlamydia 
trachomatis infection (n=6,893)
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Table 1: Number, notification rate (NR) per 100,000 population & median age of persons with STIs, 2016
STI Number NR Median Age (range)
Chlamydia trachomatis infection 6,893 144.7 25 years (15-70 years)*
Ano-genital warts (AGW) 1,593 33.5 NA
Gonorrhoea 1,957 41.1 27 years (15-81 years)*
Herpes simplex (genital) 1,369 28.7 26 years (15-77 years)
Non-specific urethritis (NSU) 740 15.6 NA
Syphilis (early infectious) 305 6.4 33 years (18-73 years)
Trichomoniasis 79 1.7 32 years (19-68 years)
Lymphogranuloma venereum (LGV) 48 1.0 35 years (20-54 years)
Total 12,984 -
*Excludes those <14 years; NA: case-based data were not collected
Ano-genital warts
During 2016, 1,593 cases of ano-genital warts were reported 
in Ireland giving a notification rate (NR) of 33.5 per 100,000 
population, a decrease from 2015 (38.7/100,000) (figure 
1). There were more notifications among men (53%) than 
women (36%). Sex was not provided for 11% of cases.  
The age- and sex-specific notification rates were higher 
in men than women in all age groups. The highest age-
specific notification rate was among men aged 25-29 years 
(129.5/100,000) Age group however was not provided for 
36% of cases.   The numbers reported here are likely to be 
an underestimate of the true numbers of cases as data were 
not reported from every STI clinic. Further details on the 
completeness of reporting are available in the report Ano-
genital warts in Ireland, 2016, available on the HPSC website, 
www.hpsc.ie.
Herpes simplex (genital)
There were 1,369 cases of herpes simplex (genital) notified 
in Ireland during 2016 corresponding to a NR of 28.7 
per 100,000 population, a small increase from 2015 
(26.8/100,000) (figure 1) and the third consecutive year in 
which the notification rate has increased. Most cases were 
reported as Herpes simplex virus (HSV) type 1 (62%), with 
36% reported as HSV type 2. Subtype was not reported for 
2% of cases. Almost three-quarters of cases (n=995) were in 
women. The highest age-specific rate was among 20-24 year 
olds (149.1/100,000). The rate among women in this age 
group (234.5/100,000) was three and a half times greater 
than among men (64.7/100,000). 
Trichomoniasis
During 2016 there were 79 cases of trichomoniasis notified in 
Ireland corresponding to a NR of 1.7 per 100,000 population, 
a slight increase on the previous year (1.2/100,000) but 
not significantly different. All reported cases were among 
women. The highest sex- and age-specific rates were among 
women aged 25-29 years (13.1/100,000). 
Lymphoganuloma venereum (LGV)
There were 48 LGV cases reported in 2016 giving a NR of 1.0 
per 100,000 population (compared with 20 cases in 2015, 35 
cases in 2014 and five cases in 2013). The majority of cases 
were reported in HSE East (n=42), two cases were reported 
in both  HSE Midwest and HSE Northeast, and one case each 
was reported in HSE Southeast and HSE West. All cases 
were among men who have sex with men (MSM). Two-thirds 
of cases (67%) were HIV positive. Thirty two cases had a 
diagnosis of another STI (excluding HIV) in 2016. Most (85%) 
of these cases (n=41) were linked to an outbreak among 
MSM in the Greater Dublin area. Multidisciplinary outbreak 
control teams (OCTs) were convened by the Department of 
Public Health, HSE East to actively investigate cases and 
instigate control measures1. 
Non-specific urethritis
A total of 740 cases of non-specific urethritis were reported 
in 2016 compared with 1,028 cases in 2015, a decrease of 
28% and a NR of 15.6 per 100,000 population.
More detailed annual reports on STIs are available on 
the HPSC website at http://www.hpsc.ie/A-Z/HIVSTIs/
SexuallyTransmittedInfections/Publications/STIReports/
STIAnnualReports/. 
Weekly reports on STIs and HIV are available on the 
HPSC website at http://www.hpsc.ie/A-Z/HIVSTIs/
SexuallyTransmittedInfections/Publications/STIReports/
STIWeeklyReports/.
Data on syphilis, HIV and hepatitis B are presented 
elsewhere in this report.
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Figure 1 Trend in notification rate (NR) per 100,000 population of selected STIs, 1995-2016
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A change in the case definition and laboratory notification 
criteria for syphilis was made in January 2014, whereby only 
laboratory diagnosed early infectious syphilis (EIS) cases, 
and re-infections of syphilis, became notifiable. These 
laboratory diagnosed notifications were then reviewed 
clinically, staged, and subsequently deactivated in the 
CIDR system by Public Health if they were not EIS cases as 
determined by clinical assessment. The staging of syphilis 
cases, Public Health follow-up and CIDR deactivation was 
found to be time consuming for both STI clinics and Public 
Health Departments with a time lag of up to six months 
following initial notification. Simplifying the surveillance 
provides more timely information which is essential to 
inform the response to the current increase in EIS amongst 
men who have sex with men (MSM). From 1st July 2016, 
updated laboratory criteria for notification of syphilis cases 
to Public Health have been applied. Laboratories were 
requested to notify any new case that fits one or more 
of the updated laboratory criteria, and any syphilis re-
infections. Laboratories continue to use their own internal 
criteria for notification of re-infections. This case definition 
remained current from 1st July 2016 onwards. 
During 2016, 430 cases of syphilis were notified in CIDR 
based on laboratory criteria (data extracted 20th Sept., 
2017); 260 between the 1st of January and the 30th of June 
and 170 between the 1st of July and the 31st of December. 
In total, 305 notified cases of syphilis met the criteria for 
laboratory diagnosis of EIS during 2016; of the 260 notified 
in the first half of the year, stage of infection was reported 
as EIS following clinical review for 135 cases (i.e. enhanced 
surveillance forms were received for 52% of cases) and 
based on the updated laboratory criteria applied from 1st 
July, the 170 cases notified in the second half of the year were 
reported as EIS. Enhanced surveillance forms were received 
for 46% of cases in the second half of the year. 
In addition to notifications of EIS there was one possible 
5.5 Syphilis
Summary
Number of early infectious syphilis cases: 305
Notification rate of early infectious syphilis: 6.4/100,000 
population
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Figure 1: Notification rate of early infectious syphilis (per 100,000 population), 2000-2016
Year 
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case of congenital syphilis notified in 2016. This child will 
be followed-up until they are 18 months old to determine 
whether positive laboratory test results were a result of 
infection or the presence of maternal antibodies. 
Between 1st January and 30th June 2016, this analysis focuses 
on cases fitting the laboratory criteria and clinical criteria 
(n=135) and so the number of early cases for the first half of 
2016 is likely to be an under-estimate of the true number of 
early infectious syphilis cases.
The notification rate for early infectious syphilis in 2016 was 
6.4 per 100,000 population, an increase of 10% compared 
to 2015 (5.8 per 100,000). Figure 1 shows the trend in 
notification rate (NR) for early syphilis cases from 2000 to 
2016.
Of the 305 early infectious syphilis cases notified in 2016:
•  124 (41%) were classified as primary syphilis, 35 (11%) as 
secondary syphilis,  48 (16%) as early latent syphilis, and 
98 (32%) as EIS, not otherwise specified (n.o.s.).
•  Rates varied throughout the country, with the age-
standardised notification rate (ASNR) (10.4 per 100,000) 
in HSE East (Dublin, Kildare and Wicklow) 1.6 times the 
national rate (6.4 per 100,000). The ASNR in four HSE 
areas (West, Southeast, Northwest and Northeast) were 
significantly lower than the national rate (figure 2).
•  The majority of cases occurred in males (n=295; 97%), with 
a male to female ratio of 30:1. 
•  The notification rates in men and women were 12.5 and 
0.4 per 100,000 population, respectively (figure 1).
•  The majority of cases (60%) were reported in people aged 
between 25 and 39 years.
•  Almost three quarters of cases were identified at a 
dedicated STI clinic and 18% were identified in general 
practice.
•  Of the 305 EIS cases in 2016, 222 (73%) were among MSM 
and 29 (10%) were among heterosexuals (8 female and 21 
male). For 54 cases (17%), the mode of transmission was 
unknown.
•  The percentage of cases among MSM who were co-
infected with HIV in 2016 continued to rise (39% compared 
to 30% in 2015).
•  One male heterosexual case was co-infected with HIV. 
•  Two out of 10 female cases were pregnant at the time of 
diagnosis. 
•  Among patients diagnosed with EIS, there were an 
additional 126 cases of STIs (other than HIV) diagnosed 
during 2016.  Since full patient identifiers were not 
provided for all cases, the true figure for STI co-infections 
is likely to be much higher.
Discussion
2016 was the third year for which only cases of early 
infectious syphilis were notifiable. The aim of reporting 
early infectious syphilis is to improve completeness of 
information and data quality. The proportion of cases for 
which enhanced surveillance forms were received decreased 
in 2016 when compared to recent years (50% versus 61% 
in 2015, 73% in 2014 and 60% in 2013). The true number of 
early infectious syphilis cases may be higher than reported 
here, as only cases with both laboratory and clinical data 
indicating early infectious syphilis were included in the 
analysis for the first half of 2016. 
In 2016, the notification rate of early syphilis increased 
to 6.4 per 100,000, the highest rate since the syphilis 
outbreak among MSM in Dublin in 2001 (6.1/100,000). The 
increase in early syphilis in 2016 was concentrated among 
men (97% of cases). The rate among men increased to 12.5 
per 100,000 compared to 7.7/100,000, 8.4/100,000 and 
11.8/100,000 in 2013, 2014 and 2015, respectively. The rate 
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Figure 2: Age-standardised notification rate of early infectious syphilis by HSE area, 2014-2016
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among women remained steady in 2016, at 0.4 per 100,000 
compared to 0.6/100,000, 0.4/100,000 and 0.4/100,000 
in 2013, 2014 and 2015, respectively. 
The increase in 2016 was among men for whom mode of 
transmission was not recorded. Cases without a reported 
mode of transmission increased from 6% in 2015 to 18% 
(n=54) in 2016. Of these, the proportion by sex is the same 
as those cases where mode of transmission is reported (96% 
among males and 4% among females). Since 2012, EIS 
among MSM has increased by 170% (from 81 in 2012 to 222 
in 2016).
Cases among heterosexuals decreased in 2016 by 12% 
(29 versus 33 in 2015). Rates of EIS in HSE East remain 
significantly higher than the national rate with most cases in 
HSE East occurring among MSM, confirming that this area 
remains a centre of transmission within Ireland. Most of the 
other cases in HSE East were among men for whom mode of 
transmission data were missing.  
The proportion of EIS cases co-infected with HIV in 2016 
increased to 34% in 2016 from 29% in 2015 and 25% in 
2014. Of those co-infected with HIV, the number diagnosed 
with HIV in the same year as their syphilis diagnosis was 
25% (compared to 39% in 2015 and 26% in 2014). The 
proportion of HIV co-infection continues to be higher among 
MSM compared to heterosexuals. The proportion of cases 
co-infected with HIV remains a concern as co-infection 
increases the risk of acquiring and transmitting HIV1. 
In December 2015, preliminary analysis of 2015 data pointed 
to a significant increase in EIS and other STIs among MSM2. 
This analysis also pointed to a change in the demographics 
of cases, with an increasing proportion of cases among 
Latin American MSM living in Ireland (up from 6% in 2012 
to 25% in 2015). A growing number of MSM acquired their 
infection in Ireland in 2015 (74%) compared to previous 
years (59% in 2014). Similar increased trends in HIV and 
other STIs were also a cause for concern. In response, 
a national multidisciplinary multi-sectoral group was 
established in early 2016. The response involves three main 
strands of work covering epidemiology, interventions, and 
communications. Throughout 2016 ongoing analysis of 
trends were undertaken by the epidemiological subgroup 
and this continues in 2017.
During 2016 a number of interventions were implemented 
including an additional clinic at the Gay Men’s Health 
Service, employment of two outreach workers, increased 
distribution of condoms and lubricant as well as health 
promotion materials. This work continues in 2017. 
Information on the work of the National MSM Outbreak 
Response Group is available at http://www.hpsc.ie/a-z/
specificpopulations/menwhohavesexwithmenmsm/.
A more detailed analysis of syphilis in Ireland in 2016 is 
available in the report Syphilis in Ireland, 2016, which is 
available on the HPSC website. 
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Table 1: Summary of early infectious syphilis cases, 2012, 2013, 2014, 2015 and 2016
  2012 2013 2014 2015 2016
  n % n % n % n % n %
Total number of early cases 115 184 204 268 305
Male 101 87.8 175 95.1 191 93.6 258 96.3 295 96.7
Men who have sex with men (MSM) 81 70.4 120 65.2 140 68.6 220 82.1 222 72.8
Heterosexuals 24 20.9 22 12.0 36 17.6 33 12.3 29 9.5
Unknown mode of transmission 10 8.7 43 23.4 28 13.7 15 5.6 54 17.7
Median age (years) 33 33 32 33 33
Age range (years) 19-68 19-73 19-70 20-65 18-73
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Encephalitis due to viruses not otherwise specified (NOS) 
are notifiable under the disease category ‘viral encephalitis’. 
Details of viral encephalitis cases caused by other notifiable 
diseases, if any, are presented in other chapters in this 
report. 
In 2016, 61 cases of viral encephalitis (NOS) (VE) were 
notified in Ireland (1.28/100,000 population) compared 
to 47 (0.98/100,000) in the previous year (Figure 1). One 
contributing factor to the increase in numbers can be 
attributable to increase in the number of herpes simplex 
virus type 2 from three to nine cases and by the increase in 
varicella/herpes zoster virus cases from two to six cases.
The number of VE cases among males (n=23) was 
considerably less than in females (n=35), a M:F ratio of 
0.66:1, with three cases remaining not attributed to either 
sex. The median age of cases was 34 years (range two weeks 
to 87 years); 15 (24.6%) cases occurred in those aged 65 or 
more years and 12 cases (19.7%) in children under five years 
of age in 2016. There were six cases each of herpes simplex 
virus type 1 (HSV1) and varicella/herpes zoster virus (VZV) 
among the 15 VE cases in those aged > 65 years (Figure 1, 
Table 1).
All 61 VE cases were laboratory tested positive and case 
classified as confirmed. All but two had a causative 
pathogen identified: herpes simplex virus (HSV) (n=28; 
45.9%), VZV (n=24; 39.3%), human herpes virus type 6 (HHV 
6) (n=6; 9.8%), parechovirus (n=1; 1.6%) and not specified 
(n=2; 3.3%) (Figure 2). 
Caution is advised regarding the detection of HHV 6 DNA 
in cerebral spinal fluid (CSF) specimens, especially in those 
cases aged less than three months as HHV 6 DNA can 
be chromosomally integrated as it may not be clinically 
relevant. Two of the six cases of HHV 6-related encephalitis 
in 2016 however, occurred in patients less than three months 
of age.
There were one reported death in a <6 months old with 
HHV6, but the actual cause of death was not known. There 
were no imported cases associated with VE in 2016. 
The figures presented in this report are based on data 
extracted from the Computerised Infectious Disease 
Reporting (CIDR) system on 9th November, 2017. These 
figures may differ from those published previously due to on-
going updating of notification data in CIDR.
6.1 Viral Encephalitis
Summary
Number of cases, 2016: 61 
Number of cases, 2015: 47
Number of cases, 2014: 67
Crude incidence rate, 2016: 1.3/100,000
Table 1. Number, age-specific incidence rates and proportion of viral encephalitis (NOS) cases by age group, Ireland, 2016
  Causative pathogen      
Age Group herpes simplex virus (HSV)
varicella/herpes 
zoster virus (VZV)
human herpes virus 
type 6 (HHV6) enterovirus
not 
specified Total ASIR % Proportion
<1 1 0 6 1 0 8 12.85 13.1
1-4 2 0 0 0 2 4 1.49 6.6
5-14 2 0 0 0 0 2 0.30 3.3
15-24 2 5 0 0 0 7 1.21 11.5
25-44 6 10 0 0 0 16 1.14 26.2
45-64 7 2 0 0 0 9 0.79 14.8
65+ 8 7 0 0 0 15 2.35 24.6
All ages 28 24 6 1 2 61 1.28 100
% total cases 45.9 39.3 9.8 1.6 3.3 100    
Note: ASIR, age specific incidence rate per 100,000 population of total cases, based on Census 2016 data
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Figure 1. Number of viral encephalitis (NOS) cases by age group and year, Ireland, 1992-2016*
* includes the late notification of 15 cases in 2013 reported in early 2014
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Figure 2. Number of viral encephalitis (NOS) cases by causative pathogen and year, Ireland, 1992-2016*
* includes the late notification of 15 cases in 2013 reported in early 2014
Meningitis due to viruses not otherwise specified (NOS) 
are notifiable under the disease category ‘viral meningitis’. 
Details of viral meningitis caused by other specified 
notifiable diseases (such as mumps and influenza viruses, if 
any) are presented in other chapters in this report. 
The steady increase in annual notifications, which started 
back in 2007 and continued up until 2014, fell sharply in 
2015 when 261 were reported, only to increase again to 299 
(Figure 1). It should be noted that the very high number of 
cases reported in 2014 include the late notification of seven 
cases from 2013 (based on their specimen dates) reported 
during weeks 5 and 6 of 2014. No viral meningitis, NOS-
related outbreaks were reported in 2016.
Since 1997, eight deaths have been reported with cases of 
viral meningitis (NOS), one of which was attributable to the 
enterovirus infection itself. None were reported in 2016.
Of the 299 cases notified in 2016, 297 (99.3%) were 
classified as confirmed and one each that was probable 
and possible (0.3% each). There were more cases among 
males (n=162) than in females (n=132), giving a male to 
female ratio of 1.23:1. Five cases were reported with unknown 
gender details in 2016.
The national crude incidence rate in 2016 was 6.3 (95% 
CI 5.6–7.0) cases per 100,000 population, a 14.6% 
increase compared with the previous year when 261 cases 
were notified (5.5/100,000). The highest age specific 
incidence rate (ASIR) in 2016 was in infants <1 year of age 
(308.4/100,000; n=192), followed by the 25-34 year age 
group (5.3/100,000; n=35). The lowest ASIR was in the 55-
64 year age group (ASIR 0.6/100,000 (n=3)) (Table 1). 
In 2016 the highest frequency of cases was in children aged 1 
to 2 months (n=81) and in those aged between 15 to 39 years 
(n=78) with an overall median age of 89 days (range one 
week to 85 years) (Figure 2). Seventy-seven percent of cases 
(n=231) occurred in those under 25 years of age (Figure 3, 
Table 1). 
By HSE region, the highest rate was in HSE E at 8.7/100,000 
(95%CI 7.3–10.1) and lowest in HSE S at 3.9/100,000 (95%CI 
2.4-5.4), with the latter rate significantly below the national 
rate (Figure 4).
In 2016, enteroviruses were the most common pathogen 
associated with viral meningitis, accounting for 81.3% 
(n=243/299) of all notifications (Figure 3, Table 1). It is only 
6.2 Viral Meningitis
Summary
Number of cases, 2016: 299 
Number of cases, 2015: 261
Number of cases, 2014: 435
Crude incidence rate, 2016: 6.3/100,0
Figure 1. Number of viral meningitis (NOS) cases by organism type and year, Ireland, 1988-2016*
* includes the late notification of seven cases in 2013 reported in early 2014
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since 2017 have enterovirus types been routinely linked to 
events on CIDR because of the enterovirus typing service in 
the NVRL, but one enterovirus-related VM case in 2016 was 
linked to a coxsackie virus infection.
Enterovirus was also the most common pathogen in infants 
under one year of age with viral meningitis (NOS) in 2016; 
159 out of total of 192 cases in that age group (82.8%) 
were reported to have this virus. Between 2006 and 2016 
enteroviruses accounted for 74.9% (n=1745/2331) of all viral 
meningitis (NOS) cases, with typical summer peaks observed 
each year (Figure 5). The large number of enterovirus-related 
viral meningitis cases observed in recent years is likely 
due in part to improved notification and investigation with 
laboratory confirmation.
In 2016, human herpes virus (type 6) (HHV 6) was the 
causative pathogen for 9.4% (n=28) notifications, varicella/
herpes zoster virus (VZV) for 3.0% (n=9), parechovirus 
for 2.3% (n=7) and herpes simplex virus (HSV) for 2.0% 
(n=6)(Figure 3, Table 1). There were 2.0% (n=6) cases with 
no viral pathogen specified. Caution is recommended 
regarding the detection of HHV 6 DNA in cerebral spinal 
fluid (CSF) specimens, especially in those cases aged less 
than 3 months (n=14/28; 50%) as HHV 6 DNA can be 
chromosomally integrated. When this occurs the HHV 6 DNA 
can be inherited through the germ line and therefore when it 
is detected, it may not be clinically relevant.
The figures presented in this report are based on data 
extracted from the Computerised Infectious Disease 
Reporting (CIDR) system on 9th November, 2017. These 
figures will differ from those published previously due to on-
going updating of notification data in CIDR.
Figure 2. Number of viral meningitis (NOS) cases by age group and sex, Ireland, 2016
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Table 1. Number, age-specific incidence rates and proportion of viral meningitis (NOS) notifications by age group and causative pathogen, 
Ireland, 2016
  Causative pathogen      
Age 
Group
enterovirus varicella/herpes 
zoster virus
human 
herpes virus 
type 6
herpes 
simplex 
virus
coxsackievirus parecho-virus Total ASIR % Proportion
<1 159 24 0 0 7 2 192 308.4 64.2
1-4 10 4 0 0 0 0 14 5.2 4.7
5-9 4 0 0 0 0 0 4 1.1 1.3
10-14 4 0 0 0 0 1 5 1.6 1.7
15-19 5 0 2 1 0 1 9 3.0 3.0
20-24 6 0 0 0 0 1 7 2.6 2.3
25-34 33 0 2 0 0 0 35 5.3 11.7
35-44 17 0 0 2 0 0 19 2.5 6.4
45-54 2 0 3 0 0 0 5 0.8 1.7
55-64 2 0 0 0 0 1 3 0.6 1.0
65+ 1 0 2 3 0 0 6 0.9 2.0
All Ages 243 28 9 6 7 6 299 6.3 100
% Total 81.3 9.4 3.0 2.0 2.3 2.0 100.0    
ASIR, age specific incidence rate per 100,000 population of total cases; based on census 2016 data
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Figure 5. Monthly number of enterovirus-related and non-enterovirus related cases of viral meningitis, NOS notifications, 
2007-2016*
* includes the late notification of seven cases in 2013 reported in early 2014
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Figure 4. Crude incidence rates per 100,000 population with 95% confidence intervals for viral 
meningitis (NOS) cases by HSE area, Ireland, 2016
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Figure 3. Number of viral meningitis (NOS) cases by age group (<25, >25 years of age) and 
year, Ireland, 2001-2016*
* includes the late notification of seven cases in 2013 reported in early 2014
Five cases of Creutzfeldt-Jakob disease (CJD) were notified 
in 2016 identical to 2015 when five cases were also notified. 
All cases in 2016 were sporadic CJD cases. Two cases were in 
the age group 55-64 years and three were in the age group 
≥65 years.  Four cases were female and one was male.
In total, 80 cases of CJD were notified since CJD was first 
specified as a notifiable disease in December 1996 (figure 1). 
Figure 2 shows the 80 CJD notifications by age group. The 
majority (81%, n=65) of the cases were aged greater than 54 
years. Of the 80 cases, 42 were female and 38 were male. 
Seventy-six cases were sporadic CJD, two were familial CJD 
and two were iatrogenic.
Variant CJD (vCJD) is specified as a separate notifiable 
disease. No cases have been notified since 2006. In total, 
four cases of vCJD were notified since vCJD became 
notifiable in December 1996. A summary of these four cases 
was provided in the 2006 HPSC annual report. 
Data presented in this summary are based on notifications 
from HSE Areas and from the Irish National Creutzfeldt-
Jakob Disease Surveillance Unit. Annual figures published 
here are based on the year the notification was entered 
on the Computerised Infectious Disease Reporting (CIDR) 
system and consequently may differ from annual figures 
published by the Irish National Creutzfeldt-Jakob Disease 
Surveillance Unit.
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6.3 Creutzfeldt-Jakob disease  
Summary
Number of cases, 2016: 5
Number of cases, 2015: 5
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Figure 1. Number of CJD notifications by year from December 1996 to 
2016
Figure 2. Number of CJD notifications (n=80) from December 1996 to 
2016 by age group
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Outbreaks
During 2016, 549 outbreaks of infectious diseases were 
reported with 6,937* associated cases of illness, including 
411 (5.9%) cases hospitalised and 23 deaths.=Regional 
variation in the numbers of outbreaks reported was observed 
between HSE areas. The highest outbreak reporting rates‡ 
were observed in HSE-NW (25.3/100,000 population) while 
the lowest rate was observed in HSE-E at (5.9) and -NE (8.5). 
Table 1 details the regional distribution of all outbreaks by 
HSE area and disease.
The number of outbreaks reported peaked in December. This 
peak was mainly due to high numbers of influenza, norovirus 
and acute infectious gastroenteritis (AIG) outbreaks. A 
secondary peak was also observed earlier in the year during 
April. This peak was mainly due to norovirus, verotoxigenic E. 
coli infection (VTEC) and AIG outbreaks. Figure 1 illustrates 
the number of IID and non-IID outbreaks by month of 
notification during 2016.
Similar to previous years, airborne/person-to-person spread 
was reported as the mode of transmission for the majority 
of outbreaks (68.9%, n=378). Mode of transmission was 
reported as unknown for 21.1% of outbreaks. Table 2 details 
all outbreaks by infectious disease and probable mode of 
transmission. 
The most frequently reported outbreak locations were private 
houses (n=155, 28.2%), nursing homes (n=99, 18.0%), 
hospitals (n=85, 15.5%) and community hospital/long-stay 
units (n=79, 14.4%). The highest numbers ill were reported 
from outbreaks in nursing homes (n=1,595), hospitals 
(n=1,342) and hotels (n=1,017). However it should be noted 
that a single hotel outbreak during 2016 resulted in 896 of 
the hotel associated cases.
General outbreaks accounted for 69.2% (n=380) of all 
outbreaks notified during 2016. The remaining outbreaks 
(30.8%, n=169) were reported as family/household 
outbreaks. 
7. Outbreaks
Summary
Number of outbreaks: 549
Number of IID outbreaks: 393
Number of non-IID outbreaks: 158
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Figure 1: Number of IID and non-IID outbreaks by month of notification and associated numbers ill, 2016
*  Two norovirus outbreaks did not report the number ill or number of 
associated laboratory confirmed cases. Three outbreaks reported zero 
symptomatic cases and consisted of laboratory confirmed asymptomatic 
individuals.
=  Outbreak data extracted from CIDR on 10/08/2017.
‡  All rates are calculated per 100,000 population as per Census 2016
Table 1 Number of IID and non-IID outbreaks by disease and HSE area, 2016
IID/ Non-IID Disease HSE-
E
HSE-
M
HSE-
MW
HPSC HSE-
NE
HSE-
NW
HSE-
SE
HSE-
S
HSE-
W
Total
IID
AIG 12 3 3 8 19 18 18 13 94
C. difficile 2 3 2 7
Campylobacteriosis 1 3 4
Cryptosporidiosis 1 2 1 1 4 5 2 4 20
Giardiasis 5 4 1 10
Hepatitis A (acute) 3 1 1 1 1 1 8
Noroviral infection 26 11 11 10 13 14 33 13 131
Rotavirus 1 3 2 1 7
Salmonellosis 2 3 1 2 1 9
Shigellosis 1 1 2
Typhoid 1 1
VTEC 7 30 13 1 4 5 10 17 11 98
Non-IID
Acinetobacter 1 1
ARI 5 6 3 11 1 26
Chickenpox 1 1 2
CPE 1 1
CRE 1 1 1 1 4
Gonorrhoea 1 1 2
Hand, foot and mouth 1 1
Hepatitis B (acute and 
chronic) 1 1
Impetigo 1 1
Influenza 18 1 8 4 7 9 13 5 65
Lymphogranuloma venereum 1 1
Malaria 1 1
Measles 1 1 2
Meningococcal disease 1 1
MRSA 1 1 1 1 4
Mumps 2 1 2 3 2 10
Pertussis 8 1 2 1 12
RSV 2 1 2 1 4 10
Scabies 1 1 2 4
Tuberculosis 1 1 1 2 5
VRE 3 1 4
Total number of outbreaks 101 50 45 3 39 65 76 112 58 549
Crude outbreak incidence rate 5.9 17.1 11.7 n/a 8.5 25.3 14.9 16.2 12.8 11.5
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Table 2: Number of IID and non-IID outbreaks by disease and probable route of transmission, 2016
IID/Non-IID Disease
Transmission
P-P / 
Airborne
Animal 
contact
Food-
borne Water-borne Unknown Other Total
IID
AIG 77   4   13   94
C. difficile 5 1 1 7
Campylobacteriosis 1 2 1 4
Cryptosporidiosis 4 7 2 7 20
Giardiasis 1 8 1 10
Hepatitis A (acute) 3 5 8
Noroviral infection 108 23 131
Rotavirus 6 1 7
Salmonellosis 3 2 3 1 9
Shigellosis 1 1 2
Typhoid   1 1
VTEC 33 9 3 11 38 4 98
Non-IID
Acinetobacter         1   1
ARI 24 2 26
Chickenpox 2 2
CPE   1 1
CRE 1 2 1 4
Gonorrhoea 2 2
Hand, foot and mouth 1 1
Hepatitis B   1 1
Impetigo 1 1
Influenza 59 6 65
Lymphogranuloma venereum 1 1
Malaria           1 1
Measles 2 2
Meningococcal disease 1 1
MRSA 2 1 1 4
Mumps 10 10
Pertussis 10 2 12
RSV 10 10
Scabies 4 4
Tuberculosis 5 5
VRE 1 3 4
Total 378 18 14 13 116 10 549
% outbreaks 68.9 3.3 2.6 2.4 21.1 1.8 100.0
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Infectious intestinal disease (IID) outbreaks
During 2016, 391 IID outbreaks were reported, accounting 
for 71.2% of all outbreaks. This was an increase of 24.1% 
compared to the number of reported during 2015 (n=315). 
After norovirus, the next most commonly reported IID 
outbreaks were VTEC and AIG. Table 3 details the total 
number ill by disease and the median number ill per 
outbreak for disease where five or more outbreaks were 
reported.
Non-infectious intestinal disease (Non-IID) outbreaks
During 2016, 158 non-IID outbreaks were reported, 
accounting for 28.8% of all outbreaks. This represents a 
decrease of 18.1% compared to the number reported during 
2015 (n=193). After influenza, the next most commonly 
reported non-IID outbreaks were acute respiratory infections. 
§ Values shown for diseases with more than five outbreaks.
Table 3: Outbreak disease§ by size of outbreak, 2016
IID/Non-IID Disease Number of outbreaks Total number ill Mean number ill Median number ill Range
IID
Noroviral infection 131 3724 28.9 16 1 - 896
VTEC 98 230 2.3 2 0 - 16
AIG 94 1424 15.1 7.5 1 - 338
Cryptosporidiosis 20 53 2.7 2 2 - 5
Giardiasis 10 29 2.9 2.5 1 - 5
Salmonellosis 9 24 2.7 2 2 - 6
Hepatitis A (acute) 8 22 2.8 2 2 - 5
Rotavirus 7 55 7.9 7 2 - 18
C. difficile 7 29 4.1 3 2 - 9
Non-IID
Influenza 65 700 10.8 9 2 - 36
ARI 26 214 8.2 6.5 3 - 24
Pertussis 12 31 2.6 2 2 - 6
Mumps 10 58 5.8 2 2 - 31
RSV 10 85 8.5 8.5 2 - 21
Tuberculosis 5 19 3.8 3 3 - 6
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Introduction
In 2016, HPSC was provided with quarterly immunisation 
uptake data for each of the Local Health Offices (LHOs). 
HPSC collated these data and quarterly reports were 
produced which are available on the HPSC website. The 
annual immunisation uptake rates presented here represent 
the collation of the 2016 quarterly data. The proportion 
of children who completed the recommended primary 
childhood immunisation schedule by 12 months (born 
between 01/01/2015 and 31/12/2015) and 24 months (born 
between 01/01/2014 and 31/12/2014) of age in 2016 are 
reported.
Children who were 12 and 24 months of age in 2016 were 
recommended one dose of vaccine against tuberculosis 
(BCG vaccine) at birth or by one month of age; three doses 
of vaccines against diphtheria (D3), tetanus (T3), pertussis 
(P3), Haemophilus influenzae type b (Hib3), polio (Polio3) and 
Hepatitis B (HepB3) with one dose of each recommended 
at two, four and six months of age; and three doses of 
pneumococcal conjugate vaccine (PCV3) recommended at 
two, six and 12 months of age (table 1). Also at 12 months 
of age a dose of MMR (MMR1) was recommended and at 13 
months a dose of Hib (Hibb) was recommended (table 1). The 
immunisation schedule changed in 2015 for children born on 
or after July 1st 2015 after the NIAC recommended changing 
the meningococcal C (MenC) immunisation schedule in 
the primary childhood programme from three doses at 4, 
6 and 13 months to two doses at 4 and 13 months because 
of evidence that a single dose of MenC vaccine provides 
protection for the first year of life. Further vaccinations are 
recommended for older children and adults. Please see the 
HSE-National Immunisation Office website at  
www.immunisation.ie for current and detailed information on 
the Irish primary childhood immunisation schedule and also 
recommended vaccinations for older children and adults.
In children at 12 months of age in 2016, born between 
01/01/2015 and 31/12/2015, uptake of BCG, D3, T3, P3, Hib3, 
Polio3, HepB3 and two doses of PCV (PCV2) was measured. In 
8.1  Immunisation uptake at 12 and 24 
months of age
Summary
Among children at 12 months of age in 2016 uptake of:
D3, T3, P3, Hib3, Polio3, HepB3 and PCV2 was 91%
MenC2 was 89% (combined Quarters 1 and 2 data only)
MenC1 was 95% (combined Quarters 3 and 4 data only)
Among children at 24 months of age in 2016 uptake of:
D3, T3, P3, Hib3, Polio3 and HepB3 reached the target of 
95%
MMR1 was 92%
PCV3 and Hibb were 91%
MenC3 was 87%
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Age Children born 01/07/2008 to 30/06/2015                      Children born 01/07/2015 to 30/09/2016
Birth BCG                                                                                  BCG
2 months DTaP/Hib/IPV/HepB (6 in 1) + PCV                               DTaP/Hib/IPV/HepB (6 in 1) + PCV
4 months DTaP/Hib/IPV/HepB (6 in 1) + MenC                             DTaP/Hib/IPV/HepB (6 in 1) + MenC
6 months DTaP/Hib/IPV/HepB (6 in 1) + PCV + MenC                 DTaP/Hib/IPV/HepB (6 in 1) + PCV
12 months MMR + PCV                                                                     MMR + PCV
13 months MenC + Hib                                                                       MenC + Hib
Please note the primary immunisation schedule changed in 2015 for children born on or after 01/07/2015 and changed in 2016 for children born on or after 
October 1st 2016. Please see the HSE-National Immunisation Office (NIO) website at www.immunisation.ie for current and detailed information on the Irish 
primary childhood immunisation schedule and also recommended vaccinations for older children and adults 
BCG  Bacille Calmette Guerin vaccine 
DTaP  Diphtheria, Tetanus and acellular Pertussis vaccine
HepB  Hepatitis B vaccine
Hib  Haemophilus influenzae type b vaccine
IPV  Inactivated Polio Virus vaccine
MenC   Meningococcal group C vaccine
MMR  Measles, Mumps and Rubella vaccine
PCV  Pneumococcal Conjugate Vaccine
Table 1. Primary childhood immunisation schedule for children born between 01/07/2008 and 30/09/2016
children at 12 months of age in Quarters 1 and 2 2016, born 
between 01/01/2015 and 30/06/2015, uptake of two doses 
of MenC (MenC2) was measured and in children at 12 months 
of age in Quarters 3 and 4 2016, born between 01/07/2015 
and 31/12/2015 uptake of one dose of MenC (MenC1) was 
measured. In children at 24 months of age in 2016, born 
between 01/01/2014 and 31/12/2014, uptake of D3, T3, P3, 
Hib3, Polio3, HepB3, MenC3, PCV3, MMR1, Hibb, one dose 
of vaccine against meningococcal group C (MenCb) on or 
after twelve months of age and one dose of vaccine against 
pneumococcal conjugate vaccine (PCVb) on or after twelve 
months of age were measured.
The immunisation uptake rates are reported here by 
Community Healthcare Organisation and LHO. The uptake 
rates presented here were rounded to zero decimal place. 
While there are 32 LHOs the immunisation uptake rates 
for the LHOs of North Lee and South Lee are reported as a 
combined figure.
Caveats to data
National BCG data for 2016 are presented in this report and 
compared to 2015 data. The available national BCG cohort 
data may be around 89% of the national birth cohort in 
2016 and 90% in 2015 (these figures are estimates only). 
In Cavan/Monaghan, Louth and Meath, i.e. the former HSE 
NE, where a neonatal BCG programme is implemented, data 
were not available for reporting. In CHO2, i.e. the former 
HSE W, the neonatal BCG programme was not routinely or 
comprehensively implemented in all LHOs. Therefore, data 
provided for CHO2 reflects BCG vaccination data for just a 
small proportion of all babies born here. 
BCG vaccine stock in all CHOs expired at the end of April 
2015. At the time of writing of this report the HSE continues 
to experience ongoing delays with the supply of BCG vaccine. 
This continues to be a Europe wide issue. The number of 
cases of TB has been steadily falling in Ireland. The number 
of cases of TB for the years 2014 and 2015 was at the lowest 
level since records began. Most European countries do not 
give BCG vaccine to all babies. The National Immunisation 
Advisory Committee (NIAC), an independent expert group 
on immunisation and the Health Information and Quality 
Authority (HIQA) have both recommended that BCG vaccine 
does not now need to be given routinely to all babies in 
Ireland. For further information please see 
https://www.hse.ie/eng/health/immunisation/news/bcg17.html
As uptake of MenC3 was low since Q3 2010 and as those over 
12 months and less than 12 years of age need only one dose 
of MenC and those aged 12-23 months need only one dose 
of PCV, data on MenCb (one dose of MenC on or after first 
birthday and before second birthday) and PCVb (one dose 
of PCV on or after first birthday and before second birthday) 
were requested in 2012 for the first time. The MenCb and 
PCVb data were available for only eight CHOs in 2015 and 
2016. The available national cohort data may be around 91% 
of the national birth cohort in 2016 and 2015 (these figures 
are estimates only).
Immunisation uptake rates at 12 months
Ninety-one per cent of children, at 12 months of age in 2016, 
received D3, T3, P3, Hib3, Polio3, HepB3 and PCV2 (table 2). 
Compared with 2015, the uptake rates for these vaccines 
were unchanged in 2016. 
The MenC immunisation schedule changed in 2015 for 
children born on or after July 1st 2015. Eighty-nine per cent 
of children, at 12 months of age in Quarters 1 and 2 2016, 
received MenC2 and 95% of children, at 12 months of age in 
Quarters 3 and 4 2016, received MenC1 (table 2).
The available 2016 BCG cohort data may be around 89% 
(estimate only) of the national birth cohort. BCG vaccine 
stock in all HSE Areas expired at the end of April 2015. At the 
time of writing of this report the HSE continues to experience 
ongoing delays with the supply of BCG vaccine. This 
continues to be a Europe wide issue. National BCG uptake 
in 2016, based on available data, was 72%, 9%, 0.08% and 
0.03% in Quarters 1, 2, 3 and 4, respectively.
Among the CHOs, uptake rates for D3, T3, P3, Hib3, Polio3 and 
HepB3 ranged from 88% to 94% and PCV2 ranged from 87% 
to 94% (table 2). MenC2 uptake rates during Quarters 1 and 
2 2016 ranged from 85% to 93% (table 2). MenC1 uptake 
rates during Quarters 3 and 4 2016 ranged from 92% to 96% 
(table 2).
Among the LHOs, uptake rates for D3, T3, P3, Hib3, Polio3 and 
HepB3 ranged from 81% to 96% and PCV2 ranged from 78% 
to 96% (table 2). The target uptake of ≥95% was reached in 
Sligo/Leitrim, Roscommon and Longford/Westmeath for D3, 
T3, P3, Hib3, Polio3, HepB3, MenC1 and PCV2, in Roscommon, 
Laois/Offaly and Longford/Westmeath for MenC2 in Quarters 
1 and 2 and in total for 18 LHOs for MenC1 in Quarters 3 and 4.
Immunisation uptake rates at 24 months
National annual immunisation uptake rates, in children at 
24 months of age in 2016, were 95% for D3, T3, P3, Hib3, Polio3 
and HepB3, 92% for MMR1, 91% for PCV3 and Hibb and 87% 
for MenC3 (table 3). This is the sixth year national annual 
uptake rates reached the target of ≥95% for D3, T3, P3, Hib3, 
Polio3 and HepB3. Compared with 2015, the uptake rates for 
D3, T3, P3, Hib3, Polio3, HepB3 and Hibb were unchanged while 
MenC3, PCV3 and MMR1 declined by one percent (figure 1). 
Eight of the CHOs were able to provide uptake data on 
MenCb (one dose of MenC on or after first birthday and before 
second birthday) and PCVb (one dose of PCV on or after first 
birthday and before second birthday) in 2016. The available 
data may be around 91% (estimate only) of the national birth 
cohort. Where data were available, national uptake was 89% 
for MenCb and 93% for PCVb at 24 months of age (table 3).
Among the CHOs uptake rates for D3, T3, P3, Hib3, Polio3 and 
HepB3 ranged from 92% to 97%, MMR1 ranged from 89% 
to 95%, PCV3 ranged from 88% to 97%, Hibb ranged from 
86% to 94% and MenC3 ranged from 83% to 94% (table 3). 
Among the eight CHOs in a position to provide data PCVb 
uptake ranged from 90% to 94% and MenCb uptake ranged 
from 86% to 91% (table 3). 
The target uptake of ≥95% was reached in six CHOs during 
2016 for D3, T3, P3, Hib3, Polio3 and HepB3, in one CHO for 
PCV3 and MMR1 and in none for Hibb, MenC3, MenCb and 
PCVb (table 3). 
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Table 2. Immunisation uptake (%) at 12 months of age in 2016 (i.e. cohort born 01/01/2015-31/12/2015) by LHO and CHO
Community 
Healthcare 
Organisation 
(CHO)
Local Health Office/
CHO
Number in 
cohort for 
BCG* 
Number in 
cohort for 
D3T3
†
Immunisation Uptake (%)
BCG D3 
# Hib3 HepB3 MenC2‡ MenC1‡ PCV2
CHO1
Cavan/Monaghan na 1909 na 92 92 92 93 97 95
Donegal 2080 2080 28 92 92 91 87 96 92
Sligo/Leitrim 1261 1261 31 96 95 95 93 97 95
CHO1 Total* 3341 5250 29 93 93 92 91 96 94
CHO2
Galway 3493 3493 1 94 94 94 93 96 94
Mayo 1583 1583 23 93 93 93 92 96 93
Roscommon 825 825 3 95 95 95 95 96 96
CHO2 Total 5901 5901 8 94 94 94 93 96 94
CHO3
Clare 1570 1579 25 93 93 93 91 96 93
Limerick 1616 1927 25 89 89 89 86 93 89
Tipperary NR/East Limerick 1782 1824 27 91 91 91 88 96 91
CHO3 Total 4968 5330 25 91 91 91 88 95 91
CHO4
North Cork 1433 1413 27 90 90 90 87 93 87
North South Lee 5612 5554 26 91 91 91 87 95 88
West Cork 729 728 26 81 81 81 77 87 78
Kerry 1757 1746 23 92 92 92 86 94 87
CHO4 Total 9531 9441 26 90 90 90 86 94 87
CHO5
Carlow/Kilkenny 1830 1830 23 91 91 91 87 96 90
South Tipperary 1211 1211 27 93 93 93 92 98 93
Waterford 1740 1740 27 91 91 91 90 95 89
Wexford 2015 2015 24 92 92 92 93 94 92
CHO5 Total 6796 6796 25 92 92 92 90 95 91
CHO6
Dublin South 1683 1683 18 92 92 92 88 96 92
Dublin South East 1582 1582 16 92 92 92 90 94 92
Wicklow 1720 1720 18 89 89 89 82 94 88
CHO6 Total 4985 4985 17 91 91 91 86 95 91
CHO7
Dublin South City 1724 1724 17 91 91 91 86 95 91
Dublin South West 2400 2400 24 93 93 93 92 96 93
Dublin West 2525 2525 6 90 90 90 90 95 91
Kildare/West Wicklow 3641 3641 19 93 93 93 90 95 93
CHO7 Total 10290 10290 17 92 92 92 90 95 92
CHO8
Laois/Offaly 2351 2351 24 94 94 94 95 94 94
Longford/Westmeath 1840 1840 20 96 96 96 97 96 96
Louth na 1852 na 90 90 90 90 94 92
Meath na 3012 na 90 90 90 90 94 93
CHO8 Total* 4191 9055 22 92 92 92 93 95 94
CHO9
Dublin North West 3476 3476 22 89 89 89 85 93 89
Dublin North Central 1897 1897 24 88 88 88 84 91 88
Dublin North 3954 3954 8 88 88 88 84 93 88
CHO9 Total 9327 9327 16 88 88 88 85 92 88
Ireland 59330 66375 20 91 91 91 89 95 91
na=not available
*BCG data were unavailable for Cavan/Monaghan, Louth and Meath    
BCG vaccine stock in all areas expired at the end of April 2015. At time of writing the HSE continues to experience ongoing delays with the supply of BCG 
vaccine. This continues to be a Europe wide issue. The number of cases of TB has been steadily falling in Ireland. The number of cases of TB for the years 
2014 and 2015 was at the lowest level since records began. Most European countries do not give BCG vaccine to all babies. The National Immunisation 
Advisory Committee (NIAC), an independent expert group on immunisation and the Health Information and Quality Authority (HIQA) have both 
recommended that BCG vaccine does not now need to be given routinely to all babies in Ireland. Please see      
http://www.hse.ie/eng/health/immunisation/pubinfo/babychildimm/vaccprevdisease/tb/ for further information.    
National BCG uptake, based on available data, was 72%, 9%, 0.08% and 0.03% in Quarters 1, 2, 3 and 4, respectively. 
†The denominator/number in cohort varied slightly according to vaccine. D3T3 cohort is shown here.     
#Since T3, P3 and Polio3 uptake identical to D3 uptake only D3 uptake figures are presented    
‡The immunisation schedule changed in 2015 for children born on or after July 1st 2015 after the National Immunisation Advisory Committee (NIAC) 
recommended changing the meningococcal C (MenC) immunisation schedule in the primary childhood programme from three doses at 4, 6 and 13 months 
to two doses at 4 and 13 months because of evidence that a single dose of MenC vaccine provides protection for the first year of life. Hence uptake of 
two doses of MenC (MenC2) was measured during Quarters 1 and 2 (birth cohort 01/01/2015-30/06/2015) and uptake of one dose of MenC (MenC1) was 
measured during Quarters 3 and 4 (birth cohort 01/07/2015-31/12/2015). Please note the immunisation schedule changed in 2016 for children born on or 
after October 1st 2016. Please see the HSE-National Immunisation Office (NIO) website at http://www.immunisation.ie for current and detailed information 
on the Irish primary childhood immunisation schedule and also recommended vaccinations for older children and adults.
Please note while North Lee and South Lee are two separate LHOs their combined immunisation uptake data are reported here.
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 Table 3. Immunisation uptake (%) at 24 months of age in 2016 (i.e. cohort born 01/01/2014-31/12/2014) by LHO and CHO
Community 
Healthcare 
Organisation 
(CHO)
Local Health Office/CHO
Number in 
cohort for 
D3*
Immunisation Uptake (%)
D3
† HepB3 Hibb MenC3 MenCb PCV3 PCVb MMR1
CHO1
Cavan/Monaghan 1934 97 97 91 89 90 93 94 94
Donegal 1971 95 93 90 83 89 87 92 90
Sligo/Leitrim 1292 97 97 96 87 96 90 96 96
CHO1 Total 5197 96 95 92 86 91 90 94 93
CHO2
Galway 3565 97 97 95 95 na 96 na 96
Mayo 1648 97 97 91 91 na 98 na 93
Roscommon 878 98 98 96 96 na 97 na 96
CHO2 Total 6091 97 97 94 94 na 97 na 95
CHO3
Clare 1496 95 95 94 90 93 91 93 93
Limerick 1874 93 93 90 87 90 90 91 91
Tipperary NR/East 
Limerick 1779 95 94 88 85 88 92 94 93
CHO3 Total 5149 94 94 90 87 90 91 93 92
CHO4
North Cork 1342 96 96 92 88 90 91 92 93
North South Lee 5611 95 95 89 86 88 91 92 91
West Cork 682 92 92 89 84 86 88 89 90
Kerry 1779 96 96 91 88 90 92 93 93
CHO4 Total 9414 95 95 90 87 88 91 92 92
CHO5
Carlow/Kilkenny 2018 95 95 93 87 90 92 94 94
South Tipperary 1232 97 96 95 88 92 94 95 95
Waterford 1836 94 93 92 86 89 90 92 92
Wexford 2126 96 96 95 89 93 93 95 94
CHO5 Total 7212 95 95 93 88 91 92 94 94
CHO6
Dublin South 1679 95 95 92 90 92 92 93 93
Dublin South East 1679 95 95 92 90 91 92 93 93
Wicklow 1762 94 94 86 82 85 89 92 90
CHO6 Total 5120 94 94 90 87 89 91 93 92
CHO7
Dublin South City 1616 95 95 89 86 89 89 91 91
Dublin South West 2443 97 97 95 89 94 92 96 96
Dublin West 2656 95 95 86 83 86 89 92 91
Kildare/West Wicklow 3834 95 95 92 89 92 92 93 93
CHO7 Total 10549 95 95 91 87 90 91 93 93
CHO8
Laois/Offaly 2509 97 97 97 90 92 93 95 96
Longford/Westmeath 1930 97 97 97 91 94 95 95 96
Louth 1824 94 94 87 83 86 89 91 90
Meath 3175 95 95 89 86 88 90 91 91
CHO8 Total 9438 96 96 92 87 90 91 93 93
CHO9
Dublin North West 3547 94 94 87 84 87 89 91 90
Dublin North Central 1862 91 91 84 80 84 86 89 88
Dublin North 4152 91 91 86 84 86 88 89 89
CHO9 Total 9561 92 92 86 83 86 88 90 89
Ireland 67731 95 95 91 87 89 91 93 92
*As the denominator/number in cohort varied slightly according to vaccine the D3 cohort is shown here
†Since T3, P3, Hib3 and Polio3 uptake identical to D3 uptake only D3 uptake figures are presented
Please note while North Lee and South Lee are two separate Local Health Offices their combined immunisation uptake data are reported here
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D3, Hibb, MenC3 and MMR1 uptake rates are mapped by LHO 
in figure 2. Among the LHOs the uptake rates ranged from 
91% to 98% for D3, T3, P3, Hib3, Polio3 and HepB3, 89% to 96% 
for PCVb, 88% to 96% for MMR1, 86% to 98% for PCV3, 84% 
to 97% for Hibb, 84% to 96% for MenCb and 80% to 96% for 
MenC3 (table 3). 
The target uptake of ≥95% was reached in 23 LHOs for D3, 
T3, P3, Hib3 and Polio3, 21 for HepB3, in eight for Hibb, in seven 
LHOs for MMR1, in six for PCVb, in four LHOs for PCV3, in two 
LHOs for MenC3 and in one LHO for MenCb (table 3). Galway 
and Roscommon were the only LHOs to reach the target of 
≥95% for D3, T3, P3, Hib3, Polio3, HepB3, Hibb, MenC3, PCV3 
and MMR1 for children at 24 months (table 3).
Conclusion
National immunisation uptake rates, in children at 12 
months of age in 2016, were 91% for D3, T3, P3, Hib3, Polio3, 
HepB3 and PCV2. The MenC immunisation schedule changed 
in 2015 for children born on or after July 1st 2015. Eighty-nine 
per cent of children, at 12 months of age in Quarters 1 and 2 
2016, received MenC2 and 95% of children, at 12 months of 
age in Quarters 3 and 4 2016, received MenC1.
In 2016, national uptake rates at 24 months for MenC3 
(87%), Hibb (91%), PCV3 (91%) and MMR1 (92%) were lower 
than the target uptake of ≥95%. In 2016, national uptake 
rates at 24 months of age for D3, T3, P3, Hib3, Polio3 and 
HepB3 reached the target rate of ≥95%. This is the sixth year 
national annual uptake rates reached the target of ≥95% 
for these vaccines. Based on available data uptake of MenCb 
was 89% and uptake of PCVb was 93%. The target uptake 
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Figure 1. National annual immunisation uptake rates (based on available data) at 24 months, 1999-2015 
Since T3 and Polio3 uptake identical to D3 uptake only D3 uptake figures presented.
P3 uptake could not be calculated accurately during 1999-2001 as DTaP/DT uptake was reported as a combined value for the HSE NE during 1999, Quarters 3 and 
4 2000 and Quarter 1 2001 and the HSE NW in 2000 and 2001. The 2002 MenC3 figure is based on uptake rates for Quarter 3 and Quarter 4 2002 only. The 2005 
MMR1 uptake figure is incomplete as the HSE E was unable to provide MMR data for Quarter 4 2005, due to technical problems. The 2006 MMR1 figure includes 
the Quarter-1 2006 HSE E figure, which is an estimate only due to technical problems. The 2007 national Hibb figure is incomplete, as the HSE W data for Quarter 
1 2007 and the HSE NW data for Quarter 3 2007 were not available. The 2007 national Hibb figure also includes the HSE SE data which are an underestimate due 
to data extraction methods.  The 2008 Hibb figure is incomplete as the HSE SE data for Q2 2008 and the HSE MW data for Quarter 3 2008 were not available. 
The 2008 national MenC3 figure is incomplete as the HSE E and HSE MW MenC3 data for Quarter 3 2008 were not available. The 2009 data are incomplete as 
the following were unavailable: the Quarter 1 2009 HSE E D3, T3, P3 and Polio3 data for those born on the 31/03/2007; the Quarter 2 2009 HSE E Dublin North 
Hibb uptake data and; the Quarter 4 2009 HSE MW data, HSE E Dublin North Hibb data and HSE SE Hibb data for those given a Hib dose as part of the five in one 
or six in one vaccine after 12 months of age. The 2010 data are incomplete as the following were unavailable: the Quarter 1 2010 HSE M and HSE S data and the 
HSE E Dublin North Hibb data; the Quarter 2 2010 HSE M data and; the Quarter 4 2010 HSE NE data. As a new childhood immunisation schedule was introduced 
in 2008, for those born on or after July 1st 2008, the 2010 HepB3 and PCV3 data at 24 months are for those born between July 1st and December 31st 2008 (i.e. 
Quarters 3 and 4 2010 data) only. The MenCb and PCVb data were available for only six of the eight HSE Areas from Q1 2012 to Q4 2014 and for seven of the eight 
HSE Areas (eight of the nine CHOs) for 2015 and 2016.
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of ≥95% was reached in six CHOs during 2016 for D3, T3, 
P3, Hib3, Polio3 and HepB3, in one CHO for PCV3 and MMR1 
and in none for Hibb, MenC3, MenCb and PCVb. Galway and 
Roscommon were the only LHOs to reach the target of ≥95% 
for D3, T3, P3, Hib3, Polio3, HepB3, Hibb, MenC3, PCV3 and 
MMR1 for children at 24 months.
 
Quarterly Reports
The immunisation reports for Quarters 1 to 4 2016 are 
available on the HPSC website in Topics A-Z under the 
heading vaccination.
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Figure 2. D3, Hibb, MenC3 and MMR1 immunisation uptake rates (%) in those 24 months of age in 2016 by Local Health Office (LHO)
LHOs in Dublin are highlighted separately for ease of viewing
North Lee and South Lee are separate LHOs, however, their combined (labelled NSL on the map) immunisation uptake rate is reported here
Please see table 4 to translate LHO abbreviations
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Table 4. Local Health Office (LHO) abbreviations used in this chapter
Local Health Office 
Abbreviations 
Local Health Office
CE Clare
CN/MN Cavan/Monaghan
CW/KK Carlow/Kilkenny
DL Donegal
DN Dublin North
DNC Dublin North Central
DNW Dublin North West
DS Dublin South
DSC Dublin South City
DSE Dublin South East
DSW Dublin South West
DW Dublin West
G Galway
KE/WW Kildare/West Wicklow 
KY Kerry
L Limerick
LD/WD Longford/Westmeath
LH Louth
LS/OY Laois/Offaly
MH Meath
MO Mayo
NC North Cork
NSL* North South Lee*
RN Roscommon
SO/LM Sligo/Leitrim
TN/EL Tipperary North /East Limerick
TS South Tipperary
WC West Cork
WD Waterford
WX Wexford
WW Wicklow 
*Please note while North Lee and South Lee are two separate LHOs their 
combined immunisation uptake data are reported
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Background
DTaP/IPV* and MMR vaccines are now primarily 
administered by the HSE school immunisation teams, with 
only two LHOs providing these vaccines via GP local services 
only. Data on the uptake of DTaP/IPV and MMR vaccines 
among junior infant schoolchildren has been collated 
nationally since the 2011/2012 academic school year and 
was first published January 20131. Since then, annual 
(academic year) reports, based on data submissions from 
each area, are published on the HPSC website.
 
Since 2015 all LHOs immunisation offices are asked to 
input the data relating to school based junior infant DTaP/
IPV and MMR vaccine programme onto the HSE School 
Immunisation System (SIS). Although most areas are now 
using SIS for recording these data, some areas continue 
to use alternate information systems. There is agreement 
that all school based vaccines will be inputted onto SIS 
for the 2016/2017 academic year. In this report we provide 
data for the 2015/2016 academic year DTaP/IPV and MMR 
vaccination programme and compare uptake with previously 
reported data.
DTaP/IPV* and MMR† vaccine uptake 2015/2016
Uptake of the DTaP-IPV* and MMR† vaccines in 4-5 year 
olds/junior infant schoolchildren was monitored across all 
LHOs during the 2015/2016 academic year. Data from HSE-
vaccine administered LHOs is based on what was recorded 
on SIS on 24th April 2017, although some LHOs had not 
entered all of their data at the time of data extraction. For 
the latter LHOs, the returns reported here are based on data 
provided directly to HPSC by mid-October 2016, except for 
Wexford, whose updated figures were reported on the 17th 
May 2017.
All uptake data, provided by immunisation coordinators and 
other administrative staff2 were entered on to a MS-Excel 
database and compared to those reported for the previous 
2014/2015 season, where possible.
8.2 DTaP/IPV* and MMR† vaccine 
uptake 2015/2016
Key Points
Uptake of the DTaP/IPV (also known as the 4 in 1) vaccine 
among junior infant schoolchildren during 2015/2016 in 
HSE-administered LHOs (Local Health Offices) was 91.9% 
and in GP-administered LHOs it was 90.4%
Uptake of the MMR vaccine among junior infant 
schoolchildren during 2015/2016 in HSE-administered 
LHOs was 91.5% and in GP-administered LHOs it was 
90.7%
Overall, uptake of the DTaP/IPV and MMR vaccines at 
national level during 2015/2016 was estimated to be 
91.8% and 91.5%, respectively.
Table 1. Proportion of DTaP-IPV vaccine and MMR uptake in HSE-administered LHOs attributable to GPs in 2015/2016
% Vaccine Uptake Administered by GPs
LHO DTaP-IPV MMR
North Cork 26% 26%
Kerry 12.5% 12.5%
South Lee 6.6% 6.6%
North Lee 6% 6%
Dublin South 5.5% 6.1%
West Cork 4.9% 4.9%
Wexford 2.1% 2.1%
Offaly 0.08% 0.16%
* DTaP-IPV = Diphtheria, Tetanus, acellular Pertussis and Polio vaccine
†MMR = Measles, Mumps and Rubella vaccine 
1 http://ndsc.newsweaver.ie/epiinsight/1s4r7v3qv7n?a=1&p=30773765&t=17517774 
2 Data for the North West area were provided to HPSC by the local Department of Public Health
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HSE-school team versus GP-vaccine administered LHOs
In 2015/2016, vaccines were delivered in 21 LHOs by HSE 
school teams only, in eight other HSE-administered LHOs 
where GPs deliver a small percentage of vaccines and in two 
LHOs based in the North West by GPs only (Table 1). 
Target populations
For the 2015/2016 academic year, the target population in 
HSE-vaccine administered LHOs was all children in junior 
infants on the school register on the 30th September 2015. 
For GP-vaccine administered LHOs, the target population 
was all children born between the 1st September 2009 and 
31st August 2010. 
The different ways in which the target populations have 
been defined in the HSE- and GP-vaccine administered 
LHOs has meant that a national uptake for either vaccine 
cannot be accurately calculated. Donegal and Sligo/Leitrim, 
two GP–vaccine administered LHOs, are part of Community 
Health Organisation (CHO) area 1, which also includes the 
HSE-vaccine administered LHO Cavan/Monaghan. This 
means that the uptake in CHO area 1 cannot be compared 
to the other eight CHO areas 2 to 9. However, in order to 
estimate uptake at a national level, the cohorts for Cavan/
Monaghan, Donegal and Sligo/Leitrim have been combined.
Uptake of DTaP-IPV vaccine
Between 2014/2015 and 2015/2016, the overall uptake of 
the DTaP-IPV vaccine in HSE-vaccine administered LHOs 
increased from 91.5% to 91.9%. In 2015/2016, the average 
uptake among these LHOs was 92.3% with a range from 
81.4% in Dublin North to 97.2% in Waterford. Of the 29 HSE-
vaccine administered LHOs, 13 reported an average uptake 
decline of -2.6% whilst 16 others reported an average 
increase of +3.7%. The largest reduction in uptake was 
reported by Dublin North (-7.7%) and the highest increase 
was each reported by Mayo and Limerick (+8.7%).
During the same period of time, overall DTaP-IPV vaccine 
uptake in exclusively GP-vaccine administered LHOs 
(Donegal; Sligo/Leitrim) fell slightly from 92.3% to 90.4%: 
Donegal reported an uptake reduction of -2.9%, whilst 
Sligo/Leitrim reported a slight decrease of -0.3%. 
Uptake of MMR vaccine
The overall uptake of the MMR vaccine between 2014/2015 
and 2015/2016 in HSE-vaccine administered LHOs 
increased from 91.3% to 91.5%. In 2015/2016, the average 
uptake among these LHOs was 91.9% with a range from 
81.7% in Dublin North to 96.8% in North Cork. Of the 29 
HSE-vaccine administered LHOs, 13 reported an average 
uptake reduction of -2.9% whilst 16 others reported an 
average increase of +3.4%. The largest reduction in uptake 
was reported by Dublin North (-7.0%) and the highest 
increase was reported by Limerick (+9.1%).
Overall MMR vaccine uptake in exclusively GP-vaccine 
administered LHOs decreased from 91.8% to 90.7% during 
the same time period: Donegal reported an uptake decrease 
of -2.1%, whilst Sligo/Leitrim reported a decrease of -0.3%.
MMR catch-up vaccination
0% 
20% 
40% 
60% 
80% 
100% 
%
 U
pt
ak
e 
of
 V
ac
ci
ne
 in
 J
un
io
r 
In
fa
nt
s 
na
tio
na
lly
 
95% threshold
2011-12 2012-13 2013-14 2014-15 2015-16 
Season 
% 4 in 1 Uptake % MMR Uptake 95% Threshold 
2011-12 2012-13 2013-14 2014-15 2015-16 
Season 
% 4 in 1 Uptake % MMR Uptake 95% Threshold 
2011-12 2012-13 2013-14 2014-15 2015-16 
Season 
% 4 in 1 Uptake % MMR Uptake 95% Threshold 
0% 
20% 
40% 
60% 
80% 
100% 
%
 U
pt
ak
e 
of
 V
ac
ci
ne
 in
 J
un
io
r 
In
fa
nt
s 
in
 G
P 
ad
m
in
 a
re
as
 
95% threshold 
0% 
20% 
40% 
60% 
80% 
100% 
%
 U
pt
ak
e 
of
 V
ac
ci
ne
 in
 J
un
io
r 
In
fa
nt
s 
in
 H
SE
 a
dm
in
 a
re
as
 
95% threshold 
0% 
20% 
40% 
60% 
80% 
100% 
%
 U
pt
ak
e 
of
 V
ac
ci
ne
 in
 J
un
io
r 
In
fa
nt
s 
na
tio
na
lly
 
95% threshold
2011-12 2012-13 2013-14 2014-15 2015-16 
Season 
% 4 in 1 Uptake % MMR Uptake 95% Threshold 
2011-12 2012-13 2013-14 2014-15 2015-16 
Season 
% 4 in 1 Uptake % MMR Uptake 95% Threshold 
2011-12 2012-13 2013-14 2014-15 2015-16 
Season 
% 4 in 1 Uptake % MMR Uptake 95% Threshold 
0% 
20% 
40% 
60% 
80% 
100% 
%
 U
pt
ak
e 
of
 V
ac
ci
ne
 in
 J
un
io
r 
In
fa
nt
s 
in
 G
P 
ad
m
in
 a
re
as
 
95% threshold 
0% 
20% 
40% 
60% 
80% 
100% 
%
 U
pt
ak
e 
of
 V
ac
ci
ne
 in
 J
un
io
r 
In
fa
nt
s 
in
 H
SE
 a
dm
in
 a
re
as
 
95% threshold 
0% 
20% 
40% 
60% 
80% 
1 0% 
%
 U
pt
ak
e 
of
 V
ac
ci
ne
 in
 J
un
io
r 
In
fa
nt
s 
na
tio
na
lly
 
95% threshold
20 1-12 2012-13 2 - 15-16 
% 4 in 1 Uptake    reshold 
20 1-12 2012-13 2 - 15-16 
% 4 in 1 Uptake    reshold 
20 1-12 2012-13 2 - 15-16 
% 4 in 1 Uptake    reshold 
0% 
20% 
40% 
60% 
80% 
1 0% 
%
 U
pt
ak
e 
of
 V
ac
ci
ne
 in
 J
un
io
r 
In
fa
nt
s 
in
 G
P 
ad
m
in
 a
re
as
 
95% threshold 
0% 
20% 
40% 
60% 
80% 
1 0% 
%
 U
pt
ak
e 
of
 V
ac
ci
ne
 in
 J
un
io
r 
In
fa
nt
s 
in
 H
SE
 a
dm
in
 a
re
as
 
95% threshold 
Figure 1. Percentage uptake of the DTaP/IPV and MMR vaccines in 
HSE administered areas between 2011/2012 and 2015/2016
Figure 2. Percentage uptake of the DTaP/IPV and MMR vaccines in 
GP administered areas between 2011/2012 and 2015/2016
Figure 3. Estimated percentage uptake of the DTaP/IPV and MMR 
vaccines nationally between 2011/2012 and 2015/2016
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Seven‡ HSE-vaccine administered LHOs reported on the 
number of children needing a catch-up MMR dose one 
month later after been given their first dose. The total 
number of children identified was 89 (range one to 30). Of 
these 89 children, 59 (66.3%) received a catch-up vaccine 
dose (range zero to 23) (data not shown).
Figures 1 to 3 present trends in the percentage uptake of 
the DTaP/IPV and MMR vaccines between 2011/2012 and 
2015/2016 in HSE administered areas, GP administered 
areas and as an national estimate, respectively.
Details of the overall uptake of the two vaccines in the HSE- 
and GP-vaccinated LHOs during 2015/2016 are presented in 
Table 2 and in the maps in Figure 4.
Discussion
Although at national level uptake of DTaP/IPV and MMR has 
improved in recent years, little progress has been made at 
national level since 2013-2014 when a plateau was reached. 
It is of concern that uptake of these vaccines is sub-optimal 
among junior infants, both nationally and in a majority of 
CHOs and LHOs. Uptake less than 95% for these vaccines 
indicates vulnerability amongst the children who have not 
availed of the vaccines aimed at preventing serious diseases 
(diphtheria, tetanus, pertussis, polio, measles, mumps, and 
rubella). Even if all children in these cohorts had received 
their vaccines in early childhood, booster doses are needed 
to provide protection in the forthcoming years. 
Limitations
The data presented here represent vaccines administered for 
these age cohorts. It is possible that some children may have 
received their booster doses prior to preschool age if they 
came from another jurisdiction or were vaccinated earlier 
than the normal schedule for other reasons (travel, exposure 
to cases of these diseases). However, if this did occur the 
proportion would be very small.
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Notes
*DTaP-IPV = Diphtheria, Tetanus, acellular Pertussis and 
Polio vaccine, also known as the 4 in 1 vaccine
†MMR = Measles, Mumps and Rubella vaccine 
‡Excludes Laois 
**In table 2, data in HSE vaccine administered LHOs 
based on what was recorded on SIS only on 24th April 2017 
although some LHOs had not entered all their data at the 
time of data extraction. For the latter LHOs the returns 
reported here are based on data provided by them directly 
to HPSC by mid October 2016, except for Wexford, whose 
updated figures were reported on the 17th May 2017.
Figure 4. LHO Maps of DTaP-IPV & MMR percentage vaccine uptake at Junior Infants level during the 2015/2016 academic year
HsE-dtap-ipV Vaccine Administered lHos
gp-dtap-ipV Vaccine Administered lHos 
HsE-mmR Vaccine Administered lHo
 gp-mmR Vaccine Administered lHos
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Background
HPV
Background
HPV
Following a recommendation from the National 
Immunisation Advisory Committee (NIAC), that human 
papillomavirus (HPV) vaccine should be given to 12 year 
old girls, a routine Health Service Executive (HSE) school 
HPV vaccination programme began in May 2010 for girls 
in the first year of second level school and age equivalent 
in special schools and home schooled. The aim of the 
programme is to protect girls from their future risk of 
developing cervical cancer. 
An HPV catch-up campaign for girls in sixth year of 
second level schools and their age equivalents in non-
second level schools (ie special schools, home schooled, 
Community Training Centres and Youthreach) was added 
in the academic year 2011/2012 and continued during the 
academic years 2012/2013 and 2013/2014.
Quadrivalent HPV vaccine, which protects against HPV 
types 6, 11, 16 and 18 associated with 70% of cervical cancer, 
has been used in the school vaccination programme since 
the programme began. A schedule of two vaccine doses 
given at least six months apart was recommended since the 
academic year 2014/2015 for girls aged <15 years. Prior to 
this a schedule of three vaccine doses given over a six month 
period was recommended. This change is based on more 
recent data which showed that the immune response to two 
doses of the vaccine in 9-13 year old girls is comparable to a 
three dose course. The HPV vaccine does not protect against 
all cervical cancers, so regular cervical screening is still 
needed.  
MenC
MenC (meningococcal group C) vaccine is recommended as 
part of the primary childhood immunisation programme. 
In recent years, evidence has emerged that immunity to 
meningococcal disease reduces over time, so a booster 
dose is recommended now to provide additional protection. 
NIAC recommends vaccination with a booster MenC 
vaccine at 12-13 years of age. The MenC booster vaccine was 
introduced into the HSE schools immunisation programme 
in September 2014. This vaccine is offered to students in 
first year of second level schools and their age equivalents in 
special schools and home schooled. 
Tdap
NIAC recommends vaccination with Tdap (tetanus and low-
dose diphtheria and acellular pertussis) vaccine at 11-14 
years of age. The Tdap vaccine was introduced to the HSE 
schools immunisation programme on a phased basis from 
September 2011. The HSE extended the Tdap vaccination 
programme to all areas from September 2012. This vaccine 
is offered to students in first year of second level school and 
their age equivalents in special schools and home schooled. 
It replaces the previous school based Td (Tetanus and low 
dose diphtheria) vaccination programme. The adolescent 
booster was changed because more cases of pertussis have 
been occurring in adolescents and adults due to the waning 
immunity that occurs over time, combined with a reduction 
in natural boosting.
The target for uptake of two doses of vaccine for the HPV 
vaccination programme is ≥80% and target uptake of MenC 
booster and Tdap vaccine is ≥95%.
The vaccinations are provided by vaccination teams from 
the Local Health Offices (LHOs) who go into schools in 
their areas to vaccinate or provide vaccination clinics free 
of charge for children in the target cohorts. Vaccinations 
provided through the schools immunisation programme are 
entered into the School Immunisation System (SIS). Please 
see the HSE-National Immunisation Office (NIO) website at 
www.immunisation.ie for detailed and current information 
on the school vaccination programme.
Cohort for vaccination in the academic year 2015/2016
The cohort for the 2015/2016 HPV, Tdap and MenC booster 
vaccination programme was children (girls only for HPV 
vaccine) 
• in first year of second level schools 
•  and their age equivalents ie those who were born 
between 01/09/2003 and 31/08/2004
○  attending special schools or
○  registered with the Child and Family Agency Education 
Welfare Services to be home schooled.
Terminology used in this report
At least stage 1 - means a girl had a stage 1 HPV vaccine 
recorded on SIS, this girl may or may not have had a stage 2 
HPV vaccine recorded on SIS.
8.3 HPV, MenC booster and Tdap 
vaccine uptake 2015/2016
Key Points
Among the recommended cohorts in the academic year 
2015/2016:
72.3% of girls had at least stage 2 HPV vaccine 
(considered to have completed a two dose HPV vaccine 
course);
86.7% of children had MenC booster vaccine and;
89.2% of children had Tdap vaccine.
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At least stage 2 - means a girl had a stage 2 HPV vaccine 
recorded on SIS, she may or may not have had stage 1 HPV 
vaccine recorded on SIS.
 
Girls with at least stage 2 HPV are considered to have 
completed a course of vaccination. Prior to the 2014/2015 
academic year girls with at least stage 3 HPV were 
considered to have completed a course of vaccination.
Home schooled - refers to children registered with the 
Child and Family Agency Education Welfare Services to be 
educated at home. These children were recorded on SIS and 
reported here as home schooled.
Out of school - refers to vaccinated children who were 
neither enrolled in a second level school, special school 
nor registered with the Child and Family Agency Education 
Welfare Services as home schooled.
Local Health Office (LHO) - refers to the LHO the school is 
located in (it does not refer to the LHO the child is resident 
in).
Outside cohort - refers to those who were vaccinated but 
who were not in first year of second level schools or their 
equivalents in non-second level schools ie they were outside 
the cohorts recommended for vaccination.
The denominator for second level schools was defined as the 
number of children (girls only for HPV vaccine) on the school 
roll on 30th September 2015 for first year. The denominator 
for age equivalent to first years in second level schools was 
defined as children (girls only for HPV vaccine) born between 
01/09/2003 and 31/08/2004 on the school roll of special 
schools or registered with the Child and Family Agency 
Education Welfare Services on 30th September 2015. All 
the denominator data was entered onto SIS by the relevant 
System Administrator.
Uptake of HPV, MenC booster and Tdap vaccines
Here we report on the uptake of HPV, MenC booster and 
Tdap vaccines in the academic year 2015/2016, provided 
through the school immunisation programme and recorded 
on SIS on the 24th January 2017. These figures are subject to 
change due to ongoing updating of data on the database.
The data presented here are the result of collaboration 
between NIO, School Immunisation Teams, Immunisation 
Coordinators, Immunisation System Administrators, 
Immunisation administrative staff and HPSC.
Uptake of HPV vaccine 
In Ireland, 72.3% of girls in second level schools and their 
age equivalents in special schools and home schooled 
were recorded as having received at least HPV stage 2 
(considered to have completed a two dose course) (Table 1). 
In the 2014/2015 academic year, 86.9% of girls in second 
level schools and their age equivalents in special schools 
and home schooled were recorded as having received 
at least HPV stage 2 (considered to have completed a 
two dose course)1. Data are not directly comparable with 
academic years prior to 2014/2015. Prior to the academic 
year 2014/2015 a three dose schedule was recommended. 
In the academic year 2013/2014 88.2% of girls in first year 
in second level schools were recorded as having received at 
least HPV stage 2 while 84.9% of girls in first year in second 
level schools were recorded as having received at least HPV 
stage 3.2 
Among the nine Community Healthcare Organisations 
(CHOs), in the academic year 2015/2016, uptake of at least 
HPV stage 2 among girls ranged from 66.3% to 77.6%; with 
none reaching the target of ≥80% uptake. While among the 
32 LHOs uptake of at least HPV stage 2 ranged from 60.2% 
to 83.5%. Five LHOs reached the target of ≥80% uptake in 
2015/2016 compared to 30 LHOs who reached the target of 
≥80% in 2014/2015.
An additional 26 girls were recorded as being outside the 
cohorts recommended for vaccination and having received 
at least HPV stage 2 (Table 1). 
Uptake of MenC booster vaccine 
In the academic year 2015/2016, uptake of the MenC 
booster vaccine in children in first year in second level 
schools and their equivalents in special schools and 
home schooled was 86.7% (Table 2). In the academic year 
2014/2015, uptake of the MenC booster vaccine in children 
in first year in second level schools and their equivalents in 
special schools and home schooled was 87.9%.3
In the academic year 2015/2016, there was some regional 
variation with uptake among the CHOs ranging from 80.8% 
to 88.9%. 
In 2015/2016, an additional 136 children were recorded as 
being outside the cohort recommended for vaccination and 
having received MenC booster vaccine (Table 2). 
Uptake of Tdap vaccine 
In the academic year 2015/2016, uptake of the Tdap vaccine 
in children in first year in second level schools and their 
equivalents in special schools and home schooled was 
89.2% (Table 3). Uptake was 89.1 % in the academic year 
2014/2015; and uptake was 83.7% in the academic year 
2013/2014 among the 31 LHOs, out of a total of 32 LHOs, 
reporting data.4, 5
In the academic year 2015/2016, there was some regional 
variation with uptake among the CHOs ranging from 84.7% 
to 91.0%.
In 2015/2016, an additional 122 children were recorded as 
being outside the cohort recommended for vaccination and 
having received Tdap vaccine (Table 3). 
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Table 1. HPV uptake data among girls in the routine cohort in the academic year 2015/2016 (data extracted from the School Immunisation 
System 24/01/2017)
Community 
Healthcare 
Organisation 
(CHO)
Local Health Office/Community 
Healthcare Organisation (CHO)
2015/2016
Girls in first year in second level schools and age equivalent* in special schools, 
home schooled and out of school
Outside cohort
Numbers vaccinated with: % Vaccinated with: Numbers vaccinated with:
Denominator at least stage 1 at least stage 2
at least 
stage 1
at least 
stage 2
Denominator
at least 
stage 1
at least 
stage 2
CHO1
Cavan/Monaghan 876 683 620 78.0% 70.8% N/A 1 1
Donegal 1081 871 777 80.6% 71.9% N/A 0 0
Sligo/Leitrim 678 547 481 80.7% 70.9% N/A 0 0
CHO1 Total 2635 2101 1878 79.7% 71.3% N/A 1 1
CHO2
Galway 1745 1395 1271 79.9% 72.8% N/A 4 4
Mayo 918 695 623 75.7% 67.9% N/A 2 1
Roscommon 283 226 190 79.9% 67.1% N/A 1 0
CHO2 Total 2946 2316 2084 78.6% 70.7% N/A 7 5
CHO3
Clare 800 677 607 84.6% 75.9% N/A 2 1
Limerick 1026 857 759 83.5% 74.0% N/A 0 0
Tipperary NR/East Limerick 967 810 717 83.8% 74.1% N/A 1 1
CHO3 Total 2793 2344 2083 83.9% 74.6% N/A 3 2
CHO4
North Cork 610 460 380 75.4% 62.3% N/A 0 0
North Lee - Cork 1267 1056 914 83.3% 72.1% N/A 0 0
South Lee - Cork 1238 1007 852 81.3% 68.8% N/A 1 1
West Cork 359 257 216 71.6% 60.2% N/A 0 0
Kerry 963 742 581 77.1% 60.3% N/A 0 0
CHO4 Total 4437 3522 2943 79.4% 66.3% N/A 1 1
CHO5
Carlow/Kilkenny 1073 945 865 88.1% 80.6% N/A 0 0
South Tipperary 550 452 395 82.2% 71.8% N/A 2 0
Waterford 829 704 646 84.9% 77.9% N/A 0 0
Wexford 1094 884 724 80.8% 66.2% N/A 0 0
CHO5 Total 3546 2985 2630 84.2% 74.2% N/A 2 0
CHO6
Dublin South 886 736 664 83.1% 74.9% N/A 8 1
Dublin South East 638 546 518 85.6% 81.2% N/A 1 1
Wicklow 756 625 557 82.7% 73.7% N/A 0 0
CHO6 Total 2280 1907 1739 83.6% 76.3% N/A 9 2
CHO7
Dublin South City 753 695 621 92.3% 82.5% N/A 0 0
Dublin South West 798 666 590 83.5% 73.9% N/A 1 1
Dublin West 1093 917 777 83.9% 71.1% N/A 1 1
Kildare/West Wicklow 1747 1584 1418 90.7% 81.2% N/A 0 0
CHO7 Total 4391 3862 3406 88.0% 77.6% N/A 2 2
CHO8
Laois/Offaly 1126 996 862 88.5% 76.6% N/A 2 2
Longford/Westmeath 1098 899 762 81.9% 69.4% N/A 0 0
Louth 992 913 828 92.0% 83.5% N/A 2 0
Meath 1397 1090 968 78.0% 69.3% N/A 4 4
CHO8 Total 4613 3898 3420 84.5% 74.1% N/A 8 6
CHO9
Dublin North West 1421 1147 987 80.7% 69.5% N/A 4 3
Dublin North Central 677 539 474 79.6% 70.0% N/A 0 0
Dublin North 1615 1262 1076 78.1% 66.6% N/A 4 2
CHO9 Total 3713 2948 2537 79.4% 68.3% N/A 8 5
Home schooled 51 1 1 2.0% 2.0% N/A 1 0
Total of LHOs and home schooled 31405 25884 22721 82.4% 72.3% N/A 42 24
Out of school N\A 0 0 N/A N/A N/A 2 2
Total of LHOs and home schooled and out of school N\A 25884 22721 N\A N\A N/A 44 26
*Age equivalents are those born between 01/09/2003 and 31/08/2004. 
Outside cohort refers to those who were vaccinated but who were outside the routine cohort for vaccination. 
Local health office (LHO) refers to the LHO of the school. Therefore, in reports the LHOs of homeschooled and out of school children do not appear. 
The denominator for second level schools was defined as the number of children on the school roll on 30th September 2015 for first year. The denominator for age equivalent 
to first years in second level schools was defined as children born between 01/09/2003 and 31/08/2004 on the school roll of special schools or registered with the Child and 
Family Agency Education Welfare Services on 30th September 2015. All the denominator data was entered onto the School Immunisation System (SIS) by the relevant System 
Administrator. 
 ‘At least stage 1’ means a girl had a stage 1 recorded on SIS, this girl may or may not have had a stage 2 recorded. Similarily, ‘at least stage 2 ‘means a girl had a stage 2 recorded 
on SIS, they may or may not have had stage 1 recorded. 
N/A-Not applicable 
Home schooled refers to children registered with the Child and Family Agency Education Welfare Services to be educated at home. These children were recorded on SIS and 
reported here as home schooled. 
Out of school refers to vaccinated children who were neither enrolled in a second level school, special school nor registered with the Child and Family Agency Education Welfare 
Services as home schooled.
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Table 2. MenC booster vaccine uptake data, provided through the school immunisation programme, among children in the academic year 
2015/2016 (data extracted from the School Immunisation System 24/01/2017)
Community 
Healthcare 
Organisation (CHO)
Local Health Office/Community 
Healthcare Organisation (CHO)
2015/2016
Children in first year in second level schools and age equivalent* in 
special schools, home schooled and out of school
Outside cohort
Denominator
Numbers 
vaccinated with 
MenC booster
% Vaccinated with 
MenC booster
Denominator
Numbers 
vaccinated with 
MenC booster
CHO1
Cavan/Monaghan 1850 1533 82.9% N/A 1
Donegal 2238 2009 89.8% N/A 0
Sligo/Leitrim 1321 1204 91.1% N/A 5
CHO1 Total 5409 4746 87.7% N/A 6
CHO2
Galway 3399 2877 84.6% N/A 9
Mayo 1774 1553 87.5% N/A 3
Roscommon 574 499 86.9% N/A 2
CHO2 Total 5747 4929 85.8% N/A 14
CHO3
Clare 1534 1358 88.5% N/A 3
Limerick 1958 1683 86.0% N/A 0
Tipperary NR/East Limerick 1949 1700 87.2% N/A 15
CHO3 Total 5441 4741 87.1% N/A 18
CHO4
North Cork 1196 1078 90.1% N/A 1
North Lee - Cork 2698 2367 87.7% N/A 0
South Lee - Cork 2565 2278 88.8% N/A 1
West Cork 695 582 83.7% N/A 1
Kerry 1983 1643 82.9% N/A 1
CHO4 Total 9137 7948 87.0% N/A 4
CHO5
Carlow/Kilkenny 2092 1934 92.4% N/A 18
South Tipperary 1159 1005 86.7% N/A 6
Waterford 1715 1591 92.8% N/A 0
Wexford 2327 1957 84.1% N/A 0
CHO5 Total 7293 6487 88.9% N/A 24
CHO6
Dublin South 1928 1661 86.2% N/A 31
Dublin South East 1182 1112 94.1% N/A 0
Wicklow 1515 1314 86.7% N/A 1
CHO6 Total 4625 4087 88.4% N/A 32
CHO7
Dublin South City 1482 1338 90.3% N/A 1
Dublin South West 1828 1484 81.2% N/A 3
Dublin West 2167 1792 82.7% N/A 1
Kildare/West Wicklow 3661 3360 91.8% N/A 0
CHO7 Total 9138 7974 87.3% N/A 5
CHO8
Laois/Offaly 2358 2140 90.8% N/A 2
Longford/Westmeath 2178 2006 92.1% N/A 0
Louth 2135 1838 86.1% N/A 0
Meath 2815 2445 86.9% N/A 3
CHO8 Total 9486 8429 88.9% N/A 5
CHO9
Dublin North West 2719 2161 79.5% N/A 5
Dublin North Central 1503 1221 81.2% N/A 0
Dublin North 3151 2572 81.6% N/A 15
CHO9 Total 7373 5954 80.8% N/A 20
Home schooled 100 3 3.0% N/A 3
Total of LHOs and home schooled 63749 55298 86.7% N/A 131
Out of school N\A 0 N\A N\A 5
Total of LHOs and home schooled and out of school N\A 55298 N\A N\A 136
*Age equivalents are those born between 01/09/2003 and 31/08/2004.
Outside cohort refers to those who were vaccinated but who were outside the routine cohort for vaccination.
Local health office (LHO) refers to the LHO of the school. Therefore, in reports the LHOs of home schooled and out of school children do not appear.
The denominator for second level schools was defined as the number of children on the school roll on 30th September 2015 for first year. The denominator for age equivalent 
to first years in second level schools was defined as children born between 01/09/2003 and 31/08/2004 on the school roll of special schools or registered with the Child and 
Family Agency Education Welfare Services on 30th September 2015. All the denominator data was entered onto the School Immunisation System (SIS) by the relevant System 
Administrator.
N/A-Not applicable
Home schooled refers to children registered with the Child and Family Agency Education Welfare Services to be educated at home. These children were recorded on SIS and 
reported here as home schooled.
Out of school refers to vaccinated children who were neither enrolled in a second level school, special school nor registered with the Child and Family Agency Education Welfare 
Services as home schooled.
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Table 3. Tdap vaccine uptake data, provided through the school immunisation programme, among children in the academic year 2015/2016 
(data extracted from the School Immunisation System 24/01/2017)
Community 
Healthcare 
Organisation (CHO)
Local Health Office/Community 
Healthcare Organisation (CHO)
2015/2016
Children in first year in second level schools and age equivalent* in 
special schools, home schooled and out of school
Outside cohort
Denominator
Numbers 
vaccinated with 
Tdap
% Vaccinated with 
Tdap
Denominator
Numbers 
vaccinated 
with Tdap
CHO1
Cavan/Monaghan 1850 1566 84.6% N/A 2
Donegal 2238 2058 92.0% N/A 0
Sligo/Leitrim 1321 1220 92.4% N/A 3
CHO1 Total 5409 4844 89.6% N/A 5
CHO2
Galway 3398 2934 86.3% N/A 3
Mayo 1694 1583 93.4% N/A 1
Roscommon 574 520 90.6% N/A 0
CHO2 Total 5666 5037 88.9% N/A 4
CHO3
Clare 1533 1378 89.9% N/A 5
Limerick 1959 1737 88.7% N/A 2
Tipperary NR/East Limerick 1949 1738 89.2% N/A 5
CHO3 Total 5441 4853 89.2% N/A 12
CHO4
North Cork 1196 1108 92.6% N/A 0
North Lee - Cork 2698 2426 89.9% N/A 0
South Lee - Cork 2565 2318 90.4% N/A 0
West Cork 695 601 86.5% N/A 1
Kerry 1983 1709 86.2% N/A 0
CHO4 Total 9137 8162 89.3% N/A 1
CHO5
Carlow/Kilkenny 2092 1951 93.3% N/A 12
South Tipperary 1159 1032 89.0% N/A 7
Waterford 1715 1615 94.2% N/A 0
Wexford 2311 2026 87.7% N/A 1
CHO5 Total 7277 6624 91.0% N/A 20
CHO6
Dublin South 1928 1686 87.4% N/A 26
Dublin South East 1182 1120 94.8% N/A 1
Wicklow 1515 1366 90.2% N/A 2
CHO6 Total 4625 4172 90.2% N/A 29
CHO7
Dublin South City 1482 1377 92.9% N/A 1
Dublin South West 1828 1515 82.9% N/A 5
Dublin West 2167 1867 86.2% N/A 1
Kildare/West Wicklow 3661 3479 95.0% N/A 1
CHO7 Total 9138 8238 90.2% N/A 8
CHO8
Laois/Offaly 2358 2164 91.8% N/A 2
Longford/Westmeath 2211 2061 93.2% N/A 0
Louth 2135 1884 88.2% N/A 1
Meath 2815 2497 88.7% N/A 12
CHO8 Total 9519 8606 90.4% N/A 15
CHO9
Dublin North West 2719 2295 84.4% N/A 6
Dublin North Central 1503 1287 85.6% N/A 1
Dublin North 3151 2660 84.4% N/A 12
CHO9 Total 7373 6242 84.7% N/A 19
Home schooled 100 6 6.0% N/A 2
Total of LHOs and home schooled 63685 56784 89.2% N/A 115
Out of school N\A 0 N\A N\A 7
Total of LHOs and home schooled and out of school N\A 56784 N\A N\A 122
*Age equivalents are those born between 01/09/2003 and 31/08/2004
Outside cohort refers to those who were vaccinated but who were outside the routine cohort for vaccination.
Local health office (LHO) refers to the LHO of the school. Therefore, in reports the LHOs of home schooled and out of school children do not appear.
The denominator for second level schools was defined as the number of children on the school roll on 30th September 2015 for first year. The denominator for age equivalent 
to first years in second level schools was defined as children born between 01/09/2003 and 31/08/2004 on the school roll of special schools or registered with the Child and 
Family Agency Education Welfare Services on 30th September 2015. All the denominator data was entered onto the School Immunisation System (SIS) by the relevant System 
Administrator.
N/A-Not applicable
Home schooled refers to children registered with the Child and Family Agency Education Welfare Services to be educated at home. These children were recorded on SIS and 
reported here as home schooled.
Out of school refers to vaccinated children who were neither enrolled in a second level school, special school nor registered with the Child and Family Agency Education Welfare 
Services as home schooled.
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8.4  Seasonal influenza vaccine uptake 
in hospitals & Long Term Care 
Facilities (LTCFs) in 2016-2017 
influenza season
Summary
Influenza Vaccine Uptake in Hospitals, 2016-2017
●    Of the 61 hospitals1, 53 provided sufficient data for 
complete analysis, 5 of which were privately run
●    98.0% (48/49) of HSE funded and staffed hospitals 
participated in the 2016-2017 survey
●    Based on 48 complete returns:
 ○   Average uptake among all categories of hospital 
HCWs was 31.9% 
 ○   14 (29.2%) hospitals exceeded the 40% national 
uptake target
 ○   Average uptake varied by Hospital Group (range 
21.5-56.2%) 
 ○   Highest average uptake was reported in Acute 
Paediatric Services Hospital Group
 ○   Average uptake varied by HSE staff category (26.4-
53.6%), the highest uptake was reported among 
‘medical and dental’ professionals and lowest 
among nursing and ‘other patient & client care’ 
staff
 ○   In general, the more staff eligible (employed) in a 
hospital the higher the uptake
Influenza Vaccine Uptake in LTCFs, 2015-2016
●    142 LTCFs participated
●    122 provided sufficient data for complete analysis, 20 
of which were privately run 
●    Based on 1022 HSE funded and staffed LTCFs:
 ○   Average uptake among all categories of LTCF-
based HCWs was 28.1%
 ○   24 (23.5%) LTCFs exceeded the 40% national 
uptake threshold
 ○   Average uptake varied by Community Health 
Organisation (CHO) (range 19.5-44.5%)
 ○   Highest average uptake was reported in CHO 
3 (Clare; Limerick; North Tipperary/East 
Limerick)
 ○   At national level, average uptake varied 
by HSE staff category (28.1-50.7%), the 
highest value was reported among ‘health & 
social care’ professionals and lowest among 
nursing staff
 ○   No association was observed between 
average uptake and number of eligible staff 
in a LTCF
 ○   Uptake among long stay residents since the 
beginning of the season was 93.5% 
 ○   Uptake among respite residents vaccinated 
within LTCFs since the beginning of the 
season was 19.1%
 ○   Uptake among respite residents vaccinated 
before admission to LTCFs since the beginning 
of the season was 14.1%
The National Immunisation Advisory Committee (NIAC) 
of the RCPI and the HSE recommends annual seasonal 
influenza vaccination to individuals at risk of severe 
influenza disease (those who are aged 65 and older, 
pregnant, morbidly obese and those with specified chronic 
medical conditions requiring regular follow up), to certain 
occupational groups (those working with poultry, wild fowl 
and pigs), health care workers (HCWs) and to those likely 
to transmit influenza to those at high risk of influenza 
complications. HSE provides the seasonal influenza 
vaccine free of charge to all health care facilities or to 
the occupational health departments of these facilities. 
Implementation of the vaccination programme is, for the 
most part, organised by the health care facility management 
or the relevant occupational health provider. 
Influenza can cause severe disease in both patients and 
staff and infection can spread rapidly in health care settings. 
Achieving a high uptake of influenza vaccination among 
HCWs is therefore recognised as an important infection 
control intervention and occupational health issue. The HSE 
Leadership Team has recommended a national influenza 
vaccination target of 40% among HCWs since October 2013.
1  C urrently there are 61 acute hospitals in Ireland, 49 of which are HSE funded and staffed and 11 are privately run
2  excludes two LTCFs that provided a survey return but with no details of vaccine uptake among its HCWs: St. Ita’s Psychiatric Hospital, Portrane, Co. 
Dublin and St. Oliver Plunkett Hospital, Drogheda, Co. Louth
HPSC has collected data on seasonal influenza vaccination 
coverage among hospitals and long term care facilities 
(LTCFs) since the 2011-2012 influenza season. A protocol has 
also been provided to all facilities outlining the rationale and 
methodology for data collection each year since then. For 
the 2016-2017 season, a similar protocol as used for previous 
years was distributed to all facilities and posted on the HPSC 
website. Separate online survey forms for hospitals and 
LTCFs were designed to capture aggregate data on eligible 
and vaccinated staff and were based on six categories of 
HSE staff: management & administration; medical & dental; 
nursing; health & social care professionals; other patient & 
client care; and general support staff. 
For hospitals, occupational health departments were asked 
to provide data on the number and category of HCWs 
vaccinated by the service (numerator). The human resource 
(HR) departments were requested to provide data on the 
numbers of staff employed (denominator). For LTCFs, 
uptake details were sought from nominated coordinators 
(or other named contacts) on the number of staff, residents 
and respite care patients present and vaccinated during the 
influenza season. 
For the 2016-2017 season, a link to an online form was 
emailed to each nominated coordinator (or contact person) 
in 61 known hospitals (including 11 private ones) and 
separately to 262 currently active LTCFs3 on 1st November 
2016. Each coordinator was asked to complete the online 
form using aggregate uptake data since the beginning of 
October 2015. A second and final survey seeking aggregate 
data for the entire season was sent on 25th April 2017. 
Reminders were sent to non-responders in mid-November 
2016 (for mid-season data) and mid-May 2017 (for end of 
year data). 
This report presents a summary of key data relating to the 
influenza vaccination uptake programme for 2016-2017, 
which is now available on the HPSC website. For this report, 
in order to present trends over all six seasons since 2011-
2012, average uptake results (rather than overall figures) 
were calculated. This was done for two reasons: 1) the 
average is a measure that takes account of the different 
number of reporting healthcare units each season and 2) 
because the numbers of participating hospitals and LTCFs 
that have provided complete data in each of the six seasons 
since 2011-2012 are relatively low. 
Figure 1. Hospital staff uptake by HSE region by season
Table 2. Details of seasonal influenza vaccine uptake among LTCF-based HCWs by influenza season*
Season Total No. Eli-gible HCWs**
Total No. Vac-
cinated HCWs
Average % 
Uptake
Average % Up-
take 95% CIs
Median % 
Uptake
Range % Up-
take
No. Participat-
ing LTCFs
2011-2012 4159.0 733 17.3 12.0-22.6 10.3 0.0-90.4 57
2012-2013 10823.0 1327 14.9 12.3-17.5 11.1 0.0-76.0 108
2013-2014 8967.4 1745 21.6 18.1-25.0 18.3 0.0-80.0 88
2014-2015 7280.0 1766 26.9 22.8-31.00 25.0 0.0-77.1 67
2015-2016 7057.6 1625 24.4 20.3-28.4 22.2 0.0-100 81
2016-2017 9916.1 2690 28.1 24.8-31.3 24.7 0.0-75.0 102
*based on complete returns only from HSE funded and staffed LTCFs; **some figures include decimal places because some LTCFs reported whole time 
equivalent staff numbers rather than their actual numbers of staff
Table 1. Details of seasonal influenza vaccine uptake among hospital-based HCWs by influenza season* 
Season Total No. Eli-
gible HCWs**
Total No. Vac-
cinated HCWs
Average % 
Uptake
Average % Up-
take 95% CIs
Median % 
Uptake
Range % Up-
take
No. Participat-
ing Hospitals
2011-2012 45058.0 8157 19.1 15.8-22.3 16.6 5.0-40.0 36
2012-2013 41490.2 7293 15.3 12.1-18.4 12.2 3.5-38.8 32
2013-2014 47760.4 11517 20.7 17.6-23.9 18.1 2.6-45.9 41
2014-2015 49917.2 11723 22.0 18.0-26.0 20.1 1.1-47.5 39
2015-2016 57493.5 14474 22.6 19.2-26.0 19.8 6.9-47.0 46
2016-2017 62396.4 21020 31.9 28.1-36.0 29.6 6.4-63.7 48
*based on complete returns only from HSE funded and staffed hospitals; **figures include decimal places because some hospitals reported whole time 
equivalent staff numbers rather than their actual numbers of staff
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Please also note that uptake figures for previous seasons’ 
annual summaries here will differ from those previously 
presented due to updating and re-analysis of data, but also 
because many of the results will apply only to hospitals 
and LTCFs that are both HSE funded and staffed, unless 
otherwise specified. Some returns from previous seasons 
were excluded as some hospitals were wrongly reported 
as LTCFs, are closed or were not part of the current HSE 
Hospital Grouping, with the exception of the National 
Rehabilitation Hospital. Among the hospitals and LTCFs 
that were not considered both HSE funded and staffed were 
those described as ‘private’, ‘public & private’, ‘section 38 
agency’, ‘section 39 agency’ or whose funding source or 
status could not be verified at the time of writing.
Figures 1 to 4 below give details of vaccine uptake among 
HCWs based in hospitals and LTCFs that reported over the 
past six seasons by category of staff and HSE Hospital Group 
or Community Health Organisation. 
Hospitals
Fifty-three hospitals participated in the 2016-2017 survey 
and all provided complete returns, of which five were 
privately run. Based on 48 HSE funded and staffed hospitals 
uptake for all HCW was 31.9%, up from 22.6% from the 
previous season when 46 hospitals provided complete 
returns, an increase that was statistically significant (Table 
1). Fourteen HSE funded and staffed hospitals (29.2%) 
exceeded the 40% national uptake target, compared to 
seven (15.2%) in 2015-2016. In 2016-2017, both hospitals 
in the acute paediatric service group exceeded the 40% 
national uptake target, as did the National Rehabilitation 
Hospital. No hospital in either the West/North West (Saolta 
UHC; NUIG) or Midwest (UL) hospital groups reached this 
target (Figure 1).
At national level, the average uptake in HSE funded and 
staffed hospitals varied by HSE staff category (26.4-53.6%), 
with the highest value reported among ‘medical and dental’ 
professionals and lowest among ‘other patient & client 
care staff’ and nurses. Between 2015-2016 and 2016-2017 
average uptake increased among all HCWs: medical and 
dental professionals (53.6%, +16.6%); health and social care 
professionals (42.2%, +13.4%); nursing staff (26.4%, +9.5%); 
management and administration (29.6%, +7.4%); general 
support staff (35.6%, +7.4%); and other patient and client 
care staff (26.4%, +4.6%) (Figure 2). 
When HSE funded and staffed hospitals were categorised in 
groups in terms of the overall staff numbers, average uptake 
increased as staff size increased: average uptake was lowest 
where staff size was <250 HCWs at 23.6% and highest when 
staff size was >=2,000 HCWs at 34.8%.
Long term care facilities
Of the 142 LTCFs that submitted data in 2016-2017, 122 
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Figure 2. Hospital staff uptake by HSE grade category by season
Figure 3. LTCF staff uptake by HSE region by season
-138-HPSC Annual Epidemiological Report 2016 8. Immunisation Uptake
LTCFs (85.9%) provided complete staff vaccine uptake 
returns, of which 102 were from HSE funded and staffed. Of 
the latter 102 LTCFs, average influenza vaccine uptake for 
all staff was 28.1%, up from 24.4% in the previous season. 
Twenty-four (23.5%) of 102 LTCFs in 2016-2017 exceeded 
the 40% national uptake target compared to seven (8.6%) 
of the 81 LTCFs in 2015-2016. CHO3 had the highest average 
uptake (44.5%) of LTCFs, the lowest was CHO2 with 19.5% 
(Figure 3).
Between 2015-2016 and 2016-2017 average uptake in HSE 
funded and staffed LTCFs increased uptake across all staff 
grades: health and social care professionals (50.7%, +17.9%), 
other patient and client care professional (28.2%, +7.1%); 
general support staff (33.7%, +5.7%), medical and dental 
staff (46.1%, +4.6%), nursing (28.1%, +4.1%); management 
and administration staff (41.4%, +3.3%) (Figure 4).
When staff sizes were categorised according to number of 
staff employed in HSE funded and staffed LTCFs, average 
uptake did not increase according to facility staff number, on 
the contrary average uptake was highest when staff size was 
<50 HCWs at 30.8% in 2016-2017.
After a decline to 8.6% in 2015-2016 the percentage of 
participating HSE funded and staffed LTCFs reporting 
uptake in excess of 40% in 2016-2017 rose to 23.5%. Uptake 
among long stay residents in HSE funded and staffed LTCFs 
since the beginning of the season increased from 90.7% 
among 82 LTCFs in the previous season to 93.5% among 
102 LTCFs in 2016-2017. The percentage of respite residents 
vaccinated prior to admission in 2016-2017 was 14.1% among 
102 reporting HSE funded and staffed LTCFs, a decline from 
25.1% from the previous season. In contrast, over the same 
period, the percentage of respite residents vaccinated in-
house among the same LTCFs increase from 10.8% to 19.1%.
The cumulative number of HSE funded and staffed LTCFs that 
reported having a policy recommending that respite residents 
are vaccinated before being admitted was 56, a 27.3% increase 
on the previous season. Similarly, the cumulative number of 
HSE funded and staffed LTCFs that reported having a staff 
vaccination policy (before taking up a position) during 2016-
2017 was 25, an increase of 13.6% since 2015-2016.
Target uptake
Overall, the average uptake of the seasonal influenza vaccine 
among HCWs in both hospitals and LTCFs in 2016-2017 
again fell short of the 40% target, despite some marked 
improvements, particularly in hospitals. Participation by 
hospitals and LTCFs was very high, the latter showing a 
marked increase compared to the previous season. 
However, more work is needed if the 75% target goal 
for influenza vaccination coverage in all at-risk groups, 
including HCWs as recommended by the European Council 
in December 20091, is to be reached. The low numbers of 
LTCFs that have a staff vaccination policy in place, despite 
the updating of national recommendations in September 
20132-4, remains a cause for concern. The absence of LTCF 
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Figure 4. LTCF staff uptake by HSE grade category by season
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vaccination policies and of staff vaccination policies in 
particular may reflect insufficient awareness at senior 
management of their responsibility in infection control and 
reducing the risk of outbreaks and disease among their 
residents and staff. 
Other countries have already achieved uptake rates well 
above our target. For example, in England vaccination 
uptake among those HCWs with direct patient contact is 
monitored (compared to Ireland where uptake among all 
HCWs is monitored). During the 2016-2017 season, influenza 
vaccine uptake among frontline HCWs was 63.2%, an 
increase of 12.6% from 50.6% for the previous season5.
Overall vaccination uptake levels among HCWs were 
reported by 15 member states as part of the European 
Union-funded Venice study in 2014-20156. A wide range 
of results were reported with the highest uptake reported 
by England (54.9%), Wales (44.3%) and Scotland (36.2%) 
and the lowest in Poland (5%). Apart from Ireland, the only 
other member state that reported HCW uptake in LTCFs was 
Portugal with a similar (overall) uptake of 22%6.
In the United States, the Centre for Disease Control and 
Prevention analysed data from an internet panel survey 
of HCWs conducted from October 27th through November 
13th, 2016. Early-season 2016–2017 influenza vaccination 
coverage among HCWs was 68.5%, similar to early-season 
coverage during the 2015–2016 season (66.7%). Vaccination 
coverage among HCWs was found to be highest in hospitals 
(80.8%) and lowest in LTCFs (55.1%). Early-season influenza 
vaccination coverage was higher among HCWs whose 
employers required (89.3%) or recommended (69.4%) that 
they be vaccinated compared with HCWs whose employer 
did not have a requirement or a recommendation regarding 
flu vaccination (26.0%)7.
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Background
In May 2008, new cases of CDI in persons two years or older 
became notifiable in Ireland under the disease category 
“acute infectious gastroenteritis” (AIG). Since January 2012, 
CDI has been a notifiable infection in its own category, with 
both new and recurrent CDI cases notifiable to Public Health 
Departments via the Computerised Infectious Disease 
Reporting (CIDR) system.
Although notifiable CDI data provides important preliminary 
information on the burden of CDI in Ireland, it does not 
capture information on the origin, onset or severity of CDI. 
National CDI enhanced surveillance commenced on a 
voluntary basis on 1st August 2009. Information on case 
type, origin, onset and infection severity is collected using 
European CDI case definitions.  
  
Notifiable C. difficile infection 
In total, 1,871 cases of Clostridium difficile infection (CDI) 
were notified to Public Health Departments via the 
Computerised Infectious Disease  Reporting (CIDR) System, 
representing an overall national crude incidence rate (CIR) 
of 40.4 cases per 100,000 population, a 1% reduction on 
2015 (41.4). The national CIR of new CDI cases alone was 
32 (2016), a 3.9% reduction on 2015 (35.9). The majority of 
CDI occurred in patients aged ≥65 years (1,237; 66%). When 
further divided by case type, there were 1,483 new cases 
(79%), 174 recurrent (9%) and for 214 cases (11%) it was 
not known whether the patient had new or recurrent 
CDI. All cases were laboratory-confirmed.
9.1 Clostridium difficile Infection
Key Points
●   In 2016, 1,871 cases of Clostridium difficile 
infection (CDI) were notified to Public Health 
Departments via the Computerised Infectious 
Disease Reporting (CIDR) System, representing a 
national crude incidence rate (CIR) of 40.4 cases 
per 100,000 population, a 1% reduction on 2015 
(41.4). The majority of CDI occurred in patients 
aged ≥65 years (1,237; 66%). When further 
divided by case type, there were 1,483 new cases 
(79%), 174 recurrent (9%) and for 214 cases (11%) 
it was not known whether the patient had new or 
recurrent CDI
●    There were 1,877 CDI cases reported to the 
CDI enhanced surveillance scheme from 
54 hospitals. Healthcare-associated (HCA) 
CDI accounted for 60% of cases (n=1,116), 
representing a national combined incidence rate 
for new and recurrent HCA CDI of 2.2 per 10,000 
bed days used in 2016, a reduction from 2.5 in 
2015 
●    Enhanced surveillance collects data on patient 
location at symptom onset and shows that 
CDI is not confined to hospitals. In 2016, CDI 
was commonly encountered in long-term care 
facilities (LTCF) (10% of all CDI) and in the 
community (39% of all CDI) 
●   Of 300 C. difficile isolates with available 
ribotyping data (16% of all cases) reported 
from 16 hospitals, the most frequent ribotypes 
reported in 2016 were: 078 (n=51, 17%), 014 
(n=33, 11%) and 002 (n=29, 10%)
Figure 1. Numbers of CDI notifications by month and case type  
(2008 – 2016).
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Since surveillance began in 2008, there has been an overall 
decrease in the incidence of CDI in Ireland, with the rate 
remaining relatively stable since 2012 (Figure 1). There was 
a slight decrease in the number of recurrent cases notified 
in 2016 than in 2015 (n=174 versus n=192) and an increase 
in the number of cases of unknown type for the same period 
(n=214 versus n=104). Identification of seasonal patterns 
from CIDR notification data is hindered by delayed and 
batched laboratory notifications.
Figure 2 displays the gender and age breakdown of patients 
with CDI. The majority were female (60%). The mean age 
was 66.9 years (range: 2 – 103), with the majority of cases 
(n=1,237; 66%) reported in patients ≥65 years.
Notifiable C. difficile infection: Outbreaks
In 2016, seven CDI outbreaks, all of which were healthcare-
associated and involving 24 patients were notified to Public 
Health Departments, as displayed in Table 1. Four were 
linked to nursing homes, two to hospitals and one to a 
residential institution.
Enhanced surveillance of C. difficile infection
To the end of 2016, 54 acute hospitals participated in 
enhanced CDI surveillance, comprising 45 public hospitals 
(96% of all public hospitals). Public hospitals were further 
categorised into: general (n=27; 100%), tertiary (n=9; 100%) 
and specialist (n=9; 75%), with nine private hospitals (75%) 
also participating.
In 2016, 1,877 CDI cases were reported to the enhanced 
surveillance scheme. Of those, 1,566 (83%) were classified 
as new, 191 (10%) as recurrent and 120 (7%) of unknown CDI 
case type. 
Of the reported cases, 44% (n=830) originated within 
the reporting hospital. The overall HCA CDI rate is based 
on the total number of CDI cases that originated in the 
participating hospital (i.e., new, recurrent and unknown 
combined). The bed days used data for acute public 
hospitals was sourced from the HSE Business Information 
Unit, with private hospital activity data provided directly by 
participating hospitals. In 2016, the overall HCA CDI rate 
was 2.2 cases per 10,000 bed days used (BDU), a decrease 
from 2.5 in 2015 and the lowest recorded annual rate since 
surveillance began in 2009 (3.1), as shown in Figure 3. 
The 2016 incidence rate of new HCA CDI was 1.9, a reduction 
from 2.3 in 2015. The incidence rate of recurrent HCA CDI 
remained stable at 0.3, as found in 2015. 
Caution should be taken when interpreting national CDI 
trends, particularly prior to 2012 due to: 
(i)   Changes in the numbers of participating hospitals, as 
displayed in Figure 3. Throughout 2012, the total number 
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Figure 2: Age and gender distribution of CDI in Ireland, 2016 
(Source: CIDR).
* Rates calculated using 2016 census of the population data 
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Table 1. CDI outbreaks reported in Ireland in 2016 by public health 
region (Source: CIDR)
Public Health Region Outbreak location Total number ill
MWHB Nursing home 2
MWHB Nursing home 8
NEHB Nursing home 3
NEHB Nursing home 3
NEHB Hospital 5
WHB Residential institution 4
WHB Hospital 3
Table 2. Origin and onset of CDI, 2014 – 2016
2014 2015 2016
% % %
ORIGIN: Location of where 
infection was acquired
Healthcare-associated 64 62 60
Hospital 48 47 44
NH/LTCF 11 9 10
Other 5 6 5
Community-associated 18 22 25
Indeterminate 5 6 7
Unknown 13 10 9
ONSET: Location of where 
patient symptoms occurred
Healthcare-onset 59 59 56
Hospital 44 45 41
NH/LTCF 11 9 10
Other 4 5 4
Community-onset 34 34 39
Unknown 7 7 5
of hospitals participating in enhanced CDI surveillance 
stabilised. Since 2012, there has been a complete 
participation in CDI enhanced surveillance by all tertiary 
and general hospitals
(ii)  Changes in C. difficile laboratory testing protocols: 
From 2014 to 2016, most hospitals have participated 
in the scheme and a similar profile of testing is evident 
over time with more hospitals incorporating molecular 
methods (Please also refer to the section on laboratory 
testing for C. difficile)
In 2016, a wide range in the CDI incidence rate in 
participating hospitals was observed (range = 0 – 5.0; 
median = 1.3). The median rate was higher in nine tertiary 
hospitals (2.9; range = 1.3 – 3.9) than in 27 general hospitals 
(1.6; range = 0 – 5.0). Since 2012, the overall trend for 
general hospitals has declined slightly (median CDI rate 
from 1.9 to 1.6). However, in the same period, the overall 
trend for tertiary hospitals increased, although the median 
CDI rate of 2.9 in 2016 was slightly lower than that of 3.2 
(2015).
The differences in CDI median incidence rates may reflect 
inter-hospital variation with regard to patient case mix, C. 
difficile ribotypes, laboratory testing protocols, antimicrobial 
prescribing policies, antimicrobial stewardship interventions, 
infrastructure and access to en suite isolation rooms and 
surveillance resources. No obvious seasonal trend for CDI is 
distinguishable from enhanced surveillance data in 2016. 
The percentage coverage of acute hospital activity was 
calculated using bed days data from participating hospitals 
as a percentage of total acute hospital bed day activity in 
Ireland.
Severe CDI
A severe case of CDI is defined as (i) a patient requiring 
admission to an intensive care unit (ICU) for treatment of 
CDI or its complications, (ii) a patient requiring colectomy or 
(iii) death within 30 days after diagnosis, if CDI is either the 
primary or contributory cause of death. The enhanced CDI 
surveillance scheme does not collect information on patient 
outcome. Therefore, surgery and ICU admission for CDI are 
the two markers of severity captured. In 2016, 30 (1.6%) 
severe CDI cases were reported, similar to 2015 (1.5%). Five 
patients required both surgery and ICU admission, eight 
required surgery only and 17 required ICU admission without 
surgery. 
Onset & Origin of CDI
Onset: Patient location when symptoms of CDI 
commenced
CDI symptom onset occurred in a healthcare facility for 56% 
of patients (n=1,047; healthcare-onset), while 39% had 
symptom onset in the community (n=735; community-onset) 
and for 5% (n=95), location at CDI onset was unknown 
(Table 2). 
Of the 1,047 patients with healthcare onset CDI, 74% (n=772) 
had onset in the reporting hospital, 5% (n=50) in another 
hospital, 18% (n=192) in a long term care facility (LTCF) and 
for the remaining 3% (n=33) onset location was unknown. 
Between 2014 and 2016, there was a slight reduction in 
the proportion of patients with CDI symptom onset in a 
healthcare facility (59 to 56%). Over the same period, 
community-onset CDI increased from 34% to 39% (Table 2). 
Origin: Location where the patient acquired the CDI
For the majority of CDI cases, the infection was acquired in 
a healthcare setting (healthcare-associated; HCA) (n=1,116; 
60%). Community-associated; CA accounted for 25% 
(n=459) and in 7% (n = 133) the origin was indeterminate and 
could not be assigned as either HCA or CA, as the patient 
had been discharged from a healthcare facility between four 
and 12 weeks prior to the CDI onset date. For the remaining 
9% (n = 169) of cases, the origin was unknown (Table 2).
Of the 1,116 healthcare-associated CDI cases, 74% (n=830) 
originated in the reporting hospital, 7% (n=74) originated 
in a hospital other than the reporting hospital, 17% (n=186) 
originated in a LTCF and 2% (n=24) originated in another 
unspecified healthcare facility or were of unknown origin.
Between 2014 and 2016, there was a decrease in the 
proportion of cases associated with a healthcare facility 
(64 to 60%), which was demonstrated primarily in the 
reporting hospital. The proportion of cases associated with 
the community increased from 18% to 25%, and there was a 
slight increase in cases classified as indeterminate (from 5% 
to 7%). Cases classified as ‘unknown’ decreased from 13% to 
9% between 2014 and 2016 (Table 2). 
    
Of the 1,116 cases of healthcare-associated CDI:
•   Healthcare-onset, healthcare-associated: 86.7% (n=968) 
experienced onset of CDI symptoms at least 48 hours 
following admission to a healthcare facility
•   Community-onset, healthcare-associated: 12.5% (n=139) 
experienced symptom onset in the community, within four 
weeks of discharge from a healthcare facility 
•   No information on symptom onset provided for 0.8% (n = 9)
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Table 3. National reporting of C. difficile ribotyping data: 2012 - 2016
Year
Total number 
of CDI cases 
reported
Number (%) 
of cases with 
ribotype data
Number of hospitals 
providing ribotype 
data
2012 1735 263 (15%) 14
2013 1801 258 (14%) 19
2014 1780 290 (16%) 20
2015 1955 219 (11%) 22
2016 1877 300 (16%) 16
Of the 459 cases of community-associated CDI: 
•   Community-onset, community-associated: 91.7% (n=421) 
experienced CDI symptom onset while outside a healthcare 
facility and without a history of discharge from a healthcare 
facility within the previous 12 weeks 
•   Healthcare-onset, community-associated: 7.4% (n=34) 
experienced symptom onset within the first 48 hours of 
admission to a healthcare facility, without a history of 
admission to or residence in a healthcare facility within the 
previous 12 weeks 
•   No information on symptom onset provided for 0.9% (n=4)
Information was also captured on the location where the 
patient’s faeces specimen was taken. The reporting hospital 
accounted for the majority (76%) of specimens (n=1,434), with 
13% (n=241) taken in the GP surgery, 7% (n=137) in a LTCF 
and 3% (n=47) in a hospital other than the reporting hospital. 
For the remaining 1% (n=18), no information was provided.
Discussion
The collation of national data on C. difficile through CIDR 
notifications and the enhanced CDI surveillance system has 
provided a valuable insight into the burden of CDI in Ireland. 
Both surveillance systems present a decreasing trend since 
2009. The notifiable surveillance system, which reflects total 
burden of disease, shows that the CDI rate remained stable 
between 2012 and 2016, while the enhanced surveillance 
system shows a decrease in the CDI rate between 2012 and 
2016. For the second consecutive year, cases reported to 
enhanced CDI surveillance in 2016 exceeded those notified to 
public health departments.
In 2016, recurrent CDI accounted for 10% of notifications 
through the enhanced surveillance scheme, which is a slight 
decrease from 11% in 2015. Recurrent CDI places a further 
burden on limited hospital isolation resources and results in 
significant patient morbidity. 
CDI is not confined to acute healthcare settings and is 
increasingly common in LTCF and the community. In 2016, 
10% of cases had onset in a LTCF, with 39% having onset 
in the community; a 5% increase since 2015 (34%). Of the 
459 community-associated cases reported in 2016, 92% 
experienced CDI symptom onset in the community, without 
a history of discharge from a healthcare facility within the 
previous 12 weeks. It is important to consider CDI in the 
differential diagnosis of all patients presenting with diarrhoea 
of potentially infectious origin, regardless of patient location 
and to send a faeces specimen in a timely fashion for 
laboratory diagnosis, which should routinely include testing 
for C. difficile in patients aged over two years, in keeping with 
national CDI guidelines. 
 
C. difficile PCR ribotyping
As part of the voluntary C. difficile enhanced surveillance 
scheme, participating hospitals are asked to provide C. 
difficile PCR ribotyping information, where available. Ireland 
does not yet have a national C. difficile reference laboratory or 
ribotyping service. Therefore, laboratories submit specimens 
abroad for ribotyping. In 2016, ribotyping data was provided 
for 300 C. difficile isolates (16% of all samples) from 16 
hospitals (Table 3). The most frequent ribotypes reported in 
2016 were: 078 (n=50, 17%), 014 (n=33, 11%) and 002 (n=29, 
10%) (Figure 4). 
Laboratory Testing of C. difficile in Ireland
Since 2010, information on C. difficile testing has been 
collected quarterly as part of the enhanced surveillance 
system. In Q1 2010, the majority of hospitals participating 
in the enhanced surveillance project were using a one-step 
Toxin EIA (60%). By Q4 2016, this had reduced to 0%, with all 
hospitals participating in the enhanced surveillance system 
using a method compliant with recommendations in the 
latest update of the Irish C. difficile guidelines. This includes 
either a PCR test for detection of toxin genes (43%, n=23) 
or a two-step testing method (57%, n=31) (Figure 5). Owing 
to variations in current Irish laboratory C. difficile testing 
methodologies, inter-hospital comparison of CDI rates is not 
recommended where testing methods differ, as the data in 
the national quarterly enhanced surveillance reports are not 
adjusted for differences in the sensitivities of the different 
diagnostic methodologies.
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Figure 3. Quarterly national rate of healthcare-associated HCA CDI 
(new and recurrent): 2009 – 2016
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Figure 4. Most frequently reported C. difficile ribotypes in Ireland: 2012 
– 2016
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Conclusion
The continued excellent participation in the voluntary CDI 
enhanced surveillance scheme ensures that a significant 
amount of information is collected regarding the burden 
of CDI in Ireland. The National Clinical Guidelines on the 
Surveillance, Diagnosis and Management of CDI in Ireland 
were updated in 2013 and endorsed by the National Clinical 
Effectiveness Committee in 2014. The updated guidelines 
may be accessed on the HPSC website at: http://www.hpsc.
ie/A-Z/Gastroenteric/Clostridiumdifficile/Guidelines/
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Figure 5. Changes in C. difficile laboratory testing protocols: 2012 - 2016
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a) Biannual Audit of Hand Hygiene Compliance 
Summary
•   On a background of on-going hand hygiene compliance 
audits in acute hospitals, national data were collated 
and reported for two audit periods during 2016
•  For both periods (Period 11: May/June and Period 12: 
October/November), 53 hospitals participated (HSE; 44, 
private; 9)
 ○  Period 11: In total, 11,089 opportunities for hand 
hygiene were observed and an average compliance of 
90.5% was reported (range = 81.4 – 96.7) 
 ○  Period 12: In total, 11,111 opportunities for hand 
hygiene were observed; and an average compliance 
of 91.2% was reported (range = 70.5 - 98.1) 
•   The overall compliance for periods 11 and 12 combined 
for HSE hospitals was 90.5%, just above the HSE target 
(90%). However, compliance for private hospitals was 
higher at 92.5%
Background
In Ireland, public reporting of biannual hand hygiene 
compliance audit data from acute hospitals commenced 
in 2011. Healthcare workers (HCWs) are observed for their 
compliance against the ‘5 moments of hand hygiene’ by 
trained auditors using the WHO methodology for hand 
hygiene audits. Each hospital is required to measure HCW 
compliance against 30 hand hygiene opportunities for each 
of seven randomly-selected wards, resulting in a maximum 
of 210 opportunities per hospital per period.
Results 
For both periods (Period 11: May/June and Period 12: 
October/November), 53 hospitals participated (HSE; 44, 
private; 9):
•   Period 11: In total, 11,089 opportunities for hand hygiene 
were observed and an average compliance of 90.5% was 
reported (range = 81.4 – 96.7) 
•   Period 12: In total, 11,111 opportunities for hand hygiene 
were observed; and an average compliance of 91.2% was 
reported (range = 70.5 - 98.1) 
9.2 Hand Hygiene in Acute Hospitals
Table 1. 2016 hand hygiene compliance audit findings (combined for two periods). Analysis by staff category and WHO 5 moments is provided 
for HSE hospitals only. 
Hand Hygiene 
Opportunities Hand Hygiene Actions % Compliance
Lower 95% Confidence 
Interval
Upper 95% 
Confidence Interval
Overall 22,200 20,170 90.9 90.5 91.3
HSE Hospitals 18,427 16,679 90.5 90.1 91.0
Private Hospitals 3,773 3,491 92.5 91.7 93.4
Nurse/Midwife 10,518 9,843 93.6 93.1 94.1
Auxiliary 2,915 2,580 88.5 87.3 89.7
Medical 3,442 2,832 82.3 80.9 83.7
Allied health/Other 1,552 1,424 91.8 90.3 93.2
Moment 1 4,890 4,500 92.0 91.2 92.8
Moment 2 1,023 905 88.5 86.4 90.5
Moment 3 1,326 1,204 90.8 89.2 92.4
Moment 4 6,465 6,017 93.1 92.4 93.7
Moment 5 5,382 4,667 86.7 85.7 87.7
Staff category: Auxiliary = healthcare assistants, porters, catering and household services; Allied health/Other = physiotherapists, radiographer, dieticians, 
social workers and pharmacists
Five moments for hand hygiene: (1) Before touching a patient; (2) Before clean/aseptic procedure; (3) After body fluid exposure; (4) After touching a 
patient; (5) After touching patient surroundings
Results for the two periods combined are displayed in Table 
1 and Figure 1. At 90.5%, compliance for HSE hospitals was 
just above the HSE target of 90%, with a trend of increasing 
compliance observed over time (Figure 2). Private hospitals 
reported an overall compliance of 92.5% in 2016.
Table 1 and Figure 1 also display further analysis of hand 
hygiene compliance for participating HSE hospitals only, by 
HCW category and breakdown by the WHO five moments 
for hand hygiene. In 2016, medical staff had the lowest 
compliance (82.3%), while nurses/midwives had the highest 
compliance (93.8%). Compliance for moment 5 (after 
touching patient surroundings) was the lowest at 86.7% and 
highest for moment 4 (after touching a patient) at 93.1%. 
Alcohol-based hand rub (ABHR) was used for 76.1% of hand 
hygiene actions, with the remainder using soap and water 
(23.9%).
 Limitations of current methodology
•   While standardised hand hygiene auditor training and 
validation (with inter-rater reliability testing) should 
ensure that measurement of hand hygiene is comparable, 
these results have not been validated by external auditors
•   All auditors measured hand hygiene compliance in the 
facility in which they work. Therefore, there may be an 
element of bias in the results 
•   It is possible that hand hygiene auditing may not have 
been performed in a comparable fashion in all hospitals 
and these results may not reflect HCW compliance at all 
times 
•   Compliance with hand hygiene is measured by auditors 
observing HCW undertaking patient care and who 
may change their behaviour if aware that they are 
being observed (Hawthorne effect). However, it is also 
known that this diminishes over time and HCWs under 
observation may not be aware of the presence of the 
auditor due to the many competing demands on their 
attention.
•   Auditors are requested to give immediate feedback 
to ward staff following an audit, thereby increasing 
awareness and knowledge of hand hygiene. This risk of 
bias should be balanced by the benefits of increasing local 
staff’s knowledge and awareness of hand hygiene.      
Further information on acute hospital hand 
hygiene compliance audit in Ireland is available 
on the HPSC website: http://www.hpsc.
ie/a-z/microbiologyantimicrobialresistance/
europeansurveillanceofantimicrobialconsumptionesac/
publicmicrobreports/ 
                                  
b) Surveillance of Alcohol-Based Hand Rub 
Consumption 
2016 Summary
•   Thirty-seven hospitals participated in ABHR 
surveillance, a reduction from 39 in 2015
•   A 9% reduction in the national median rate of alcohol-
based hand rub (ABHR) consumption expressed as 
litres per 1,000 bed days used (L/1,000 BDU) in acute 
hospitals in Ireland was observed (29.7 versus 32.5)
Background
National and international guidelines recommend alcohol-
based hand rub (ABHR) as the recommended product 
for hand hygiene where hands are not visibly soiled. 
Measurement of hospital-level ABHR consumption, inclusive 
of gel and foam formulations, is expressed as a rate: volume 
in litres per 1,000 bed days used (L/1,000 BDU). ABHR 
consumption is a recommended process measure of hand 
hygiene activity by both the World Health Organization 
(WHO) and the US Centers for Disease Control & Prevention 
(CDC). 
Figure 2. Overall hand hygiene audit compliance in HSE acute 
hospitals: 2011 – 2016. HSE target for each year shown as red line.
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ABHR consumption data in acute public hospitals in Ireland 
has been collated by HPSC since 2006. The data are 
collected quarterly from participating hospitals. Depending 
on the hospital, ABHR consumption data originates from 
one of two sources: 
1.   Pharmacy: The total volume of ABHR dispensed to wards, 
clinics and other hospital areas
2.   Supplies Department: The total volume of ABHR 
purchased by the hospital 
Quantities used for pre-operative surgical hand hygiene 
were excluded. 
In 2016, a 9% reduction in the national median rate of 
alcohol-based hand rub (ABHR) consumption expressed 
as litres per 1,000 bed days used (L/1,000 BDU) in acute 
hospitals in Ireland was observed (29.7 versus 32.5) 
(Table 1). While any observed decrease is undesirable, the 
underlying trend over three years has remained relatively 
stable. Using the median ABHR consumption figure 
provides a stable indicator of the national rate over time. 
However, the volume of ABHR consumed remains a crude 
measure of hand hygiene activity at individual hospital level 
and must be viewed in conjunction with other indicators, 
such as direct observation of hand hygiene compliance. As 
ABHR is the recommended product for the vast majority of 
hand hygiene opportunities in hospital settings, surveillance 
of ABHR consumption remains a useful process measure for 
hand hygiene activity.
Caveats to the ABHR surveillance system
•   The inter-hospital variation in ABHR consumption rates 
(14.7 – 74.0), although not as wide as observed in past 
years may be explained by different local methods for 
data collection and reporting, along with differences in 
the type and range of hand hygiene agents used 
•   This surveillance system includes ABHR only, and does 
not include other hand hygiene agents (e.g., liquid soap)
•   ABHR consumption data does not capture information 
on a hospital’s hand hygiene frequency, opportunities or 
technique, nor does it distinguish between who has used 
the ABHR (visitor, patient or healthcare worker)
•   The data are prone to reporting artefacts, particularly 
for hospitals that report supplies (rather than pharmacy 
dispensing) data. For example, the hospital with the 
highest reported rate in past years had undergone a 
change in suppliers and the products had been restocked 
in all areas of the hospital over a relatively short period of 
time. It is expected that there will be occasional outliers of 
this nature.
Further information on acute hospital ABHR consumption in 
Ireland is available on the HPSC website: 
http://www.hpsc.ie/A-Z/Gastroenteric/Handwashing/
Acknowledgements: 
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Table 1. Annual national ABHR consumption rates in acute public 
hospitals in Ireland: 2006 – 2016.
 
Number of 
participating 
hospitals
National 
consumption 
rate*
Range for 
participating 
hospitals 
2006 52 10 0.5 - 29.0
2007 50 15 5.2 - 47.1
2008 50 18.1 5.9 - 67.0
2009 49 20.3 4.1 - 47.7
2010 45 18.8 4.2 - 36.4
2011 43 21.3 10.9 - 130.0
2012 44 23.8 9.6 - 160.0
2013 44 26.3 16.4 - 132.5
2014 43 27.7 4.3 - 72.1
2015 39 32.5 10.1 - 96.8
2016 37 29.7 14.7 - 74.0
* The consumption rate is the total volume of ABHR consumed in the 
defined time period in litres per 1,000 bed-days used. The national 
consumption rate represents the median of the national sample for each 
time period.
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Background
Ireland participates in the European Surveillance of 
Antimicrobial Consumption Network (ESAC-Net), which is 
coordinated by the European Centre for Disease Prevention 
and Control (ECDC), with the aim of collecting systemic 
antimicrobial usage data from outpatient (ambulatory, 
community or primary care) and hospital (inpatient) 
settings. Antimicrobial consumption is measured in 
defined daily dose (DDD), which is the assumed average 
maintenance dose per day for a drug used for its main 
indication in adults. Rates are calculated in DDD per 1,000 
inhabitants per day (DID) for outpatients and DDD per 
100 bed-days used (DBD) for inpatients. Please refer to 
“Antimicrobial consumption” and “Denominator data” parts 
of the explanatory notes section for further details.
2016 Results 
Outpatient Antimicrobial Consumption
The overall outpatient antimicrobial consumption was 
24.0 DID, a 4% reduction on the updated 2015 rate of 
25.0 DID. In the 2016 ESAC-Net report, the reported use 
of systemic antibacterial agents (termed outpatient J01) 
among European countries ranged from 10.5 to 36.3 DID; 
the median for 30 European countries with reliable data was 
20.3 DID. 
The underlying outpatient antimicrobial consumption trend 
for Ireland has increased since 2000. (Figure 1) There is 
a marked seasonal fluctuation in usage, with the highest 
consumption contemporaneous with periods of increased 
influenza activity.
The penicillin class accounted for majority of use (58%; 
13.9 DID), followed by macrolides (18%; 4.3 DID), 
tetracyclines (10%; 2.5 DID), cephalosporins (5%; 1.2 
DID), sulphonamides/trimethoprim (5%, 1.1 DID) and 
fluoroquinolones (4%, 0.9 DID). 
Beta lactam-beta-lactamase inhibitor combinations [e.g., 
co-amoxiclav] accounted for the largest proportion of all 
penicillins (49%; 6.8 DID), followed by broad-spectrum 
penicillin [e.g., amoxicillin] (33%; 4.6 DID). Table 1 displays 
the breakdown by pharmacological drug groups.
There was considerable variability in the overall outpatient 
antimicrobial usage at county level (19.5 to 32.2 DID), as 
shown in Figure 2.
 
Hospital Antimicrobial Consumption
In 2016, 42 acute public hospitals provided antimicrobial 
usage data. The median rate of antimicrobial consumption 
was 84.8 DBD (mean = 86; range = 26.8 – 114.8), a 3.7% 
increase on the updated 2015 median rate of 81.8 DBD. 
These levels are mid-to-high in Europe.
Penicillins accounted for 50% of all hospital antimicrobial 
usage (43.2 DBD), followed by cephalosporins, 
monobactams and carbapenems combined (10%; 8.7 
DBD), glycopeptides [e.g., vancomycin], imidazoles [e.g., 
metronidazole] and nitrofurans combined (10%; 8.4 
DBD), fluoroquinolones [e.g., ciprofloxacin] at 6%; 5.1 
DBD and macrolides [e.g., clarithromycin] (3%; 2.3 DBD). 
Tetracyclines, sulfonamides/trimethoprim, aminoglycosides 
and other systemic antimicrobials collectively accounted for 
<10% of antimicrobial use (Figure 3).
While antimicrobial consumption data in Ireland are 
comprehensive, gaps remain. Consumption data from 
9.3  Surveillance of Antimicrobial Consumption 
in Outpatient and Acute Hospital Settings
Key Points
2016 summary
•  The overall outpatient antimicrobial consumption was 
24.0 defined daily doses (DDD) per 1,000 inhabitants 
per day (DID), a 4% reduction on the updated 2015 rate 
of 25.0 DID. This rate is mid-to-high in comparison with 
other European countries
•  In 2016, 42 acute public hospitals contributed 
data, with a median rate of hospital antimicrobial 
consumption of 84.8 DDD per 100 bed days used (DBD) 
(range = 26.8 – 114.8), representing a 3.7% increase on 
2015. This rate is mid-range in comparison with other 
European countries 
-150-HPSC Annual Epidemiological Report 2016 Healthcare Associated Infections
private hospitals are missing. All hospitals dispense to 
outpatients, day cases and may also serve external long 
term facilities. The data representing these groups is 
excluded from national hospital consumption analyses. 
Outpatient data is incomplete, representing 95% of 
wholesale-to-retail pharmacy transactions. Collectively, 
these gaps represent about 10% of the total antimicrobial 
consumption for Ireland.
 
While HPSC provides antifungal consumption data to ESAC-
Net, this report focuses on antibacterial consumption only. 
ESAC-Net also collects data on antiviral and antiprotozoal 
agents in Europe, which are not currently analysed in 
Ireland. 
Quarterly hospital antimicrobial consumption surveillance 
does not indicate whether or not the level of antimicrobial 
use is appropriate for a given patient population. For 
example, higher levels of antimicrobial consumption 
among tertiary hospitals may be appropriate depending on 
the patient case mix. Furthermore, DDD calculations are 
based on adult dosing and may therefore under-estimate 
antimicrobial consumption in paediatric settings.
In September and October 2016, the national annual 
antimicrobial point prevalence survey (PPS) was undertaken, 
using a protocol and data entry form developed in 
conjunction with the Irish Antimicrobial Pharmacists Group, 
with 41 hospitals participating (including three private and 
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Figure 1. Quarterly outpatient antimicrobial consumption in Ireland: 2000 – 2016.
Table 1. Annual breakdown by pharmacological drug groups for outpatient antimicrobial use in Ireland: 2015 and 2016.
Penicillins 201515.1
Percent of 2015
60.6%
2016
13.9
Percent of 2016
58.0%
Percent Change  2015 to 2016
-8.1%
Narrow spectrum penicillins 1.0 4.1% 1.1 4.5% 5.0%
Beta-lactamase resistant penicillins 2.2 8.9% 1.5 6.3% -32.1%
Broad spectrum penicillins 5.3 21.1% 4.6 19.1% -13.1%
Penicillin with beta-lactamase inhibitor 6.6 26.5% 6.8 28.2% 1.9%
Macrolides and related drugs 4.1 16.5% 4.3 18.1% 4.9%
Tetracyclines 2.5 10.1% 2.5 10.5% -0.7%
Cephalosporins and other beta-lactam drugs 1.1 4.6% 1.2 4.8% 0.8%
First-generation cephalosporins 0.3 1.1% 0.3 1.3% 15.3%
Second-generation cephalosporins 0.8 3.3% 0.8 3.3% -3.5%
Third-generation cephalosporins 0.0 0.2% 0.0 0.1% -11.9%
Quinolones 0.9 3.6% 0.9 3.6% -4.5%
Sulfonamides and Trimethoprim 1.0 4.1% 1.1 4.6% 7.0%
Other antibiotics 0.1 0.4% 0.1 0.4% -1.9%
TOTAL 25.0 100.0% 24.0 100.0% -4.0%
one non-acute hospital) and representing a 51% increase in 
participation since the first PPS in 2009. Results were similar 
to previous surveys. The overall antimicrobial use prevalence 
was 37.8%, compliance with choice was 81.6%, with dose 
was 94.3%, with overall restricted policy was 85.7% and 
specifically with meropenem restriction was 73%.
 
More detailed analyses of antimicrobial usage data can be 
found on the www.hpsc.ie website, through “Topics A-Z”, 
under “Antibiotic Consumption Surveillance”. Details of the 
WHO ATC/DDD system of classifying and measuring drug 
consumption can be found at www.whocc.no/atc_ddd_index/. 
The figures presented in this report may vary from previously 
published levels owing to methodological changes.
Figure 2. County-level outpatient antimicrobial consumption in 
Ireland in DDD per 1000 inhabitants per day (DID): 2016. 
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Figure 3. Annual national hospital antimicrobial consumption rate (DDD per 100 BDU) by pharmacological subgroup (ATC level 3).
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•   Estimated 99% coverage of the Irish population versus 
97% in 2015
•   There were 3,057 reports of invasive E. coli infection, an 
increase from 2,697 in 2015:  
 ○   The proportion of invasive E. coli that were ESBL-
producers (11.1%) was at its highest levels since 
surveillance began
 ○   One invasive E. coli isolate was a carbapenemase-
producer, also known as carbapenem-resistant 
Enterobacteriaceae (CRE or CPE)
•   There were 1,168 reports of S. aureus bloodstream 
infection (BSI), an increase from 1,082 in 2015:
 ○   Of those, 172 (14.7%) were meticillin-resistant  
S. aureus (MRSA). Compared with 2015, there was a 
13.6% reduction in the number of MRSA BSI in 2016
       For acute hospitals, the rate of MRSA BSI was 0.043 
cases per 1,000 bed days used (BDU), a decrease 
from 0.050 in 2015. An increase was observed 
in both the number (12.7% on 2015) and rate of 
meticillin-susceptible S. aureus (MSSA) BSI to 0.245 
from 0.223 (2015)
 ○   The number, proportion and rate of MRSA BSI are at 
their lowest level since surveillance began; while the 
number and rate of MSSA BSI are at their highest 
level
•   There were 431 reports of E. faecium BSI, an increase 
from 421 in 2015:
 ○    Vancomycin-resistant E. faecium (VREfm) 
accounted for 44.4%, one of the highest annual 
proportions reported to date
•   There were 469 reports of invasive K. pneumoniae 
infection, an increase from 401 in 2015:
 ○    Resistance to all indicator antimicrobials decreased 
 ○   In 2013, a multi-drug resistant K. pneumoniae 
(MDRKP) outbreak control team was established. 
The specific case definition for MDRKP is 
simultaneously an ESBL-producer and non-
susceptible to both ciprofloxacin and gentamicin. 
       The proportion of MDRKP causing invasive 
infections subsequently decreased to 7.1% (2016) 
from 12.3% (2013)
 ○    Four invasive K. pneumoniae isolates were 
carbapenemase-producers (CRE/CPE)
•   There were 365 reports of invasive S. pneumoniae 
infection, an increase from 304 in 2015:
 ○   Of those, 60 (16.5%) were penicillin non-susceptible 
S. pneumoniae (PNSP), a decrease from 17.5% in 
2015
 ○   The national rate of invasive pneumococcal infection 
increased compared with 2015 (7.7 per 100,000 
population versus 6.6)
 ○   Serotype data were available for 341 (93.3%) 
of 365 invasive S. pneumoniae isolates. Results 
indicate good coverage (71.2%) for the 23-valent 
pneumococcal polysaccharide vaccine (PPV23) in its 
target population (adults ≥65 years)
•   There were 250 reports of invasive P. aeruginosa 
infection, an increase from 201 in 2015, and resistance 
to all indicator antimicrobials, except for carbapenems, 
increased
•   The data in this report was extracted from the EARS-
Net database on 23rd October 2017
•   Enhanced surveillance data were provided on 2,593 
records (cases or isolates under the EARS-Net 
definition) from 21 laboratories, representing 43% of all 
reported cases in 2016
Background
The European Antimicrobial Resistance Surveillance Network 
(EARS-Net), formerly known as the European Antimicrobial 
Resistance Surveillance System (EARSS), collects routinely-
generated antimicrobial susceptibility testing (AST) data 
on seven important bacterial pathogens using the EARS-
Net case definition. Participating laboratories in Ireland 
submit data on the “primary” or first isolate from blood or 
cerebrospinal fluid (CSF) per patient per quarter. EARS-
Net does not distinguish clinically significant isolates from 
contaminants, nor does it distinguish between hospital-
9.4 Antimicrobial Resistance
a)  Key Pathogens causing Bloodstream 
Infections
2016 Summary
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Table 1. Summary of EARS-Net data by pathogen and year, 2010-2016
 Pathogen 2010 2011 2012 2013 2014 2015 2016
Number laboratories by year-end 40 41 41 41 39 38 37
%Coverage of population 100 100 100 100 100 97 99
E. coli
Number of isolates 2170 2210 2450 2530 2771 2697 3057
%Ampicillin-R* 68.4 71.9 69.6 70.9 69.9 66.7 68.4
%3GC-R* 8.0 9.1 10.3 12.3 12.0 12.5 12.3
%ESBL-producers* 6.1 7.5 8.8 10.5 10.2 10.6 11.1
%Ciprofloxacin-R* 23.6 23.8 25.2 25.3 26.2 24.4 24.1
%Gentamicin-R* 9.4 8.7 9.7 9.8 11.2 11.0 10.2
%Gentamicin/Amikacin/Tobramycin-R* 11.9 12.4 12.8 12.9 14.5 13.4 13.2
%Carbapenem1-R* 0.0 0.0 0.1 0.1 0.1 0.2 0.2
%MDR* 11.8 13.2 13.6 14.6 15.0 14.5 14.3
S. aureus
Number of isolates 1251 1095 1060 1094 1117 1082 1168
Number Meticillin-R (or MRSA) 305 263 242 222 217 199 172
%Meticillin-R (or MRSA) 24.4 24.0 22.8 20.3 19.4 18.4 14.7
K. pneumoniae
Number of isolates 326 312 345 326 358 401 469
%Ampicillin-R* 99.1 100.0 98.5 99.1 100.0 99.3 99.4
%3GC-R* 10.2 8.0 11.9 21.2 13.1 17.5 16.8
%ESBL-producers* 5.1 5.6 8.8 18.4 11.0 13.3 12.9
%Ciprofloxacin-R* 10.5 13.2 11.9 20.9 17.3 21.6 16.6
%Gentamicin-R* 6.8 7.4 9.6 16.9 12.6 17.0 11.5
%Gentamicin/Amikacin/Tobramycin-R* 7.1 8.3 9.9 17.8 13.2 18.0 12.6
%Carbapenem1-R* 0.0 1.9 0.3 1.2 1.1 2.2 1.1
%MDRKP2* 2.2 4.6 5.3 12.3 8.2 9.8 7.1
%MDR* 8.0 9.0 10.2 19.7 13.7 19.8 14.7
E. faecium
Number of isolates 392 364 392 409 405 421 431
%Ampicillin-R* 95.6 95.9 92.9 93.2 95.3 94.3 94.6
%Vancomycin-R (VREfm) 39.3 37.4 45.4 43.1 45.9 45.6 44.4
%HLG-R* 39.6 36.8 39.3 41.4 44.3 49.5 58.3
%Linezolid-R* 2.2 1.1 1.5 1.2 2.0 0.7 0.2
%MDR* 25.0 21.1 20.3 19.6 22.1 21.3 28.2
S. pneumoniae
Number of isolates 314 327 321 311 331 304 365
%Penicillin-NS* 18.2 19.6 19.6 20.7 17.1 17.5 16.5
of which:   %HLR 4.8 6.1 4.7 2.6 2.4 0.3 0.0
 %Int 12.7 13.5 15.0 18.0 14.5 17.2 16.5
%Erythromycin-R* 15.7 18.9 16.9 17.9 13.8 15.2 13.2
%Penicillin-NS/Erythromycin-R 12.6 13.8 12.5 13.0 11.0 10.8 9.9
E. faecalis
Number of isolates 298 265 298 336 315 294 296
%Ampicillin-R* 0.7 0.8 4.0 2.7 1.6 0.7 0.7
%Vancomycin-R (VREfa) 0.3 4.9 3.0 2.1 2.9 1.4 1.0
%HLG-R* 29.7 29.1 32.9 33.6 32.8 28.0 29.5
%Linezolid-R* 2.5 1.2 0.0 0.6 1.0 0.4 0.0
P. aeruginosa
Number of isolates 222 184 219 207 182 201 250
%Piperacillin/tazobactam-R* 10.0 2.8 17.4 15.7 16.5 14.0 17.2
%Ceftazidime-R* 9.2 8.2 15.2 10.7 8.9 8.5 13.2
%Imipenem/meropenem-R* 8.3 12.0 19.4 13.1 11.6 16.4 13.2
%Ciprofloxacin-R* 13.2 12.6 20.6 15.0 13.7 13.5 16.4
%Gentamicin-R* 8.7 6.5 11.9 11.6 4.9 3.5 11.2
%Gentamicin/Amikacin/Tobramycin-R* 8.6 6.5 11.9 11.6 5.5 7.0 12.4
%MDR* 6.5 4.0 13.0 9.4 6.7 7.5 13.2
Acinetobacter spp.
Number of isolates
No data No data No data
91 93 87 69
%Ciprofloxacin-R* 3 8 7 1
%Gentamicin-R* 0 3 4 2
%Gentamicin/Amikacin/Tobramycin-R* 1 3 5 3
%Imipenem/meropenem-R* 4 4 6 0
%MDR* 0 2 3 0
    * Not all isolates tested
Number of isolates presented in bold; proportions (%) presented in italics
R, Resistant; NS, Non-Susceptible [includes isolates with intermediate (Int) and high-level resistance (HLR)]
MRSA, Meticillin-Resistant S. aureus; VREfm, Vancomycin-Resistant E. faecium; VREfa, Vancomycin-Resistant E. faecalis
HLG, High-Level Gentamicin; 3GC, 3rd-Generation Cephalosporin (includes cefotaxime, ceftriaxone, ceftazidime)
ESBL, Extended-Spectrum Beta-Lactamase; MDR, Multi-Drug Resistant
1 Carbapenems include imipenem, meropenem and ertapenem; 2 MDRKP, MDR K. pneumoniae phenotype (ESBL-producer 
plus non-susceptibility to Ciprofloxacin and Gentamicin) OR carbapenemase-producer (e.g. KPC, OXA-48) 
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acquired, healthcare-associated and community-acquired 
infections. EARS-Net primarily serves as a surveillance 
system to measure national levels of antimicrobial resistance 
(AMR). In 2016, two of the 39 microbiology laboratories 
suspended their participation in EARS-Net, one in Q3 and 
one in Q4, resulting in an estimated 99% coverage of the 
Irish population. Overall, coverage has remained at over 
95% since 2004.
EARS-Net encourages the use of EUCAST guidelines 
and clinical breakpoints for AST in line with the EU case 
definitions. By the end of 2016, 35 of the 39 Irish clinical 
microbiology laboratories had switched to EUCAST, with just 
four laboratories still using CLSI guidelines. 
2016 Results
Escherichia coli
There were 3,057 reports (blood; 3,055 and CSF; 2) from 
2,985 patients, an increase of 13% compared with 2,697 
reports in 2015. Table 1 displays the annual trends since 
2008 in the proportion of E. coli isolates resistant to the five 
“indicator” antimicrobials/antimicrobial classes [ampicillin, 
third-generation cephalosporins (3GCs; cefotaxime, 
ceftriaxone or ceftazidime), fluoroquinolones (ciprofloxacin), 
aminoglycosides (gentamicin, amikacin or tobramycin) and 
carbapenems (meropenem or ertapenem)]:  
•   Of 3,055 isolates, 376 (12.3%) were resistant to 3GCs and 
of those, 324 were extended-spectrum beta-lactamase 
(ESBL)-positive and 51 ESBL-negative 
•   Of 3,056 isolates, 736 (24.1%) were resistant to 
ciprofloxacin 
•   Of 3,057 isolates, 311 (10.2%) were resistant to gentamicin 
[404 (13.2%) of 3,057 were aminoglycoside-resistant (i.e. 
resistant to gentamicin, tobramycin or amikacin)]
•   Five (0.2%) of 3,047 isolates were resistant to 
carbapenems, one of which was confirmed to be a 
carbapenemase-producer (NDM)
Figure 1. Trends for E. coli – total numbers of E. coli and percentage resistance to 3rd 
generation cephalosporins (3GC)/ESBL-positive
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Table 2. Age and gender breakdown of patients by organism with major resistance profiles (data from laboratories participating in enhanced 
surveillance for 2016). The proportion of isolates detected <48 hours and >5 days post-admission is also shown 
Total for 2016 Percent female Mean age in years
Detected <48 hours 
after admission
Detected >5 days 
after admission
Staphylococcus 
aureus
Meticillin Resistant (MRSA) 95 31% 68 64% 28%
Meticillin Susceptible 533 39% 61.7 68% 21%
Streptococcus 
pneumoniae
Penicillin non-Susceptible 18 28% 71.3 89% 6%
Penicillin Susceptible 129 51% 62.6 92% 6%
Enterococci Vancomycin Resistant 67 39% 65.7 4% 84%
Vancomycin Susceptible 204 40% 65.6 43% 49%
Escherichia coli
Fluoroquinolone Resistant 307 47% 73.4 72% 21%
Fluoroquinolone Susceptible 961 56% 67.5 80% 17%
Klebsiella pneumoniae 168 38% 67 60% 33%
Pseudomonas aeruginosa 111 36% 68.2 59% 32%
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The trend in resistance to 3GCs has stabilised at 12.0-
12.5% since 2013 (Figure 1). Resistance to ciprofloxacin and 
aminoglycosides decreased in 2016 compared with 2015. 
In 2016, Ireland had moderately high levels (10 to <25%) 
of resistance to 3GCs (Figure 2), ciprofloxacin and 
aminoglycosides (ranking 18th, 18th and 14th, respectively, 
out of 30 countries reporting to EARS-Net). The median 
proportions for resistance among EARS-Net countries 
were 14.3% for 3GCs, 26.5% for ciprofloxacin and 12.5% for 
aminoglycosides.
ESBLs are enzymes that confer resistance to most penicillins 
and cephalosporins (including 3GCs). ESBL-producing 
bacteria (including E. coli and K. pneumoniae) are also 
often resistant to other classes of antimicrobials and have 
emerged as important causes of healthcare-associated 
infection (HCAI). In 2016, ESBL producing invasive E. coli 
isolates were at the highest level since surveillance began 
(11.1%). 
Of 3,055 isolates tested against all five “indicator” 
antimicrobials, 436 (14.3%) reported from 50 hospitals/
institutions were identified as multi-drug resistant (MDR) 
E. coli, defined as resistance to three or more of the 
indicator antimicrobials OR any isolate with resistance to 
carbapenems, similar to 2015 (14.5%). 
Staphylococcus aureus
There were 1,168 reports of S. aureus BSI from 1,143 patients, 
compared with 1,082 reports in 2015. Of those, 172 (14.7%) 
were MRSA, which represents the lowest annual proportion 
since surveillance began in 1999 (Table 1 shows data from 
2010 - 2016). In 2010, the proportion was 24.4%, the first 
year that MRSA accounted for <25% of S. aureus BSI in 
Ireland, thus changing from red to orange on the EARS-
Net map and 2016 was the tenth successive year in which 
a decrease was observed (Figure 3). Overall, there was 
a 13.6% reduction in the number of reported MRSA BSI 
compared with 2015 (172 versus 199). In contrast, the total 
number of MSSA BSI increased by 12.7% compared with 
2015 (996 versus 883). 
Despite the decrease in numbers and proportion of MRSA 
BSI in 2016, Ireland still had one of the higher proportions 
of MRSA in Europe (see http://ecdc.europa.eu/en/
healthtopics/antimicrobial_resistance/database/Pages/
database.aspx for more detailed European data, including 
EARS-Net tables, charts and maps) (Figure 4). Ireland 
ranked 12th out of 30 countries reporting to EARS-Net 
(compared to 11th of 30 countries in 2015), with the median 
proportion of MRSA BSI at 13.8%. All countries with MRSA 
proportions higher than Ireland are located in Southern and 
Central/Eastern Europe.
The MRSA rate for all acute hospitals in 2016 was 0.043 
cases per 1,000 BDU, a decrease from 0.050 in 2015, 
while the MSSA rate increased from 0.223 to 0.245 [rates 
are calculated from denominator data (BDU) obtained 
from the HSE’s Business Information Unit for all acute 
public hospitals; and directly from private hospitals where 
available, where both numerator (S. aureus numbers) and 
denominator data have been provided]. 
Klebsiella pneumoniae
There were 469 reports of invasive K. pneumoniae infection 
(all from blood) from 453 patients, an increase of 17% from 
2015 (n=401). Table 1 displays annual trends since 2010 in 
the proportion of K. pneumoniae isolates resistant to the five 
“indicator” antimicrobials (as for E. coli above): 
Figure 2. Distribution of 3rd-generation cephalosporin resistant E. coli in EARS-Net countries in 2016
Map downloaded from ECDC’s TESSy database on 13/10/2017:
http://ecdc.europa.eu/en/healthtopics/antimicrobial_resistance/database/Pages/database.aspx
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•   Of 469 isolates, 79 (16.8%) were resistant to 3GCs, of 
which 58 were ESBL-producers and 21 were ESBL-negative 
•   Of 469 isolates, 78 (16.6%) were resistant to ciprofloxacin
•   Of 469 isolates, 54 (11.5%) were resistant to gentamicin 
[59 (12.6%) of 469 were aminoglycoside-resistant (i.e. 
resistant to gentamicin, tobramycin or amikacin)]
•   Of 467 isolates, five (1.1%) were resistant to carbapenems, 
with four confirmed to be carbapenemase-producers 
reported from two hospitals (KPC; 3 and OXA-48; 1) and 
one confirmed not to be a carbapenemase-producer. This 
compares with seven in 2015 (OXA-48; 6 and KPC; 1), two 
in 2014 (OXA-48; 1 and KPC; 1), two in 2013 (both OXA-48) 
and four in 2011 (OXA-48; 3 and KPC; 1)
Three invasive K. pneumoniae isolates were reported 
as susceptible to ampicillin, which is suggestive of 
misidentification of species or misclassification, as   
K. pneumoniae are inherently resistant to ampicillin.
Resistance to 3GCs (Figure 7), ciprofloxacin and gentamicin/
aminoglycosides all decreased in 2016 compared with 2015.
ESBLs were detected in 60 (12.9%) of 464 isolates tested. 
This represents a slight decrease from 13.3% in 2015. 
Of 468 isolates, 69 (14.7%) reported by 25 hospitals/
institutions that were tested against all five “indicator” 
antimicrobials were identified as MDR Klebsiella pneumoniae, 
a decrease from 19.8% in 2015. 
In 2013, the Antimicrobial Resistance and Microbial Ecology 
(ARME) group at NUI Galway alerted HPSC to the presence 
of two predominant K. pneumoniae clones implicated in 
both patient infection and colonisation in a number of Irish 
hospitals. Both clones were simultaneously ESBL-positive 
and non-susceptible to ciprofloxacin and gentamicin. Some 
were also found to produce carbapenemases. Isolates 
meeting the definition are termed multi-drug resistant  
K. pneumoniae (MDRKP). From 2012 to 2013, the proportion 
of invasive K. pneumoniae that were MDRKP increased 
from 5.3% (18 of 342 isolates) to 12.3% (40 of 325 isolates), 
as displayed in Figure 8. An outbreak control team was 
established in October 2013 to evaluate this emerging threat 
and the proportion of MDRKP has subsequently decreased 
to 7.1% (33 of 464 isolates) in 2016.
In 2016, Ireland ranked 21st for 3GC, fluoroquinolone and 
aminoglycoside resistance in invasive K. pneumoniae among 
30 countries reporting to EARS-Net. The median proportions 
among EARS-Net countries were 31.1%, 34.5% and 23.8%, 
respectively. With four reports of invasive carbapenem-
resistant K. pneumoniae (0.9%), Ireland ranked joint 17th of 
30 countries in 2016, with the median proportion among 
EARS-Net countries being 1.0% (Figure 9).
Enterococcus faecium 
There were 431 reports of E. faecium BSI from 422 patients, 
an increase of 2.4% from 2015 (n=421). Table 1 displays the 
annual trends since 2010 in the proportion of E. faecium 
isolates resistant to the three “indicator” antimicrobials 
(ampicillin, vancomycin and high-level gentamicin):  
•   Of 430 isolates, 191 (44.4%) were resistant to vancomycin 
E. faecium (VREfm), which is a slight decrease from 45.6% 
in 2015 (Figure 5) 
•   Of 410 isolates, 239 (58.3%) were resistant to high-level 
gentamicin, which is the highest proportion reported to 
date (Figure 5)
•   Of 426 isolates, one (0.2%) was resistant to linezolid 
•   Of 404 isolates tested against the three “indicator” 
antimicrobials, 114 (28.2%) reported from 25 hospitals/
institutions [with the majority (88; or 77%) coming from 
the nine tertiary hospitals] were resistant to all three and 
termed MDR E. faecium, which represents an increase 
from 21.3% in 2015
The proportion of VREfm first exceeded 40% in 2012 and 
appears to have levelled off at 43-45% since then.
Between 2008 and 2015, Ireland had the highest proportion 
of VREfm in Europe. In 2016, Ireland ranked second 
0%
5%
10%
15%
20%
25%
30%
35%
40%
45%
0
200
400
600
800
1000
1200
1400
1600
2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016
%
M
RS
A
N
um
be
r o
f i
so
la
te
s
Year
Total S. aureus MRSA %MRSA
Figure 3. Trends for S. aureus – total numbers of S. aureus/MRSA and percentage MRSA
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after Cyprus (46.3%; note: overall numbers were low). In 
addition, five other countries reported proportions over 25%: 
Romania, Latvia, Greece, Slovakia and Poland (Figure 6). 
The median proportion of VREfm in EARS-Net countries was 
8.1%, a decrease from 9.9% in 2015.
Streptococcus pneumoniae
There were 365 reports of invasive S. pneumoniae infection 
(360 from blood and five from CSF) from 364 patients, a 
20% increase on 2015 (n=304). Table 1 displays annual 
trends since 2010 in the proportions of S. pneumoniae 
isolates non-susceptible/resistant to penicillin and 
erythromycin.  
Penicillin non-susceptible S. pneumoniae (PNSP) accounted 
for 16.5% (n=60) of all isolates tested against penicillin 
(n=364) (Figure 10), a reduction from 17.5% (2015). Of 
the PNSP isolates, all were intermediately-resistant (Int; 
MIC = 0.1 – 1mg/L) for laboratories following the Clinical 
Laboratory Standards Institute (CLSI) guidelines (for non-
meningitis syndrome via oral administration) and (MIC 
= 0.1 – 2 mg/L) for those following European Committee 
on Antimicrobial Susceptibility Testing (EUCAST) non-
meningitis guidelines. Penicillin susceptibility was not 
determined for one isolate. Forty-seven (13.2% of 355) 
isolates were resistant to erythromycin.  
Ireland remained among European countries with the 
highest proportions of PNSP ranking 8th of 29 countries in 
2016 (median proportion, 10.5%). Moderately high levels of 
erythromycin resistance were seen, with Ireland ranking 14th 
of 29 countries (median proportion, 13.8%). This is similar 
Figure 4. Distribution of MRSA in EARS-Net countries in 2016
Map obtained from ECDC on 13/10/2017:
http://ecdc.europa.eu/en/healthtopics/antimicrobial_resistance/database/Pages/database.aspx
Figure 5. Trends for E. faecium – total numbers of E. faecium and percentage resistance to 
vancomycin (VREfm) 
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to the situation observed in much of Southern and Central/
Eastern Europe. 
 
Of 354 isolates tested against both penicillin and 
erythromycin in 2016, 35 (9.9%) were simultaneously PNSP 
(all intermediately resistant) and erythromycin-resistant, 
which is a decrease from 2015 (10.8%).
In 2007, a national pilot project was established as a 
collaborative initiative between RCSI/Beaumont Hospital, 
Children’s University Hospital, Temple St and HPSC, 
with the aim of providing baseline serotyping data on 
invasive S. pneumoniae isolates. This project pre-dates 
the introduction of the 7-valent pneumococcal conjugate 
vaccine (PCV7) into the childhood immunisation schedule 
in September 2008. PCV13 replaced PCV7 from September 
2010. 
In 2016, serotype data were available for 341 pneumococcal 
isolates reported by 30 of the 31 laboratories reporting 
pneumococcal isolates to EARS-Net, representing 93.4% of 
all pneumococcal isolates reported: 
•   Of 184 isolates from patients aged ≥65 years, 131 (71.2%) 
belonged to serotypes included in the PPV23 vaccine
•   Twenty isolates were referred for typing from patients 
aged <2 years (the target population for the PCV13 
vaccine) and three of these were serotypes included in the 
vaccine
Figure 7. Trends for K. pneumoniae – total numbers of K. pneumoniae and percentage resistance to 
3rd generation cephalosporins (3GCs) and carbapenems (CBP)
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Figure 6. Distribution of vancomycin-resistant E. faecium (VREfm) in EARS-Net countries in 
2016. Map downloaded from ECDC’s TESSy database on 13/10/2017:
http://ecdc.europa.eu/en/healthtopics/antimicrobial_resistance/database/Pages/database.aspx
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The most common serotypes identified were: 8 and 12F 
(n=39), 3 (n=30), 19A (n=27), 22F (n=25), 33F (n=23), 9N 
(n=19), 15F (n=14) and 24F (n=11) representing 66.6% of all 
isolates typed. 
Of the 60 PNSP isolates, 56 (93%) were serotyped: 
•   Of 18 isolates from patients age ≥65 years, 16 (89%) 
belonged to serotypes included in the pneumococcal 
polysaccharide vaccine (PPV23) vaccine
•   Of five isolates from children <2 years, one belonged to a 
serotype included in the PCV13 vaccine
The most common serotypes identified were: 19A (n=17), 15A 
(n=10) and 5B (n=5) representing 57% of all PNSP isolates 
typed. 
Ongoing surveillance of the predominant serotypes is 
required, as strains with non-vaccine serotypes have been 
reported to increase in prevalence following the introduction 
of conjugate vaccines in other countries. Hence the need for 
a fully-resourced Irish pneumococcal reference laboratory. 
The separate chapter on invasive pneumococcal disease 
(IPD) in Ireland in 2016 contains additional information on 
pneumococcal serotyping.
In 2016, the rate of IPD in Ireland was estimated at 7.7 cases 
per 100,000 population, a decrease compared with 6.6 
in 2015 [note that both rates were calculated using 2016 
Census data; with the rates adjusted to account for the 
reduced population coverage by EARS-Net in each year]. 
Enterococcus faecalis
There were 296 reports of E. faecalis BSI from 289 patients, 
compared with 294 reports in 2015. Table 1 displays annual 
trends since 2010 in the proportions of E. faecalis isolates 
resistant to the three “indicator” antimicrobials (as for 
E. faecium):  
•   Of 295 isolates, three (1.0%) were resistant to vancomycin 
(VREfa), with Ireland ranking 9th amongst European 
countries for resistance. The proportion of VREfa in Ireland 
has decreased from the highest reported proportion of 
4.9% in 2011. In 2016, the median proportion in Europe 
was 0.1%
•   Of 271 isolates, 80 (29.5%) were resistant to high-level 
gentamicin
•   Of 292 isolates, none were resistant to linezolid 
Two isolates were reported resistant to ampicillin, 
which is suggestive of misidentification of species or 
misclassification, as resistance to ampicillin is rare in 
E. faecalis.
Pseudomonas aeruginosa
There were 250 reports of invasive P. aeruginosa infection 
(blood; 245 and CSF; 5) from 243 patients, a 24.3% increase 
on 2015 (n=201). Table 1 displays annual trends since 2010 
in the proportion of the 250 P. aeruginosa isolates resistant 
to the five “indicator” antimicrobials/antimicrobial classes 
[piperacillin-tazobactam, ceftazidime, carbapenems 
(meropenem or imipenem), fluoroquinolones (ciprofloxacin) 
and aminoglycosides (gentamicin, amikacin or tobramycin)]: 
•   43 (17.2%) were resistant to piperacillin-tazobactam 
•   33 (13.2%) were resistant to ceftazidime
•   33 (13.2%) were resistant to imipenem or meropenem
•   42 (16.8%) were resistant to ciprofloxacin
•   28 (11.2%) were resistant to gentamicin [31 (12.4%) of 
250 were aminoglycoside-resistant (i.e. resistant to 
gentamicin, tobramycin or amikacin)] 
In 2016, resistance to all but one of the indicator 
antimicrobials (imipenem/meropenem) increased compared 
with 2015.
Thirty-three (13.2%) of 250 isolates reported from 18 
hospitals that were tested against all five “indicator” 
Figure 8. Trends for K. pneumoniae isolates with the MDRKP phenotype (simultaneously ESBL-
producers and non-susceptible to both ciprofloxacin and gentamicin and/or a carbapenemase-
producer) –– numbers and percentage with MDRKP phenotype
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antimicrobials were identified as MDR Pseudomonas 
aeruginosa, defined as resistance to three or more of the 
indicator antimicrobials. This is the highest proportion of 
MDR Pseudomonas aeruginosa since surveillance began in 
2006.
Antimicrobial resistance levels amongst P. aeruginosa 
isolates in Ireland are at moderately low levels in comparison 
with other European countries, with Ireland ranking 
between 16th and 24th of 30 countries for all five indicator 
antimicrobials.
Acinetobacter spp.
There were 69 reports of invasive infection caused by 
Acinetobacter spp. (blood; 67 and CSF; 2) from 68 patients, 
a reduction on 87 reports in 2015. Table 1 displays annual 
trends since 2013 in the proportion of Acinetobacter spp. 
isolates resistant to the three “indicator” antimicrobials/
antimicrobial classes [carbapenems (meropenem or 
imipenem), fluoroquinolones (ciprofloxacin) and gentamicin]: 
•   Of 65 isolates, none were resistant to imipenem or 
meropenem
•   Of 68 isolates, one was resistant to ciprofloxacin
•   Of 63 isolates, one was resistant to gentamicin [two 
of 65 were aminoglycoside-resistant (i.e. resistant to 
gentamicin, tobramycin or amikacin)]
Of 63 isolates, none were identified as MDR Acinetobacter 
spp., i.e. resistant to all three “indicator” antimicrobials.
Enhanced Surveillance
The voluntary EARS-Net enhanced surveillance programme 
was established in 2004. Laboratories participating in 
EARS-Net are invited to provide additional demographic and 
clinical data on invasive pathogens causing BSI.
In 2016, enhanced surveillance data on 2,593 individual 
records (cases or isolates under the EARS-Net definition) 
were submitted from 21 participating laboratories, 
representing 43% of all reports to EARS-Net. Table 2 
displays demographic and other basic data for the major 
resistance profiles of pathogens reported to EARS-Net 
enhanced surveillance.
 •   S. aureus BSI
 ○   54% of MRSA and 45% of MSSA BSIs were 
healthcare-associated
 ○   24% of MRSA BSIs were device-associated with
	 	 	5% CVC/CVC-PICC-associated, 8% PVC-associated 
 ○   20% of MSSA BSIs were device-associated with
	 	 	10% CVC/CVC-PICC-associated, 5% PVC-associated 
•   Enterococcal BSI 
 ○   91% of VRE and 61% of vancomycin-susceptible 
enterococcus (VSE) BSIs were healthcare-associated
 ○   30% of VRE BSIs were device-associated with
	 	 	24% CVC/CVC-PICC-associated
 ○   18% of VSE BSIs were device-associated with
	 	 	11% CVC/CVC-PICC-associated
 
•    E. coli BSI 
 ○   39% of fluoroquinolone-resistant E. coli (FQREC) and 
27% of fluoroquinolone-susceptible E. coli (FQSEC) 
BSIs were healthcare-associated
 ○   The most common source of E. coli bloodstream 
infection was urinary tract infection, with 48% FQREC 
BSI and 44% FQSEC urinary catheter-associated
 
Conclusion
For the tenth consecutive year, the proportion of S. aureus 
BSI attributable to MRSA further declined to 14.7%, the 
lowest reported level since Ireland joined EARS-Net in 1999. 
The decline may be partly attributable to improvements 
in infection prevention and control interventions, such as 
improved healthcare worker awareness of the importance 
of hand hygiene, standard and contact precautions, 
Figure 9. Distribution of carbapenem-resistant K. pneumoniae in EARS-Net countries in 2016
Map downloaded from ECDC’s TESSy database on 13/10/2017:
http://ecdc.europa.eu/en/healthtopics/antimicrobial_resistance/database/Pages/database.aspx
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screening of patients for MRSA carriage and the availability 
of decolonisation regimens to eradicate MRSA carriage. The 
development of and strengthening of hospital invasive device 
insertion and maintenance protocols (e.g., care bundles), 
antimicrobial stewardship programmes and restricted 
prescribing of certain broad spectrum antimicrobials, 
particularly in response to other healthcare associated 
infections, such as Clostridium difficile infection, may also 
have positively contributed to the decreasing proportion of 
MRSA BSI. 
Unfortunately, antimicrobial resistance in other important 
BSI causative pathogens increased further and remains a 
cause for concern. 
In 2016, Ireland had the second highest proportion of VREfm 
BSI (44.4%) in Europe after Cyprus (46.3%; but note low 
numbers). Five other countries also reported proportions over 
25% and therefore appeared red on the map. 
Following the establishment of the national multi-drug 
resistant K. pneumoniae (MDRKP) outbreak control team 
(OCT) in 2013 to look at the emerging problem of MDRKP, 
initial recommendations were made to try to control the 
spread of MDRKP strains in healthcare settings. Due to 
the wide-reaching nature of this outbreak and the growing 
threat posed by antimicrobial resistance, the OCT proposed 
that a national task force should be established with greater 
powers to influence and implement changes in policy and 
infrastructure needed. In 2016, there were five reported cases 
of invasive carbapenemase-producing K. pneumoniae (CRE) 
infection in Ireland. 
Infections caused by antimicrobial-resistant bacteria result 
in excess patient mortality, morbidity and costs to the 
healthcare system. Rising levels of AMR threaten many 
aspects of healthcare that we currently take for granted. 
It is critical that comprehensive infection prevention and 
control and antimicrobial stewardship programmes continue 
to be developed and maintained at all levels and settings 
within the Irish health service. To this end, it is vital that 
recommendations and guidelines produced by the HSE RCPI 
Clinical Advisory Group on HCAI and AMR are implemented.
HPSC thanks all the microbiology laboratories for their 
continued participation and enthusiasm for the EARS-Net 
project.
See http://www.hpsc.ie for further details of EARS-Net, 
antimicrobial resistance and enhanced BSI surveillance in 
Ireland
European data are available at: 
http://ecdc.europa.eu/en/healthtopics/antimicrobial_
resistance/database/Pages/database.aspx
b)  Enhanced surveillance of Carbapenemase-
Producing Carbapenem Resistant 
Enterobacteriaceae (CRE/CPE) 
2016 Summary
Number of cases of colonisation or infection 
with enhanced data = 107. This represented an 
increase compared with 98 (2015) and 63 (2014). In 
contrast, the National Carbapenemase Producing 
Enterobacteriaceae Reference Laboratory Service 
(CPEaRLS) at Galway University Hospital confirmed 
carbapenemase production in 362 Enterobacteriaceae 
isolates in 2016 compared to 139 (2015)
The clinical significance of the CRE isolate was 
reported for 100 patients, representing colonisation in 
the majority (n=78; 78%). CRE infection was reported 
for 22 patients
Background
Carbapenem-resistant Enterobacteriaceae (CRE) are 
multi-drug resistant Gram-negative bacteria and includes 
Figure 10. Trends for S. pneumoniae – total numbers of S. pneumoniae/PNSP and percentage PNSP
HLR, High-level resistant; I, Intermediately resistant
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carbapenemase enzyme producers and those bacteria that 
are resistant to carbapenems (e.g. imipenem, meropenem) 
as a result of a combination of resistance mechanisms 
(such as broad-spectrum β-lactamases and bacterial cell 
porin loss). These bacteria can be easily spread between 
patients in healthcare settings and have the ability to cause 
infections for which effective antimicrobial therapy may be 
lacking. 
Detection of confirmed carbapenemase-producing CRE, 
hereafter known as CRE, became notifiable in Ireland 
in March 2011 under the category of ‘unusual cluster or 
changing pattern of illness’. Upon amendment to the 
Infectious Diseases Regulations in September 2011, invasive 
CRE infection (blood, CSF or normally sterile site) became 
notifiable in its own category. A voluntary CRE enhanced 
surveillance scheme was established in June 2011 and 
reporting of isolates from any site, whether colonisation or 
infection is encouraged.
 
Enhanced surveillance data
Data was received on 107 confirmed CRE cases from 14 
laboratories. Five CRE outbreaks from three acute hospitals 
and one nursing home were reported in 2016 (OXA-48; 3, 
OXA-48 and VIM CRE combined; 1 and NDM; 1). Figure 1 
displays annual trends in CRE cases and types reported to 
enhanced surveillance since 2011. Of 104 patients, 68 were 
male (65%). The median age was 75 years (range: 8 months 
– 99 years). 
Patient location 
At the time of CRE detection, 73 patients (77%) were 
hospitalised, 18 (19%) were in long-term care facilities (vs. 
three in 2015) and four (4%) were in the community. 
Of the 73 hospitalised patients, 47 (64%) had been admitted 
from home, 14 (19%) were transfers from another acute 
hospital, seven had been admitted from long-term care/
nursing homes (10%) and the source of admission was 
not provided for the remaining four patients (5%). Of the 
14 patients who had been transferred from another acute 
hospital, one was repatriated from a hospital abroad 
(Guatemala). 
Time to CRE colonisation/infection (interval between 
admission to first detection of CRE) could be calculated for 
65 patients (89%), with a median interval of 10 days (range: 
0 – 181).
Presence of other multi-drug resistant organisms (MDROs)
At the time of CRE detection, 50 patients (47%) were already 
known to be colonised or infected with at least one other 
MDROs, including MRSA; 22, VRE; 25, ESBL-producing 
Enterobacteriaceae; 11, C. difficile infection; 2 and MDR  
K. pneumoniae; 1 (note: 10 patients were colonised with two 
other MDROs and one with three others), and 35 of those 
were inpatients. 
Travel history
Foreign travel in the past 12 months was reported for seven 
patients (7%) to six countries (Cyprus, Guatemala, India, 
Moldova, Morocco, Spain and UK) and 45 (42%) reported 
no foreign travel. The travel history was unknown for the 
remaining 55 (51%). 
Risk factors
Risk factor data were reported on 96 patients; 53 (50%) 
had more than one risk factor. Hospitalisation in the past 
12 months (75; 70%); history of admission to intensive care 
in the last 12 months (22; 21%) and history of surgery in the 
past six months (18; 17%). Risk factor data was unknown or 
not provided for 11 patients and five had no identifiable risk 
factors (5%).
Reported underlying co-morbidities included: diabetes 
mellitus (18); chronic lung disease (17); immunocompromise 
(11); renal disease (11); urological abnormality (10) and liver 
disease (2). 
Prior antimicrobial exposure
Antimicrobial exposure history prior to isolation of CRE 
was provided for 55 patients (53%), 46 of whom were 
hospitalised and 22 of whom received more than one 
antimicrobial class: 
•  β-lactam/β-lactamase inhibitor combination agents - 41 
(75%) 
•  Carbapenems - 16 (29%) 
•  Cephalosporins - 10 (18%)
•  Fluoroquinolones - 10 (18%) 
•  Aminoglycosides - 9 (16%)
•  Co-trimoxazole - 4 (7%) 
•  Colistin - 2 (4%)
Clinical significance and source of infection
The clinical significance of the CRE isolate was reported 
for 100 patients, representing colonisation in the majority 
(n=78). CRE infection was reported for 22 patients; urinary 
tract infection (n=7), respiratory tract infection (n=5), skin/
soft tissue infection (n=3), two cases of intra-abdominal 
infection (n=2) and BSI (n=1). 
Specimen type
The majority of CRE (n=69; 66%) were isolated from 
screening swabs (rectal or stoma) or faeces. Blood 
accounted for six (6%), one from gall bladder, 17 from urine 
(16%), five from sputum (5%) and seven from various other 
wound swabs and tips. Specimen type was unknown for two 
isolates.
Outcome
Outcome was reported for 54 of the 73 hospitalised patients 
(74%):
•  Discharged = 35 (65%)
•  Still inpatient at the time the surveillance form was 
returned (n=11; 20%, six of whom had already had CRE 
infection. However, it is not known if the remaining five 
CRE colonised patients subsequently went on to develop 
CRE infection later in the hospital admission) 
•  Death (n=8; 15%). For one death, CRE detection 
represented infection. However, the potential contribution 
of CRE infection to patient death was not collected. Date of 
death was provided for all patients, with a median interval 
from detection of CRE to death of 13.5 days (range = 2 – 
99) 
•  Outcome was also reported for fifteen non-hospitalised 
patients, five of whom survived, all of whom were residents 
in a long-term care facility: two of these were reported to 
have had CRE infection and these patients died 10 and 39 
days post-diagnosis, respectively. The interval to death for 
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the remaining three patients was greater than 200 days.
 
Enterobacteriaceae species 
Klebsiella pneumoniae accounted for the majority (n=44; 
41%) of CRE isolates (compared with 33% of isolates in 
2015). In addition, there were nine K. oxytoca, 16 Escherichia 
coli, 22 Citrobacter spp., 11 Enterobacter spp., two Serratia 
marcescens and one Raoultella spp.
Carbapenemase types reported
The carbapenemases were: OXA-48 (44; 41%), KPC (37; 
35%), NDM (18; 17%), VIM (5) and IMP (1), with two not 
specified. 
Susceptibility of isolates 
Susceptibility testing data was provided on 104 of 107 
isolates (97%):
	 	Carbapenems 
  ○   Meropenem: reported on 94 isolates, with 
73 resistant (77%); minimum inhibitory 
concentrations (MIC) ranged from 0.064 to >256 
mg/L 
  ○   Ertapenem: reported on all 96 isolates, with 87 
resistant (91%); MIC ranged from 0.094 to >256 
mg/L 
	 		Aminoglycosides: reported on 104 isolates, 
with 62 (60%) resistant to one or more of the 
aminoglycosides listed below 
  ○   Gentamicin: 103 isolates; 55 resistant (53%)
  ○   Tobramycin: 60 isolates; 33 resistant (55%)
  ○   Amikacin: 93 isolates; 11 resistant (12%)
	 	Fluoroquinolones: 93 isolates; 66 resistant (71%) 
	 	Tigecycline: 70 isolates; 24 resistant (34%) 
	 	Colistin: 58 isolates; one resistant 
Conclusion
In 2016, 107 cases reflected a 9% increase on 98 cases in 
2015. However, reference laboratory data indicated there 
were at least three-times (314%) more confirmed cases. 
In response to the emergence of CRE and suboptimal 
participation in voluntary enhanced surveillance, it was 
decided to replace voluntary with mandatory reporting by 
microbiology laboratories from January 2017. 
Acknowledgements: 
Sincere thanks to colleagues working in microbiology 
laboratories and infection prevention and control teams 
across Ireland for submitting enhanced surveillance data on 
patients with CRE.
Sincere thanks also to colleagues in the CPEaRLS, Galway 
University Hospital for data on confirmed carbapenemase-
producing Enterobacteriaceae in 2016 (Source: CPEaRLS 
annual report 2016). 
Figure 1. Annual trends in CRE cases and carbapenemase types reported to voluntary 
enhanced surveillance (2011 – 2016) 
Please note that the reduction in reported cases between 2012 and 2013 reflects under-reporting rather 
than a true decline in CRE. Almost twice as many isolates were confirmed by the CPEaRLS, Galway 
University Hospital in 2013 (n=50), approximately one-third as many isolates in 2014 (n=87) and 2015 
(n=143) and over three-times as many isolates in 2016 (n=362) than were reported to the voluntary CRE 
enhanced surveillance scheme
-164-HPSC Annual Epidemiological Report 2016 Healthcare Associated Infections
-165-HPSC Annual Epidemiological Report 2016 Healthcare Associated Infections
c)  Enhanced Surveillance of Multi-Drug 
Resistant K. pneumoniae (MDRKP)
2016 Summary
•   Comparing 2016 with 2015, there was a 19% increase 
in the total numbers of MDRKP reported
•   The MDRKP/CRE phenotype increased by 
approximately two-fold (195%): with 119 cases 
reported, compared with 61 cases in 2015
Background
A national increase in multi-drug-resistant Klebsiella 
pneumoniae (MDRKP) was first identified by the 
Antimicrobial Resistance and Microbial Ecology (ARME) 
Group at NUI Galway in the autumn of 2013. Following this, 
an increase in BSI caused by MDRKP was also confirmed 
through the Irish EARS-Net data reported to the HPSC. 
An outbreak control team (OCT) was established at HPSC 
in October 2013 to review existing surveillance data and 
request additional data from hospital laboratories. Following 
this, prospective mandatory national surveillance for MDRKP 
commenced in January 2014. 
Case definition
The first isolate per patient per quarter of K. pneumoniae 
derived from any specimen type (both clinical and screening) 
that are (1) ESBL-producers and non-susceptible to both 
ciprofloxacin and gentamicin OR non-susceptible to 
3rd generation cephalosporins (3GC) and ciprofloxacin 
and gentamicin, where investigation for ESBLs is not 
routinely carried out [MDRKP/Non-CRE] AND/OR (2) 
carbapenemase-producers [MDRKP/CRE].
Results (2014 – 2016)
For the three years of surveillance, 1,449 MDRKP cases were 
reported by 53 (88%) of 60 acute hospitals in Ireland (Table 
1). Seven acute hospitals; specialty (n=5), general (n=1) and 
private (n=1) did not report any cases. 
MDRKP/Non-CRE accounted for 1,215 (84%) and MDRKP/
CRE for 234 (16%). Of the MDRKP/CRE cases, 23% also 
fulfilled the MDRKP/Non-CRE criteria, but were categorised 
as MDRKP/CRE for the purposes of this report
Clinical specimens accounted for the majority of MDRKP 
isolates (n=1,171; 81%). However, an upward trend is evident 
in the proportion detected from screening specimens (rectal 
swabs/faeces); 25% in 2016 versus 16% in both 2014 and 
2015 
While two-thirds of cases were associated with patients 
admitted to or attending an acute hospital, one-third of 
cases were detected in patients attending general practice or 
residents of long-term care facilities (LTCF)
Of 804 MDRKP cases from hospital inpatients: 
•   Information on antimicrobial therapy for MDRKP infection 
was provided for 484 (58%), of whom 282 (58%) had 
required antimicrobial therapy for MDRKP infection prior 
to case notification
•   Information on patient isolation was provided for 553 
(66%), of whom 465 (84%) were isolated within 24 hours 
of the laboratory reporting MDRKP detection. Therefore, 
16% were not isolated and the isolation status of 34% was 
either not provided or unavailable
Trends (2016 versus 2015) 
In 2016, there were 534 cases of MDRKP (415 MDRKP/Non-
CRE and 119 MDRKP/CRE) from 480 patients, with some 
previously known patients with MDRKP reported again in a 
different quarter. This reflects an increase of 19% from 449 
cases (388 MDRKP/Non-CRE and 61 MDRKP/CRE) from 
385 patients in 2015. Excluding repeat notifications from the 
same patient, defined as one isolate per patient over the 
12-month period, there was an increase of 25% from 385 
cases in 2015 to 480 cases in 2016 (Table 1).
In 2016, the number of MDRKP/CRE cases increased by 
almost two-fold (or 195%), with 119 cases (representing 
22% of all MDRKP cases) reported (Table 1) compared with 
61 cases in 2015 (14% of all MDRKP cases).
By the end of 2016, it was evident that MDRKP was widely 
distributed across the Irish healthcare system, with rapid 
and concerning increases in the proportion that were 
also carbapenem resistant. In light of these findings, it 
was decided to step down mandatory national enhanced 
MDRKP surveillance at the end of Q4 2016 and to replace 
it with mandatory national enhanced surveillance 
for carbapenemase-producing carbapenem resistant 
Enterobacteriaceae (CRE/CPE) effective Q1 2017.
 
Table 1. Annual summary of MDRKP cases: 2014 to 2016
TIME PERIOD
2014 2015 2016 TOTAL
Jan-Dec Jan-Dec Jan-Dec Jan 2014-Dec 2016 COMMENT ON TOTAL DATA
n % n % n % n %
MDRKP (based on case definition of 
1st isolate per patient per quarter, see 
Table 1 above)
466 449 534 1449 of which 976 cases (67%) associated with 53 (of 60) acute hospitals (including outpatients)
Patients with MDRKP (based on one 
isolate per patient per year) 411 385 480 1276
of which 876 cases (69%) associated with 53 (of 
60) acute hospitals (including outpatients)
of which:                            MDRKP/Non-
CRE 363 88% 332 86% 379 79% 1074 84%
MDRKP/CRE 48 12% 53 14% 101 21% 202 16% 71 KPC, 88 OXA-48, 42 NDM, 1 NDM/OXA-48
Further information on MDRKP in Ireland is available on the 
HPSC website at: 
http://www.hpsc.ie/a-z/
microbiologyantimicrobialresistance/
europeanantimicrobialresistancesurveillancesystemearss/
referenceandeducationalresourcematerial/
klebsiellapneumoniae/
dataonmultidrugresistantkpneumoniae/MDRKP%20
Update_Jan2014-Dec2016%20data_Final.pdf 
Acknowledgements: 
Sincere thanks to colleagues working in microbiology 
laboratories and infection prevention and control teams 
across Ireland for submitting enhanced surveillance data on 
patients with MDRKP.
Figure 1. Quarterly MDRKP cases (CRE and Non-CRE): Q1 2014 – Q4 2016
*No data from one tertiary hospital for Q1-2 2014; ** No data from one general hospital for Q3-4 2015 and Q4 
2016
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In May 2016, 10,044 residents in 224 Irish long-term 
care facilities (LTCF) were included in a European point 
prevalence survey (PPS) of healthcare-associated infections 
(HCAI) and antimicrobial use. The survey is also known as 
the HALT survey.
Table 1 summarises the characteristics of participating LTCF 
by ownership and by care type. LTCF were stratified into 
eight main care type categories, with some also based on the 
estimated duration of residence for the majority of residents 
(short stay <12 months, long stay >12 months) 
•   Of the 224 LTCF, the majority were owned by the HSE 
[n=136; 61%], followed by private [n=54; 24%] and 
voluntary services [n=34; 15%]
•   The median capacity of participating LTCF was 42 beds 
(range = 5 – 176) and the median bed occupancy on the 
HALT survey date was 93%
•   Overall, single room accommodation accounted for a 
median of 71% of available beds. The proportion of single 
room accommodation in HSE-owned (52%) was lower 
than that of private (83%) and voluntary (87%) LTCF
Nurse and healthcare assistant staffing, medical care 
and coordination, infection prevention & control & 
antimicrobial stewardship
•   Overall, resident medical care was provided by the 
resident’s own general practitioner (GP) in 49.5%, by a 
directly-employed doctor in 28.5% and by a mix of GP plus 
directly-employed doctor care in 22% of LTCF. However, 
when LTCF were stratified by ownership, GP-led medical 
care was 96% in private LTCF versus 33% in HSE LTCF
•   A designated coordinating physician, with responsibility 
for coordination and standardisation of policies/practices 
for resident medical care within the LTCF was available for 
65% of LTCF overall and for 56% of private LTCF
•   An active local infection prevention and control committee 
(IPCC) was reported by 61% of LTCF
•   Access to a staff member with infection prevention and 
control (IPC) training was reported by 76% of LTCF overall 
and by 57% of private LTCF. For the vast majority of LTCF 
with a trained IPC staff member, that person was an 
infection prevention and control nurse (IPCN) (93.5%). 
However, for the majority of LTCF (58%), the IPCN was not 
based in the LTCF on a day-to-day basis
9.5.  Point Prevalence Survey of Healthcare-
Associated Infections & Antimicrobial Use in 
Long-Term Care Facilities (HALT): May 2016
 Table 1. Breakdown of participating LTCF, by ownership and care type.
Category No. of LTCF Size of facility
Total residents Sur-
veyed
Median proportion of 
single rooms
Median percentage of 
beds occupied
n median min max n % %
by Ownership
HSE 136 33 5 167 5213 52 91
Private 54 59 19 140 3031 83 95
Voluntary 34 51 10 176 1800 87 94
by Care Type
General nursing >12 
months 88 55 18 167 4722 73 98
Mixed >12 months 46 50 20 142 2499 61 91
LTCF <12 months 14 35 16 72 441 52 87
Intellectually disabled 31 28 5 176 1251 92 96
Psychiatric 23 22 10 86 505 57 86
Palliative care 7 19 8 48 134 80 79
Physically disabled 1 14 14 14 13 100 93
Rehabilitation 5 64 14 72 245 44 90
Other 9 27 13 60 234 53 85
National 224 42 5 176 10044 71 93
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•   A written local hand hygiene policy was available in 95% 
of LTCF, with provision of a staff hand hygiene training 
session in the past 12 months reported by 83% of LTCF. 
The available products for hand hygiene were alcohol-
based hand rub (ABHR) and liquid soap in 96% and 95% 
of LTCF, respectively
•   Compliance with hand hygiene opportunities was not 
collected in HALT 2016
•   The provision of seasonal influenza vaccination for 
residents was not universal, with 9% of LTCF overall 
reporting this was not routine local practice
•   The vast majority (98%) reported having no active local 
antimicrobial stewardship committee (ASC). Training 
on antimicrobial prescribing was not provided by 94% 
and 56% of LTCF reported having no local antimicrobial 
prescribing guidelines
•   Prescriber feedback regarding local antimicrobial 
consumption was available in just 14% of LTCF
•   LTCF with a designated coordinating physician were 
significantly more likely to demonstrate positive local 
antimicrobial stewardship practices such as; an active 
ASC, training for prescribers and local prescribing 
guidelines
Resident demographics, nursing care requirements and 
HCAI risk factors
•   Female residents predominated in most care types, other 
than psychiatric and palliative LTCF. The proportion of 
residents aged ≥85 years was highest in GN>12m (49%), 
Mixed>12m (47%) and LTCF<12m (41%). In contrast, 1% of 
intellectually disabled LTCF residents were aged ≥85 years
•   Selected indicators of resident nursing care requirements 
(incontinence, disorientation and impaired mobility) were 
evident in all care types, but most prevalent in GN>12m, 
Mixed>12m and LTCF<12m 
•   HCAI risk factors (presence of urinary or vascular catheter, 
pressure ulcers or ‘other’ wounds) were most prevalent in 
palliative care LTCF
•   Almost two percent (n=170) of residents with an infection 
or taking antimicrobials, had a history of hospitalisation 
within three months of the survey 
LTCF-acquired infections (LAI)
•   For infections acquired in long-term care, the national 
crude prevalence was 4.4% and the median prevalence 
was 3.4%. The median prevalence was higher in 
LTCF<12m (6.6%), rehabilitation (4.9%) and mixed>12m 
(4.5%). The highest prevalence was reported in palliative 
care LTCF (8.3%), which may reflect underlying illness and 
the prevalence of HCAI risk factors encountered in that 
unique resident cohort
•   The most prevalent LAI types were: respiratory tract 
infections (RTI), urinary tract infections (UTI) and skin 
infections; affecting 1.5%, 1.5% and 1.1% of all residents, 
respectively
•   A relevant microbiological specimen had been obtained 
for 37% of infections, with microorganisms isolated in 
14%. Escherichia coli (35%) and Staphylococcus aureus 
(29%) were the most frequently reported microorganisms. 
Of those with available antimicrobial susceptibility 
results, 4% of E. coli were resistant to 3rd generation 
cephalosporins and 16% of S. aureus were meticillin/
flucloxacillin resistant (i.e., MRSA). There were no LAI 
associated with carbapenem resistant Enterobacteriaceae 
(CRE) reported during the HALT survey  
Hospital-acquired infections (HAI)
•   Data was collected on hospital-acquired infections (HAI), 
whereby the resident was transferred to the LTCF with 
an active HAI or developed a HAI on day one or day two 
following transfer to the LTCF. No HAI were reported by 
88% of LTCF. The crude national prevalence of HAI in Irish 
LTCF was 0.4%. Therefore, the vast majority of HCAI in 
LTCF in Ireland are acquired within the LTCF
Antimicrobial use and antimicrobial resistance
•   The national crude antimicrobial use prevalence was 
9.8%, with a median antimicrobial use prevalence of 8.3%. 
The median prevalence was higher in LTCF<12m (12.1%) 
and rehabilitation LTCF (10.9%). At 30.8%, the prevalence 
in palliative care LTCF was more similar to that reported in 
acute hospitals
•   The majority of antimicrobials were prescribed within the 
LTCF (83%)
•   Overall, 59% of antimicrobials were prescribed to treat 
infection. However, antimicrobial prophylaxis accounted 
for the majority of prescriptions in intellectually disabled 
LTCF (54%)
•   During HALT 2016, 3.4% of Mixed>12m and 3.1% of 
GN>12m residents were prescribed antimicrobials for UTI 
prophylaxis. Prophylaxis against RTI was most prevalent 
in intellectually disabled (2.0%) and palliative care (1.5%) 
LTCF
The 2016 HALT national report is available 
on the HPSC website: http://www.hpsc.
ie/a-z/microbiologyantimicrobialresistance/
infectioncontrolandhai/surveillance/
hcaiinlongtermcarefacilities/haltreports/2016report/ 
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●   CIDR OPERATIONS
INFORMATION SECURITY ACCREDITATION
The HPSC Information Security Management System (ISMS) 
which includes CIDR was fully re-accredited in April 2016 to 
ISO 27001:2013 standard. 
The HPSC Information Governance Framework, which 
includes CIDR, provides re-assurance to users and partners 
of the CIDR system, the Data Protection Commissioner 
and the data subjects relating to sensitive data stored and 
managed by the system.  Maintenance of this accreditation 
standard is vital to information security.
CIDR USER TRAINING
Forty-seven new CIDR users were trained during 2016.  
There were 35 public health users and 12 laboratory users 
trained. Six existing public health users received advanced 
application training during 2016.
CIDR APPLICATION SOFTWARE UPDATES AND SYSTEM 
AVAILABILITY
Three functional releases of the CIDR Web Application 
software were deployed during 2016 - in February, June and 
July. These were made to improve performance, browser 
compatibility, session management and security.
CIDR availability was 99.8% during core working hours in 
10. Computerised Infectious Disease 
 Reporting (CIDR)
Figure 1. The volume of  statutory infectious disease notifications and corresponding number of diseases in CIDR 
per year, since 2006 when national implementation commenced (as of 21st August, 2017)
Summary
●   The highest ever annual number of notifications 
was recorded on CIDR in 2016 (n=33,170). Zika virus 
infection became notifiable in May 2016 and was 
added to the diseases notified via CIDR, bringing the 
total to 77 diseases of all 84 notifiable diseases
●   The average number of active CIDR users in 2016 was 
269
●   A full IS27001 Information Security re-accreditation 
audit was performed and certification was retained
●   47 new users were trained and 6 existing users 
received advanced training during 2016
●   3 CIDR Web application releases were deployed 
during 2016
●   CIDR was available for 99.8% of core working hours 
during 2016 
●   A failover / failback test of the CIDR Disaster Recovery 
/ Business Continuity infrastructure completed 
successfully
●   Phase 1 of a project to develop a STI / HIV Clinic 
Module on CIDR was completed
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2016.  71% of down-time was scheduled; either between 
13:00 and 14:00 or outside core working hours; with users 
aware in advance of service interruptions.  Un-scheduled 
down-time amounted to 4 hours of service unavailability 
during core working hours over the year.
CIDR DISASTER RECOVERY / BUSINESS CONTINUITY
A successful failover / failback test to the off-premises 
CIDR disaster recovery infrastructure was completed in 
February 2016. The test confirmed that the system may 
be failed over, continue to operate, and failed back to the 
main infrastructure in the event of unexpected or prolonged 
unavailability.
CIDR STI / HIV CLINIC MODULE DEVELOPMENT PROJECT
In conjunction with the Sexual Health and Crisis Pregnancy 
Programme (SHCPP), a project team was assembled in July 
2016 to address phase one of a multi-phase project intended 
to contribute to successful implementation of the Sexual 
Health Strategy by delivering a major improvement in the 
quality of the information available for monitoring sexual ill-
health. The objectives of Phase 1 of the project were:
•  To complete a feasibility assessment of the capacity for 
electronic surveillance based on an analysis of existing STI/
HIV clinics and systems in Ireland, documenting existing 
processes and the capabilities of the systems to provide 
data for surveillance
•  To define the dataset(s) feasible for extraction for 
surveillance 
•  To complete Requirements and Functional Specifications 
for the development of a STI/HIV clinic module on CIDR
This project was completed in 2016 and pending funding 
approval, will move to phase 2, to include system 
development in 2017.
GOVERNANCE AND COMMUNICATIONS
The National CIDR Steering Group continued to provide 
guidance and oversight of CIDR through 2016 and met 
by teleconference on four occasions during the year. The 
National CIDR User Group convened on four occasions 
throughout the year, also by teleconference, to discuss the 
on-going use of CIDR and associated developments.
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Figure 2. The number of users of the CIDR system in Departments of 
Public Health, in diagnostic and reference laboratories and in HPSC 
in 2016 (total=269)
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Notes:
Figures for the year 2016 presented in this appendix were extracted from the Computerised Infectious Disease 
Reporting (CIDR) system on the 22nd November, 2017. Please note that some figures may differ from figures 
published previously or other chapters in this report, due to ongoing updating of notification data on CIDR.
Figures for the EARS-Net pathogens (Escherichia coli, Enterococci, Klebsiella pneumoniae, Pseudomonas 
aeruginosa and Staphylococcus aureus) and certain sexually transmitted infections (specifically, ano-genital 
warts and non-specific urethritis) are not provided here, as these diseases were not notified via the CIDR 
system during the above period.
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Table A1.1. List of notifiable infectious diseases and their respective causative pathogens (relevant to 2016) under Infectious Diseases (Amendment) 
Regulations 2016 (S.I. No.276 of 2016) (May 2016)
Infectious Disease Causative Pathogen(s)
Acute anterior poliomyelitis Polio virus
Ano-genital warts Human papilloma virus
Anthrax Bacillus anthracis
Bacillus cereus food-borne infection/intoxication Bacillus cereus
Bacterial meningitis (not otherwise specified)  
Botulism Clostridium botulinum
Brucellosis Brucella spp.
Campylobacter infection Campylobacter spp.
Carbapenem-resistant Enterobacteriaceae infection (invasive) Carbapenem-resistant Enterobacteriaceae (blood, CSF or other normally sterile site)
Chancroid Haemophilus ducreyi
Chickenpox – hospitalised cases Varicella-zoster virus
Chikungunya disease Chikungunya virus
Chlamydia trachomatis infection (genital) Chlamydia trachomatis
Cholera Vibrio cholerae
Clostridium difficile infection Clostridium difficile
Clostridium perfringens (type A) food-borne disease Clostridium perfringens
Creutzfeldt Jakob disease  
variant Creutzfeldt Jakob disease  
Cryptosporidiosis Cryptosporidium parvum, hominis
Cytomegalovirus infection (congenital) Cytomegalovirus
Dengue fever Dengue virus
Diphtheria Corynebacterium diphtheriae or ulcerans (toxin producing)
Echinococcosis Echinococcus spp.
Enterococcal bacteraemia Enterococcus spp. (blood)
Escherichia coli infection (invasive) Escherichia coli (blood, CSF)
Giardiasis Giardia lamblia
Gonorrhoea Neisseria gonorrhoeae
Granuloma inguinale Klebsiella granulomatis
Haemophilus influenzae disease (invasive) Haemophilus influenzae (blood, CSF or other normally sterile site)
Hepatitis A (acute) infection Hepatitis A virus
Hepatitis B (acute and chronic) infection Hepatitis B virus
Hepatitis C infection Hepatitis C virus
Hepatitis E infection Hepatitis E virus
Herpes simplex (genital) Herpes simplex virus
Human immunodeficiency virus infection Human immunodeficiency virus
Influenza Influenza A and B virus
Klebsiella pneumoniae infection (invasive) Klebsiella pneumoniae (blood or CSF)
Legionellosis Legionella spp.
Leprosy Mycobacterium leprae
Leptospirosis Leptospira spp.
Listeriosis Listeria monocytogenes
Lyme disease (neuroborreliosis) Borrelia burgdorferi
Lymphogranuloma venereum Chlamydia trachomatis
Malaria Plasmodium falciparum, vivax, knowlesi, ovale, malariae
Measles Measles virus
Meningococcal disease Neisseria meningitidis
Mumps Mumps virus
Non-specific urethritis  
Noroviral infection Norovirus
Paratyphoid Salmonella Paratyphi
Pertussis Bordetella pertussis
Plague Yersinia pestis
Pseudomonas aeruginosa infection (invasive) Pseudomonas aeruginosa (blood or CSF)
Q Fever Coxiella burnetii
Rabies Rabies virus
Respiratory syncytial virus infection Respiratory syncytial virus
Rotavirus infection Rotavirus
Rubella Rubella virus
Salmonellosis Salmonella spp. other than S. Typhi and S. Paratyphi
Severe Acute Respiratory Syndrome (SARS) SARS-associated coronavirus
Shigellosis Shigella spp.
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Infectious Disease Causative Pathogen(s)
Smallpox Variola virus
Staphylococcal food poisoning Enterotoxigenic Staphylococcus aureus
Staphylococcus aureus bacteraemia Staphylococcus aureus (blood)
Streptococcus group A infection (invasive) Streptococcus pyogenes (blood, CSF or other normally sterile site)
Streptococcus group B infection (invasive) Streptococcus agalactiae (blood, CSF or other normally sterile site)
Streptococcus pneumoniae infection (invasive) Streptococcus pneumoniae (blood, CSF or other normally sterile site)
Syphilis Treponema pallidum
Tetanus Clostridium tetani
Toxoplasmosis Toxoplasma gondii
Trichinosis Trichinella spp.
Trichomoniasis Trichomonas vaginalis
Tuberculosis Mycobacterium tuberculosis complex
Tularemia Francisella tularensis
Typhoid Salmonella Typhi
Typhus Rickettsia prowazekii
Verotoxigenic Escherichia coli infection Verotoxin producing Escherichia coli
Viral encephalitis  
Viral haemorrhagic fevers  
Viral meningitis  
West Nile fever West Nile virus
Yellow fever Yellow fever virus
Yersiniosis Yersinia enterocolitica,Yersinia pseudotuberculosis
Zika virus infection Zika virus
Table A1.1. List of notifiable infectious diseases and their respective causative pathogens (relevant to 2016) under Infectious Diseases 
(Amendment) Regulations 2016 (S.I. No.276 of 2016) (May 2016) Continued.
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Table A1.2 Number of notifiable infectious diseases, 2014-2016 and crude incidence rates of diseases, 2016
Infectious Disease 2014 2015 2016 CIR 2016
Acute anterior poliomyelitis 0 0 0 0.00
Anthrax 0 0 0 0.00
Bacillus cereus food-borne infection or intoxication 0 1 0 0.00
Bacterial meningitis (not otherwise specified) 23 32 15 0.32
Botulism 1 0 0 0.00
Brucellosis 3 0 2 0.04
Campylobacter infection 2611 2448 2513 52.77
Carbapenem-resistant Enterobacteriaceae infection (invasive) 5 8 14 0.29
Chancroid 0 0 0 0.00
Chickenpox - hospitalised cases 61 69 106 2.22
Chikungunya disease 1 1 1 0.02
Chlamydia trachomatis infection (genital)^ 6687 6786 6893 144.75
Cholera 0 0 0 0.00
Clostridium difficile infection* 1801 1943 1871 40.36##
Clostridium perfringens (type A) food-borne disease 0 1 0 0.00
Creutzfeldt Jakob disease 2 5 5 0.11
Creutzfeldt Jakob disease (variant) 0 0 0 0.00
Cryptosporidiosis 394 439 561 11.78
Cytomegalovirus infection (congenital) 12 15 20 0.42
Dengue fever 21 8 18 0.38
Diphtheria 0 1 1 0.02
Echinococcosis 0 0 2 0.04
Giardiasis 71 145 202 4.24
Gonorrhoea 1309 1294 1956 41.08
Granuloma inguinale 0 0 0 0.00
Haemophilus influenzae disease (invasive) 61 52 58 1.22
Hepatitis A (acute) 21 36 38 0.80
Hepatitis B (acute and chronic) 442 548 488 10.25
Hepatitis C 692 674 645 13.55
Hepatitis E# NA 3 90 1.89
Herpes simplex (genital) 1234 1274 1369 28.75
Human immunodeficiency virus infection 377 483 508 10.67
Influenza 1757 2680 4764 100.04
Legionellosis†† 8 12 10 0.21
Leprosy 0 0 1 0.02
Leptospirosis 23 16 26 0.55
Listeriosis 15 19 13 0.27
Lyme disease 18 11 21 0.44
Lymphogranuloma venereum 35 20 48 1.01
Malaria 80 81 88 1.85
Measles 33 2 43 0.90
Meningococcal disease 82 74 87 1.83
Mumps 742 2014 491 10.31
Noroviral infection^ 807 1262 1832 38.47
Paratyphoid 5 1 7 0.15
Pertussis 73 117 213 4.47
Plague 0 0 0 0.00
Q fever 0 4 6 0.13
Rabies 0 0 0 0.00
Respiratory syncytial virus infection^ 2479 2201 2690 56.49
Rotavirus infection^ 2061 4157 2371 49.79
Rubella 3 2 1 0.02
Salmonellosis 260 269 302 6.34
Severe Acute Respiratory Syndrome (SARS) 0 0 0 0.00
Shigellosis 57 90 84 1.76
Smallpox 0 0 0 0.00
Staphylococcal food poisoning 0 0 0 0.00
Streptococcus group A infection (invasive) 164 107 148 3.11
Streptococcus group B infection (invasive) || 68 69 65 -
Streptococcus pneumoniae infection (invasive)** 679 549 381 8.00
Syphilis*^ 273 421 446 9.37
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Infectious Disease 2014 2015 2016 CIR 2016
Tetanus 1 1 0 0.00
Toxoplasmosis 20 25 24 0.50
Trichinosis 0 0 0 0.00
Trichomoniasis 92 56 79 1.66
Tuberculosis 313 283 318 6.68
Tularemia 0 0 0 0.00
Typhoid 7 9 10 0.21
Typhus 0 0 0 0.00
Verotoxigenic Escherichia coli infection 706 730 839 17.62
Viral encephalitis 67 47 61 1.28
Viral haemorrhagic fevers 0 0 0 0.00
Viral meningitis 435 261 299 6.28
West Nile fever 0 0 0 0.00
Yellow fever 0 0 0 0.00
Yersiniosis 5 13 3 0.06
Zika virus infection† NA NA 13 0.27
Total 27197 31869 33160  
Notes
1. NA: Indicates that data not available in CIDR for the diseases and years indicated above
2. CIR, Crude incidence rate per 100,000 total population
*Since 01/01/2012, both new and recurrent cases of Clostridium difficile infection are notifiable.##The CIR was calculated for the population aged 2 years and 
above
#Hepatitis E became notifiable on the 15/12/2015.
**Streptococcus pneumoniae infection (invasive) figures relate to confirmed cases only since 01/07/2015.
*^From 1st July, 2016, laboratory criteria for the notification of syphilis cases have been updated further to reduce the volume of latent or treated cases being 
notified. Direct comparison of 2016 syphilis notification data with notification data for previous years (which includes non-infectious cases) is not valid
^Since 17/03/2013, figures for Chlamydia trachomatis, noroviral infection, respiratory syncytial virus infection and rotavirus infection may refer to notifications 
from HSE E rather than events. Such notifications from HSE E may also refer to area of laboratory testing rather than patient’s area of residence
††Legionellosis figures include both Legionnaires’ disease and Pontiac fever cases
||Streptococcus group B (Streptococcus agalactiae) infection (invasive) in infants <90 days old or stillborn infants
†Zika virus became notifiable in May 2016    
For more information on notifiable infectious diseases please see HPSC’s Case Definitions document available at http://www.hpsc.ie
Table A1.2 Number of notifiable infectious diseases, 2014-2016 and crude incidence rates of diseases, 2016. Continued.
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Table A1.3 Number of notifiable infectious diseases by HSE area, 2016
Infectious Disease HSE E
HSE 
M
HSE 
MW
HSE 
NE
HSE 
NW
HSE 
SE
HSE 
S
HSE 
W Total
Bacterial meningitis (not otherwise specified) 4 0 1 0 1 4 3 2 15
Brucellosis * * * * * * * * 2
Campylobacter infection 787 204 229 169 92 341 394 297 2513
Carbapenem-resistant Enterobacteriaceae infection (invasive) 7 0 0 2 0 1 0 4 14
Chickenpox - hospitalised cases 54 7 2 14 3 8 13 5 106
Chikungunya disease * * * * * * * * 1
Chlamydia trachomatis infection (genital)^ 3497 184 551 308 244 636 901 572 6893
Clostridium difficile infection‡ 715 72 163 117 112 207 251 234 1871
Creutzfeldt Jakob disease 1 0 0 0 0 2 2 0 5
Cryptosporidiosis 69 58 58 38 41 117 94 86 561
Cytomegalovirus infection (congenital) 14 0 1 2 1 0 2 0 20
Dengue fever 11 1 1 1 0 1 2 1 18
Diphtheria * * * * * * * * 1
Echinococcosis * * * * * * * * 2
Giardiasis 63 7 5 4 2 53 35 33 202
Gonorrhoea 1389 40 99 54 37 95 133 109 1956
Haemophilus influenzae disease (invasive) 19 6 5 5 5 5 7 6 58
Hepatitis A (acute) 10 3 3 4 0 5 8 5 38
Hepatitis B (acute and chronic) 295 20 26 45 5 33 35 29 488
Hepatitis C 450 30 21 37 11 25 41 30 645
Hepatitis E# 43 5 7 8 3 5 11 8 90
Herpes simplex (genital) 792 32 84 36 39 113 153 120 1369
Human immunodeficiency virus infection 360 14 22 23 5 13 51 20 508
Influenza 1518 244 568 345 148 942 556 443 4764
Legionellosis‡ 3 2 0 3 1 0 0 1 10
Leprosy * * * * * * * * 1
Leptospirosis 10 0 7 3 0 2 2 2 26
Listeriosis 4 0 2 1 2 1 2 1 13
Lyme disease 3 2 5 0 1 0 8 2 21
Lymphogranuloma venereum 42 - 2 2 - 1 - 1 48
Malaria 46 5 1 13 2 5 10 6 88
Measles 4 0 4 1 0 5 27 2 43
Meningococcal disease 24 6 5 8 12 8 18 6 87
Mumps 140 45 31 21 19 66 111 58 491
Noroviral infection^ 1020 75 117 210 79 58 187 86 1832
Paratyphoid 1 1 2 0 1 0 1 1 7
Pertussis 110 6 3 12 5 29 35 13 213
Q fever 0 0 1 2 0 1 0 2 6
Respiratory syncytial virus infection^ 1427 94 216 160 187 198 253 155 2690
Rotavirus infection^ 831 207 172 196 99 290 332 244 2371
Rubella * * * * * * * * 1
Salmonellosis 118 26 24 21 17 27 39 30 302
Shigellosis 42 4 4 6 2 8 9 9 84
Streptococcus group A infection (invasive) 68 10 12 15 3 15 12 13 148
Streptococcus group B infection (invasive) 25 1 7 9 4 5 11 3 65
Streptococcus group B infection (invasive)|| 153 21 31 29 17 51 52 27 381
Syphilis 315 15 19 16 4 15 48 14 446
Toxoplasmosis 8 1 1 0 1 1 6 6 24
Trichomoniasis 47 - 15 2 5 3 5 2 79
Tuberculosis 136 16 26 22 5 31 52 30 318
Typhoid 4 0 1 0 0 0 2 3 10
Verotoxigenic Escherichia coli infection 131 92 124 52 31 131 159 119 839
Viral encephalitis 32 4 3 4 4 4 7 3 61
Viral meningitis 149 17 20 24 13 27 27 22 299
Yersiniosis * * * * * * * * 3
Zika virus infection† 9 0 0 2 1 0 0 1 13
Notes:          
1. This table does not include details of diseases for which a zero number of cases were notified; see Table A1.1 for details of these diseases in 2016  
*Data not reported to HSE area level when total number in Ireland <5 cases      
#Hepatitis E became notifiable on the 15/12/2015.        
^Since 17/03/2013, figures for Chlamydia trachomatis, noroviral infection, respiratory syncytial virus infection and rotavirus infection may refer to 
notifications from HSE E rather than events. Such notifications from HSE E may also refer to area of laboratory testing rather than patient’s area of 
residence         
‡C. difficile figures in the C. difficile chapter are presented by quarter rather than using the 2016 epidemiological calendar year as shown here
‡Legionellosis figures include both Legionnaires’ disease and Pontiac fever cases     
||Streptococcus group B (Streptococcus agalactiae) infection (invasive) in infants <90 days old or stillborn infants   
†Zika virus became notifiable in May 2016
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Table A1.4 Number of notifiable infectious diseases by age group (years), 2016
Infectious Disease 0-4 5-9 10-14 15-19 20-24 25-34 35-44 45-54 55-64 65+ Unknown Total
Bacterial meningitis (not otherwise specified) 4 1 1 1 1 3 0 1 1 2 0 15
Brucellosis 0 0 0 0 0 0 0 1 0 1 0 2
Campylobacter infection 552 158 69 83 159 302 248 260 255 423 4 2513
Carbapenem-resistant Enterobacteriaceae 
infection (invasive) 0 1 0 0 0 0 2 0 1 10 0 14
Chickenpox - hospitalised cases 55 14 7 3 4 7 6 2 2 6 0 106
Chikungunya disease * * * 0 0 0 1 0 0 0 0 1
Chlamydia trachomatis infection (genital)^ *  * * 608 2754 2679 616 163 40 15 3 6893
Clostridium difficile infection† 31 24 10 27 28 106 108 104 196 1237 0 1871
Creutzfeldt Jakob disease 0 0 0 0 0 0 0 0 2 3 0 5
Cryptosporidiosis 247 132 58 24 24 43 17 7 2 7 0 561
Cytomegalovirus infection (congenital) 19 0 0 0 0 0 1 0 0 0 0 20
Dengue fever 0 0 1 2 2 6 2 5 0 0 0 18
Diphtheria 0 0 0 0 0 0 0 1 0 0 0 1
Echinococcosis 0 1 0 1 0 0 0 0 0 0 0 2
Giardiasis 27 11 5 5 16 41 32 24 14 27 0 202
Gonorrhoea * * * 208 524 750 331 95 32 10 1 1956
Haemophilus influenzae disease (invasive) 11 1 1 1 3 6 6 4 4 21 0 58
Hepatitis A (acute) 8 6 6 0 0 6 9 1 2 0 0 38
Hepatitis B (acute and chronic) 2 0 0 14 32 205 126 65 22 22 0 488
Hepatitis C 2 1 0 2 22 172 232 115 76 23 0 645
Hepatitis E# 0 0 0 3 9 7 20 19 18 14 0 90
Herpes simplex (genital) * * * 173 410 477 189 84 25 10 1 1369
Human immunodeficiency virus infection 1 0 0 4 36 200 169 78 14 6 0 508
Influenza 851 461 169 175 189 640 577 418 379 901 4 4764
Legionellosis‡ 0 0 0 0 0 2 1 1 2 4 0 10
Leprosy 0 0 0 0 0 1 0 0 0 0 0 1
Leptospirosis 0 1 0 2 2 4 6 6 3 2 0 26
Listeriosis 2 0 0 0 0 1 0 1 4 5 0 13
Lyme disease 0 4 0 0 1 2 5 3 3 3 0 21
Lymphogranuloma venereum * * * 0 3 21 16 8 0 0 0 48
Malaria 3 7 4 5 4 21 23 12 6 3 0 88
Measles 14 8 4 6 2 7 2 0 0 0 0 43
Meningococcal disease 34 4 8 14 6 2 2 5 4 8 0 87
Mumps 34 23 31 103 89 81 51 41 21 16 1 491
Noroviral infection^ 516 42 17 23 27 67 65 78 110 885 2 1832
Paratyphoid 0 0 1 0 0 2 2 0 0 2 0 7
Pertussis 112 18 12 6 9 13 16 14 6 7 0 213
Q fever 0 0 0 0 0 0 2 1 3 0 0 6
Respiratory syncytial virus infection^ 2349 35 22 12 6 19 30 52 38 126 1 2690
Rotavirus infection^ 2177 79 9 4 4 10 11 7 16 52 2 2371
Rubella 1 0 0 0 0 0 0 0 0 0 0 1
Salmonellosis 66 22 18 11 26 43 25 25 28 38 0 302
Shigellosis 7 5 6 0 8 24 11 14 4 5 0 84
Streptococcus group A infection (invasive) 20 18 2 1 2 14 19 11 9 52 0 148
Streptococcus group B infection (invasive)|| 64 0 0 0 0 0 0 0 0 0 1 65
Streptococcus pneumoniae infection (invasive) 42 10 4 4 2 9 40 24 59 187 0 381
Syphilis * * * 7 43 202 104 59 27 3 0 446
Toxoplasmosis 0 1 1 2 3 7 8 2 0 0 0 24
Trichomoniasis * * * 3 11 31 22 10 1 1 0 79
Tuberculosis 4 5 8 8 21 80 52 45 38 56 1 318
Typhoid 3 1 0 0 1 1 3 1 0 0 0 10
Verotoxigenic Escherichia coli infection 314 62 34 35 37 76 52 40 50 139 0 839
Viral encephalitis 12 1 1 3 4 10 6 2 7 15 0 61
Viral meningitis 206 4 5 9 7 35 19 5 3 6 0 299
Yersiniosis 0 0 0 0 0 1 0 0 1 1 0 3
Zika virus infection† 1 0 0 0 1 4 6 1 0 0 0 13
Notes:
1. This table does not include details of diseases for which a zero number of cases were notified; see Table A1.1 for details of these diseases in 2016  
*Data for the age groups 0-4 years, 5-9 years and 10-14 years are not presented here, but data for the age group 0-14 years are available in the STI annual 
slide-set at http://www.hpsc.ie 
#Hepatitis E became notifiable on the 15/12/2015.           
^Since 17/03/2013, figures for Chlamydia trachomatis, noroviral infection, respiratory syncytial virus infection and rotavirus infection may refer to notifications 
from HSE E rather than events. Such notifications from HSE E may also refer to area of laboratory testing rather than patient’s area of residence  
†C. difficile figures in the C. difficile chapter are presented by quarter rather than using the 2016 epidemiological calendar year as shown here  
‡Legionellosis figures include both Legionnaires’ disease and Pontiac fever cases       
||Streptococcus group B (Streptococcus agalactiae) infection (invasive) in infants <90 days old or stillborn infants    
†Zika virus became notifiable in May 2016           
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Table A1.5 Number of notifiable infectious diseases by gender, 2016
Infectious Disease Male Female Unknown Total
Bacterial meningitis (not otherwise specified) 5 10 0 15
Brucellosis 1 1 0 2
Campylobacter infection 1338 1170 5 2513
Carbapenem-resistant Enterobacteriaceae infection (invasive) 10 4 0 14
Chickenpox - hospitalised cases 51 54 1 106
Chikungunya disease 1 0 0 1
Chlamydia trachomatis infection (genital)^ 3388 3484 21 6893
Clostridium difficile infection† 741 1130 0 1871
Creutzfeldt Jakob disease 1 4 0 5
Cryptosporidiosis 298 263 0 561
Cytomegalovirus infection (congenital) 10 8 2 20
Dengue fever 6 12 0 18
Diphtheria 1 0 0 1
Echinococcosis 1 1 0 2
Giardiasis 114 88 0 202
Gonorrhoea 1709 243 4 1956
Haemophilus influenzae disease (invasive) 18 39 1 58
Hepatitis A (acute) 16 22 0 38
Hepatitis B (acute and chronic) 283 196 9 488
Hepatitis C 460 182 3 645
Hepatitis E# 57 33 0 90
Herpes simplex (genital) 369 995 5 1369
Human immunodeficiency virus infection 393 115 0 508
Influenza 2184 2569 11 4764
Legionellosis‡ 6 4 0 10
Leprosy 0 1 0 1
Leptospirosis 21 5 0 26
Listeriosis 8 5 0 13
Lyme disease 13 8 0 21
Lymphogranuloma venereum 48 0 0 48
Malaria 60 27 1 88
Measles 24 19 0 43
Meningococcal disease 49 38 0 87
Mumps 237 248 6 491
Noroviral infection^ 867 963 2 1832
Paratyphoid 3 4 0 7
Pertussis 99 114 0 213
Q fever 5 1 0 6
Respiratory syncytial virus infection^ 1448 1238 4 2690
Rotavirus infection^ 1268 1100 3 2371
Rubella 1 0 0 1
Salmonellosis 142 160 0 302
Shigellosis 51 33 0 84
Streptococcus group A infection (invasive) 77 71 0 148
Streptococcus group B infection (invasive)|| 32 28 5 65
Streptococcus pneumoniae infection (invasive) 207 174 0 381
Syphilis 422 22 2 446
Toxoplasmosis 8 16 0 24
Trichomoniasis 0 79 0 79
Tuberculosis 194 124 0 318
Typhoid 6 4 0 10
Verotoxigenic Escherichia coli infection 394 444 1 839
Viral encephalitis 23 35 3 61
Viral meningitis 162 132 5 299
Yersiniosis 0 3 0 3
Zika virus infection† 6 7 0 13
Total 17336 15730 94 33160
Notes:     
1. This table does not include details of diseases for which a zero number of cases were notified; see Table A1.1 for details of these diseases in 2016  
#Hepatitis E became notifiable on the 15/12/2015.    
^Since 17/03/2013, figures for Chlamydia trachomatis, noroviral infection, respiratory syncytial virus infection and rotavirus infection may refer to 
notifications from HSE E rather than events. Such notifications from HSE E may also refer to area of laboratory testing rather than patient’s area of 
residence    
†C. difficile figures in the C. difficile chapter are presented by quarter rather than using the 2016 epidemiological calendar year as shown here
‡Legionellosis figures include both Legionnaires’ disease and Pontiac fever cases    
||Streptococcus group B (Streptococcus agalactiae) infection (invasive) in infants <90 days old or stillborn infants   
†Zika virus became notifiable in May 2016    
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Table A1.6 Number of notifiable infectious diseases by case classification, 2016
Infectious Disease Confirmed Probable Possible Total
Bacterial meningitis (not otherwise specified) 5 5 5 15
Brucellosis 2 0 0 2
Campylobacter infection 2513 0 0 2513
Carbapenem-resistant Enterobacteriaceae infection (invasive) 14 0 0 14
Chickenpox - hospitalised cases 72 5 29 106
Chikungunya disease 1 0 0 1
Chlamydia trachomatis infection (genital)^ 6893 0 0 6893
Clostridium difficile infection† 1871 0 0 1871
Creutzfeldt Jakob disease 5 0 0 5
Cryptosporidiosis 558 3 0 561
Cytomegalovirus infection (congenital) 20 0 0 20
Dengue fever 18 0 0 18
Diphtheria 1 0 0 1
Echinococcosis 2 0 0 2
Giardiasis 202 0 0 202
Gonorrhoea 1956 0 0 1956
Haemophilus influenzae disease (invasive) 58 0 0 58
Hepatitis A (acute) 37 1 0 38
Hepatitis B (acute and chronic) 488 0 0 488
Hepatitis C 645 0 0 645
Hepatitis E# 90 0 0 90
Herpes simplex (genital) 1347 22 0 1369
Human immunodeficiency virus infection 508 0 0 508
Influenza 4753 2 9 4764
Legionellosis‡ 10 0 0 10
Leprosy 1 0 0 1
Leptospirosis 26 0 0 26
Listeriosis 13 0 0 13
Lyme disease 21 0 0 21
Lymphogranuloma venereum 48 0 0 48
Malaria 88 0 0 88
Measles 43 0 0 43
Meningococcal disease 85 0 2 87
Mumps 253 41 197 491
Noroviral infection^ 1830 2 0 1832
Paratyphoid 7 0 0 7
Pertussis 169 14 30 213
Q fever 6 0 0 6
Respiratory syncytial virus infection^ 2690 0 0 2690
Rotavirus infection^ 2371 0 0 2371
Rubella 0 0 1 1
Salmonellosis 300 2 0 302
Shigellosis 84 0 0 84
Streptococcus group A infection (invasive) 147 1 0 148
Streptococcus group B infection (invasive)|| 65 0 0 65
Streptococcus pneumoniae infection (invasive) 381 0 0 381
Syphilis 431 0 15 446
Toxoplasmosis 24 0 0 24
Trichomoniasis 79 0 0 79
Tuberculosis 242 40 36 318
Typhoid 10 0 0 10
Verotoxigenic Escherichia coli infection 740 97 2 839
Viral encephalitis 61 0 0 61
Viral meningitis 297 1 1 299
Yersiniosis 3 0 0 3
Zika virus infection† 13 0 0 13
Total 32597 236 327 33160
Notes:     
1. This table does not include details of diseases for which a zero number of cases were notified; see Table A1.1 for details of these diseases in 2016  
2. The case definitions booklet, available at http://www.hpsc.ie has been updated since 2016; case classifications are assigned to notifications as per the 
Case Definitions for Notifiable Diseases during 2016    
^Since 17/03/2013, figures for Chlamydia trachomatis, noroviral infection, respiratory syncytial virus infection and rotavirus infection may refer to 
notifications from HSE E rather than events. Such notifications from HSE E may also refer to area of laboratory testing rather than patient’s area of 
residence    
†C. difficile figures in the C. difficile chapter are presented by quarter rather than using the 2016 epidemiological calendar year as shown her
‡Legionellosis figures include both Legionnaires’ disease and Pontiac fever cases  
||Streptococcus group B (Streptococcus agalactiae) infection (invasive) in infants <90 days old or stillborn infants   
†Zika virus became notifiable in May 2016        
-180-HPSC Annual Epidemiological Report 2016 Appendix 1 - Notifiable Infectious Diseases in Ireland
ExplAnAtoRy notEs
glossARy of tERms
AnnuAl 
EpidEmiologicAl 
REpoRt 
20
1 6
Notifiable Infectious Diseases
Computerised Infectious Disease Reporting (CIDR) system
For the majority of the notifiable infectious diseases (see 
Appendix 1), data were collated using the Computerised 
Infectious Disease Reporting (CIDR) system. Notification 
data were inputted directly by areas using the system. 
Enhanced surveillance was undertaken for certain diseases 
and these data are collated on CIDR. Outbreak data were 
also collated on CIDR using the same process outlined 
above. Weekly Reports on infectious disease notifications 
(including a separate report for Clostridium difficile 
associated disease, HIV & STIs) and outbreaks were produced 
by HPSC and published on the HPSC website,   
www.hpsc.ie. Throughout the year data were cleaned and 
validated on an ongoing basis and final data checks and 
cleaning were undertaken following year end by HPSC 
and the Departments of Public Health. Data analysis was 
performed using CIDR Business Objects Reporting and MS 
Access and Excel. Figures for the relevant chapters within 
this report were extracted from CIDR between February 
and November 2017. These figures may differ from those 
previously published due to ongoing updating of data on 
CIDR.
HIV
HIV was made a notifiable disease in Ireland in September 
2011. Since 1st January 2012, CIDR has been used to record 
notifications of HIV, thereby allowing the replacement of HIV 
case based reporting. Since 1st January 2012, AIDS diagnoses 
are only reported if they occur at the time of HIV diagnoses. 
In January 2015, there was a change to the surveillance case 
definition for HIV in HSE East (Dublin, Kildare and Wicklow). 
Previously, confirmatory testing by the National Virus 
Reference Laboratory (NVRL) was required on two separate 
samples prior to notification. From January 2015 onwards, 
confirmatory testing by NVRL on one sample was sufficient 
prior to notification. This change has resulted in increased 
notifications and more timely notifications. 
Sexually Transmitted Infections (STIs)
Data on ano-genital warts (AG) and non-specific urethritis 
(NSU) are not collated using the CIDR system. Instead, 
clinicians notified their respective Departments of Public 
Health of cases of ano-genital warts and non-specific 
urethritis. Data were collated and analysed by Departments 
of Public Health and aggregated data were reported 
quarterly to HPSC. National data were collated on an MS 
Excel database, analysis preformed and reports produced by 
HPSC.
Data on all other STIs are collated using the CIDR system, 
including: chancroid, Chlamydia trachomatis infection, 
gonorrhoea, granuloma inguinale, herpes simplex (genital), 
lymphogranuloma venereum, syphilis and trichomoniasis.
Other Surveillance Systems
Influenza/Influenza-like illness Surveillance Systems
Since 2000, HPSC has worked in collaboration with the 
National Virus Reference Laboratory (NVRL), the Irish 
College of General Practitioners (ICGP) and the Departments 
of Public Health on the influenza sentinel surveillance 
project. Sixty-one general practices (located in all HSE-
Areas and representing 6.2% of the Irish population) were 
recruited to report electronically, on a weekly basis, the 
number of patients who consulted with influenza-like illness 
(ILI). ILI is defined using the Irish case definition for ILI 
which is sudden onset of symptoms AND at least one of the 
following four systemic symptoms: fever, malaise, headache, 
myalgia; AND at least one of the following three respiratory 
symptoms: cough, sore throat, shortness of breath. Sentinel 
GPs were requested to send combined nasal and throat 
swabs on ILI patients each week to the NVRL. The NVRL 
routinely tested sentinel GP and non-sentinel respiratory 
specimens (including specimens from hospitals, non-sentinel 
GPs, nursing homes and other institutions) for influenza 
and a panel of other seasonal respiratory viruses. Other 
surveillance systems set up to monitor influenza/ILI activity 
include a network of sentinel hospitals reporting admissions 
data. The Departments of Public Health also notified HPSC 
of all cases of influenza (including hospitalisation status), 
all acute respiratory infection and influenza outbreaks and 
enhanced surveillance data on all hospitalised cases of 
confirmed influenza in 0-14 year olds. HPSC was notified 
of all registered deaths on a daily basis from the General 
Register Office.
Other influenza surveillance systems included:
•  Surveillance of all calls to GP out-of-hours (OOHs) centres 
monitored for self-reported influenza. These data were 
provided by HSE-NE.  
•  Intensive Care Society of Ireland (ICSI) and the Critical Care 
Programme (CCP) enhanced surveillance of all critical care 
patients with confirmed influenza in all critical care units. 
•  Enhanced surveillance of all confirmed influenza deaths.
•  All-cause excess mortality monitoring associated with the 
European mortality monitoring group (EuroMOMO).
•  Monitoring influenza vaccine effectiveness (I-MOVE study)
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Other routine surveillance include the monitoring of the 
uptake of the seasonal influenza vaccine among residents in 
long term care facilities (LTCFs) and that of the health care 
workers in both LTCFs and hospitals since the 2011/2012 
season. Uptake levels by different categories of staff over 
time, along with other details are presented in the influenza 
chapter of this report.
At HPSC, data were collated from the various sources, 
analysed and routine reports were produced. Influenza 
surveillance reports were posted on the HPSC website www.
hpsc.ie. Aggregated clinical and virological sentinel and non-
sentinel data, genetic and antigenic data from the NVRL and 
anonymised data on confirmed influenza cases admitted to 
hospital were routinely reported to the European Centre for 
Disease Prevention and Control (ECDC) during the influenza 
season.
Immunisation Uptake
•  Immunisation uptake among children at 12 and 24 
months of age
  Each HSE Area maintains a childhood immunisation 
database. HSE Areas provided HPSC with immunisation 
uptake data for their area and for each of the Local 
Health Offices in their area on a quarterly basis. National 
data were collated and analysed at HPSC using a MS 
Excel database. Quarterly reports were produced and 
are available on the HPSC website. For further details 
on methods used, please see the immunisation uptake 
chapter within this report.
•  HPV, MenC booster and Tdap vaccine uptake 
  HPV, MenC booster and Tdap vaccinations provided 
through the schools immunisation programme are collated 
on the national School Immunisation System (SIS). 
Uptake of these vaccines, provided through the school 
immunisation programme per academic year and recorded 
on the database, are reported in the chapter within this 
report. Further details are provided within the chapter.
• DTaP/IPV and MMR vaccine uptake 
  Since the 2011/2012 academic year, the uptake of the 
DTaP/IPV and MMR vaccines in 4-5 year old schoolchildren 
(at Junior Infant level) has been monitored across all Local 
Health Offices (LHOs) each year. Each LHO provides details 
of the cohort size and the number of vaccinated children 
and the returns collated to calculate uptake levels which 
are also presented in maps in the ‘DTaP/IPV and MMR 
vaccine uptake 2015/2016’ chapter. 
European Antimicrobial Resistance Surveillance Network 
(EARS-Net)
Data were collected by participating EARS-Net (formerly 
the European Antimicrobial Resistance Surveillance 
System, EARSS) laboratories on the first invasive isolate per 
patient per quarter on Staphylococcus aureus, Enterococcus 
faecium and Enterococcus faecalis from blood only and 
on Streptococcus pneumoniae, Escherichia coli, Klebsiella 
pneumoniae, Pseudomonas aeruginosa and Acinetobacter 
spp. from blood and/or cerebrospinal fluid (CSF). Data were 
reported quarterly to HPSC, via WHONET software, and 
collated in an MS Access database. Quarterly and annual 
reports were produced.
Antimicrobial consumption
Community (outpatient) consumption data were obtained 
from IMS Health and represent wholesaler to retail pharmacy 
sales figures for Ireland. Hospital (inpatient) consumption 
data were obtained directly from clinical pharmacies 
and validated with the support of the Irish Antimicrobial 
Pharmacists Association. Quarterly and annual  
consumption trends by named public acute hospitals are 
published on the HPSC website. All data were interpreted 
using the WHO Anatomical Therapeutic Chemicals index 
(www.whocc.no/atcddd/) in line with European Surveillance 
of Antimicrobial Consumption (ESAC-Net) methodology, 
which is now managed by the ECDC. See relevant section for 
notes on the denominator data.
Healthcare associated infections
•  Clostridium difficile: Data on C. difficile enhanced 
surveillance were collected by participating hospitals, 
reported quarterly to the HPSC and stored in an MS Access 
database. Quarterly and annual reports were produced. 
•  Data were also collected on the total volume of alcohol-
based hand rub used per hospital per year/quarter, 
excluding that used for pre-operative surgical “scrub”. 
See relevant section for notes on the denominator data. 
The rate of usage per hospital was calculated as the total 
volume of hand rub consumed (in litres) per 1000 bed days 
used, and quarterly and annual reports were produced for 
publication on the HPSC website.
Denominator Data
To calculate disease incidence rates, Census of Population 
data were used as the denominator (available from the 
Central Statistics Office, http://www.cso.ie).  Population 
figures were applied as follows: 
•  Census 2016 for analysis of 2014-2016 data unless 
otherwise specified
•  Census 2011 for analysis of 2009-2013 data 
•  Census 2006 for analysis of 2004-2008 data
•  Census 2002 for 2000-2003 data 
•  Census 1996 for 1999 data 
Monthly population changes were estimated between 
1993 and 2014 using a curve interpolation method for the 
calculation of outpatient antibiotic consumption rate. 
Bed-days used and other activity data for public acute 
hospitals were provided by the Business Information Unit 
of the HSE and used to calculate rates of MRSA, hospital 
antibiotic consumption and rates used in other hospital-
based surveillance systems. Similar activity data were 
obtained directly from private acute hospitals.
HSE Areas
Although organisational changes have taken place in the 
Health Services, the term HSE Areas are used in this report 
when analysing and presenting data by geographical area 
(equating to the eight former health board regions/areas). 
This is because operationally the surveillance, prevention 
and control of infectious diseases are still managed by eight 
Departments of Public Health, one in each HSE Area.
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Regional Directors of Operations (RDO’s)
The range of health and personal social services provided by 
the HSE and its funded agencies were managed within four 
regions known as RDOs. Details of the four RDOs and their 
relationship with the eight HSE areas are shown below.
1.  Dublin Mid Leinster (HSE-Midland plus CCA1-5 and CCA9-
10 of HSE-East)
2.  Dublin North East (HSE-North East plus CCA6-8 of HSE-
East)
3.  South (HSE-South and HSE-South East)
4.  West (HSE-Midwest, HSE-North West and HSE-West)
Community Healthcare Organisations
Community Healthcare Services are the broad range of 
services that are provided outside of the acute hospital 
system and includes Primary Care, Social Care, Mental 
Health and Health & Wellbeing Services. These services 
are delivered through the HSE and its funded agencies to 
people in local communities, as close as possible to people’s 
homes. The document Community Healthcare Organisations 
– Report and Recommendations of the Integrated Service 
Area Review Group, published in October 2014, sets out  
how health services, outside of acute hospitals, will be 
organised and managed. This document is available at 
http://www.hse.ie/eng/services/publications/corporate/
CHOReport.html  
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Glossary of Terms 
ABHR  Alcohol-based hand rub
BDU  Bed-days used
CDI  Clostridium difficile infection 
CIDR  Computerised Infectious Disease Reporting 
CIR  Crude incidence rate 
DoH  Department of Health 
EARS-Net  European Antimicrobial Resistance Surveillance Network 
ECDC  European Centre for Disease Prevention and Control 
EISN  European Influenza Surveillance Network 
ESAC-Net  European Surveillance of Antimicrobial Consumption Network 
HCAI  Healthcare associated infections 
HCWs  Healthcare Workers 
HPSC  Health Protection Surveillance Centre 
HPV  Human papilloma virus
HSE  Health Service Executive 
HSE E  HSE Eastern Region 
HSE M  HSE Midland Area 
HSE MW  HSE Mid-Western Area 
HSE NE  HSE North Eastern Area 
HSE NW  HSE North Western Area 
HSE SE  HSE South Eastern Area 
HSE S  HSE Southern Area 
HSE W  HSE Western Area 
ICGP  Irish College of General Practitioners 
ILI  Influenza-like illness 
IMSRL  Irish Meningitis and Sepsis Reference Laboratory
IPD  Invasive pneumococcal disease 
LTCFs  Long term care facilities 
MRSA  Meticillin Resistance Staphylococcus aureus 
MSM  Men who have sex with men 
NSSLRL  National Salmonella, Shigella and Listeria Reference Laboratory 
NIAC  National Immunisation Advisory Committee
NIO  National Immunisation Office 
NVRL  National Virus Reference Laboratory 
PWID  People who inject drugs 
SIS  School Immunisation System 
STIs  Sexually Transmitted Infections 
TB  Tuberculosis 
WHO  World Health Organization
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